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Thesis Summary 
 
The incidence of skin cancer is increasing and conventional treatments such as surgery 
are not suitable for all patients. This study aimed to develop an elastic liposomal gel to be 
applied directly to the tumour for the controlled release of anti-cancer agents to the dermal 
layer. The proposed anti-cancer flavonoids EGCG and naringenin as well as the novel potent 
cytotoxic agent MTL-004 were loaded into the bilayer of liposomes. Furthermore, aqueous gels 
HEC and HPMC were investigated as carriers for the liposomes to be applied topically. 
 Liposomes loaded with either Tween 80, Tween 20 or sodium cholate were found to 
have increased elastic properties, liposomes with an average size of 400 nm were able to pass 
through a pore size of 100 nm. Release studies from liposomes loaded with either EGCG, 
naringenin and MTL-004 as well as varying ratios of Tween 20 were carried out. Within 24 
hours, EGCG liposomes loaded with 0% or 10% w/w Tween 20 gave a release of 13.7 ± 1.1 
% and 94.4 ± 4.9 % respectively; naringenin liposomes loaded with 0% or 10% w/w Tween 20 
gave a release of 109.7 ± 5.0 % and 48.5 ± 2.1 % respectively; MTL-004 liposomes loaded 
with 0% or 10% w/w Tween 20 gave a release of 59.8 ± 1.2 % and 74.0 ± 1.8 % respectively. 
This indicates a compounds individual physiochemical properties influences release of 
compound from liposomes.  
EGCG, naringenin and MTL-004 loaded liposomes added into the aqueous gel HEC or 
HPMC gels may have had an additive effect in terms of retarding drug release. Release was 
faster from HEC gels and liposomes formulated with Tween 20. 
 
In vitro cellular uptake of liposome uptake into HDFa and HaCat cells was apparent. 
Thus it appears elastic liposomes are useful in enhancing drug penetration into dermal cells 
and furthermore may be useful in the development of a controlled release formulation. 
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1.1 Background  
 
Skin cancer is emerging as an increasing public health problem especially in developed 
countries (Lomas et al., 2012).  The large number of cases diagnosed present as a substantial 
burden to healthcare services in the U.K (Diepgen and Mahler, 2002; Donaldson and Coldiron, 
2011). There were around 15,400 new cases of skin cancer in the UK in 2014 and is the fifth 
most common cancer (CancerResearchUK, 2014). 
 
Skin cancer can be categorised as either non melanoma skin cancer (NMSC) or melanoma 
skin cancer (MSC), with the former being more common than the latter. NMSC is an increasing 
problem for health care services worldwide (Lomas et al., 2012). NMSC is the most common 
cancer affecting Caucasians and the incidence is rapidly increasing worldwide (Lomas et al., 
2012). In Caucasian populations in Europe, the U.S., Canada, and Australia the average 
annual increase of NMSC since 1960 was 3–8% (Glass and Hoover, 1989; Green, 1992). 
Additionally, the incidence rates in the U.K. appear to be increasing at a faster rate when 
compared with the rest of Europe. The increase in the incidence of NMSC can be attributed to 
an amalgamation of increased sun exposure or exposure to ultraviolet (UV) light, increased 
life span, and ozone depletion (Gloster and Brodland, 1996). In fact, the incidence of NMSC in 
the Caucasian populations increases with closer proximity to the equator (Giles et al., 1988). 
 
Whilst the incidence of MSC is lower compared with NMSC’s, it occurs across all ethnicities. 
However, it’s prevalence has been rising in the Caucasian population worldwide for several 
decades, in fact being the most rapidly rising cancer within this population grouping (Armstrong 
and Kricker, 1993; MacLennan et al., 1992). Within the U.K., the rate of MSC incidences has 
doubled every 10–20 years in North Humberside, between 1978 and 1991 (Ko et al., 1994). In 
comparison to NMSC, which mainly affecting the elderly population, MSC peaks in people 
aged between 20–45 year (Holme et al., 2000).  
 
The majority of skin cancers are treatable; however poor treatment or particularly malignant 
forms of cancer results in 2,500 deaths annually (Skin Cancer in the UK, 2011; Cancer 
Research UK 2011, a, b, c). The most common treatment for both NMSC and MSC is local 
surgery to remove the tumour. However, it can be the case that surgical removal is not suitable 
for the patient thus development of alternative treatments is necessary. 
1.1.1 Cancer 
Cancer can be characterised by the uncontrolled multiplication and spread of atypical body 
cells. Both benign and malignant forms manifest as uncontrolled cell proliferation, however 
malignant forms are distinguished by their ability to de-differentiate, invade surrounding tissue 
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and metastasise. The main treatment for cancer is surgical excision, irradiation or 
chemotherapy. Cancer cells are in many ways similar to normal cells making them difficult to 
target and eliminate. Drugs currently used in chemotherapy include cytotoxic agents (such as 
alkylating agents, anti-metabolites, cytotoxic antibiotics and plant derivatives), hormones 
(steroids and antagonistic agents) and miscellaneous agents (including more recent 
treatments e.g. monoclonal antibodies). These drugs however cannot differentiate between 
fast-growing cancer cells and the other types of fast-growing cells including skin cells, blood 
cells, and cells inside the stomach. They therefore have a toxic effect on these cells as well 
causing side effects including nausea, vomiting, lethargy, hair loss, anaemia and even 
immunosuppression (Coates et al., 1983; Conklin, 2000; Lindley et al., 1999; Sitzia and 
Huggins, 1998). Therefore, one of the current challenges in cancer treatment is to enhance 
tumour-specific targeting so as to improve chemotherapy outcomes and reduce side effects.  
 
1.1.2 Skin cancers 
Skin cancers are usually caused by a combination of cumulative and intense sun exposure. 
NMSC develops slowly in the upper layers of the skin whilst MSC spreads faster in the body 
(Figure 1.1). NMSC can be classified further into either basal cell carcinoma (BCC) or 
squamous cell carcinoma (SCC). BCC and SCC are the most common tumours in the 
Caucasian human population, accounting for greater than 95% of NMSCs (Marcil and Stern, 
2000; Urosevic and Dummer, 2002). 
 
The BCCs subsect of NMSC can be described as the abnormal, uncontrolled growth arising 
within the basal cells, which line the deepest layer of the epidermis. BCCs appear as red 
patches, pink growths, shiny bumps, or scars (Figure 1.1). Nodular BCC presents as a pearly 
papule or nodule often exhibiting central crusting or ulceration. Superficial BCC presents as a 
scaly erythematous patch or plaque. Both nodular and superficial forms have a darker 
colouring as they contain melanin, imparting a brown, blue, or black colour to these tumours. 
Infiltrative BCC, appears as a white, scar-like plaque with indistinct margins (Rubin et al., 
2005). The presentation of skin cancer can influence absorption of the formulation; tough scaly 
skin is harder to impregnate than an open ulcer.   
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Figure 1.1: Illustrations of the various sub classifications of skin cancer 
a) NMSC basal cell carcinoma b) NMSC squamous cell carcinoma and c) MSC (Sun Spot 
Melanoma Awareness, 2013) 
 
SCC is generally a proliferative exophytic tumour growing steadily over months. Depending on 
duration of growth, size ranges from a few millimetres up to centimetres. In the early stage an 
SCC may resemble a solar keratosis. A clinical indication of malignant transformation is 
thickening and tenderness of the skin. Sometimes, the tumours can become infiltrating and 
firm without an exophytic component. Additionally, a verrucous form of SCC may occur on the 
sole of the foot. The tumours induce an inflammatory reaction thus becoming crusted and 
erythematous with bleeding possible. A definite edge is difficult to distinguish on stretching the 
tumour, which is in contrast to a BCC (Figure 1.1) (R. Marks, 1996). Metastasis from cutaneous 
SCC appears most commonly in the regional lymph nodes followed by the lungs, liver and 
other organs (Marks, 1996). 
 
MSC can be classified as superficial spreading, lentigo maligna melanoma and acral 
melanoma. Superficial spreading MSC observes slow cell growth at first which then spread out 
across the surface of the skin. Nodular melanoma observes faster cell growth than other 
melanomas. Lentigo maligna melanoma is observed more so in the elderly population and is 
localised to areas of skin that have experienced greater sun exposure. Acral melanoma is very 
rare and not thought to be related to sun exposure (Grossman et al., 1999; Katalinic et al., 
2003; Madan et al.).  
 
Both types of skin cancer are more likely to occur in light complexion individuals who have had 
considerable sunlight exposure, and are more common in the Southern latitudes of the 
Northern hemisphere. Furthermore, the immune system may have a role in pathogenesis of 
skin cancers thus may be exploited in treatment (de Visser et al., 2006). 
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1.1.3 Skin structure 
The skin limits the passage of chemicals into and out of the body, helps maintain blood 
pressure and temperature and mediates sensations ranging from heat to pain. The skin is a 
multilayered organ with three major tissue layers, the epidermis, dermis and subcutaneous 
tissue (Figure 1.2). The epidermis has five layers, the cells of the basal layer proliferate and 
migrate upwards to produce the stratum corneum (Alexander et al., 2012). The epidermis is 
composed of keratinocytes but also includes melanocytes, sensory perception cells and 
immunological cells (Prow et al., 2011). There are tight junctions between the cells and 
expression of tight junction proteins are altered in skin diseases such as psoriasis, in which 
there is a compromised skin barrier (Cevc and Vierl, 2010).  As skin ages the lipid packing 
arrangement is disrupted therefore lowering skin resistance (Cevc and Vierl, 2010) conversely, 
there is a depletion of skin lipids causing dry patches which can increase skin resistance 
(Brooks and Idson, 1991).  
 
Figure 1.2: Anatomy of the skin 
The skin consists of three main layers; the epidermis, dermis and subcutaneous layer (adapted 
from (McGraw-HillCompanies, 2003)). 
 
 
The SC is the outermost layer of the epidermis and it is the layer that most limits drug 
penetration (Thomas and Finnin, 2004), It has a brick and mortar structure (Prow et al., 2011) 
consisting of corneocytes embedded multiple lipid bilayers of ceramides, cholesterol and fatty 
acids (Alexander et al., 2012). The dermis is thicker than the epidermis and is composed of 
connective tissues including collagen and elastic fibres. This layer has a copious blood supply 
to provide nutrients and remove toxins, thus the skin acts a sink for ‘diffusing’ molecules by 
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removing them from the site (Alexander et al., 2012). This can be useful for transdermal drug 
delivery as a concentration gradient will be maintained encouraging drug delivery by diffusion. 
  
1.1.4 Common skin cancer therapies 
The most common treatment to remove both NMSC and MSC are local surgery (curettage and 
electrodessication as well as Mohs micrographic surgery) to excise the tumour (Gaspari and 
Sauder, 2003; Neville et al., 2007). If the melanoma is identified at an early stage, this is usually 
the only treatment needed.  
 
In specific circumstances, ionising radiation therapy may be used in skin cancer therapy. 
Radiation is usually delivered in fractionated doses in the form of superficial X-rays, 
orthovoltage or deep X-rays, or electron-beam therapy (Neville et al., 2007; Voss and Kim-
Sing, 1998).  
 
Additionally, cryosurgery is an option utilising liquid nitrogen at -196.5 °C to destroy tumour 
cells via freezing and vascular stasis. Ice crystal formation develops intracellularly and 
extracellularly, resulting in tissue damage and cell death (Kuflik, 1994; Neville et al., 2007; 
Nguyen and Ho, 2002).  
 
Surgical treatments, radiation therapy and cryotherapy may not be suitable for all patients. 
Considerable disfigurement can result because of the nature of the tumours and their common 
localisation on highly visible, cosmetically important areas. That, in turn, represents a serious 
problem in cases of multiple tumours observed with certain genodermatoses or 
immunosuppressed patients (Marcil and Stern, 2000). Therefore, development of alternative 
treatments is important. Topical treatments are available and are effective alternatives for 
NMSC (Neville et al., 2007; Romero and Morilla, 2013a). These treatments may be useful after 
surgery when it has not been possible to remove all cancer cells or if there is a high risk of the 
tumour returning (Felicio et al., 2009; Neville et al., 2007).  
 
Both BCC and SCC occur more so on the head and neck, the rest being divided between other 
sites of high UV exposure. These include the hands and forearms, upper trunk, and lower leg, 
in that order (Marks, 1996; Rubin et al., 2005). Thus an appealing aesthetic outcome of 
treatment is desirable. The choice of treatment approach depends on the location of the 
cancer, age and health status of the patient, and risk factors for tumour recurrence. Irrespective 
of the approach used, the treatment goal is to remove the tumour, achieve a high cure rate, 
preserve the maximal amount of normal surrounding tissue, whilst providing an optimum 
cosmetic outcome.  
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1.1.4.1 Topical skin cancer formulations  
 
Topical chemotherapy, topical immunomodulators, or intralesional chemotherapy may be used 
to treat non-melanoma skin cancer (NMSC). Existing topical therapies have been found to be 
successful in NMSC treatment, a study found that for topical Imiquimod cure rates ranged from 
65 % to 100 %, while for 5-flurouracil (5-FU) rates ranged from 61 % to 92 %. For intralesional 
agents, cure rates varied depending on which medication was used and the NMSC subtype 
treated. Keratoacanthomas (a low grade skin tumour) had high cure rates with intralesional 
agents: 98 % for 5-FU, 91 % for methotrexate, 100 % for bleomycin, 100 % for interferon α-2, 
83 % for interferon α-2a, and 100 % for interferon α-2b (Chitwood et al., 2013). 
 
Topical photodynamic therapy (PDT) refers to topical application of a photosensitizer onto the 
site of skin disease which is followed by illumination which results in selected cell death. 
Photodynamic therapy is effective in treating SCC in situ and superficial BCCs. Compounds 
used in this manner include the photosensitizing porphyrin 5-aminolevulinic acid (ALA) and the 
methyl ester of ALA (mALA), both of which are converted to protoporphyrin IX once absorbed 
into the skin (Neville et al., 2007). Liposomes have been investigated as carriers for 
photosensitizers and were found to enhance penetration while decreasing absorption into the 
systemic circulation (Dragicevic-Curic and Fahr, 2012). 
 
Immunotherapy of NMSC has been attempted with the use of agents such as imiquimod, 
interferon and interleukins, these treatments however have a lower efficacy compared with 
surgical approaches (Gaspari and Sauder, 2003; Urosevic and Dummer, 2002).  
 
Imiquimod is a topical immune-response modulator effective when applied topically at the 
tumour site against superficial BCCs, small nodular BCCs and SCCs. The drug is a novel 
synthetic imidazoquinolone that modulates the immune system's response to cancer cells  
(Berman, 2002; Chitwood et al., 2013; Gaspari and Sauder, 2003; Good et al., 2011; Marks et 
al., 2001; Sauder, 2003). Imiquimod promotes innate and acquired immune responses via 
secretion of cytokines, and activation of Th-1 cell-mediated immunity (Figure 1.3) (Berman, 
2002). This cytokine-induced immune response is responsible for the antiviral and antitumor 
effects of imiquimod. Additionally, imiquimod stimulates natural killer cells and the proliferation 
of B-lymphocytes whilst activating Langerhans cells, the key antigen-presenting cell of the skin, 
and stimulates their migration to regional lymph nodes (Berman, 2002). Responses provide 
long-term immune memory thus possibly offering future protection against the previously 
encountered tumour cells. Futhermore, imiquimod may promote cellular apoptosis (Meyer et 
al., 2003; Sullivan et al., 2003). 
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Dose-related inflammatory skin reactions such as  erythema, burning, impetigo or tenderness 
at the treatment site at the site of application are common as this is caused by the cell death 
(Gaspari and Sauder, 2003). Unfortunately, clinical development of local inflammation seems 
to correlate with the success rate therefore, some degree of local reaction is necessary (Neville 
et al., 2007).  
 
 
Figure 1.3: Imiquimod mechanism of action 
Image depicting how Imiquimod immune responses via secretion of cytokines, and activation 
of Th-1 cell-mediated immunity. This cytokine-induced immune response is responsible for the 
antiviral and antitumor effects of imiquimod (adapted from (Drobits et al., 2012)). 
 
Interferon is naturally produced by the body to fight infection. It has been synthesised and 
formulated into a cream. Though there is no evidence it improves survival rates it may help 
delay melanoma returning and therefore it may be used as an adjuvant treatment (Chitwood 
et al., 2013; Good et al., 2011). Interferon initiates apoptosis of BCC cells via the CD-95 ligand-
receptor interaction and the stimulation of interleukin (IL)-2 and IL-10 (Chakrabarty and Geisse, 
2004). However, treatment may cause flu-like symptoms including headache and fever. Whilst 
complete response rates of 50–80% have been reported, these results might not be obtained 
with high-risk tumours (Oguz Acartürk and Edington, 2005). Aside from the low cure rate, a 
further drawback of interferon therapy is the need for multiple intralesional injections.  
 
Interleukin-2 is a cytokine secreted by CD4+ T lymphocytes following antigen recognition. It 
has no direct effect on cancer cells, instead, its antitumor activity is accomplished through 
immunomodulation by stimulating cytotoxicity of T lymphocytes, NK cells, and macrophages 
(Rogalski et al., 1999). It has been found to be valuable in the treatment of BCC, (Dummer et 
al., 1992; Mihara et al., 1990). Side effects however include fever, flu-like symptoms, and pain 
at the injection site (Kaplan and Moy, 2000). 
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5-FU functions by inhibiting thymidylate synthetase thereby inhibiting DNA synthesis causing 
cell death (Chitwood et al., 2013; Good et al., 2011; Marks et al., 2001). Its usefulness in 
treating invasive NMSC is hindered by inability of the topical cream formulation to penetrate 
into the skin sufficiently. Because of the potential for persistent, deeper, invasive tumours to 
remain following treatment, application is limited to treating superficial BCC or SCC (Dillaha et 
al., 1963). 
 
Patients at high risk of developing numerous or invasive NMSC’s may be suitable for 
chemoprevention. Oral retinoids have been proven to be effective in the suppression of new 
SCC development but require careful monitoring (Neville et al., 2007). Topical retinoids 
however are not effective for prevention. Further, photodynamic therapy, imiquimod, 5-FU, 
ingenol mebutate, or diclofenac sodium may theoretically decrease the risk of SCC through 
treatment of precancerous changes though there is limited data regarding efficacy of these 
agents. Nonsteroidal anti-inflammatory agents may even have a protective effect against 
NMSC (Soltani-Arabshahi and Tristani-Firouzi, 2013). 
 
Though there are some effective topical formulations for the treatment of skin cancer, poor 
patient compliance stemming from perhaps a lack of understanding of needing to adhere to 
the treatment regimen or unpleasant side effects can result in treatment failure. In addition 
these treatments may cause skin irritation; the skin may peel, weep, crack or blister. The area 
treated can become painful, itchy, and ulcerated (Felicio et al., 2009; Kaplan and Moy, 2000; 
Neville et al., 2007). Therefore development of a treatment with a slow release profile to 
minimise product application with minimal side effects to normal skin cells would be ideal. 
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1.2 Topical, dermal and transdermal drug delivery formulation considerations 
The skin is an effective route for either local or systemic drug delivery. It is the largest, most 
easily accessed organ of the body (Thomas and Finnin, 2004). Topical, dermal and 
transdermal drug delivery are advantageous as the methods employed to delivery drugs are 
generally pain free and offer dose flexibility with an ease of drug removal (Alexander et al., 
2012; Thomas and Finnin, 2004). Topical systems allow medicament to act on the surface of 
the skin, dermal systems deliver drug to the dermal layer and transdermal systems allow drug 
to cross the dermal later and enter the blood stream. Dermal and transdermal drug delivery 
systems are able to deliver drug in a controlled way ensuring steady drug-plasma levels 
thereby avoiding the peak-trough phenomenon of drug concentration in the plasma seen with 
multiple drug doses (Alexander et al., 2012). This is especially important for drugs that have a 
short half-life or those with a narrow therapeutic index (Chaudhary et al., 2013; Thomas and 
Finnin, 2004). Thus drug concentration remains within the therapeutic window avoiding 
potentially toxic side effects and sub therapeutic drug concentrations (Alexander et al., 2012). 
Furthermore the skin has a copious blood supply and drug can be delivered directly into the 
systemic circulation and avoid first pass metabolism and the variables that affect GI absorption 
such as pH, enzymes, drug-food interactions, and gastric emptying time (Alexander et al., 
2012). 
 
The principle function of mammalian skin is to protect the organism from foreign body invasion 
including any applied drug formulation (Alexander et al., 2012). Whilst this is not a concern for 
topical formulations, transdermal and dermal drug delivery systems must be formulated to 
overcome this barrier function. The extent of drug penetration is dependent on race, skin 
condition, age, sweat gland density, and skin hydration levels (Thomas and Finnin, 2004). Skin 
temperature can also affect drug flux and rate of clearance due to the adjustment of cutaneous 
blood flow (Cevc and Vierl, 2010; Thomas and Finnin, 2004). Further, structural differences in 
skin, for example stratum coreum (SC) thickness, lipid content and enzyme activity can affect 
drug delivery across the skin (Thomas and Finnin, 2004). Other aspects to consider when 
developing transdermal and dermal products include how other external products including 
soap, creams, and body sprays affect drug delivery and also the potential of dose transfer to 
another person (Thomas and Finnin, 2004). 
 
Drug delivery via the skin offers many benefits over other drug delivery routes including the 
oral and parenteral routes by avoiding first pass metabolism, delivering the drug at a steady 
state and being ‘user friendly’. Drug penetration however is limited by the stratum corneum 
(SC), drug formulations are therefore required to penetrate the SC in order reach target 
locations. Nanoparticulates including liposomes can be employed to carry drug across the skin 
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and deliver the drug to the dermal layer or even transdermally. Dermal drug delivery may be 
useful in delivering chemotherapy for treatment of skin cancer. 
 
Drugs are able to penetrate the skin through either intercellular routes or intracellular routes 
(Figure 1.4). The transcellular route involves the drug moving though the cell. This may be 
passively by diffusion, being carrier mediated, being actively transported, or being receptor 
mediated (endocytosis). Drugs are also able to pass through using the follicular pathways 
which is useful as follicles extend deep into the skin and is well vascularised however, the area 
available for drug transport is only about 0.1% of the skin (Alexander et al., 2012; Barry, 2001; 
Brooks and Idson, 1991; Prow et al., 2011). 
 
 
Figure 1.4: Diagrammatic representation of potential drug penetration pathways 
The intracellular and intercellular pathways (depicted on the upper right corner) adapted from 
(Alexander et al., 2012). 
 
 
1.2.1 Drug physiochemical considerations 
When developing transdermal preparations drug physiochemical, pharmacokinetic and 
pharmacological properties need to be considered. Though smaller drug molecules are ideal 
for transdermal delivery, if local drug delivery is required, this is not the case as the drug is 
more likely to be cleared via cutaneous blood flow (Cevc and Vierl, 2010). Drug flux across the 
skin is influenced by the drug concentration gradient. For a drug to move through the 
intercellular pathways, it must be able to diffuse through a complex mixture of lipids with 
hydrophilic and hydrophobic domains. This is determined by ability of drug to partition into the 
skin and then out of the skin into the underlying tissues; the octanol: water partition coefficient 
is used to predict this (Thomas and Finnin, 2004). Thus only drugs with suitable 
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physiochemical properties will be able to pass through this route, usually, only smaller drug 
molecules (Prow et al., 2011). Ideal properties of a drug intended for the transdermal route are 
summarised in Table 1-1. Chemical structure of the drug influences diffusivity as the polar 
head groups of the intracellular lipids can interact with the hydrogen bond forming functional 
groups in drug structure (Cevc and Vierl, 2010). Therefore, ideal physiochemical properties of 
a drug for transdermal drug delivery include a low molecular mass, a high diffusion coefficient, 
high drug concentration and a high but balanced partition coefficient. 
 
Table 1-1: Summary of drug characteristics required for transdermal drug delivery  
(Alexander et al., 2012; Guy & Hadgraft, 1985) 
Molecular weight < 500 Da 
Log P < 5 
Melting point 200 °C 
 
  
1.2.2 Overcoming the barrier function of the skin 
The most obstructive layer of the skin which must be overcome is the SC. Many methods have 
been developed to help carry drug across the skin and further the use of skin as a viable drug 
delivery pathway. Passive drug penetration enhancers may be added to a formulation and may 
either carry the drug across or decrease the resistance of the skin. These include chemical 
enhancers, supersaturated solutions, ion pairing techniques, eutectic mixtures, oils and 
amphipaths and nanoparticles. Active penetration enhancers force the drug across the skin 
layers by using physical force usually by electrically assisted means. Such methods include 
iontophoresis, ultrasound (sonophoresis), electroporation, photomechanical waves and 
electron bean irradiation. 
 
1.2.2.1 Passive drug penetration enhancers  
Chemical enhancers temporarily diminish the skin barrier. Few compounds have been 
successful and it is difficult to correlate in vitro to in vivo action due to live skin responding 
differently to the chemicals used (Thomas and Finnin, 2004). Ideally their effect would diminish 
once the drug has passed through leaving no lasting damage. There is a need to develop the 
understanding of the mechanism of such substances so predictions can be made to how they 
would improve drug flux (Barry, 2001). Some solvents, for example ethanol, can remove lipids 
from the SC thus reducing its barrier capabilities (Naik et al., 2000). Additionally, the effect has 
been shown to be reversible (Bommannan et al., 1991). Such penetration enhancers may 
intercalate into the structured lipids of the skin where it can disrupt the packing thus rendering 
them more ‘fluid’ thereby increasing the diffusion coefficient of the permeant (Cornwell et al., 
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1996; Garrison et al., 1994; Gay et al., 1989; Golden et al., 1986). The second approach in 
which excipients (for example, propylene glycol) can improve skin permeability is to shift the 
solubility parameter of the skin in the direction of that of the permeant. The solubility of the 
permeant in the outer layers of the skin will be increased and this, in turn, improves the flux 
(Hadgraft, 1999). One of the concerns however is that this type of molecule usually has irritant 
properties (Hadgraft, 1999). 
 
A supersaturated formulation is a solution that has exceeded equilibrium solubility. As drug 
concentration increases, the thermodynamic activity of the drug increases thus drug flux 
across the skin increases (Alexander et al., 2012). A saturated formulation of the drug will in 
fact provide the maximal flux, irrespective of the selected vehicle and drug solubility therein 
(Naik et al., 2000). They are, however know to be inherently unstable due to crystallization 
over increased time periods (Hadgraft, 1999). Co-solvents able to decrease drug solubility are 
useful in the formulation of super saturated solutions to keep the drug from reaching potentially 
toxic levels (Thomas and Finnin, 2004; Valenta and Auner, 2004). 
 
The ion pairing technique enables the permeation of ionisable drugs. Charged molecules are 
unable to easily penetrate the skin due to the lipids in which the cells are surrounded thus the 
formation of a neutral ion pair can aid the penetration of a charged drug (Alexander et al., 
2012). This has been proved to be successful in the delivery of retinoic acid and glipizide (Tan 
et al., 2009; Trotta et al., 2003). 
 
Eutectic mixtures transform solid drugs into an oily state at ambient temperature thereby 
increasing the thermodynamic activity and thus the drug flux across the skin. Skin permeability 
is enhanced by the formation of a low melting mixture and also by directly disrupting the skin 
structure to allow passage of the drug (Alexander et al., 2012). EMLA cream is a eutectic 
mixture of lignocaine and prilocaine which, when applied under an occlusive film, provides 
effective local anaesthesia for pain-free venepuncture and other procedures (Ehrenstrom Reiz 
and Reiz, 1982). Additionally, the delivery of ibuprofen across the skin has been improved with 
eutectic mixtures (Stott et al., 1998; Yong et al., 2003). 
 
Oils and amphipaths in polar solvents spontaneously form a plethora of structures including 
micelles, cyclodextrins, liposomes, micro emulsions, and vesicles depending on the shape of 
the molecules used (section 1.2.4.3). Some improve transdermal drug delivery acting as drug 
carriers or skin permeation enhancers. When formulating such structures for application 
additional factors to consider include how the structure will change as the solvent evaporates 
and how temperature affects the stability (Cevc and Vierl, 2010). 
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Liposomes are colloidal particles that consist of phospholipids and cholesterol. These lipid 
molecules form concentric bimolecular layers in the form of vesicles. The drug can be trapped 
in this structure and transported across the skin. They can also act as penetration enhancers 
as the lipid components are able to penetrate into the stratum corneum (Schreier and 
Bouwstra, 1994; Vázquez-González et al., 2014). As well as the lipid component being able to 
act as penetration enhancers themselves, chemicals can be added to improve vesicular bilayer 
fluidity and reduce the SC barrier function (Romero and Morilla, 2013b). Further, in addition to 
protecting the drug from degradation they can be formulated to provide a controlled release of 
drug (Alexander et al., 2012). 
 
1.2.2.2 Active drug penetration enhancers 
Active penetration enhancers force drug to move across the skin layers by using physical force 
usually by electrically assisted means. Iontophoresis is the process of using an electrical 
potential difference to force ions across the skin. The power of iontophoresis depends on 
polarity, valency, mobility of the drug molecule as well as the formulation (Alexander et al., 
2012; Cevc and Vierl, 2010). This method has been successful in the delivery of buspirone (Al-
Khalili et al., 2003). Different sources of energy can be used to create pores that remain open 
for up to 24hrs. The use of ultrasound (sonophoresis) is useful for local drug delivery 
(Alexander et al., 2012; Cevc and Vierl, 2010). Electroporation is the temporary structural 
disturbance of the lipid bilayer due to a short high voltage pulse. Other methods include the 
use of photomechanical waves and electron bean irradiation (Alexander et al., 2012). 
Effectiveness of such methods is also dependent on the physiochemical properties of the drug 
(Alexander et al., 2012). Combinational approaches are being investigated and developed 
using a multidisciplinary approach; scientists from engineering, pharmaceutical sciences, 
physics, chemistry, biology and medicine are working to lower the skin barrier in a controlled, 
safe, reversible way.  
 
1.2.2.3 Nanoparticle carriers as penetration enhancers 
A nanoparticle is defined as a particle with a size between 1 to 100 nm (Prow et al., 2011). The 
term nanoparticle can be applied to dendrimers, micelles, liposomes, nanoemulsions and to 
solid particulates provided they possess a size range of < 100 nm. Benefits of using a 
nanoparticle include enhanced drug absorption, sustained drug release and drug protection. 
Additionally, such particles may offer sustained release of drugs, less irritation and moisturising 
properties (Vázquez-González et al., 2014). Another benefit of nanoparticles is that the use of 
skin digestion or permeation enhancer substances may be avoided (Alexander et al., 2012). 
Nanoparticles are increasingly being used in local and targeted delivery (Prow et al., 2011).  
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Dendrimers are highly branched three-dimensional, immensely branched, well-organized 
polymer nanoscopic macromolecules (Küchler et al., 2009). A drug can be entrapped within 
this structure. They have already been investigated as carriers for chemotherapeautics (Teow 
et al., 2013). 
 
Micelles are lipid molecules that arrange themselves in a spherical form in aqueous solutions. 
The formation of such structures is a response to the amphipathic nature of fatty acids. 
Micellular nanoparticles can accommodate water soluble and non-water soluble, crystalline 
and amorphous drugs and a drug loading of up to 20% w/w can be achieved (Lee et al., 2010).  
 
Solid particulate nanoparticles refer to the nanosizing of solid drug particles, solid polymeric 
nanoparticles, solid protein nanoparticles and solid lipid nanoparticles.  Most drug delivery 
particle technologies are based on solid lipid carrier’s (solid lipid nanoparticles) (Prow et al., 
2011). These are colloidal particles made of solid lipids e.g. solid triglycerides, saturated 
phospholipids. They have an occlusive effect which reduces transepidemal water loss thus 
enhancing penetration (Bhaskar et al., 2009).  
 
Most environmental nanoparticles for example viruses, dust and bacteria are unable to breach 
the skin barrier. Studies suggest particles greater than 10 nm are unlikely to penetrate the SC 
without the aid of penetration enhancers and instead amass in hair follicles (Prow et al., 2011). 
However in aged or damaged skin the potential for drug penetration increases (for example, 
ulcerated squamous cell carcinoma) (Prow et al., 2011).  
 
Further, mechanical effects such as flexing of the skin or massage may affect penetration 
though results are inconclusive. Though some studies have found flexing increased 
penetration, skin massage did not, however others have found the opposite result. These 
studies used different methods and different sized particles therefore implying flexing and 
massage effects are dependent on the drug and formulation used (Prow et al., 2011). 
 
The safety of nanoparticles however is a concern, particularly if they are insoluble and non-
biodegradable. These may be taken up and retained by the reticulo-endothelial system or 
accumulate in target organs and it is unclear as to what effects they may have. They can also 
cause local toxicity such as keratinocyte apoptosis (Prow et al., 2011). 
 
Interest in the use of nanoparticles for drug delivery has grown considerably over the last 
decade. They can be designed to control drug release, protect the drug and even provide 
targeted drug delivery. Improving the understanding of how nanoparticles interact and 
penetrate through the skin layers is vital to improve transdermal drug delivery.  
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1.3 Liposomes 
Liposomes consist of amphoteric lipid molecules (phospholipids) that form spherical, self-
closed structures in aqueous media to minimise the entropically unfavourable interaction 
between hydrophobic chains and aqueous medium (Figure 1.5). Drugs may be loaded into 
these vesicles for targeted, controlled release. Hydrophilic drugs with a log P <1.7 are retained 
well in the aqueous core. Lipophilic drugs with a log P >5 remain trapped with the bilayer. 
Intermediate drugs with a log P of 1.7-5, partition between the bilayer and aqueous phase 
resulting in rapid loss from the liposome (Gregoriadis, 1973). 
 
 
Figure 1.5: Liposome structure in aqueous media summary. 
The lipid bilayer is arranged so that the aqueous head group is in contact with the aqueous 
media and the lipid tails are contained within the bilayer. Hydrophilic drug is contained within 
the core whilst hydrophobic drug is encapsulated within the bilayer. Surface properties may be 
modified with the attachment of polymeric groups at the bilayer surface. 
 
Topically applied liposomal formulations are an effective delivery system for the treatment of 
skin diseases. In the treatment of health related dysfunctions, it is desirable that the drug 
reaches its site of action at the therapeutic dose range and remains constant over a sufficiently 
long period of time to elicit an effect. Liposomal formulations provide sustained drug levels in 
the dermis whilst reducing the incidence of undesirable side effects arising from systemic 
administration and enhanced systemic absorption of drug after topical application with 
permeation enhancers which irreversibly disrupt the SC (du Plessis et al., 1994a; Park et al., 
2013).  
  
1.3.1 Lipids  
Phospholipids are the most important component in liposomes. They consist of two 
hydrocarbon tails joined to a polar head group with a glycerol backbone. The choice of the 
head and tail groups will inform the type, size and charge of aggregate formed in polar solvents. 
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Further, the formation of structures depends on lipid concentration, temperature, and 
electrostatic and electrodynamic interactions of polar lipids with the solvent and solute 
molecules. The choice of lipid employed determines the release profile of the drug, lipids with 
higher transition temperatures are more rigid thus providing slower drug leakage from the 
liposome (Szoka Jr and Papahadjopoulos, 1980).  
 
When selecting lipids for liposome composition, it is necessary to consider that phospholipids 
form smectic (liquid crystal) mesophases that undergo a characteristic gel-liquid crystalline 
phase transition. The phase transition temperature is the temperature at which the lipid 
changes from being in the ordered gel phase in which the hydrocarbon chains are closely 
packed, to the disordered liquid crystalline phase in which there is no order and they are fluid. 
Vesicles composed of phospholipids below this transition temperature are considered "solid" 
whereas above this temperature they are considered fluid (Chapman, 1975; Lee, 1975; 
Melchior and Steim, 1976).  Controlling the transition temperature of the lipid is useful as it can 
help determine the properties of the liposome (Szoka Jr and Papahadjopoulos, 1980). As the 
transition temperature increases a more rigid liposome structure is achieved allowing for less 
drug leakage and sustained release properties. The transition temperature is influenced by the 
hydrocarbon chain length, charge, degree of unsaturation, and the head group. As chain length 
increases, more energy is required to disrupt the ordered packing due to the increase in 
strength of the van der Waals interaction between the phospholipids whereas the double bond 
in unsaturated chains puts a kink in the chain which requires less energy to disrupt ordered 
lipid arrangements (Szoka Jr and Papahadjopoulos, 1980). 
 
Lipids can be classified as either non-polar or polar (Fahy et al., 2011). Polar lipids can be 
further sub divided as shown in Table 1-2 (Phan and Tso, 2001). 
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Table 1-2: Classification and attributes of polar lipids 
 
 
The molecular shape of an amphiphile influences its geometrical packing properties in a given 
solution environment which governs the type of aggregate produced (Figure 1.6). Mismatched 
lipids used to form the bilayer can create voids which may be exploited for the inclusion of a 
hydrophobic drug in the liposomal bilayer (Ali et al., 2013).  
 
 
 
Figure 1.6: Lipid shape influence on lipid aggregate formation. 
Lipid shape determines the type aggregate formed in aqueous media (adapted from 
(Proceedings of the National Academy of Sciences of the United States of America, 2014)). 
 
•Insoluble in water, do not swell in water 
•Form unstructured oil phase or crystals in water, not micelles 
•Triglycerides, long chain fatty acids, long chain fatty alcohols, 
cholesterol
Class 1
•Insoluble in water, do swell
•Form liposomes
•Phospholipids
Class 2 
•Some solubility in bulk phase, unstable surface films 
•Form micelles (no aqueous core) 
•Most anionic, cationic and non-ionic surfactants (polysorbates)
Class 3
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The shape of a lipid can be expressed as its critical packing parameter (p). It is a ratio of 
hydrophobic tail volume v, head group area, and chain length (Cullis et al., 1986; Nagarajan, 
2002) (Equation 1.1).  
 
Equation 1.1: critical packing parameter (p) 
 
𝑝 =
𝑣
𝑎0𝑙
 
where v is the molecular volume of hydrophobic part of polar lipid, ao is the surface area per 
molecule at hydrocarbon water interface and l is the length of hydrocarbon region 
 
Cholesterol is usually included in the liposome membrane (Ali et al., 2013; Doolittle and Chang, 
1982; Liu and Krieger, 2002). It provides rigidity to the liposome by modulating the membrane 
elasticity, fluidity, and permeability. It plugs gaps in the bilayer created by imperfect packing of 
the lipids (Papahadjopoulos and Kimelberg, 1974; Papahajdopoulos, 1976). However it can 
cause stability issues for lipid based drug products as it is readily oxidized (Szoka Jr and 
Papahadjopoulos, 1980). 
 
Phosphatidylcholine (PC), derived from both natural and synthetic sources is a common 
phospholipid employed in liposomes. At neutral pH, PC is uncharged (zwitter-ionic) (Mashaghi 
et al., 2012). It can form structures consisting of one or multiple concentric lipid bilayers termed 
unilamellar (small or large termed SUV’s and LUV’s correspondingly) or multilamellar (MLV’s) 
respectively with a size range from 25 nm to several micrometres (Figure. 1.7) (Szoka Jr and 
Papahadjopoulos, 1980). MLV’s are formulated following rehydration and shaking whilst SUV’s 
require the additional step of sonication. MLV’s can offer a depot effect for release of 
hydrophilic substances for example, acyclovir (Jain et al., 2005), SUV’s have a better bio 
distribution of drugs and LUV’s have a good entrapment efficiency of hydrophilic drugs (Szoka 
Jr and Papahadjopoulos, 1980). 
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Figure 1.7: Diagram of liposome subtypes  
Formulation parameters determine formation of multilammellar (MLV), large unilammellar 
(LUV) and small unilammellar (SUV) vesicles.  
 
Skin permeation and skin retention has been found to decrease with the amount of PC in 
formulations for both hydrophilic and hydrophobic drugs (microemulsion > micelles > 
transfersomes > liposomes). A lipophilic drug would have a higher skin permeability when 
incorporated into a system containing mainly hydrophilic excipients. Skin retention, however, 
has not been found to be affected by the drug hydrophilicity to the same extent as skin 
permeability. Furthermore, occlusion increased both skin retention and skin permeation for 
model drugs (Ferderber et al., 2009). 
 
1.3.2 Topical liposomes  
Liposomes can be very useful for topical drug delivery as the bilayer structure is similar to 
natural membranes allowing them to fuse (Laouini et al., 2012). Topical liposomes may serve 
as a solubilisation matrix, as a local depot for sustained release of dermally active compounds, 
as penetration enhancers, or as rate-limiting membrane barrier for the modulation of systemic 
absorption of drugs. Advantages of using liposomes as a drug in topical drug formulations 
include reduced irritation and side effects and improved drug targeting (Egbaria and Weiner, 
1990). Further, they have a moisturizing effect which can aid transdermal drug delivery 
(Laouini et al., 2012). Skin permeability of encapsulated drug is affected by the vesicle 
structure, size (Verma et al., 2003), membrane fluidity, and the type of anchored polymer (Park 
et al., 2013). 
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Liposomes are useful in the topical delivery of lipophilic drugs as they can be contained in the 
lipid bilayer. A depot effect is formed in the SC liposome by way of transformation into planar 
lipid bilayers or multilayer structures from which sustained release into the dermis can take 
place (Fig. 1.8) (Vázquez-González et al., 2014). A study comparing liposomal formulations 
compared to solutions observed a reduction of percutaneous absorption of hydrocortisone 
from the liposomal formulation (du Plessis et al., 1994a). These vehicles act 
as transdermal permeation enhancers without the use of additional permeation enhancers 
(Shakeel et al., 2010). 
 
Figure 1.8: Representation of how conventional liposomes may interact with the skin 
(a) initial application, (b) liposome deformation (c) planer layer formation. Adapted from 
(Vázquez-González et al., 2014). 
 
1.3.3 Deformable liposomes 
Deformable liposomes are an innovative approach for the non-invasive delivery of active 
pharmaceuticals. These carriers can transport agents through intact skin by changing their 
shape to be able to fit through a pore size smaller than their original diameter and then reform 
to their original shape and size once they have passed through the pore (Figure 1.9). This 
ability depends on the self-regulating carrier deformability which surpasses that of the related 
but not optimized lipid aggregates by several orders of magnitude. Conventional lipid 
suspensions, such as standard liposomes or mixed lipid micelles, do not mediate a systemic 
biological effect upon epicutaneous applications. Conversely, deformable liposomes are able 
to transport therapeutic amounts of molecules into the body. This process can be nearly as 
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efficient as an injection needle, as seen from the results of experiments in mice and humans 
using such liposomes as insulin-carrying vesicles (Cevc et al., 1998). 
 
 
Figure 1.9: Deformable liposome movement thought the intact stratum coreum into the dermal 
layer 
 
 
Deformable liposomes include single chain surfactants that have a high radius of curvature 
(examples include sodium cholate, Span 65, and Tween 80 (Cevc, 1996; Ita et al., 2007; Oh 
et al., 2006). This extra component destabilizes the vesicle bilayers by reducing the amount of 
work required to expand the interface allowing the liposome to become more elastic thus 
increasing the flux across the skin (Cevc, 1996; Ita et al., 2007; Oh et al., 2006). By being able 
to change shape and volume at minimal energetic cost these structures may even penetrate 
across hydrophilic pathways of intact skin (Romero and Morilla, 2013a) across the SC to reach 
the viable epidermis (Warner and Lilly, 1994). Cevc et al., suggested it may be based on 
concentration intensive, hydrogen based transepidermal gradient. Further it was shown that, 
modifying the chemical composition of bilayers to decrease the Young’s modulus (stress to 
strain ratio used to describe the stiffness of an elastic material) the resulting deformable 
liposomes were able to penetrate the SC (Cevc, 1996; Romero and Morilla, 2013a). 
Additionally, it has been observed that such carriers to the skin may induce changes in the SC 
resulting in the formation of pores ranging between 50 and 200 nm. This phenomenon is 
observed as deformable liposomes are able to intercalate into the lipid matrix causing enlarged 
pores thereby increasing the permeation ability of the drug. Deformable vesicles have already 
been successfully employed in transdermal delivery of anti-inflammatory agents, plasmid DNA 
and anti-tumour agents (Cevc and Vierl, 2010; Romero and Morilla, 2013a) 
 
Deformable liposomes have also been produced using nonionic surfactants (L-595 and PEG-
8-L with sulfosuccinate as stabilizer) (van den Bergh et al., 1999). These liposomes have been 
found to quickly partition into the SC, through a fine meshwork of thread-like channels 
(Honeywell-Nguyen et al., 2002). The liposomes remain in the SC where the drug is released 
and do not penetrate into the deeper skin layers (Honeywell-Nguyen and Bouwstra, 2003). 
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However, only mechanistic, not preclinical applications have been studied (Romero and 
Morilla, 2013b). 
 
Celecoxib applied topically is an effective skin cancer prevention technique, further it has been 
found to improve anticancer drug effectiveness in tumour treatment. An investigation into the 
use of liposomes, transfersomes and ethosomes, containing suitable edge activators as 
penetration enhancers found all formulations improved the drug penetration into the skin with 
respect to an aqueous suspension (Bragagni et al., 2012).  
 
Ketoconazole is a lipophilic drug with a large molecular weight of 531.44 Da and a low aqueous 
solubility of 0.04 mg/mL. It has a poor transdermal delivery profile. Elastic vesicles formulated 
with Span 60 and Tween 80 have showed significantly higher skin penetration and retention 
compared with free drug suspension. Incorporation into a hydrogel showed a significant 
retention which was even more than the market formulation. The results of the present study 
indicate that such elastic liposomes can be used to enhance skin delivery of the model high 
molecular weight and poorly water-soluble drug ketoconazole (Kakkar and Pal Kaur, 2013).  
 
1.3.4 Ethosomes 
Ethosomes are a form of liposomes prepared with ethanol. In comparison to liposomes, 
ethosomes are less rigid allowing them to penetrate more easily into deeper layers of skin. The 
ethanol can increase the solubility of the drug in the liposome and disturb the packing of the 
SC lipid bilayer therefore behaving as a drug permeation enhancer. Further, the high ethanol 
content results in a negative zeta potential therefore these liposomes have an increased 
stability with some studies finding that the average size remains constant for at least 2 years 
at room temperature (Laouini et al., 2012; Touitou et al., 2000). 
1.3.5 Liposome preparation techniques   
When a lipid mixture is first introduced into a polar liquid, it will first form a monolayer at the 
air-water interface. As the concentration increases aggregates in which the tails do not have 
interaction with the polar solvent are formed. The concentration at which aggregates begin to 
form is termed the critical micelle concentration and is influenced by lipid tail length and 
surfactants used (Ali et al., 2010; Mohammed et al., 2004; Szoka Jr and Papahadjopoulos, 
1980). There are a range of different methods used to prepare liposomes including freeze 
drying, extrusion method, hydration of a thin film, reverse-phase evaporation technique and 
the solvent injection technique.  
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1.3.5.1 Freeze dying method  
After dissolving the lipids in chloroform and mixing in the desired ratio the organic solvent must 
be removed by purging the system with nitrogen. The mixture must be re-suspended in 
cyclohexane which is then frozen. This must then quickly be placed in a high vacuum system 
until completely dry and a white powder is produced. This is readily suspended in water thus 
producing liposomes (Cui et al., 2006; van Winden et al., 1997). 
 
1.3.5.2 Extrusion method 
Phospholipid and cholesterol are dissolved in an organic solvent and this suspension is forced 
through a polycarbonate membrane with a defined pore size to produce liposomes with a 
diameter similar to the pore size of the membrane used to prepare them (Laouini et al., 2012; 
Lapinski et al., 2007) 
 
1.3.5.3 Hydration of a thin lipid film 
This method was first developed in 1965 by Alec Bangham (Bangham et al., 1965). 
Phospholipid and cholesterol are dispersed in organic solvent which is removed by 
evaporation. A dry film is deposited on the flask wall which is then hydrated by adding an 
aqueous solution under agitation at temperature above the transition temperature. The greater 
the degree of agitation, the smaller the liposome size produced. Further size reduction 
techniques include sonication to obtain SUVs or extrusion through polycarbonate filters 
(Laouini et al., 2012). 
 
1.3.5.4 Reverse-phase evaporation technique 
The organic solvent is removed from the lipid solution by evaporation under reduced pressure 
forming a lipidic film. The system is purged with nitrogen to ensure there is no organic solvent 
left. The lipids are then re-dissolved in a second organic phase (usually diethyl ether and 
isopropyl ether).  An aqueous buffer is added producing large unilamellar and multilamellar 
liposomes. The organic solvent is again removed and the system is maintained under nitrogen. 
These liposomes can also contain large macromolecular assemblies effectively (Szoka and 
Papahadjopoulos, 1978). 
 
1.3.5.5 Solvent injection technique 
The lipid is dissolved in either ethanol or ether which is injected into a heated aqueous solvent 
forming liposomes with a narrow size distribution. The aqueous phase is heated to above the 
boiling point of the ether to ensure that upon injection of the organic phase the ether 
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evaporates. This produces primarily unilamellar liposomes (Laouini et al., 2012; Schubert and 
Müller-Goymann, 2003). 
 
1.3.6 Characterising liposomes   
1.3.6.1 Zeta potential  
The zeta potential (ζ) of a particle is the overall charge that a particle acquires in a particular 
medium. Zeta potential measurements give information about the difference in potential 
between the static layer and bulk media layer around a particle and how this is affected by 
changes in the environment for example the pH, presence of counter-ions, adsorption of 
proteins. Electrostatic interaction is an important force affecting the structure, stability, and 
function of liposomes (Sou, 2011). Furthermore, zeta potential can also be used to determine 
the type of interaction between the active substance and the carrier; i.e. whether the drug is 
encapsulated within the body of the particle or simply adsorbed on the surface (Laouini et al., 
2012).  
 
1.3.6.2 Liposome size 
Several techniques are available for determining liposome size and size distribution including 
microscopy techniques, size-exclusion chromatography (SEC) and static or dynamic light 
scattering (DLS) measurements. 
 
Electron microscopy can offer important information on liposome preparations since they yield 
a view of morphology and can resolve particles of varying size. However, sample preparation 
requires removal of liposomes from their native environment and such procedures can cause 
shrinkage and shape distortion (Sternberg et al., 1994). 
 
Use of HPLC-SEC can provide information on liposome population size distribution. However, 
use of HPLC for such size determination can destroy the liposome due to  adsorption of lipids 
on to the column (Laouini et al., 2012).  
 
Dynamic light scattering (DLS) is also used in liposome size distribution analysis (Szoka Jr and 
Papahadjopoulos, 1980). The sample is placed in front of a light source and as the light hits 
the small particles it scatters. The Brownian motion of the particles causes time-dependent 
fluctuation in the scattering intensity and this causes a constant change in the distance 
between particles. Analysis of this fluctuation produces information on particle size. The 
sample does not need to be modified prior to analysis and this technique is sensitive to small 
quantities of high molecular weight aggregate (Laouini et al., 2012). 
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1.3.6.3 Confocal laser scanning microscopy 
Confocal laser scanning microscopy (CLSM) uses an increased optical resolution and contrast 
of a micrograph to enable the reconstruction of three dimensional structures. This imaging 
technique uses point illumination and a spatial pinhole to eliminate out-of-focus light in 
specimens. CLSM can be used to determine the extent of liposomes penetration into the skin 
(Verma et al., 2003). Fluorescent labels are added to the liposome, when light hits the sample 
these fluoresce and this is what is then detected. Thus this technique does not provide 
information about the permeation of the entire liposome, but only about the penetration of the 
fluorescent label (van Kuijk-Meuwissen et al., 1998). 
 
1.3.6.4 Encapsulation efficiency  
Liposome preparations consist of encapsulated and un-encapsulated drug. To determine the 
encapsulation efficiency the encapsulated drug and the free drug must be separated. Several 
separation techniques have been reported including the mini-column centrifugation and the 
use of a dialysis membrane with a corresponding cut-off size. Following separation the lipid 
bilayer is disturbed with methanol or Triton X-100 and the released drug can then be measured 
(Laouini et al., 2012). 
 
1.3.6.5 Stability   
Studies on the stability and the effective storage of liposomes preparations are areas of 
research assuming increasing importance in liposomal preparation development. Stability 
encompasses a number of parameters including the chemical stability of the lipids, 
maintenance of liposome size, examination for aggregation, maintenance of liposomal 
structure, retention of entrapped drug as well as the influence of biological fluids on the integrity 
and permeability properties of the liposomes. Therefore stability protocols evaluating these 
interactions over a period time must be developed and carried out (Laouini et al., 2012; Szoka 
Jr and Papahadjopoulos, 1980).  
 
A formulation should maintain its physical integrity and the chemical integrity of the drug. The 
average size distribution of liposomes increases during storage (Szoka Jr and 
Papahadjopoulos, 1980). Systems tend to decrease the total free energy to reach a more 
thermodynamically favourable state thus liposomes will aggregate to reduce the interfacial 
area and fuse into bigger structures. This can affect how the liposome will distribute in the body 
and could potentially cause drug leakage (Sabın et al., 2006). The presence of excess or bulk 
water can lead to degradation via hydrolysis. This is influenced by temperature, buffer species, 
pH, head group and hydrocarbon chain length. The phospholipids used in liposome 
formulations are often derived from biological sources and contain polyunsaturated fatty acids. 
43 
 
These undergo oxidative reactions which can alter the permeability of the bilayer (Szoka Jr 
and Papahadjopoulos, 1980). Saturated lipids are less prone to oxidation. Further, the drug 
may interact with the lipids used affecting either the chemical stability of the drug or the 
liposome.  
 
1.4 Gel formulations for topical and transdermal delivery 
Due to the liquid nature of liposome preparation, an appropriate vehicle must be selected to 
increase preparation viscosity, for example using creams or gel based formulations. 
Liposomes have been confirmed to be compatible with viscosity increasing agents including 
gelling polymers (Foldvari, 1996; S˘ kalko et al., 1998). 
 
A gel is a semi-solid jelly-like substance that can display properties ranging from hard and 
tough to soft and weak. Gels can further be defined as a dilute cross-linked system, exhibiting 
no flow in the steady-state (Ferry, 1980). By weight, gels are mainly liquid, however due to a 
three-dimensional cross-linked network, they behave like solids. The crosslinked polymer 
within the fluid gives the gel its structure and contributes to the adhesive stick. Thus gels are 
a dispersion of molecules of a liquid within a solid network in which the solid is the continuous 
phase and the liquid is the discontinuous phase. 
 
Aqueous semi-solid polymeric gels, such as those based on hydroxyethylcellulose (HEC) and 
hydroxypropyl methylcellulose (HPMC) are often used in transdermal drug delivery and are 
useful in designing controlled delivery formulations (Ghosal and Nanda, 2013; Valenta and 
Auner, 2004). Both are cellulose derivatives and have limited solubility for poorly water-soluble 
compounds (Forbes et al., 2011a; Gupta et al., 2002). These gels are polymeric networks 
already swollen to equilibrium, and the further addition of fluids results in dilution of the 
polymeric network (Figure 1.10). These gels may also develop a small degree cross-linking 
due to a gain in energy under the influence of shear forces, however these are weak, reversible 
physical forces (Gupta et al., 2002). Drug release from gels usually occurs through the process 
of diffusion, or swelling caused by water penetration into the polymer followed by diffusion 
(Kajihara et al., 2001; Mashak and Rahimi, 2009). Additionally aqueous gels are easy to spread 
therefore suitable for topical application due to their pseudoplastic nature (a decrease in 
viscosity as the rate of shear stress increases) (Forbes et al., 2011a). 
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Figure 1.10: Aqueous gel structure 
The polymer networks swell following addition of fluid (modified from Gupta, et al., 2002). 
 
Ideally the polymer should be stable, non-reactive with the drug, easily manufactured and 
fabricated into the desired product, whilst being inexpensive. Additionally, polymer properties 
(including the molecular weight and glass transition temperature) should be such that the drug 
diffuses through it and is released appropriately. The polymer should exhibit biocompatibility 
and chemical compatibility with drug and excipients, whilst providing consistent and effective 
delivery of a drug throughout the product's life (Keith, 1983). 
 
Drugs administered by the topical route are limited by the SC layer, although topical gels may 
enhance drug delivery through the skin (Valenta and Auner, 2004). Gels consist of one phase 
and can either be hydrophilic hydrogels or lipophilic lipogels (Valenta and Auner, 2004). 
Hydrophilic gels are polymers with a linear structure formed by long-chain monomer units 
linked by covalent bonds. Further interactions such as hydrogen bonds or Van der Waals 
forces contribute to achieve the three-dimensional structure which bind the solvent to the 
polymeric network (Gupta et al., 2002; Valenta and Auner, 2004; Vilar et al., 2012). The 
majority of drugs formulated as gels do not pass the skin and act on the surface of the 
epidermis, although this does depends on the physiochemical properties of the drug (Valenta 
and Auner, 2004). 
  
5-FU is formulated as a cream but is associated with skin irritation, poor skin permeation and 
retention at the target site. A liposomal gel has been investigated for the delivery of 5-FU with 
Carbopol 934P used as the gelating agent (Puri and Jain, 2012). An in vitro skin permeation 
and deposition study found an increase in the amount of drug deposition and a larger reduction 
in tumour density with the gel formulation in comparison with the cream. Further the gel was 
found to be less irritating. Thus it is clear a liposomal gel may be beneficial in the delivery of 
chemotherapeutic compounds for the local treatment of NMSC as it can be developed to 
provide a suitable release of drug whilst being patient friendly.  
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1.5 Models of skin absorption 
1.5.1 In silico approaches 
Dermal absorption is a multi-factorial multi-step process, affected by many factors including 
the type of skin, skin pre-treatment, physicochemical properties of the drug and delivery 
systems, as well as environmental factors. It is notable that in some cases, the 
pharmacodynamic effect and absorption profiles are higher than could be presumed from in 
vitro permeation data. This may be as a result of efficient clearance of the penetrant by skin 
microcirculation (Godin and Touitou, 2007). Tissue culture human skin and epidermis 
equivalents generally possess lower barrier characteristics than human skin, making them 
questionable for permeation studies. In vitro permeation experiments despite their limitations, 
provide important tools for screening drug delivery systems, skin permeation enhancers and 
drug delivery carriers  
 
In vitro skin permeation studies are frequently performed for screening of molecules and drug 
carrier systems aimed at optimising dermal or transdermal delivery. Therefore, one of the main 
objectives of in vitro permeation studies is prediction of in vivo absorption. A number of reports 
present attempts to mathematically correlate or predict from in vitro permeation data to in vivo 
drug levels based on a diffusion model (Guy and Hadgraft, 1985; Touitou et al., 1988; 
Yamashita et al., 1994) or a convolution technique (Sato et al., 1988).  
 
Mathematical modelling of percutaneous absorption of a compound is often applied in an 
attempt to predict or extrapolate data. Unfortunately, a great number of these interactions is 
nonlinear, making mathematical modelling of percutaneous absorption problematic. Since the 
main hindrance of skin permeation of a drug lies in the SC layer, Fick's diffusive law’s are 
generally accepted to describe skin transport of drug (Godin and Touitou, 2007).  
 
Mathematic relationships become more complicated when considering a broad variety of 
molecules (especially highly hydrophilic ones) due to the heterogeneity of skin structure having 
at least two parallel diffusion patterns (polar and nonpolar) (Godin and Touitou, 2007).  
 
Fick's first law can be used to describe diffusion (Equation 1.2).  
Equation 1.2: 
J =  −D
∂C
∂X
 
where C is the donor concentration, D is the diffusion coefficient, J is the rate of transfer per 
unit area (flux) and X is the area. J is a multiple variable and can be expressed as the mass 
moved per unit time. Therefore Fick’s Second Law can also be used to express drug movement 
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across the skin as it predicts how diffusion causes the concentration to change with time 
(Equation 1.3). 
Equation 1.3: 
∂C
∂t
=  (D
𝜕2C
∂𝑋2
) 
where t is time 
 
For steady state flux (sink conditions) further equations can be used to describe drug 
movement across the skin (Equation 1.4 and 1.5). According to this law, diffusion is assumed 
to be the mass transfer of individual solutes, driven by random molecular movement and the 
rate of transport  
Equation 1.4: 
𝜕𝐶
𝜕𝑡
=   𝐾 × 𝐷 × 𝐶/ℎ 
where h is the thickness of the barrier and K is the partition coefficient. 
Equation 1.5 
Dm
dt
=
DA𝐶𝑠
h
 
 
Where m is mass and Cs is the concentration in donor solution. 
 
1.5.2 In vitro approaches  
1.5.2.1 Franz cell 
When designing a study to investigate skin permeation an appropriate mathematical model 
used to characterise permeation and diffusion apparatus used to conduct the study needs to 
be selected. An important in vitro permeation method is the Franz diffusion cell (Figure 1.11) 
and it consist of three components; the donor compartment where the drug is uniformly applied, 
the membrane (synthetic membrane (Cevc et al., 1998), animal skin or human skin (Aungst, 
1989)) and a receptor solution (El-Kattan et al., 2000). 
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Figure 1.11: Franz cell diagram 
Franz cell apparatus used in in vivo studies to observe drug diffusion from a formulation across 
a membrane into a receiver compartment filled with appropriate media. 
 
The topical formulation would be applied to the membrane and samples can be taken from the 
sampling port at different time points to determine flux of drug across the membrane. When 
the drug is intended to be delivered topically the use of the franz cell is useful to investigate 
the quantity of drug that moves into the systemic circulation.  
 
An additional method to determine drug levels in different layers of the skin the stripping 
method can be used. A skin patch is mounted on a board and a piece of adhesive tape is used 
to strip the skin. Each strip is then analysed for drug (du Plessis et al., 1994b). 
 
1.5.2.2 Cell culture techniques  
With an increasing desire to limit animal and human exposure to drug testing, cell culture 
provides an excellent model system for studying the effects of pharmaceuticals on cells.  
It is useful in drug screening and development and is useful in providing consistent and 
reproducible results from a batch of cells and may help limit animal and human exposure to 
drug testing. Additionally, there are significant differences in between human and animal skin 
for example it is known the lipid composition is not akin (Pappinen et al., 2008). 
 
Cells are removed from human tissue and grown in controlled conditions. Cells are removed 
directly from the tissue and disaggregated (enzymatically or mechanically) before cultivation, 
or are derived from an already established cell line. Cell lines derived from primary cultures 
have a limited life span. As cells are passaged, those with the best growth capacity 
predominate resulting in a degree of genotypic and phenotypic uniformity in the population.  
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Each cell type will require its own culture conditions. Usually the artificial environment will 
contain a substrate or medium that supplies the essential nutrients (amino acids, 
carbohydrates, vitamins, minerals), growth factors, hormones and gases (O2, CO2).  
Cells may be stored at temperatures below –130°C (cryopreservation) with an appropriate 
protective agent (e.g., DMSO) until required.  
 
Skin models have been used to predict skin permeation. In a comparative study, organotypic 
cultures of both transformed and native dermal and epidermal cells were used for permeation 
studies for a cream and gel formulation containing ibuprofen acid. Results were compared with 
excised human SC. Studies using excised human stratum corneum showed differences in drug 
permeability for these two formulations which were also observed with the native organotypic 
cultures. Organotypic cultures showed a higher permeability for topically applied preparations 
than excised human stratum corneum (Specht et al., 1998). 
SC intercellular lipid composition and organisation of human skin models differ to some extent 
from that of human SC ex vivo, resulting in the models exhibiting less pronounced barrier 
properties, together with increased hydration of the outermost SC layers. These features may 
explain the differences observed in vehicle effects in human skin ex vivo versus human skin 
models (Dreher et al., 2002). However due to the homogeneous structure of the SC and the 
lack of special structures present in human skin, like hair follicles, glands and sebum lipids, 
cell culture models might be useful for an estimation of the importance of such structures on 
drug permeation and effects of different formulations particularly in an early stage of evaluation 
(Kuntsche et al., 2008). 
Whilst cells cultured from animal models may be useful, they are with limitations. The dermal 
drug delivery of various lipid nanoparticle formulations on human skin and rat organotypic cell 
culture was investigated. Potential alterations of SC lipid domains were studied using 
fluorescence assays with labelled liposomes and thermal analysis of isolated SC. The results 
of the permeation and DSC studies differed distinctly in human skin and the rat organotypic 
culture models. Therefore, it is important to use human cells in culture studies (Kuntsche et 
al., 2008).  
Human Dermal Fibroblasts, adult (HDFa) are primary human dermal fibroblasts isolated from 
adult skin, cryopreserved at the end of the primary culture. This cell line has previously been 
used in studies concerning the development of targeted formulations for anticancer drugs (Liu 
et al., 2007; Wadajkar et al., 2012) for example new magnetic-based core–shell particles 
(MBCSPs) developed to target skin cancer cells while delivering chemotherapeutic drugs in a 
controlled fashion (Wadajkar et al., 2012). Human immortalized keratinocytes cells (HaCaT) 
are a spontaneously transformed aneuploid immortal keratinocyte cell line from adult human 
skin, used widely in scientific research. HaCaT cells are utilized for their high capacity to 
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differentiate and proliferate in vitro. This cell line has previously been used in the development 
of targeted skin delivery formulations for example photoinduced intracellular controlled release 
drug delivery from gold-capped mesoporous silica nanospheres (Vivero-Escoto et al., 2009).  
 
1.6 Novel compounds for the treatment of skin cancer  
1.6.1 MTL-004 
Morvus (Morvus Technology Ltd © 2013,) has developed MTL-004 [5-(Aziridin-1-yl)-4-
hydroxylamino-2-nitrobenzamide], a low-molecular weight (238 g/mol) compound that has 
been demonstrated to show a lack of systemic toxicity whilst having no effect on slowly dividing 
(normal) cells. The cytotoxic effect of MTL-004 requires cell division thus there is little effect 
on non-dividing cells in normal adjacent tissue. Synthesis of hydroxylamine compounds such 
as MTL-004 is conventionally associated with low yields and potentially explosive reactions. 
However, Morvus have developed a simple method suitable for the large scale preparation of 
MTL-004 from a commercially available precursor (Knox et al., 1993). MTL-004 is obtained as 
a stable yellow powder.  
 
This agent can be applied as a cream for skin cancers. Such administration will deliver the 
cross-linking agent MTL-004 directly to the tumour to be treated, causing damage to the tumour 
cells, which will die once they enter the dividing phase (Anlezark et al., 1992).  
 
MTL-004 is the active form of the prodrug Tretazicar, that is reduced to the cytotoxic 
bifunctional alkylating agent MTL-004 when in the presence of an endogenous enzyme 
following the mechanism shown in Figure 1.12 (Anlezark et al., 1992). At first, Tretazicar 
appeared to represent the ideal vision of cancer chemotherapy; a simple, low molecular weight 
tumour selective compound able to treat tumours with minimal toxic side-effects. Unfortunately, 
while the drug proved very effective in rat models, it was not active against human cancers 
(Gusterson et al., 1997).  
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Figure 1.12: Mechanism of action of MTL-004. 
This hydroxylamine derivative can react with thioesters to produce a DNA reactive species. It 
is postulated that this is the N-acetoxy derivative. Formation of the amine is in competition with 
reactions with DNA (Knox, 2012). 
 
MTL-004, however, had been previously disregarded as an anti-tumour agent in its own right, 
as it is rapidly deactivated in serum by serum proteins thus cannot migrate far from the site of 
administration (Knox et al., 1988). However, it remains that MTL-004 has two main advantages 
over conventional treatments: a lack of systemic toxicity and lack of toxicity to normal cells. 
Therefore, Morvus believe that MTL-004 has considerable potential as a topical skin cancer 
treatment. 
 
The formation of DNA interstrand crosslinks is responsible for the high cytotoxicity of MTL-004 
(Anlezark et al., 1992). The interstrand crosslinks are formed with a very high frequency and 
can contribute up to 70% of the total lesions (Boland et al., 1991; Friedlos et al., 1992). The 
interstrand crosslink is, in terms of molar efficacy, a more intrinsically toxic lesion than single-
strand di-adducts and monofunctional lesions. Furthermore, the crosslinks are poorly repaired 
which may cause them to be even more intrinsically cytotoxic than those induced by other 
difunctional agents (Boland et al., 1991; Friedlos et al., 1992). Additionally, the frequency of 
cross links is much higher than that reported for most other agents. For example, interstrand 
crosslinks represent 2% or less of the total DNA reactions of Cisplatin or Carboplatin (Knox et 
al., 1986).  
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Further, it is advantageous because the compound is deactivated by serum proteins therefore, 
should the drug permeate through the skin, there would be no systemic toxic side effects. 
These properties may be useful in the development of a topical skin cancer treatment.  
 
1.6.2 Flavonoids  
Flavonoids are a widely distributed group of polyphenolic compounds characterized by a 
common benzo-pyrone structure. Flavonoids may be further categorised into flavonols, 
flavones, flavanones, isoflavones, flavonols, and anthocyanidins. These compound occur 
naturally in fruits and vegetables, mainly as flavonoid glycosides, and are thus important 
constituents of the human diet (Semalty et al., 2010b).  
 
Flavonoids may be useful in chemoprevention and chemotherapeutic treatment whilst 
possessing the additional advantages of having good anti-inflammatory activities, free of 
harmful side-effects and to the skin (Jaeger et al., 1988; Middleton Jr, 1998). Specific 
oncogenic pathways can be associated with significant changes in the tumour 
microenvironment. The tumour microenvironment is a complex system of many cell types, 
including endothelial cells and their precursors, pericytes, smooth-muscle cells, fibroblasts of 
various phenotypes, myofibroblasts, neutrophils and other granulocytes, mast cells, T, B and 
natural killer lymphocytes, and antigen presenting cells such as macrophages and dendritic 
cells. These cells are all able to affect tumour progression. Control of the immediate 
microenvironment of a developing tumour may therefore be as vital as control of the 
dysfunctional cells within the tumour (Albini and Sporn, 2007). Several possible agents, 
including flavonoids, which can potentially inhibit some of these targets have been identified 
(Casey et al., 2015; Gupta et al., 2004). 
 
Curcumin is a flavonoid isolated from turmeric that has been found to have a positive effect in 
the treatment of a range of cancerous tumours (Kunnumakkara et al., 2008). A study to 
investigate the growth inhibition of curcumin on melanoma cells, treated three types of 
melanoma cell lines (A375, MV3 and M14) with varying concentrations of curcumin for 24, 48, 
72 and 96 hours. The control cell line used was normal human lung fibroblast cell line MRC- 
5. MTT assays were conducted to evaluate cell proliferation. Curcumin-induced growth 
inhibition was observed to be both time- and dose-dependent in the melanoma cells. The IC50 
doses of curcumin for cultured melanoma cells (A375, MV3 and M14) at 48 h were 8.29, 18.29 
and 14.25 µM, respectively. No significant growth inhibition was observed in MRC-5 cells at 
5–30 µM, under similar conditions showing that curcumin at lower concentrations is able to 
selectively inhibit the growth of melanoma cells without affecting normal cells (Jiang et al., 
2015). 
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Berberine, a compound isolated from plants such as Berberis, has been reported with many 
pharmacological effects related to anti-cancer and anti-inflammation capabilities (Peng et al., 
2006). A study observing the effects of berberine on small cell lung cancer found berberine 
exerted a dose- and time-dependent inhibitory effect on the motility and invasion ability of a 
highly metastatic A549 cells under non-cytotoxic concentrations. This suggests that berberine 
possesses an anti-metastatic effect in non-small lung cancer cell and may, therefore, be helpful 
in clinical treatment (Peng et al., 2006). Additionally, the effects of berberine, on human 
melanoma cancer cell migration and the molecular mechanisms underlying these effects using 
melanoma cell lines, A375 and Hs294 has been studied.  The treatment of A375 and Hs294 
cells with berberine resulted in concentration-dependent inhibition of migration of these cells, 
which was associated with a reduction in the levels of COX-2, PGE2 and PGE2 receptors. Cell 
migration is an essential step in invasion and metastasis thus these results indicate for the first 
time that berberine may have a vital role in the inhibition of cancer progression (Singh et al., 
2011b). 
 
Epigallocatechin gallate (EGCG) is a polyphenolic catechin that has been found to have 
cytotoxic effects in cancerous skin cells as well as cancerous cells in the colon (Chen et al., 
2003; Hwang et al., 2007; McLoughlin et al., 2004), pancreas (Shankar et al., 2008), lung 
(Yang et al., 2002), prostate (Singh et al., 2011a) and breast carcinomas (Singh et al., 2011a). 
Additionally, it may increase the efficacy of chemotherapeutic treatment as well as have chemo 
protective effects (Chen et al., 2003; Gupta et al., 2004; Hwang et al., 2007; McLoughlin et al., 
2004; Shankar et al., 2008; Siddiqui et al., 2009; Yang et al., 2002). The anti-cancer properties 
of EGCG are extensively supported by results from epidemiological, cell culture, animal and 
clinical studies. EGCG is a known antioxidant able to suppress the inflammatory processes 
that lead to transformation, hyperproliferation, initiation of carcinogenesis as well as 
suppressing the final steps of carcinogenesis (namely angiogenesis and metastasis) (Mukhtar 
and Ahmad, 2000; Thawonsuwan et al., 2010). 
EGCG has been recognised to suppress colonic tumorigenesis in animal models and 
epidemiological studies. After oral administration EGCG is retained in the gastrointestinal tract 
thus creating the potential to function as a chemo preventive agent against colon cancer. 
Human colorectal carcinoma HT-29 cells have been treated with EGCG to examine the anti-
proliferative and pro-apoptotic effects of EGCG, as well as the molecular mechanism 
underlying these effects. After 36 hours of treatment, EGCG was observed to inhibit HT-29 cell 
growth with an IC50 of approximately 100 µM. Additionally, HT-29 cells treated with doses 
higher than 100 µM showed apparent nuclear condensation and fragmentation. EGCG 
treatment also caused damage to mitochondria, and induced apoptotic cell death (Chen et al., 
2003).  
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Treatment of epidermal carcinoma A431 cells with EGCG (10-40 µg/mL) resulted in dose-
dependent inhibition of NF-kappa B/p65, induction of DNA breaks, cleavage of poly (ADP-
ribose) polymerase (PARP) and morphological changes consistent with apoptosis. Treatment 
of cells also resulted in significant activation of caspases and protein expression of caspase-
3, -8 and -9. This study found that EGCG-mediated activation of caspases was critical for cell 
subsequent apoptosis (Gupta et al., 2004). 
 
Naringenin is the predominant flavanone in grapefruit. It is an antioxidant, free radical 
scavenger, anti-inflammatory agent, and immune system modulator thus may be potentially 
useful as a pharmacological anti-cancer agent (Casey et al., 2015; Huang et al., 2011). 
A study investigating melanogenesis in murine B16-F10 melanoma cells observed exposure 
of cells to naringenin resulted in morphological changes accompanied by the induction of 
melanocyte differentiation-related markers, such as melanin synthesis, tyrosinase activity, and 
the expression of tyrosinase and microphthalmia-associated transcription factor. Additionally 
an increase in the intracellular accumulation of beta-catenin as well as the phosphorylation of 
glycogen synthase kinase-3 beta (GSK3 beta) protein was observed after treatment with 
naringenin. Moreover, the activity of phosphatidylinositol 3-kinase (PI3K) was up-regulated by 
naringenin since the phosphorylated level of downstream Akt protein was enhanced. Thus 
naringenin was found to induce melanogenesis through the Wnt-beta-catenin-signalling 
pathway (Huang et al., 2011). 
Additionally, naringenin is able to regulate fibrosis (Du et al., 2009; Lee et al., 2004). 
Fibroblasts and myofibroblasts play a critical role in the formation of the extra-cellular matrix 
and inducing fibrosis within growing tumours (Casey et al., 2015; Chtourou et al., 2015). Tissue 
fibrosis is frequently observed in the tumour microenvironment associated with rapid 
proliferation of fibroblast cells (Kalluri and Zeisberg, 2006; Kerkar and Restifo, 2012).  
A study observing the effect of naringenin on induced pulmonary fibrosis in mice found that 
increased fibrosis resulted in an increase in the incidence of lung cancer. Furthermore, 
naringenin was observed to significantly reduce lung metastases in mice with pulmonary 
fibrosis and increases their survival by improving the immunosuppressive environment through 
down-regulating transforming growth factor-β1 and reducing regulatory T cells. Therefore, 
naringenin may be an ideal therapeutic agent in the treatment of both cancer and fibrosis (Du 
et al., 2009). A study investigating the effect of naringenin on induced hepatic injury in rats 
observed naringenin to prevent the elevation of serum alanine transaminase, aspartate 
transaminase, alkaline phosphatase, and bilirubin levels. Naringenin also restored serum 
albumin and total protein levels, and reduced the hepatic level of malondialdehyde. These 
results exhibit naringenin displayed in vivo hepatoprotective and anti-fibrogenic effects against 
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liver injury suggesting suggests that naringenin may be useful in preventing the development 
of hepatic fibrosis (Lee et al., 2004). 
Additionally, naringenin can increase both tyrosinase activity and melanin content, indicating 
naringenin can be used to prevent oxidative skin damage (Chen et al., 2003; Huang et al., 
2011). In previous in vitro studies naringenin has been proven to be a good candidate for 
employment as a protective agent against photooxidative damage (Kootstra, 1994). An in 
vitro run-off transcription assay was used to determine if naringenin could prevent the 
accumulation of UV-B-induced DNA damage. Template plasmid DNA was irradiated with UV-
B light, which resulted in a decreased capacity to support transcription. Naringenin was 
observed to prevent the accumulation of DNA damage. The results support the hypothesis that 
flavonoids protect DNA from UV-induced DNA damage (Kootstra, 1994). Thus naringenin is a 
clear candidate for use in the development of a novel skin cancer formulation.  
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1.7 Aims and objectives  
The overall aim of this thesis was to formulate and characterise a drug carrier to deliver anti-
cancer agents into the dermal layer of the skin at a controlled rate. Aqueous gel systems 
loaded with deformable liposome preparations formulated with a surfactant were chosen as 
administration approaches/vehicles. The formulation of EGCG, naringenin and MTL-004 was 
considered.  
Chapter 2 concerns the basic development and characterisation of deformable liposomes. 
Liposomes were formulated with PC, cholesterol, and either Tween 80, Tween 20 or sodium 
cholate. The stability of these liposomes was observed over 28 days. The deformability of 
these liposomes was then calculated to observe the effect of the surfactant on elasticity of the 
liposome. An optimal formulation was then selected for application to fibroblast and 
keratinocyte cell lines to characterise toxicity and observe internalisation. 
Chapters 3, 4 and 5 concern liposomes formulated with either EGCG, naringenin or MTL-004 
respectively. Compound loaded deformable liposomes were developed and characterised. 
Release profiles of the compound from the liposomes formulated with and without surfactant 
was observed and compared. The aqueous gels HEC and HPMC were formulated with up to 
5% w/v of polymer and were then loaded with 1% w/w of compound. One compartment and 
two compartment release was then observed and compared. Aqueous gels loaded with 
liposomes containing compound formulated both with and without surfactant were then 
formulated and release observed. Compound and liposomal formulation were then applied to 
fibroblast and keratinocyte cell lines to characterise toxicity as well as cell localisation. 
All compounds were detected with High Performance Liquid Chromatography (HPLC) coupled 
with Ultra Violet (UV) analysis. HPLC methodology was developed for the detection of MTL-
004 and validated. HPLC methods were also validated for EGCG and naringenin. 
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2 Formulation development 
of elastic liposomes for 
controlled dermal drug 
delivery 
  
57 
 
2.1 Introduction 
The skin is a very efficient and effective physical barrier to the external environment.  The 
barrier function is, in part, a result of the multilayer anatomy, organised as the hypodermis, 
dermis and finally the non-vascularised epidermal layers which culminate in the stratum 
corneum (SC).  Furthermore, the penetration of small molecular weight molecules is often 
limited in intact skin, to a molecular weight of < 500 Da (Bos and Meinardi, 2000) and a log P 
of < 5. 
These layers forming the skin are significantly altered in disease states. In particular, NMSC 
tumours are often accompanied with dry, scaly patches of skin (Mogensen et al., 2009). In 
inflammatory disorders such as dermatitis and even NMSC the barrier function itself can 
become compromised with cellular alterations in the SC and keratinocytes (Schmuth et al., 
2015). Such disorders may require increased penetration enhancers to be able to permeate 
the toughened skin however, such skin is usually more sensitive therefore a careful balance 
must be struck. Furthermore, the release of inflammatory mediator compounds alongside an 
altered microbial environment often leads to altered local microenvironments (Brandner et al., 
2015).  
The use of nanoparticle formulations as drug-delivery vehicles provide a novel approach to the 
delivery and targeting of the dermal layer with benefits for both transport of poorly permeable 
molecules and larger (often impermeable) biologics. Indeed, reports have identified that 
smaller nanoparticles (< 200 nm) demonstrate internalisation by keratinocytes and dendritic 
cells (Vogt and Blume-Peytavi, 2014). The use of nanoparticle carrier technologies specifically 
allow for the development of novel and often ‘responsive’ systems which can be developed to 
possess temperature (Feng et al., 2013) or  pH-specific (Baier et al., 2014) trigger release 
conditions, alongside possessing physical ‘flexibility’ (Tsai et al., 2015). 
Chemotherapy agents are notoriously difficult to formulate, with one of the principle concerns 
being solubility. Formulations must overcome this limitation with the use of appropriate 
excipients all the while limiting adverse effects. Unfortunately some of the excipients used in 
chemotherapy formulations to enhance solubility, including polyoxyethylated castor oil and 
polysorbates, may cause irritation such as rashes and itchiness (Aungst, 1989; Lorenz et al., 
1982; ten Tije et al., 2003; Utreja et al., 2011). Liposomes have successfully been used to limit 
the use of these excipients, improve drug delivery as well as reduce the side effect profile 
(Trotta et al., 2004; Utreja et al., 2011). 
However, the use of liposomes in dermal drug delivery remains controversial due to their large 
size (Cevc et al., 1995). Previous studies have demonstrated that liposomes accumulate in the 
SC, and only rarely penetrate into viable skin (Dayan and Touitou, 2000; Trotta et al., 2004). 
Elastic liposomes have been reported to penetrate the skin if applied non-occlusivley by virtue 
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of the very high and self-optimizing deformability. They have already been successfully 
employed in transdermal delivery of lipophilic and hydrophilic drugs including anti-inflammatory 
agents (Cevc and Blume, 2001), retinol (Oh et al., 2006), anti-tumour agents (Paolino et al., 
2008) and hormones (El Maghraby et al., 1999). Liposome adhesion, fusion and penetration 
into the stratum corneum is possible with potentially deeper penetration into the dermal layer 
of deformable vesicles compared with traditional liposomes (El Maghraby et al., 1999).  
The lipid bilayer of elastic liposomes include single chain surfactants that have a high radius 
of curvature (examples include Span 65, Tween 80 and sodium cholate (Cevc, 1996; El 
Maghraby et al., 1999; Ita et al., 2007; Oh et al., 2006). This extra component destabilises the 
vesicle bilayers by reducing the amount of work required to expand the interface allowing the 
liposome to become more elastic thus increasing the flux across the skin (Cevc, 1996; Ita et 
al., 2007; Oh et al., 2006). By being able to change shape and volume at minimal energetic 
cost these structures may even penetrate across hydrophilic pathways of intact skin (Romero 
et al., 2013) across the SC to reach the viable epidermis (Warner and Lilly, 1994). This may 
be based on an osmotic transepidermal gradient created by the difference in the total water 
concentrations between the skin surface and the skin interior (Cevc et al., 1995). Further it was 
shown that, modifying the chemical composition of bilayers to decrease the Young’s modulus 
(stress to strain ratio used to describe the stiffness of an elastic material) the resulting 
deformable liposomes were able to penetrate the SC (Cevc, 1996; Romero et al., 2013).  
Reported mechanisms of drug release from liposomes depends on the physicochemical 
properties of the drug. Drug may be released from liposomes before diffusing through the skin 
(drug release being the rate-limiting step); or there may be a direct transfer of drug from the 
liposome to the skin cells (El Maghraby et al., 1999). Entrapment efficiency of the formulation 
would also affect drug delivery and release (Ganesan et al., 1984). Furthermore, depending 
on the choice of lipid and other bilayer constituents, liposomes have been found to interact 
with the SC and destabilise the lipid matrix thus having a penetration enhancing effect 
(Kirjavainen et al., 1996).  
Polysorbates (Tween®) are a class of emulsifiers used in pharmaceuticals. They are oily 
liquids derived from PEG-ylated sorbitan esterified with fatty acids. As non-ionic surfactants, 
they have advantages over ionic surfactants including increased stability, and compatibility 
with a range of other excipients. Chemotherapy agents have commonly been formulated with 
surfactants to increase solubility. Paclitaxel has been formulated in a vehicle containing 
polyoxyethylated castor oil, a non-ionic surfactant whilst docetaxel is currently formulated in 
the polysorbate Tween 80 (ten Tije et al., 2003). 
Tween 80, Tween 20 and sodium cholate were selected as surfactants in the present study to 
improve the elasticity of liposomes. They have all been used in dermal drug delivery and are 
known to be safe in terms of their lack of toxicity and irritation to the skin (Ita et al., 2007; Oh 
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et al., 2006; Tsai et al., 2015). Tween 80 (Figure 2.1a) is derived from polyethoxylated sorbitan 
and oleic acid. Tween 20 (Figure 2.1 b) is a polyoxyethylene derivative of sorbitan 
monolaurate, and is distinguished from the other members in the polysorbate family by the 
length of the polyoxyethylene chain and the fatty acid ester moiety lauric acid (Croda Europe 
Ltd, Span and Tween, 2009). Sodium cholate (Figure 2. 1c) is an anionic emulsifying agent 
(Sigma-Aldrich(c), 2017).  
 
 
Figure 2.1: Chemical structures of a) Tween 80, b) Tween 20, c) sodium cholate  
(Sigma-Aldrich(a), 2017; Sigma-Aldrich(b), 2017; Sigma-Aldrich(c), 2017) 
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2.2 Aims and objectives 
The aim of this study was to formulate and characterise deformable liposomes with the aim to 
be able to load drug into the bilayer for the local sustained release into the dermal layer of the 
skin. 
To achieve the aims, the overall objectives were 
 Formulate and characterise liposomes loaded with either Tween 80, Tween 20 and 
sodium cholate in terms of size and zeta potential. 
 Observe the stability of these liposomes over the course of 28 days in terms of liposome 
size 
 Study the deformability index of these liposomes 
 Select an optimal formulation for further studies 
 Apply formulations to fibroblast (HDFa) and keratinocyte (HaCat) cell lines to 
characterise toxicity and observe internalisation. 
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2.3 Materials and method 
2.3.1 Materials  
Phosphatidylcholine (PC) was obtained from Avanti Polar Lipids. Cholesterol Tween 80, 
Tween 20 and sodium cholate were all obtained from Sigma-Aldrich. All other reagents 
including methanol and chloroform were obtained from Fisher Scientific. Ultrapure water was 
obtained from a Milli-Q purification system (Millipore, Billerica, MA, US). Human dermal 
fibroblasts (HDFa) isolated from adult skin along with all cell culture reagents (medium 106, 
Low Serum Growth Supplement. Supplemented medium contained fetal bovine serum, 2% 
v/v, hydrocortisone 1 µg/mL, human epidermal growth factor, 10 ng/ml, basic fibroblast growth 
factor, 3 ng/mL, heparin, 10 µg/mL, DMEM media supplemented with 1% L-glutamine, 10% 
FBS, 1% Penicillin Streptomycin, 0.25% amphotericin) was obtained from Life technologies 
(Carlsbad, California, US). HaCat cells were a kind gift from Dr Andrew Sanders (Cardiff China 
Medical Research Collaborative, Cardiff University, Henry Wellcome Building, Heath Park, 
Cardiff, CF14 4XN). 
2.3.2 Elastic liposome preparation 
Liposomes were prepared by adapting the film hydration method established by Bangham et 
al., (1965). Briefly, PC, cholesterol and surfactant were dispersed in an organic solvent mixture 
consisting of chloroform and methanol in a 9:1 ratio in a round bottomed flask (Table 2.1) 
(Bangham et al., 1965; Hiruta et al., 2006; Ita et al., 2007; Oh et al., 2006; Tsai et al., 2015). 
Subsequently, the organic solvent was removed by rotary evaporation for 5 minutes at 35°C, 
followed by purging with nitrogen gas. The resultant dry film residue was hydrated by the 
addition of 4 mL water at a temperature above the transition temperature of the phospholipid 
(between -7 to -15°C) (Pagano and Weinstein, 1978) and vortexed for 5 min to form 
multilamellar vesicles (MLV). The formed MLV were equilibrated for 30 min above their 
transition temperatures before being subjected to further characterisation (Ali et al., 2013; 
Lasic and Barenholz, 1996; Pagano and Weinstein, 1978). 
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Table 2-1: Details of liposome formulation composition.   
Formulation PC        
(% w/w) 
Cholesterol 
(% w/w) 
Tween 80 
(% w/w) 
Tween 20 
(% w/w) 
Sodium cholate 
(% w/w) 
1 (Control)  80 20 0   
2 78 20 2   
3 76 20 4   
4 74 20 6   
5 72 20 8   
6 70 20 10   
7 78 20  2  
8 76 20  4  
9 74 20  6  
10 72 20  8  
11 70 20  10  
12 79.75 20   0.25 
13 79.5 20   0.5 
14 79 20   1 
15 78 20   2 
16 76 20   4 
17 74 20   6 
18 72 20   8 
19 70 20   10 
 
2.3.3 Liposome characterisation: particle size, polydispersity index and zeta potential  
Mean particle size and the polydispersity index (measurement of the level of homogeneity of 
particle sizes) of liposomes were measured by dynamic light scattering (DLS) using a Zetaplus 
(Brookhaven Instruments). A clear cuvette was filled with 3 mL of a 1:4 solution of liposomes 
to purified water. A small polydispersity value (< 0.2) indicates a homogenous vesicle 
population, while a larger polydispersity (> 0.3) indicates heterogeneity (Song, Y.-K. and C.-K. 
Kim, 2006). The particle charge was quantified as zeta potential (ζ). Zeta potential was 
determined by photon correlation spectroscopy using a Zetaplus (Brookhaven Instruments). 
The samples were diluted three fold and assessed in triplicate.  
2.3.4 Liposomes stability  
The stability of liposomes was determined, as prepared in water, through the assessment of 
particle size over a 28-day period, stored in a stability cabinet maintained at 25 ± 2 °C (Firlabo, 
France) at a humidity of 60 % ± 5 %.  Mean particle sizes were determined on days 1, 2, 7, 14, 
21 and 28 by DLS. 
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2.3.5 Assessment of liposomal deformability 
2.3.5.1 Assessment of liposomal deformability following extrusion 
To assess the deformability of elastic liposomes, a liposome suspension (6 mL) was passed 
through a polycarbonate filter of either 200, 100 or 50 nm using a syringe driver (Cole Parmer, 
UK) set at 0.6 mL/min for 10 min. The mean particle size and the polydispersity index of 
liposomes were measured by DLS as described in section 2.3.3. The deformability was 
quantified through the calculation of a deformability index (equation 2.1) (Goindi et al., 2013): 
Equation 2.1: 
𝐷 = 100 − 
𝐿𝑒
𝐿
 × 100 
where D is deformability, Le is size of extruded liposomes, L is size of liposomes prior to 
extrusion. 
2.3.5.2 Assessment of liposomal deformability following the mechanistic 
determination of energy contained within the liposomal bilayer 
The previous method concerns comparing liposome size pre and post extrusion. However, it 
is unable to distinguish between lipid aggregates and liposomes thus negative DI values were 
obtained. The following method is an alternate way of determining liposomal elastic properties 
using the volume of formulation forced through without having to use liposomal size such as 
the DI determination.  
According to the Bernoulli equation (Bernoulli, 1738), pressure is a function of both the force 
applied and the exertion area, which can be further related to the energy applied per unit 
volume (Equation 2.2): 
Equation 2.2: 
𝑃𝑟𝑒𝑠𝑠𝑢𝑟𝑒 =
𝐹𝑜𝑟𝑐𝑒
𝐴𝑟𝑒𝑎
=
𝐸𝑛𝑒𝑟𝑔𝑦
𝑉𝑜𝑙𝑢𝑚𝑒
 
with force being a product of mass and acceleration (Equation 2.3): 
 
Equation 2.3: 
𝐹𝑜𝑟𝑐𝑒 = 𝑀𝑎𝑠𝑠 × 𝐴𝑐𝑐𝑒𝑙𝑒𝑟𝑎𝑡𝑖𝑜𝑛 = 𝑀𝑎𝑠𝑠 ×
𝑆𝑝𝑒𝑒𝑑
𝑇𝑖𝑚𝑒
 
The transit of the syringe driver will be a function of the pore size and the subsequent 
resistance to the outlet of fluid from the syringe.  The ‘energy’ was therefore calculated by 
determining the force and pressure under each surfactant condition. 
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2.3.5.3 Assessment of liposomal deformability following lipid quantification after 
extrusion  
The previous two methods assessing liposome deformability are unable to provide information 
of the composition of the liposome being extruded. The following method was employed to 
quantity lipid pre and post extrusion. Quantification of the lipid content, pre- and post- extrusion, 
was performed by reverse phase high performance liquid chromatography (HPLC) (YL 
instrument, Anyang, Korea) using a SEDEX 90LT ELSD detector (Sedex Sedere, Alfortville, 
France) connected to the instrument. A Phenomenex Luna column 5 µm C18(2), 4.60 mm 
inner diameter and 150 mm length with 100 Ă pore size (Phenomenex, Macclesfield, UK) was 
used. Separation of lipids and surfactant was carried out using an elution gradient analysis as 
detailed in Table 2.2, with flow rate maintained at 1.5mL/min throughout each run. Mobile 
phase A consisted of 0.1% TFA in water, and mobile phase B consisted of 100% methanol. 
Standard lipid solutions were dissolved in chloroform:methanol (9:1 v/v) prior to injection, and 
liposome formulations were injected both pre- and post- extrusion. 30 µL of sample was 
injected and the column temperature was maintained at 35 °C, whereas the ELSD temperature 
was maintained at 52 °C during all runs. Nitrogen was employed as the carrier gas at 3.5 psi 
inlet pressure. The total run time was 28 minutes. All chromatograms were evaluated with 
Clarity DataApex version 4.0.3.876 software. 
 
Table 2-2: Gradient elution method for quantitative analysis of cholesterol, 
phosphatidylcholine (PC). TFA: trifluoroacetic acid. 
Time 
(min) 
% Eluent A % Eluent B 
0.1% TFA in 
water 
Methanol 
0 15 85 
6 0 100 
25 0 100 
26 15 85 
28 15 85 
 
2.3.6 Development of an in vitro skin model: growth and passage of cells 
HDFa isolated from adult skin, cryopreserved at the end of the primary culture were revived in 
Medium 106 supplemented with Low Serum Growth Supplement. Supplemented medium 
contained fetal bovine serum, 2% v/v, hydrocortisone 1 µg/ml, human epidermal growth factor, 
10 ng/mL, basic fibroblast growth factor, 3 ng/mL, heparin, 10 µg/mL.  
HaCaT is a spontaneously transformed aneuploid immortal keratinocyte cell line from adult 
human skin. HaCaT cells are utilised for their high capacity to differentiate and proliferate in 
65 
 
vitro. Cells were revived and sustained in high glucose DMEM media supplemented with 1% 
L-glutamine, 10% FBS, 1% pen-strep, 0.25% amphotericin. 
Cells were fed with the supplemented media every 3 days. Once cells reached 70-80% 
confluency, media was discarded and cells detached using 2 mL of Trypsin/EDTA and 
incubated for 5-10 min, prior to trypsin neutralization with 3 mL growth media and subsequent 
centrifugation at 1200 rpm for 10 min. The supernatant was then discarded and the pellet was 
re-suspended in 2 mL of media and subsequently used for father cell proliferation. Flasks were 
then placed into a humidified 37 °C incubator with 5 % CO2. 
 
2.3.7 Impact of liposomal formulation on In vitro cytotoxicity on HDFA and HaCat cells 
To assess the cytotoxicity of either formulation component or drugs towards HDFa and HaCat 
cells, an 2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide (XTT) 
assay was performed to measure cell death after exposure of cells to formulation or drug for 
24 hours. 
Cells suspensions were counted using a hemacytometer following which the cell suspension 
was diluted with supplemented media to 50000 to 75000 cells/mL. 100 µL of cells suspension 
were added into each well and incubated overnight (37 °C, 5% CO2) to attach. Thereafter, 
media was removed and fresh media added. Each concentration of liposome was assayed in 
six wells and run in three independent experiments and results expressed as percentage 
cytotoxicity relative to a control. 
Cells were treated with 100 µL of either a 50, 25, 10, 5, 1 or 0.1 % v/v of a liposomal solution 
in media without serum. The liposomal solution was either a ratio of 16:8 µM of PC : cholesterol 
loaded with 0 %, 2 % or 10 % w/w of Tween 20. Wells were incubated for 24 hours (37 °C, 5 
% CO2) following which 25 µL of 12.5:1 mixture of XTT to menadione was added each well of 
a 96 well plate. Plates were subsequently incubated for 3 hours at 37°C and the absorbance 
read at 450 nm on a Thermo Scientific Multiskan Spectrum. Assessment of EGCG toxicity to 
these cells was conducted through analysis of changes in XTT absorbance with increasing 
drug concentration. 
2.3.7.1 Haemocytometer counting protocol  
A glass hemocytometer and coverslip were cleaned with alcohol before use. The coverslip was 
moistened with water and affixed to the hemocytometer. The cell suspension was prepared by 
gently swirling the flask to ensure cells are evenly distributed. Thereafter 0.1 mL of cell 
suspension was removed into an Eppendorf tube to which Trypan Blue (final concentration 
0.2%) was added. 100 µL of Trypan Blue-treated cell suspension was removed and applied to 
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the haemocytometer, both chambers underneath the coverslip were filled. A microscope with 
a 10x objective was used to focus on the grid lines of the hemocytometer. 
The number of unstained cells (live cells) in each of the four sets of 16 outer squares (Figure 
2.2) was counted.  
To calculate the number of viable cells/mL the average cell count from each of the sets of 16 
corner squares was calculated and then multiplied by 10,000. This was then multiplied by 2 to 
correct for the 1:1 dilution from the Trypan Blue addition. The final value is the number of viable 
cells/mL in the original cell suspension. 
 
Figure 2.2: Hemocytometer gridlines. 
Hemocytometer diagram indicating one of the sets of 16 squares that should be used for 
counting. 
 
2.3.8 Cellular liposomal uptake assay on HDFa and HaCat cells 
Liposomes, both deformable and non-deformable, were formulated with the addition of 0.25 
mL of a 0.1mg/mL DilC fluorescent dye during the lipid mixing stage. The free marker was 
removed by centrifuging liposomes at 18,000 g for 30 minutes, removing the supernatant, re-
suspending in water and centrifuged again. Coverslips were sterilised with ethanol and 
aseptically coated with 1.0 mL/25 cm2 of poly-l-lysine and rocked gently to ensure even coating 
of the culture surface. After 30 min, solution was removed by aspiration and thoroughly rinsed 
surface with sterile tissue culture grade water. These were then allowed to dry for 2 hours 
before introducing cells and medium which were left to attach overnight. DilC loaded liposomes 
were diluted with 1 part of supplemented media and were then added to the coverslips and left 
for 2 hours in a cell culture incubator at 37°C. Supernatant was then removed and the cells 
washed by adding 1 mL of sterile water, removing, and repeating once more. 
Paraformaldehyde 4% was used to fix the cells and then the fluroshield DAPI was then added 
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onto the coverslips and fixed. Cover slips were subsequently analysed in an upright confocal 
microscope (Leica SP5 TCS II MP) and visualised with a 40× oil immersion objective. Images 
were acquired using a helium-neon laser at 633 nm to visualise DilC and a helium–neon laser 
to visualise DAPI at 461 nm. 
 
2.3.9 Statistical analysis  
Unless otherwise stated in the text, a total of three independent experiments were carried out 
for each study method. The statistical significance was evaluated using one-way ANOVA or a 
paired two-tail Students t-test employing GraphPad Prism version 6 for Windows (GraphPad 
Software, La Jolla California USA, www.graphpad.com) for statistical analysis. 
A paired T test or a one way repeated measures ANOVA was used to determine any 
statistically significant difference between means tested. Furthermore, within the ANOVA test 
the Tukey’s multiple comparison test was run to compare between each data set. Unless 
otherwise stated, data is reported as mean ± standard deviation (SD). A significance level (P-
value) of ≤ 0.05 was considered as statistically significant. 
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2.4 Results and discussion  
Elastic liposomes have been found to be advantageous in the topical administration of drugs. 
Whilst being able to act as solubilising agents for low solubility drugs, they may also protect 
the drug from degradation in the body and may be formulated for targeted, sustained drug 
release.   
Blank MLV liposomes were formulated using a dry film method. The PC used in this study was 
derived from egg and is a mixture of saturated and unsaturated alkyl chains 16-18 carbons in 
length. The use of cholesterol in liposomes is to stabilise the membrane structure through 
occupying voids between the phospholipids constituent of the bilayer (Gregoriadis and Davis, 
1979). Thereby, it reduces permeability and prevents drug leaching out of the liposome 
structure (Demel et al., 1972). Surfactant was incorporated with the aim of increasing the 
deformability of the liposomes by imparting ‘elastic’ properties to the lipid bilayer by decreasing 
the interfacial tension. In this study, three different surfactants; Tween 80, Tween 20, and 
sodium cholate, were investigated in five different ratios for their suitability to form novel 
deformable liposomes possessing requisite formulation characteristics. 
2.4.1 Liposome characterisation: particle size and polydispersity and zeta potential 
Liposome size is a key component in determining how nanoparticles will permeate across the 
skin. The presence of surfactant in the bilayer caused a decrease in size across all three 
surfactants (Figure 2.3). Liposomes formulated with no surfactant had an average size of 
1032.3 ± 182.3 nm, this decreased to 390.6 ± 46.5 nm, 336.5 ± 24.9 nm and 329.2 ± 139.3 nm 
when formulated with 10% w/w Tween 80 (Figure 2.3a), Tween 20 (Figure 2.3b) and sodium 
cholate (Figure 2.3c) respectively. For liposomes formulated with Tween 80, the size decrease 
between liposomes formulated with no surfactant compared with all other loadings of 
surfactant was significant (P ≤ 0.0001). The size decrease between liposomes formulated with 
2% w/w and 10% w/w of Tween 80 was also significant (P ≤ 0.01). Finally, the size decrease 
between liposomes formulated with 2% w/w and both 6 and 8% w/w of Tween 80 was 
significant (P ≤ 0.05). For liposomes formulated with Tween 20, only the size decrease 
between liposomes formulated with no surfactant compared with all other loadings of 
surfactant was significant (P ≤ 0.0001). 
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Figure 2.3: Impact of surfactants on liposome size distribution  
Liposomes were prepared adapting the dry film method adding the surfactant during the lipid mixing stage. The preparation was then vortexed 
for 5 minutes. Liposome size was then determined by DLS, comparing up to 10% w/w loadings of either a) Tween 80, b) Tween 20 or c) sodium 
cholate loaded formulations. Data represents mean ± SD. n=6 independent batches. 
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Liposomes formulated with sodium cholate (Figure 2.3c) proved to be problematic in terms of 
size, polydispersity and DI (discussed in section 2.4.1 and 2.4.4) when formulated beyond 4 
% w/w, therefore, additional loadings of 0.25, 0.5 and 1 % w/w of the surfactant were 
investigated. The size decrease between liposomes formulated with no surfactant compared 
with 0.5-10 % w/w as well as between 0.25 % and both 4 and 6 % w/w of surfactant was 
significant (P ≤ 0.0001). The size decrease between liposomes formulated with 0.25 % and 2, 
8 and 10 % w/w of surfactant was significant (P ≤ 0.001). Finally, the size decrease between 
0.25 % and both 0.5 and 1 % w/w of surfactant as well as 0.5 and 4 % w/w loading of surfactant 
was significant.  
The inclusion of surfactant has been previously reported to decrease liposome size in 
comparison to conventional liposome. A study formulating liposomes with Phospholipon® 90 
G and both Tween 80 and Span 80 saw a size reduction from 207 nm to 139 nm following 
inclusion of the surfactants  (Goindi et al., 2013). This may be a result of the surfactant allowing 
a greater interaction of the phospholipid bilayer with the aqueous phase resulting in the overall 
formation of a greater number of liposomes of a smaller diameter resulting in a greater surface 
area in contact with the aqueous phase.  
There was no significant differences in the sizes formulated between each of the surfactants 
(at respective loadings) although sodium cholate appeared to produce the smallest liposomes 
(up to 182.8 ± 70.8 nm).  
Another study has found that the state of aggregation (micellar or vesicular) and the size 
distribution of micelles or vesicles obtained are a function of the sodium cholate to PC molar 
ratio (Almog et al., 1986a). When this ratio is higher than 0.4, micelles will be produced, the 
size of which decreases with an increase in sodium cholate loading. When the ratio is less 
than 0.3, the dispersion is vesicular, and the mean size of the vesicles is an increasing function 
of the sodium cholate to PC ratio. Almog et al., (1986) found addition of sodium cholate to 
vesicular dispersions, resulted in vesicle size growth through a concentration-independent 
lipid-exchange mechanism; larger liposomes will be formed as the sodium cholate will 
accumulate in between the two lipid layers that make up the bilayer. Addition of cholate to 
higher loadings of sodium cholate PC liposomes resulted in a decrease in vesicle size and 
eventually, micellisation of vesicles.  
At lower loadings of sodium cholate, e.g.  0.25 % w/w, an increase in vesicle size was not 
observed. Thus, at this loading, there may have been insufficient sodium cholate available to 
act at the lipid bilayer/water interface to reduce interfacial tension and reduce liposome size. 
However, as the loading of sodium cholate surpassed 4 % w/w, liposome size appeared to 
increase which goes against the general trend of what was expected. Furthermore, liposomes 
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loaded with more than 4 % w/w of sodium cholate had a larger standard deviation. This 
suggests formation of particles other than liposomes including micelles and lipid aggregates.  
 
A liposome preparation homogenous in size is important, as size will determine liposome 
distribution in vivo as well as influencing drug release kinetics. A polydispersity of > 0.3 is 
considered homogenous (Chen et al., 2012; Goindi et al., 2013; Kang et al., 2013). The general 
trend observed was that as surfactant was added into the formulation, the polydispersity 
decreased. The polydispersity of liposomes formulated with no surfactant was 0.33 ± 0.1, 
compared with 0.31 ± 0.04, 0.30 ± 0.02 for a 2% w/w loading of Tween 80 and Tween 20 
respectively. The polydispersity for sodium cholate however decreased to 0.31 ± 0.05 at 0.25 
% w/w of sodium cholate but then increased to 0.42 ± 0.01 at 10 % w/w (Figure 2.4).  This, 
coupled with the increase in size variability, and cloudy/particulate appearance of sodium 
cholate liposomal formulations loaded with more than 4% w/w loading provides evidence 
suggesting the formation of particles other than liposomes such as micelles or lipid aggregates. 
Studies observing structure formation from PC and sodium cholate (up to 30% w/w loading) 
formulations found micelles were formed alongside liposomes and noted that these were not 
as suitable for drug delivery as deformable liposomes (Almog et al., 1986a; El Maghraby et al., 
2000). This indicates sodium cholate may not be a suitable surfactant to use in this formulation 
as it was unable to provide a homogenous mix. 
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Figure 2.4: Impact of surfactants on polydispersity of liposomes   
Liposomes were prepared adapting the dry film method adding the surfactant during the lipid mixing stage. The preparation was then vortexed 
for 5 minutes. Polydispersity, when formulated with increasing loadings of a) Tween 80, b) Tween 20 and c) sodium cholate up to a maximum of 
10% w/w was determined with DLS. Data represents mean ± SD. n=6 independent batches.
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Due to the problems associated with sodium cholate including the large size variability, the 
range of surfactant loadings was further extended to cover the range of 0.25-10 % w/w. A lower 
loading of the surfactant was required to decrease the interfacial tension therefore smaller 
liposomes where produced in comparison to liposomes loaded with the same amount of either 
Tween 80 or 20 (Figure 2.2). This difference was not found to be significant. Furthermore, a 
loading of equal to and greater than 4 % w/w sodium cholate seemed to produce unstable 
liposomes alongside other particles as demonstrated by the increase in size (from 211.9 to 
329.2 nm) and polydispersity (from 0.33 to 0.41). However, elastic liposomes loaded with up 
to 30 % w/w of sodium cholate and Tween 80 have been formulated in another study although 
they did not include cholesterol in the bilayer (El Maghraby et al., 2000). Sodium cholate has 
a similar steroidal structure to that of cholesterol and may have displaced cholesterol from the 
bilayer therefore negating cholesterols bilayer stabilising property (El Maghraby et al., 2000). 
(El Maghraby et al., 2004). 
The zeta potential is defined as the potential difference between the dispersion medium and 
the stationary layer of fluid directly surrounding the dispersed particle. The magnitude of the 
zeta potential indicates the degree of electrostatic repulsion between adjacent, similarly 
charged particles in a dispersion. Thus it is one of the fundamental parameters known to affect 
stability. The zeta potential of liposomes formulated with Tween 80, Tween 20 and sodium 
cholate is displayed in Table 2-3.  
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Table 2-3: Zeta potential of liposomal formulations formulated with up to 10% w/w loading of 
Tween 80, Tween 20 and sodium cholate 
 Surfactant loading 
(w/w %) 
Zeta potential 
(mV) 
No surfactant 0 5.03 ± 1.03 
Tween 80 
2 0.51 ± 2.63 
4 3.14 ± 1.83 
6 2.12 ± 2.46 
8 7.80 ± 2.61 
10 -6.23 ± 2.45 
Tween 20 
2 4.67 ± 1.08 
4 6.67 ± 2.55 
6 3.71 ± 0.90 
8 2.56 ± 1.11 
10 -2.79 ± 0.20 
Sodium cholate 
0.25 9.68 ± 9.67 
0.5 -1.97 ± 12.17 
1 4.09 ± 11.35 
2 2.67 ± 10.61 
4 -2.14 ± 4.91 
6 12.86 ± 11.31 
8 7.98 ± 13.87 
10 9.94 ± 13.33 
 
 
This study has found the majority of formulations for liposomes to have a near neutral charge. 
Liposomes formulated with no surfactant had a zeta potential of 5.03 ± 1.03 mV. Liposomes 
formulated between 2 and 8% w/w of Tween 80 observed a general increase in the zeta 
potential from 0.51 ± 2.63 mV to 7.80 ± 2.61 mV. At a 10% w/w loading of Tween 80, zeta 
potential dropped to -6.23 ± 2.45 mV. The difference in zeta potential was not significant across 
the loadings. Tween 80 is a non-ionic surfactant thus was not expected to influence the surface 
charge. In a similar study preparing liposomes with PC and Tween 80, the zeta potential value 
was -6.63 mV. They were unable to conclude why a negative value was obtained as Tween 
80 is a non-ionic edge activator and put this down to the chemical structure of Tween 80 and 
its interaction with their specific formulation parameters (Lee et al., 2005). 
Liposomes formulated between 2-10% w/w of Tween 20 observed a general decrease in zeta 
potential from 4.67 ± 1.08 mV to -2.79 ± 0.2 mV. Again, the difference in zeta potential was not 
significant across the loadings. Tween 20 is a non-ionic surfactant thus was not expected to 
influence the surface charge.  
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Liposomes formulated between 0.25 and 10% w/w of sodium cholate observed no trend in 
zeta potential, once more, the difference in zeta potential was not significant across the 
loadings of surfactant. Sodium cholate is an ionic surfactant, thus was expected to influence 
surface charge. A study formulating liposomes with PC and sodium cholate observed a zeta 
potential of -2.45 mV (Lee et al., 2005). This is in contrast to a similar study that observed a 
zeta potential of -29 mV (Essa et al., 2002). These negative values are due to sodium cholate 
being an anionic detergent. However, in this study, the zeta potential values were less 
negative. The difference between these studies may be due to several differences in methods 
between the two studies. For instance, Lee at al. utilised a PBS buffer for measurements 
whereas Essa et al. utilised the organic solvent ethanol, but in this study water was used.  
A key benefit of using liposomes in topical drug delivery system is that they are miscible with 
the lipids in the skin thus allowing the liposomes to penetrate into deeper layers. Thus a neutral 
surface charge is ideal (Prausnitz and Langer, 2008). However,  neutrally charged liposomes 
have been found to flocculate and aggregate together due to the lack of like-charge causing 
repulsion between liposomes (Weiner et al., 1992). Furthermore, positively charged liposomes 
have been found to be irritating to the skin. Negatively charged liposomes have been found to 
provide better skin retention for drugs intended for topical use (Katahira et al., 1999). 
Liposomes formulated with sodium cholate had the highest positive charge therefore would be 
least likely to flocculate however may also be most irritating to the skin. Use of anionic lipids 
could be investigated for an enhanced formulation stability as well as increasing the flux across 
the skin.  
2.4.2 Stability of deformable liposomes 
The stability of deformable liposomes during storage at 20 °C was studied in terms of size. It 
is important to assess stability of liposomes in terms of size to assess liposome aggregation 
and fusion as this may affect compound encapsulation and release. Confocal images were 
observed on day 1 of formulation to ensure the presence of liposomes (Figure 2.5). The size 
of blank and surfactant loaded liposomes was measured on days 1, 2, 7, 14, 21 and 28 (Figure 
2.6).  
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Figure 2.5: Confocal images of MLV liposomes 
Confocal images of MLV liposomes formulated with 4% either a) Tween 80, b) Tween 20 or c) 
sodium cholate. Fluorescently labelled liposomes where formulated by the addition of the 
fluorescent dye Dil C to the lipid mixing stage. The unentrapped marker was removed by 
centrifuging liposomes, removing the supernatant, re-suspending in water. Liposomes where 
imaged using an upright confocal microscope (Leica SP5 TCS II MP) and visualised with a 
40× oil immersion objective.  
 
Confocal images clearly show the presence of liposomes formulated with Tween 80 (Figure 
2.5a), Tween 20 (Figure 2.5b), and sodium cholate (Figure 2.5c).  
All liposomal formulations appear to slightly decrease in size over 4 weeks (Figure 2.6). 
Liposomes formulated with no surfactant decreased in size from 1032.3 ± 126.4 nm to 619.4 
± 16.8 nm. The decrease in size for these liposomes was non-significant up until day 14 where 
a significant difference in size was noted (P ≤ 0.05). The decrease in size was significant 
between days 1 and 21 (P ≤ 0.001), 1 and 28 (P ≤ 0.0001), 2 and 21 (P ≤ 0.001), 2 and 28 (P 
≤ 0.0001), 7 and 14 (P ≤ 0.05), 7 and 21 (P ≤ 0.001) and 7 and 28 (P ≤ 0.0001). 
The size decrease in liposomal formulations formulated with 2% w/w of Tween 80 was 
significant between days 1 and 21 and 1 and 28 (P ≤ 0.05). The size decrease in liposomal 
formulations formulated with 4% w/w of Tween 80 was significant between days 1 and 14, 1 
and 28 (P ≤ 0.05), 2 and 14, 21 and 28. (P ≤ 0.01).  The size decrease in liposomal formulations 
formulated with 6% w/w of Tween 80 was not significant. The size decrease in liposomal 
formulations formulated with 8% w/w of Tween 80 was not significant. The size decrease in 
liposomal formulations formulated with 10% w/w of Tween 80 was only significant between 
days 1 and 28 (P ≤ 0.05). 
The size decrease in liposomal formulations formulated with 2% w/w of Tween 20 was 
significant between days 1 and 2 (P ≤ 0.05) as well as days 1 and 7, 14, 21 and 28 (P ≤ 0.01). 
The size decrease in liposomal formulations formulated with 4% w/w of Tween 20 was not 
significant.  The size decrease in liposomal formulations formulated with 6% w/w of Tween 20 
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was significant between days 1 and 7 (P ≤ 0.01) as well as days 1 and both 14 and 28 (P ≤ 
0.05). The size decrease in liposomal formulations formulated with 8% w/w of Tween 20 was 
not significant. The size decrease in liposomal formulations formulated with 10% w/w of Tween 
20 was not significant. 
The size decrease in liposomal formulations formulated with 2% w/w of sodium cholate was 
not significant. The size decrease in liposomal formulations formulated with 4% w/w of sodium 
cholate was not significant.  The size decrease in liposomal formulations formulated with 6% 
w/w of sodium cholate was significant between days 1 and 7 (P ≤ 0.01) as well as days 1 and 
both 14 and 28 (P ≤ 0.05). The size decrease in liposomal formulations formulated with 8% 
w/w of sodium cholate was significant between days 1 and 7, 14, 21 and 28 (P ≤ 0.05). The 
size decrease in liposomal formulations formulated with 10% w/w of sodium cholate was only 
significant between days 1 and 14 (P ≤ 0.05) and days 1 and both 21 and 28 (P ≤ 0.05). 
The general trend observed, was that liposome size did not significantly alter between days 7 
and 28 and that the inclusion of increasing surfactant concentration appears to prevent 
liposome size changes. Conventional liposomes usually increase in size over time due to 
aggregation and then fusion of vesicles (Heurtault et al., 2003; Rashidinejad et al., 2014). 
Liposomes would aggregate and fuse to reduce the interfacial tension and reach a more 
energetically stable state (Lentz et al., 1987). The inclusion of a surfactant destabilises the 
bilayer by reducing the amount of work required to expand the interface thus allowing 
maintenance of smaller structures. It appears the inclusion of surfactant prevents this 
phenomenon which correlates with similar studies (Seras et al., 1992). This was expected with 
liposomes loaded with sodium cholate as it is an ionic surfactant thus these structures repel 
one another in suspension and would not aggregate.  
Furthermore, a creamy layer of lipids were observed following formulation, for liposomes 
formulated with Tween 80 and Tween 20, thus larger liposomes may have settled and 
aggregated at the bottom of the container resulting in only smaller ones remaining in 
suspension and being detected. Long-term stability of liposomes depends on the average 
elastic energy of the membrane being higher than the thermal energy. When this is no longer 
the case, liposomes will disintegrate (Lipowsky 1991). Thus the elastic energy must be 
maintained higher than the thermal energy (by use of surfactant), or the thermal energy 
maintained lower than the elastic energy (temperature control). 
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Figure 2.6: The stability of blank and deformable liposomes 
The stability of blank and deformable liposomes as determined by size with DLS formulated with loadings varying between 0-10 % w/w of either 
Tween 80, Tween 20 or sodium cholate. a) blank liposomes, b) liposomes formulated with 2 % w/w of surfactant, c) liposomes formulated with 4 
% w/w of surfactant, d) liposomes formulated with 6 % w/w of surfactant, e) liposomes formulated with 8 % w/w of surfactant, f) liposomes 
formulated with 10 % w/w of surfactant. Data represents mean ± SD. n=6 independent batches. 
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2.4.3 Assessment of liposomal deformability  
2.4.3.1 Assessment of liposomal deformability following extrusion  
The addition of surfactant within the liposomal bilayer has been found to impart elastic 
properties to the liposome (Almog et al., 1986a; Cevc, 1996; Trotta et al., 2002). This may be 
beneficial in dermal drug delivery to allow the transport of molecules across the stratum 
corneum into the dermal layers. Liposomes loaded with up to 10 % w/w of Tween 80, Tween 
20 and sodium cholate were formulated and the degree of deformability of each formulation 
was determined by extruding through a polycarbonate filter with a pore size of 200 nm (Figure 
2.7).  
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Figure 2.7: Deformability index following extrusion 
Blank liposomes and liposomes loaded with a) up to a maximum of 10% w/w of Tween 80, 
Tween 20 and sodium cholate and additionally, b) up to 1% sodium cholate were extruded 
through 200 nm filters. Data represents mean ± SD. n=6 independent batches. 
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The DI is defined as the degree the liposomes deformed following extrusion and did not regain 
their original size. The greater the DI the less elastic the liposomes are as they were unable to 
regain their previous larger size. Blank liposomes were first sonicated to bring the size into 
range (between 400 and 500 nm). The deformability index was calculated; an index of 100 
demonstrating liposomes have deformed by 100% following extrusion and not regained their 
previous larger size (Figure 2.7).  
In general, liposomes were observed to have deformed permanently to a smaller extent when 
formulated with surfactant. The DI of liposomes formulated with Tween 80 decreased from 
70.8 ± 6.5 % to 12.5 ± 4.6 %. This decrease was significant between 0% and 2% w/w of 
surfactant (P ≤ 0.01) as well as 0% and 4-10% w/w surfactant (P ≤ 0.0001). There was also a 
significant decrease in DI between 2% w/w and 6% w/w of surfactant (P ≤ 0.01) as well as 
between 2% and both 8 and 10% w/w of surfactant (P ≤ 0.0001). Finally, there was a significant 
decrease in DI between surfactant loadings of 4% and 8% w/w (P ≤ 0.05), as well as 4% and 
10% w/w (P ≤ 0.01). 
Liposomes formulated with Tween 20 observed a decrease in DI from 70.8 ± 6.5 to 25.6 ± 2.9 
%. This decrease was significant between 0% and all other loadings of surfactant (P ≤ 0.0001). 
There was also a significant decrease between the DI of liposomes formulated with 2% and 
4% (P ≤ 0.01), 2% and 6% (P ≤ 0.001) as well as between 2% and both 8 and 10% w/w 
surfactant (P ≤ 0.0001). There was also a significant decrease in the DI of liposomes 
formulated with 4% and 10% (P ≤ 0.0001). Finally there was also a significant difference 
between 10% and both 6% (P ≤ 0.0001) and 8% (P ≤ 0.01) w/w of surfactant.  
The DI of liposomes formulated with sodium cholate decreased from 70.85 to 30.9 ± 48.1 %. 
None of the differences between DI of liposomal formulations was significant (P ≥ 0.05). 
Beyond 4% w/w loading of sodium cholate the standard deviation increases showing that the 
DI values were widely distributed. Due to unreliable data observed at higher loadings of sodium 
cholate, additional loadings of sodium cholate between 0 and 2% w/w were investigated to 
observe liposomal behaviour at these loadings (Figure 2.7b). 
 
A consequence of the strong hydrophobic effect of the lipids used to prepare the liposomes is 
a very high (and negative) internal lateral tension within bilayers. Therefore, rather than 
complete vesicle destruction, these bilayers have a self-healing effect (Sackmann, 1994). 
Surfactants may have interacted with the PC with strong affinity but in reversible mode 
therefore improving their ability to self-heal. The fast reconstruction of liposome spheres after 
extrusion may be due to the strong affinity between the surfactant, cholesterol and PC. The 
reversible binding mode might have provided the flexibility upon the application of physical 
stress (Oh et al., 2006). 
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Liposomes formulated with PC containing the surfactant dipotassium glycyrrhizinate have 
been found to retain their size when passed through a membrane with pores narrower than 
their diameter; liposome size pre and post extrusion through a membrane with a pore size of 
100 nm was 352 and 345 nm respectively. These liposomes are able to deform as the 
surfactant has a propensity for highly curved structures (e.g. micelles), thus accommodating 
particle shape changes under stress by diminishing the energy required for the particle to 
deform and then reform its shape (Trotta et al., 2004). 
Following 4% w/w loading of sodium cholate, the standard deviation of the DI increased, 
suggesting these liposomes where not stable and did not deform uniformly. It has already been 
observed liposomes formulated beyond 4% w/w of sodium cholate where unstable, following 
extrusion, some smaller liposomes were undoubtedly formed, but also some lipid aggregates. 
This is in contrast with a study observing the deformability of a liposomal solution containing 
approximately 87% w/w soya PC and 13% w/w sodium cholate where liposomes could deform 
when extruded through a pore size one quarter of their size, yet still regain their initial 
formulation size (Cevc et al., 1995). Considering sodium cholate reduced liposome size to the 
greatest extent, it would be sensible to assume this surfactant produced the most elastic 
liposomes in this study. However, it was possible that this molecule was capable of close 
physicochemical interactions with PC in the lipid membrane bilayer, perhaps displacing 
cholesterol which is inherently known to provide stability to the liposome structure (Oh et al., 
2006).  
Following analysis of liposome size, polydispersity, stability and DI, it is clear sodium cholate 
is not a suitable surfactant to continue for use in these studies. Homogenous preparations 
were not obtained leading to aggregation, and negative DI values. Studies observing drug 
delivery from liposomes formulated with PC and sodium cholate found that not only were 
micelles formed alongside liposomes, but that sodium cholate also led to a lower drug delivery 
as surfactant decreased the entrapment efficiency and disrupted the lipid membrane so that it 
became more leaky to the entrapped drug (Almog et al., 1986a; El Maghraby et al., 2000). 
There were no significant differences between liposomes formulated with Tween 80 and 
Tween 20. Tween 80 is formed from polyethoxylated sorbitan and oleic acid. Tween 20 is 
derived from the ethoxylation of sorbitan before the addition of lauric acid. Whilst Tween 80 
has been used in the development of topical liposomes, the oleic acid component has often 
been found to be more irritating to the skin and cause hypersensitivity reactions (Aungst, 1989; 
Lorenz et al., 1982; ten Tije et al., 2003). This further drove the selection of Tween 20 for the 
subsequent studies.  
An investigation into the use of liposomes, transfersomes and ethosomes, containing suitable 
edge activators as penetration enhancers found all formulations improved the drug penetration 
into the skin with respect to an aqueous suspension (Bragagni et al., 2012). Ethosomes 
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containing Tween 20 as edge activator demonstrated the best vesicle dimensions and 
homogeneity, and highest encapsulation efficacy, and enabled the highest increase in drug 
penetration through the skin due to the presence of both ethanol and Tween 20 which act as 
permeation enhancers. Thus ethosomes formulated with Tween 20 were found to be the most 
effective carrier for topical celecoxib applications used in skin cancer prevention and treatment 
(Bragagni et al., 2012). 
Based upon these results, Tween 20 was selected for further liposomal studies at a loading of 
0%, 2%, 6% and 10% w/w.  
2.4.3.2 Assessment of the impact of pore size on the deformability of Tween 20 
liposomes  
The DI of liposomes formulated with up to 10% w/w Tween 20 was investigated further by 
forcing liposomes through pore sizes of 200 nm, 100 nm and 50 nm to observe the ability of 
the liposome to deform and reform (Figure 2.8). 
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Figure 2.8: Deformability index of liposomes following extrusion through a membrane with pore size of 200 nm, 100 nm and 50 nm 
Deformability index of liposomes formulated with loadings of up to 10% w/w of Tween 20 after having been forced through a membrane with a 
pore size of either a) 50 nm, b) 100 nm or c) 200 nm. Data represents mean ± SD. n=6 independent batches. 
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Across the 3 pore sizes, as surfactant loading increased, liposome DI decreased. Liposomes 
formulated with Tween 20 forced through a 200 nm pore size (Figure 2.8a) saw the DI 
decrease from 70 to 26% as the Tween 20 loading increased from 0% w/w to 10% w/w, this 
decrease was significant between all loadings of surfactant (P ≤ 0.0001). Liposomes 
formulated with Tween 20 forced through a 100 nm pore size (Figure 2.8b) saw the DI 
decrease from 83 to 66%. The difference in DI was significant between surfactant loadings of 
0% and both 2 and 6% w/w (P ≤ 0.001) as well as between 0% and 10% (P ≤ 0.0001) and 
between 2% and 10% w/w (P ≤ 0.01). Liposomes formulated with Tween 20 forced through a 
50 nm pore size (Figure 2.8c) saw the DI decrease from 71 to 32%. Only the decrease in DI 
between 0% and 10% w/w of Tween 20 was significant (P ≤ 0.05). Furthermore, there was no 
significant difference between the DI of liposomes forced through 200 and both 100 and 50 nm 
pore sizes, however there was a significant difference between the DI of liposomes forced 
through a 100 and 50 nm pore size (P ≤ 0.05). 
As expected liposomes deformed the least when forced through 200 nm. Liposomes forced 
though a pore size of 50 nm would be expected to have the highest deformability index. 
However this was not observed, instead liposome breakdown and formation of aggregates 
following extrusion may have occurred. The standard deviation was large for this set of data, 
up to ± 41.28 at a 10% w/w loading of Tween 20 highlighting variability in the size of structures 
obtained. These studies indicate liposomes sized around 400 nm in diameter prior to extrusion 
cannot be forced through a pore size of a quarter of that without destroying some of the 
structures.   
2.4.3.3 Assessment of liposomal deformability following the mechanistic 
determination of energy contained within the liposomal bilayer  
The energy stored within the liposome bilayer was determined to quantify how the presence 
of Tween 20 influenced energy storage thus liposome elasticity (Figure 2.9). As the loading of 
Tween 20 increased from 0% to 10% w/w, the energy retained in the formulation increased 
from 7.53 × 10-8 J to 9.46 × 10-8 J when the formulations were forced through 200 nm pores. 
This energy increase was significant between 0% w/w and all other loadings of surfactant (P ≤ 
0.0001) as well as between 2% and 10% w/w (P ≤ 0.05). As the loading of Tween 20 increased 
from 0% to 10% w/w, the energy retained in the formulation increased from 7.43 × 10-8 to 9.3 
× 10-8 J when the formulations were forced through 100 nm pores. This energy increase was 
significant between 0% w/w and all other loadings of surfactant (P ≤ 0.0001) as well as between 
2% and 10% w/w (P ≤ 0.05). As the loading of Tween 20 increased from 0% to 10% w/w, the 
energy retained in the formulation increased from 6.46 × 10-8 to 9.09 × 10-8 J when the 
formulations were forced through 50 nm pores. This energy increase was significant between 
0% w/w and both 2 and 6% w/w loadings of surfactant (P ≤ 0.001) as well as between 0% and 
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10% w/w loadings of surfactant (P ≤ 0.0001). As the pore size decreased, less energy was 
retained due to more energy being lost as friction, heat and liposome rupture. The increased 
turbulence in this closed system because of smaller pore size would result in an increase of 
the aforementioned outcomes.  
Liposomes were expected to deform more so as pore size decreased. Deformation can be 
either elastic (reversible) or plastic (irreversible). This study shows that despite being forced 
though a pore size as small as 50 nm, some liposomes retained enough elastic energy to 
maintain the same size as when forced through the 200 nm membrane. Thus, the surfactant 
retained enough energy to allow liposomes to fit through a smaller gap and reform, at least 
between a pore size of 50 and 200 nm. Figure 2.9 shows that liposomes formulated with 
surfactant had the greatest capacity for energy storage. More energy would have gone into 
deforming the liposomes rather than being lost as friction and heat.  
Further it shows liposomes forced though 50 nm pores retained less energy compared with 
greater pore sizes indicating energy was lost due to liposome rupture. This corresponds with 
deformation index data (Figure 2.9). 
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Figure 2.9: Mechanistic determination of energy stored in the liposome as determined by extrusion  
Energy stored in the liposome when loaded with up to 10% w/w Tween 20 and forced through a membrane with a pore size of a) 200 nm, b) 100 
nm and c) 50 nm. Data represents mean ± SD. n=6 independent batches. 
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There is an energy cost to deform the bilayers, and this has been referred to as the ‘curvature 
elastic energy’ (Chung and Caffrey, 1994). Energy was supplied to this system in terms of 
pressure. Further, the temperature of the solution (room temperature) will also contribute to 
this. This energy will be converted to kinetic (movement and friction) and elastic energy. Elastic 
energy is defined as the energy stored because of deformation of an elastic object, such as 
the stretching of a spring or in this case the compression of the liposome to fit though the pore.  
The more surfactant included within the bilayer, the more energy the liposome as a whole will 
be able to retain (Figure 2.9). The energy would be used to bend the surfactant structure, and 
since all systems gravitate toward minimising the free energy, the energy stored in this 
structure will be expelled once the liposome has passed the pore (Chung and Caffrey, 1994). 
This energy can then be expended into reforming the liposome following passage through the 
pore. Some energy will be lost during passage as heat or non-plastic deformation. Therefore, 
even at 10% w/w of Tween 20, 100% size was not recovered. Blank liposomes have less 
capacity to store energy, therefore energy will be used to rupture the membrane causing 
liposome size to decrease.  
It follows that to pass through a pore size of 50 nm, more energy is required to deform the 
liposome. At this pore size, the amount of energy stored in the liposome membrane was 
enough to reform some of the liposomes to the same extent as for when forced through a 200 
nm membrane. Some energy however will always be lost in the friction of the particles moving 
through the pores as heat, this energy loss increases with decreasing pore size resulting in the 
rupture of some liposomes. An increase in surfactant loading may bring allow liposomes to 
achieve greater reformation. Furthermore, studies observing liposome extrusion through a 50 
nm pore size have a larger standard deviation. This indicates there may have been some 
smaller liposomes that didn’t reform alongside side some destroyed liposomes clumping 
together as lipid aggregates. Linear elastic deformation is governed by Hooke’s law: the strain 
(deformation) of an elastic material is proportional to the stress (force) applied to it (Figure 
2.10).  
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As the stress increases, the liposome will deform elastically up until a certain point. Beyond 
this point plastic deformation will occur and eventually, as the stress is increased further the 
liposomes will rupture.  
 
Figure 2.10: Stress – strain graph 
Increasing applied force will firstly cause elastic deformation and then plastic deformation and 
eventually reach fracture point adapted from (Cockcroft and Latham, 1968). 
 
This liposome destruction may not necessarily occur when applied to the skin. This was an in 
vitro study used to aide commentary on liposome deformability, it does not reflect what would 
happen in vivo and suggests liposomes would breakdown following application onto the skin. 
Liposomes would not be forced through the SC in vivo as they were forced through the artificial 
membrane, they would instead be expected to travel through into the dermal layer based on 
an osmotic transepidermal gradient (Cevc et al., 1995). When a lipid suspension is placed on 
the skin surface and partly dehydrated by the water evaporation loss, the lipid vesicles would 
respond to this gradient and try to avoid complete dehydration by moving along this gradient. 
Liposomes would only achieve this if they were sufficiently deformable to pass through the 
narrow pores within in the skin sublayers. Less deformable vesicles, including standard 
liposomes, would be confined to the skin surface where they would dehydrate and fuse. (Cevc 
and Blume, 2001; Cevc et al., 1995). Furthermore, due to experimental limitations of this study, 
the study was carried out at 20°C, the skin has a temperature of 35°C therefore the liposomes 
would be expected to be more flexible at this temperature and therefore less prone to 
destruction following passage through smaller gaps. Temperature governs the energy term of 
enthalpy therefore the liposomes would have more energy to be even more flexible and cross 
the SC. Furthermore, the bending energy can be drastically reduced by suitable solutes. The 
SC consists of cells embedded in a lipid mix, the liposomes will be more flexible in a lipid mix 
as opposed to an aqueous medium as less energy is required to maintain the structure 
(Sackmann, 1994). 
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2.4.3.4 Assessment of liposomal deformability following lipid quantification following 
extrusion 
Following extrusion of liposomal formulations, the DI as well as the energy stored in the bilayer 
was calculated. This does not however provide information on the components of the liposome 
being passed through the pore. It may be possible that more PC and surfactant passed through 
as they are more fluid than cholesterol. To clarify this, quantification of the lipid content pre- 
and post- extrusion was performed by reverse phase HPLC with an ELSD detector connected 
to the instrument (Table 2-4 and 2-5). Generally, comparison of the concentration in the 
extruded solution to that in the syringe is lower for both cholesterol and PC across all three 
pore sizes implying liposomes did resist extrusion. 
 
Table 2-4: Cholesterol quantification pre- and post- extrusion of liposomal formulations 
through membranes of pore size 200 nm, 100 nm, and 50 nm formulated with up to 10% w/w 
Tween 20. 
Surfactant 
loading 
(% w/w) 
50 nm 100 nm 200 nm 
Post-  
(mg/mL) 
Pre- 
(mg/mL) 
Post- 
(mg/mL) 
Pre- 
(mg/mL) 
Post- 
(mg/mL) 
Pre- 
(mg/mL) 
0 0.010 ± 
0.008 
0.210 ± 
0.012 
0.113 ± 
0.007 
0.201 ± 
0.013 
0.140± 
0.010 
0.192 ± 
0.005 
2 0.121 ± 
0.006 
0.184 ± 
0.008 
0.136 ± 
0.010 
0.189 ± 
0.007 
0.173 ± 
0.006 
0.175 ± 
0.007 
6 0.149 ± 
0.007 
0.168 ± 
0.005 
0.151 ± 
0.005 
0.179 ± 
0.004 
0.179 ± 
0.005 
0.168 ± 
0.005 
10 0.156 ± 
0.004 
0.160 ± 
0.016 
0.159 ± 
0.005 
0.160 ± 
0.008 
0.173 ± 
0.008 
0.168 ± 
0.008 
Results are presented as the mean ± standard deviation (n=3) 
  
90 
 
 
Table 2-5: PC quantification pre- and post- extrusion of liposomal formulations through 
membranes of pore size 200 nm, 100 nm, and 50 nm formulated with up to 10% w/w Tween 
20. 
Surfactant 
loading 
(% w/w ) 
50 nm 100 nm 200 nm 
Post-  
(mg/mL) 
Pre- 
(mg/mL) 
Post- 
(mg/mL) 
Pre- 
(mg/mL) 
Post- 
(mg/mL) 
Pre- 
(mg/mL) 
0 0.204 ± 
0.014 
0.830 ± 
0.018 
0.283 ± 
0.004 
0.790 ± 
0.011 
0.314 ± 
0.011 
0.726 ± 
0.018 
2 0.290 ± 
0.023 
0.740 ± 
0.023 
0.315± 
0.004 
0.718 ± 
0.013 
0.338 ± 
0.004 
0.698 ± 
0.008 
6 0.341 ± 
0.028 
0.680 ± 
0.013 
0.362 ± 
0.011 
0.675 ± 
0.010 
0.415 ± 
0.018 
0.643 ± 
0.014 
10 0.423 ± 
0.010 
0.632 ± 
0.015 
0.479 ± 
0.011 
0.615 ± 
0.0128 
0.488 ± 
0.016 
0.563 ± 
0.019 
Results are presented as the mean ± standard deviation (n=3) 
 
The difference between the pre- and post- extrusion concentrations for both cholesterol and 
PC was then analysed (Figure 2.11 and 2.12). The general trend observed was that the 
difference in lipid concentrations decreases as surfactant increases and as pore size 
increases. At 0% w/w loading of surfactant, the difference in cholesterol concentration 
decreased from 0.11 to 0.05 mg/mL as pore size increased. Furthermore, as surfactant loading 
increased for liposomes being forced through a 200 nm pore size, the difference in cholesterol 
concentration decreased from 0.05 to 0.01 mg/ml. This indicates more liposomes were able to 
move across the membrane as both the pore size and surfactant loading increased. 
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Figure 2.11: The difference in cholesterol concentration in pre- and post- liposomal extrusion 
The difference in cholesterol concentration in pre- and post- extrusion of liposomal formulations loaded with up to 10% w/w of Tween 20 when 
forced through a) 200 nm, b) 100 nm and c) 50 nm. Data represents mean ± SD. n=6 independent batches. 
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Figure 2.12: The difference in PC concentration in pre- and post- liposomal extrusion 
The difference in PC concentration in pre- and post- extrusion liposomal formulations loaded with up to 10% w/w of Tween 20 when forced through 
a) 200 nm, b) 100 nm and c) 50 nm. Data represents mean ± SD. n=6 independent batches.
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The decrease in the difference of lipid concentration for both cholesterol and PC as surfactant 
was increased was significant across the three different pore size membranes (200 nm, 100 
nm and 50 nm) the formulation was forced through.  
The difference in cholesterol concentration for liposomes forced through 200 nm decreased 
significantly between surfactant loadings of 0% w/w and all other loadings of surfactant (P ≤ 
0.001). The difference in cholesterol concentration for liposomes forced through 100 nm 
decreased significantly between surfactant loadings of 0% and 2% w/w (P ≤ 0.05), 0% and 
both 6 and 10% w/w (P ≤ 0.001) as well as between 2% and 10% w/w of surfactant (P ≤ 0.01). 
The difference in cholesterol concentration for liposomes forced through 50 nm decreased 
significantly between surfactant loadings of 0% and 2% w/w (P ≤ 0.01), 0% and both 6 and 
10% w/w (P ≤ 0.0001), 2% and both 6 and 10% w/w (P ≤ 0.01).  
The difference in PC concentration for liposomes forced through 200 nm decreased 
significantly between surfactant loadings of 0% and 2% w/w (P ≤ 0.05) as well as between 0% 
and both 6 and 10% w/w, between 2% and both 6 and 10% w/w and between 6% and 10% 
w/w (P ≤ 0.0001). The difference in PC concentration for liposomes forced through 100 nm 
decreased significantly between surfactant loadings of 0% and 2% w/w (P ≤ 0.001), 0% and 
both 6 and 10% w/w (P ≤ 0.0001) as well as between 2% and 6% w/w of surfactant (P ≤ 0.001), 
between 2% and 10% w/w and between 6% and 10% w/w (P ≤ 0.0001). The difference in PC 
concentration for liposomes forced through 50 nm decreased significantly between surfactant 
loadings of 0% and 2% w/w (P ≤ 0.01), 0% and both 6 and 10% w/w (P ≤ 0.0001), and finally 
between 2% and both 6 and 10% w/w (P ≤ 0.01).  
Similar observations were made in a similar study regarding lipid recovery following extrusion 
of liposomes formulated with PC, L-α-phosphatidyl-L-serine and cholesterol; a decrease in the 
detection of the phospholipids was observed (Jousma et al., 1987), however their study was 
limited by the fact that they did not quantify the recovery of cholesterol. Additionally, they 
attributed some of the loss in lipid recovery to retention of phospholipid or some large vesicles 
on the Sephadex® column. Conversely, another study concerning lipid recovery following 
extrusion observed 100% lipid recovery (Berger et al., 2001). This may have been due to a 
lower extrusion pressures employed in their study or water loss from the sample during a 
thawing process prior to analysation.  
 
This method was unable to detect and quantify and differences in surfactant concentration 
differences pre- and post- extrusion. Further method development would be required and this 
may be useful in determining the composition of the liposomes passing through the membrane. 
The difference in cholesterol concentration was lower than that of PC overall, but the initial 
concentration of cholesterol was around 4 times lower. Furthermore, although PC is more fluid 
and less rigid than cholesterol (Papahadjopoulos and Kimelberg, 1974; Papahajdopoulos, 
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1976; Thewalt and Bloom, 1992), it is also a large molecule and may have become lodged 
within the pores of the membrane and not passaged fully through the membrane. Nonetheless, 
as the loading of Tween 20 increased, the difference in pre- and post- extrusion lipid 
concentration decreased implying the liposome, in its original composition was able to pass 
through the pore. The Tween 20 would increase fluidity of the liposome, thus decreasing 
liposome destruction, therefore less constituents become stuck within the pores.  
2.4.4 Impact of liposomal formulation on In vitro cytotoxicity on HDFA and HaCat cells 
There is an increasing desire to limit animal and human exposure to drug testing, thus there is 
a need to develop validated in vitro test systems. Whilst animal testing has provided valuable 
information regarding the pharmacokinetic or pharmacodynamic profile of formulation 
systems, there are vast differences interspecies difference in the anatomy and physiology of 
skin.  
To determine the cellular toxicity of liposomes to HDFa and HaCat cells to be able to determine 
the compatibility of these formulations with skin, an XTT assay was performed to measure cell 
death after exposure of cells to different concentrations of blank liposomal formulations, those 
loaded with 2% w/w of Tween 20 and those loaded with 10% w/w Tween 20 for 24 hours. 
Results of cell viability are shown in Figure 2.13 and 2.14. 
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Figure 2.13: Cellular toxicity of liposomal formulations towards HDFa cells.  
Cells were grown on a 96-well plate at a density of 50 x 103 cells per well and exposed to 
various percentages of liposomal solution (up to 50% of a 16:8 mM of PC : cholesterol loaded 
with a) 0%, b) 2% or c) 10% w/w of Tween 20). After 24 hour incubation following which 25 µL 
of a 12.5:1 parts mixture of XTT to menadione was added each well. Plates were incubated 
for 3 hours at 37°C in a humidified atmosphere of 5% CO2 in air and the absorbance read at 
450 nm. The control cell (without drug) corresponded to a cell viability of 100%. Data is 
reported as mean ±SD with 6 replicates per compound in at 3 independent experiments. 
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Figure 2.14: Cellular toxicity of liposomal formulations towards HaCat cells. 
Cells were grown on a 96-well plate at a density of 50 x 103 cells per well and exposed to 
various percentages of liposomal solution (up to 50% of a 16:8 mM of PC : cholesterol loaded 
with a) 0%, b) 2% or c) 10% w/w of Tween 20). After 24 hour incubation following which 25 µL 
of a 12.5:1 parts mixture of XTT to menadione was added each well. Plates were incubated 
for 3 hours at 37°C in a humidified atmosphere of 5% CO2 in air and the absorbance read at 
450 nm. The control cell (without drug) corresponded to a cell viability of 100%. Data is 
reported as mean ±SD with 6 replicates per compound in at 3 independent experiments. 
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HDFa cells treated with blank liposomes maintained cell viability with no significant difference 
between control cells and cells treated with liposome solution up until 50% of liposome solution 
(of which stock solution contained 16:8 mM of PC to cholesterol) was applied where viability 
dropped to 19.0 ± 4.9 % (P ≤ 0.0001). The IC50 value was 38.87 % of a solution containing 
16:8 mM of PC to cholesterol. HDFa cells treated with liposomes loaded with 2% w/w Tween 
20 maintained cell viability with no significant difference between control cells and cells treated 
with liposome solution up until 50% of liposome solution (of which stock solution contained 
16:8 mM of PC to cholesterol) was applied where viability dropped to 37.8 ± 9.2 % (P ≤ 0.0001). 
The IC50 value was 43.16% of a solution containing 16:8 mM of PC to cholesterol. HDFa cells 
treated with liposomes loaded with 10% w/w Tween 20 maintained cell viability with no 
significant difference between control cells and cells treated with liposome solution up until 
25% of liposomes where viability dropped to 11% (P ≤ 0.0001). At 50% of liposome solution, 
viability dropped furthermore to 8% (P ≤ 0.0001). The IC50 value was 22.24 % of a solution 
containing 16:8 mM of PC to cholesterol.   
HaCat cells treated with blank liposomes maintained cell viability at all concentrations of 
liposomes. There was no significant difference between the cell viability of the cells treated 
with the range of liposome concentrations observed in this study. HaCat cells treated with 
liposomes loaded with 2% w/w Tween 20 maintained cell viability at all concentrations of 
liposomes. HaCat cells treated with liposomes loaded with 10% w/w Tween 20 also maintained 
cell viability at all concentrations of liposomes. 
Keratinocytes exist in the SC and their primary function is to act as a barrier to foreign objects. 
They are therefore more resilient than fibroblasts in that they form a part of the SC barrier  
(Thomas and Finnin, 2004) which explains why fibroblast cell viability decreased at higher 
liposome concentrations whereas keratinocyte viability did not. Liposomes loaded with 10% 
w/w of Tween 20 also seemed to have more of a toxic effect on fibroblasts and even the 
keratinocytes at higher concentrations. Tween 20 is a surfactant that may have interfered with 
the cell membrane of the cells.   
2.4.5 Cellular liposomal uptake assay on HDFa and HaCat cells 
Liposomes formulated beyond 2% w/w loading of Tween 20 did not show significant 
differences between the size, polydispersity, zeta potential and deformability. Therefore, only 
liposomes formulated with 0 and 2% w/w of Tween 20 were selected for further studies.  
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Liposomes fluorescently labelled with DilC, formulated with and without Tween 20, were 
incubated with both HDFa and HaCat cells to assess the cellular uptake of these formulations.  
Following a 2-hour incubation with the cells, the labelled liposomes were identified using 
confocal microscopy (Figure 2.15 and 2.16). Cytoplasmic accumulation of the formulations 
was apparent, confirming the successful uptake into both HDFa and HaCat cells.   
 
 
 
Figure 2.15: Localisation of DilC loaded liposomes in HaCat cells.  
Localisation of DilC labelled a) blank liposomes b) liposomes loaded with 2% w/w Tween 20 
in HaCat cells. Cells were grown on the coverslips for 2 days. Cell nuclei were visualised using 
DAPI (Blue).Liposomes were formulated with DilC for visualisation (yellow). 
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Figure 2.16: Localisation of DilC loaded liposomes in HDFa cells. 
Localisation of DilC labelled a) blank liposomes b) liposomes loaded with 2% w/w Tween 20 
in HDFa cells. Cells were grown on the coverslips for 2 days. Cell nuclei were visualised using 
DAPI (Blue). Liposomes were formulated with DilC for visualisation (red). 
 
 
Liposome uptake was observed within 2 hours of exposure to liposomes formulation with and 
without Tween 20. There are four proposed methods of liposome interaction with cells. The 
first one, termed ‘stable adsorption’ is the association of intact liposomes with the cell surface, 
without cell uptake. This adsorption may be mediated by specific components (including 
surface receptors and antibodies), or by nonspecific forces (including electrostatic and 
hydrophobic interactions). The second proposed interaction of liposomes is endocytosis 
(Pagano and Weinstein, 1978). This is the uptake of intact liposomes into endocytotic vesicles. 
Usually, this results in delivery to the lysosomal apparatus, but it is not unusual to see liposome 
contents escape into the cytoplasm. Both pinocytosis and phagocytosis is capable of mediating 
liposome uptake (Pagano and Weinstein, 1978). The third method of interaction is fusing of 
the lipid bilayer with the cell plasma membrane thus the concomitant release of liposome 
contents into the cytoplasm. Some liposome contents may leak into the medium or deposit 
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within other intracellular compartments. In the case of MLV, a multilamellar form with one less 
bilayer than the original should be found in the cytoplasm which may be beneficial when 
attempting to achieve a controlled release formulation (Martin and MacDonald, 1976). Finally, 
the fourth proposed method of liposome and cell interaction is lipid transfer. This is defined by 
the transfer of lipid molecules between liposomal bilayer and cells without actual cell 
association of aqueous liposome contents (Pagano and Weinstein, 1978). It is difficult to 
determine which of these occurred in this study, however, these methods of uptake are not 
mutually exclusive and any combination may be occurring in a given experimental 
circumstance (Pagano and Weinstein, 1978). 
 
A study observing deformable liposomal uptake into dermal cells using excised human skin 
from female patients also observed uptake following a 14 hour incubation period. Liposomes 
were formulated from Phospholipon 90, α-tocopherol and sodium cholate with a size range of 
120 -810 nm. Liposomes toward the smaller end of the size range observed greater penetration 
into the excised skin (Verma et al., 2003). A greater incubation period may have been 
necessary by Verma et al., due to the presence of surface lipids. Surface lipids (the ‘mortar’ in 
the ‘brick and mortar’ analogy), which are not present to the same extent in the cell culture 
model than in human epidermis, seem to play an important role in liposomal uptake (Kuntsche 
et al., 2008). The restricted permeation of nanoparticles in human skin might be caused by the 
adhesion of the nanoparticles onto the skin surface. Surface lipids appear to play an important 
role in nanoparticle adhesion, consequently, for restricted drug permeation. Therefore whilst 
cell culture studies are useful, they are not conclusive (Kuntsche et al., 2008). Occlusion 
caused by the triglyceride nanoparticles (fat emulsion, solid lipid nanoparticles) was less 
pronounced in the cell culture model where surface lipids are not present to the same extent 
as in human skin. Interestingly, corticosterone permeation was nearly comparable in human 
and rat epidermis when applied in a dispersion of smectic nanoparticles indicating that the 
surface lipids seem to be less important for this carrier system (Kuntsche et al., 2008). 
 
This formulation is aimed to be targeting the dermal layer. It is unclear whether or not the 
liposomes would completely pass through the keratinocytes into the dermal layer or whether 
they would accumulate in the stratum corneum. To be able to determine this, application onto 
excised skin would be necessary. Nonetheless it is clear liposomes were taken up by the cells, 
more importantly the fibroblasts where anti-cancer agents are aiming to be delivered.  
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2.5 Conclusion  
The dermal delivery of pharmaceutical actives used in the treatment of skin cancer is limited 
by the SC. Although cream formulations of chemotherapeutic agents do exist, the side effect 
profile, high daily dose frequency coupled with dose transference raise compliance and 
therefore treatment issues. Therefore, there is an inherent need to develop formulations able 
to penetrate the SC and provide a sustained release of drug delivery.  
This study investigated the use of the surfactants Tween 80, Tween 20 and sodium cholate in 
the development of elastic liposomes intended to pass through the SC and remain in the 
dermal layer where they would give a sustained release of drug. As the amount of surfactant 
in the bilayer is increased, liposome size decreases. Furthermore, the inclusion of surfactant 
within the bilayer seemed to produce a more homogenous formulation as defined by the 
polydispersity index.  
Stability studies concerning liposome size found that over the first 2 days, liposome size 
decreased although this may have been due to lipid aggregates settling out (as confirmed by 
creaming at the bottom of the liposome container). Beyond this, over 28 days, the liposome 
size was maintained for liposomes formulated with Tween 20 and sodium cholate, a slight 
decrease in size was observed for liposomes formulated with Tween 80. 
Inclusion of surfactant in the bilayer decreased the liposome DI and increased the amount of 
lipid able to pass through a membrane. Increasing the loading of the surfactant decreased the 
DI across all three surfactants. This implies that inclusion of surfactant would increase the 
ability of the liposome to pass through the gaps in the SC into the dermal layer. Sodium cholate 
appears to increase deformability the greatest, however, at the loadings investigated, Tween 
80 and Tween 20 appeared the most stable. Furthermore, presence of surfactant appears to 
aid liposome movement across a membrane with a smaller pore size than liposomal diameter. 
Liposomes were able to move across a 200 nm pore size easier than a 50 nm pore size which 
appeared to cause some destruction of the liposomal structure.  
Increasing loadings of Tween 20 within the liposomal bilayer appeared to increase the amount 
of energy stored within the bilayer that allowed the liposome to reform following extrusion rather 
than deforming permanently into smaller liposomal structures/aggregates. As the loading of 
Tween 20 increased, the difference in pre- and post- extrusion lipid concentration decreased. 
The Tween 20 increased fluidity of the liposome, thus decreasing liposome destruction, 
therefore less constituents become stuck within the pores. This implies that increasing loadings 
of Tween 20 allow the liposome, closer to its original composition, to pass through the pore.  
Following application of liposomes onto dermal cell lines, 50% of the liposome solution 
(containing 16:8 mM of PC to cholesterol) decreased fibroblast cell viability. This was only the 
case for liposomes formulated with 10% w/w Tween 20 on the keratinocytes; these cells were 
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not affected by blank liposomes or those formulated with 2% w/w of Tween 20. This highlights 
fibroblast cells are more sensitive to the liposomes formulated in this study therefore further 
formulation development must consider this phenomenon. Cell uptake of both blank and 2% 
w/w Tween 20 loaded liposomes was apparent into both the keratinocyte cell line and the 
fibroblast cell line.  
It appears elastic liposomes are useful in enhancing drug penetration through the SC into 
dermal cells and may be useful in the development of a controlled release formulation. Choice 
of surfactant influences liposomes size and deformability and thus the ability of the liposome 
to penetrate the SC. Investigation of Tween 80, Tween 20 and sodium cholate found that in 
terms of liposome stability, Tween 20 was the most suitable surfactant to continue to 
incorporate into the liposome formulation for all further studies.  
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3 Development of sustained 
release EGCG liposomal 
gel formulations for 
dermal drug delivery 
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3.1 Introduction 
Epigallocatechin gallate (EGCG) is a polyphenolic catechin (Figure 3.1) that been reported to 
posses a variety of anti-tumour effects towards cancerous skin cells including skin tumours 
(Gupta et al., 2004; Katiyar, 2011)and other neoplastic tumour types (e.g. colon (Chen et al., 
2003; Hwang et al., 2007; McLoughlin et al., 2004) pancreas (Shankar et al., 2008), lung, 
prostate and breast (Yang et al., 2002)). 
 
Figure 3.1: Molecular structure of EGCG 
 
The tumour microenvironment is both a cause and consequence of tumorigenesis. This 
environment affects how the tumour and host cells co-evolve through direct and indirect 
cellular interactions. This then elicits multistage effects on many biological processes, including 
cellular proliferation, growth, metabolism, as well as angiogenesis and hypoxia and immunity 
(Albini and Sporn, 2007).  
Emerging strategies for cancer management are primarily focused on chemoprevention and 
chemoprotection utilising naturally occurring nontoxic agents including EGCG (Hwang et al., 
2007; Siddiqui et al., 2009; Singh et al., 2011a). EGCG has been found to affect specific 
biological processes that could be exploited as targets for the prevention and treatment of 
cancer (Casey, S. C., et al. 2015). Specific properties include induction of apoptosis (Gupta et 
al., 2004), promotion of cell growth arrest by altering the expression of cell cycle regulatory 
proteins (Gupta et al., 2004), activation of killer caspases and the suppression of oncogenic 
transcription factors (Singh et al., 2011a; Singh et al., 2011b; Thawonsuwan et al., 2010) and 
pluripotency maintain factors (Sigler and Ruch, 1993). Furthermore, clinical studies have found 
that treatment with EGCG inhibits tumour incidence and metastasis in additional organ sites 
(Mukhtar and Ahmad, 2000; Singh et al., 2011a). 
The application of the use of naturally occurring compounds as chemopreventative and 
chemoprotective strategies has so far been received with limited success and this may be 
largely due to inefficient delivery systems and a limited bioavailability of promising agents. 
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Consequently, to achieve maximum clinical efficacy, novel approaches are required to 
enhance the bioavailability. A nanoparticle mediated delivery would be valuable in enhancing 
the bioavailability of these compounds.  
The skin is an efficient and effective physical barrier to the external environment.  The barrier 
function is, a result of the multilayer anatomy of the epidermis, dermal layer, and finally the 
subcutaneous layer.  The use of liposomal nanoparticle formulations as drug-delivery vehicles 
provide a novel approach to the delivery and targeting of the dermal layer alongside site-
specific delivery with benefits for both delivery of existing (poorly permeable) molecules and 
larger (often impermeable) biologics.  Elastic liposomes have been reported to penetrate the 
skin if applied non-occlusivley by the very high and self-optimizing deformability. They have 
already been successfully employed in the transdermal delivery of lipophilic and hydrophilic 
drugs including anti-inflammatory agents, plasmid DNA, anti-tumour agents and hormones 
(Cevc and Blume, 2001; El Maghraby et al., 1999; Oh et al., 2006; Romero et al., 2013). 
Liposome adhesion, fusion and penetration into the SC is possible with potentially deeper 
penetration into the dermal layer of deformable vesicles compared with traditional liposomes 
(El Maghraby et al., 1999). 
Furthermore, liposomes intended for topical application are required to be delivered in a carrier 
due to the liquid nature of the preparation. Liposomes are compatible with viscosity increasing 
agents such as cellulose based gels including HEC and HPMC (Foldvari, 1996). These are 
known to be safe in topical, dermal and transdermal delivery (Forbes et al., 2011b; Hascicek 
et al., 2009; Patton et al., 2007).  
 
3.2 Aims and objectives 
In this body of work, a formulation aiming to deliver EGCG to the dermal layer in the 
management of skin cancer was developed. The effectiveness of the in vitro delivery of EGCG 
encapsulated in liposomes in an aqueous gel system to the dermal layer was assessed. The 
aim of this study was to formulate and characterise an aqueous gel system loaded with elastic 
liposomes formulated with Tween 20 for the dermal delivery of EGCG. Liposomes were loaded 
with up to 10% w/w Tween 20 and 0.25 mg/mL of EGCG. They were characterised by size, 
zeta potential, DI and stability. EGCG release was observed from these liposomal formulations 
as well as from HEC and HPMC gels and from gels loaded with liposomes. Toxicity and uptake 
into HDFa and HaCat cells was subsequently determined. 
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To achieve the aims, the overall objectives were to 
 Validate a HPLC method for EGCG detection.  
 Formulate and characterise EGCG loaded liposomes and investigate the release 
profiles. 
 Characterise EGCG loaded deformable liposomes formulated with Tween 20 and 
investigate the release profiles. 
 Formulate and compare EGCG release from EGCG loaded HEC and HMPC aqueous 
gels 
 Formulate and compare EGCG release from aqueous gels loaded with EGCG loaded 
liposomes  
 Apply formulations to fibroblast (HDFa) and keratinocyte (HaCat) cell lines to 
characterise toxicity as well as cell localisation. 
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3.3 Materials and methods 
3.3.1 Materials 
The materials used to prepare liposomes, all reagents as well as materials used to grow HDFa 
and HaCat cells are detailed in section 2.3.1. EGCG, HEC and HPMC polymers were obtained 
from Sigma-Aldrich.  
3.3.2 Elastic liposome preparation  
Liposomes were prepared by using the film hydration method established by Bangham et al., 
(1965) detailed in section 2.3.2. Briefly, PC, cholesterol and surfactant were dispersed in 
chloroform and methanol in a 9:1 ratio. Ratios of lipids are detailed in Table 3-1 rational of 
which has been adapted from previous studies concerning the formulation of elastic liposomes 
(Hiruta et al., 2006; Ita et al., 2007; Oh et al., 2006; Tsai et al., 2015). EGCG loaded liposomes 
were prepared by adding the required amount of EGCG to the lipid mixing stage.  
Table 3-1: Details of liposome formulation composition.  
Formulation 
PC         
(% w/w) 
Cholesterol 
(% w/w) 
Tween 20 
(% w/w) 
1 80 20 0 
2 78 20 2 
3 76 20 4 
4 74 20 6 
5 72 20 8 
6 70 20 10 
Formulation 1 was the control formulation to which no surfactant was added 
 
3.3.3 Liposome characterisation: particle size and polydispersity and zeta potential 
Mean particle size, polydispersity index and zeta potential of liposomes was measured as 
detailed in section 2.3.3 using a Zetaplus (Brookhaven Instruments). Each sample was 
measured 3 times.  
3.3.4 Assessment of liposomal deformability  
The deformability index (DI) of the elastic vesicles was determined using a mini filtration 
technique as detailed in section 2.3.3. 
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3.3.5 HPLC Methodology 
Detection of EGCG was assessed using a reverse phase HPLC methodology. A Waters 
Alliance separation module HPLC with UV detection was utilised at an operating wavelength 
of 275 nm (Bradfield and Penney, 1948) with a Waters X select column (5 µm C18 4.6 x 150 
mm). 10 μL of sample at room temperature was injected. The mobile phase comprised of a 
70:30 ratio of 0.1% TFA in water to methanol at a flow rate of 1 mL/min.  
Stock solutions and standard solutions of EGCG were prepared with both water and ethanol 
ranging from 0.5-500 µg/mL.   
3.3.5.1 HPLC validation 
The method was validated by assessing the linearity and range, repeatability and sensitivity in 
terms of the limit of detection (LOD) limit of quantification (LOQ) and precision. The system 
was flushed with 100% methanol before each use for 30 min. 
For the linearity and range assessment, standard solutions ranging between 0.5-500 µg/mL of 
EGCG in water were prepared. The mean peak area ± SD was calculated and plotted against 
the known concentration of the standard.  
The repeatability of the method was assessed by determination of the intraday (same day) and 
interday (over the course of three days) variability.  
A study of the sensitivity of the method was assessed by means of the calculation of the LOD 
(equation 3.2), and the LOQ (equation 3.3) from the standard deviation (Equation 3.1). Values 
were determined from the standard deviation of the response (σ) and the slope (S) obtained 
from the calibration curves carried out during the linearity assessment. According to the ICH 
guidelines (Guideline, 2005), a signal-to-noise ratio of three was assumed for the quantification 
of the LOD, whereas for the LOQ, a signal-to-noise ratio of ten was set.  
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Equation 3.1: Standard deviation 
𝜎 =  
∑(𝑦 − 𝑦𝑖)
2
𝑛2
 
Equation 3.2: Detection limit 
𝐿𝑂𝐷 =  
3.3 ×  𝜎
𝑠
 
Equation 3.3: Quantitation limit 
𝐿𝑂𝑄 =
(10 ×  𝜎)
𝑠
 
where σ is the standard deviation, y is a data value, yi is the mean, n is the total sample 
population, and s is the slope of the curve. 
 
3.3.6 Determination of entrapment efficiency 
The entrapment efficiency of EGCG loaded in elastic liposomes was determined by 
centrifuging samples and quantifying drug in the supernatant. The sample was centrifuged at 
18,000 rpm for 30 min at 4°C in an Optimatm MAX-XP ultracentrifuge to separate the 
incorporated drug from the free form. The supernatant was then analysed using HPLC (section 
3.3.5) to determine the drug encapsulation percentage of the total EGCG load. The percentage 
encapsulation efficiency of EGCG in liposomal formulations was calculated using Equation 3.4:  
 
Equation 3.4:  
𝐸 =  
𝐷𝑡  −  𝐷𝑠
𝐷𝑡
 ×  100%  
where E is the encapsulation efficiency, Dt is the total drug content and Ds is drug content in 
supernatant. 
3.3.7 Differential scanning calorimetry investigations of EGCG and EGCG lipid blends 
EGCG and ratios of lipid, surfactant and drug mixtures corresponding to liposome ratios were 
was analysed in the solid state using a TA Instruments Q200 Thermal Analysis DSC. 3 mg of 
EGCG was weighed into T-Zero aluminium pans and then hermetically sealed. All 
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experimental runs started at an initial temperature of 0°C, purged under nitrogen gas, with a 
scan rate of 10°C/min to 300°C. 
3.3.8 EGCG loaded aqueous gel formulation  
Aqueous gels were prepared using HEC (1, 3 and 5% w/v) and HPMC (1, 3 and 5% w/v) which 
were mixed overnight using a mechanical mixer (Polytron PT 3100 D) at a speed of 3000 rpm. 
HEC and HPMC gels with a drug loading of 1% w/v polymer were formulated.  
3.3.9 In vitro EGCG release studies 
Drug release from gels, liposomes and liposomal gels over 24 hours was observed using 
multiple methods.  
A one compartment model to observe drug release requires formulation to be place directly 
into the release media and aliquots of media removed and quantified for drug release. A two 
compartment model may be used in which formulation and release media are separated by a 
membrane.  A one compartment model can be used to study release and gel swelling 
behaviour whilst a two compartment diffusion cell observes drug release across a membrane 
and allows for the comparison of release from solution (which would require a membrane to 
separate the donor and receiver compartments) to formulation. A one compartment model and 
a two compartment model was used to observe release from gels. A one compartment model 
was not suitable for release from liposomes as the additional step of ultracentrifugation or 
ultrafiltration to separate free drug must be applied. This however is time consuming and 
requires greater sample sizes. 
3.3.9.1 One compartment release model 
To study the in vitro release and swelling behaviour of gels over 24 hours 1 g of each EGCG 
loaded gel was syringed into plastic containers with 20 mL of dermal dissolution media (DDM) 
and these were then placed into a shaking water bath at 34 °C and 60 rpm. The release media 
was sampled with volume replacement (0.5 mL) at 15, 30, 60, 120, 180, 240, 300, 360, 420, 
480 and 1440 minutes and analysed using HPLC quantification with UV analysis (section 
3.3.5). 
3.3.9.2 Two compartment release model 
A diffusion cell dialysis system (PermeGear diffusion cell, Hellertown, USA) was used to 
evaluate in vitro drug release from aqueous solution (0.1 mg/mL), gels (formulated with 1% 
w/w of drug) and liposomes into release media. Drug release was quantified over 24 hours 
using a side by side diffusion chamber maintained at 35 °C. 10 mL of the formulation was 
placed into the donor side of the diffusion cell with a stirrer and release across a 50 nm 
membrane into the receiver side containing 100 mL of water with a stirrer was measured.  
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The release media was sampled with volume replacement (0.5 mL) at 15, 30, 60, 120, 180, 
240, 300, 360, 420, 480 and 1440 minutes and analysed using HPLC quantification with UV 
analysis. 
3.3.9.3 Liposomal gel release study 
In order to assess drug released from drug-loaded liposomes entrapped within polymer gels, 
a permeable insert models system was used.  A 4 cm2 cylindrical cell culture ThincertTM insert 
(400 µm pore size) was filled with 1 mL of formulation. Release into 4 mL of DDM in a 6-well 
ThincertTM plate from solution, and gels loaded with liposomes was quantified. HEC and HPMC 
gels loaded with 3% w/v of polymer were manufactured. These gels were then loaded with 
non-surfactant loaded liposomes formulated or liposomes formulated with 2% w/w Tween 20. 
The plates were maintained at 35 °C on a shaking plate. This system was used to investigate 
if drug/drug loaded liposome was able to diffuse out from the gel rather than to test and 
compare rates of release.  
The release media was sampled with volume replacement (0.5 mL) at 15, 30, 60, 120, 180, 
240, 300, 360, 420, 480 and 1440 minutes and analysed using HPLC quantification with UV 
analysis (section 3.3.5). 
3.3.10 Release kinetics 
To analyse the mechanism of drug release-rate kinetics, data obtained from in vitro release 
profiles can be quantified in many kinetic models including zero order, first order, Higuchi, and 
Korsmeyer-Peppas (Higuchi, 1963b; Korsmeyer et al., 1983; Peppas, 1985; Siepmann and 
Peppas, 2012). Mathematical modelling increases understanding of the release mechanism 
and can help reduce the number of experiments required to optimize drug formulations.  
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Zero order release: drug is released at a constant rate independent of the initial concentration 
(Equation 3.5).  
Equation 3.5: 
𝐶 =  𝐶0 −  𝑘𝑡 
where C is the concentration, Co is the original concentration, k is the rate constant and t is 
time. 
 
First order release: drug is released at a constant rate in proportion to the amount of drug 
available at that time (Equation 3.6).  
Equation 3.6: 
𝐶 = 𝐶0 𝑒
−𝐾𝑡 
where C is the concentration, Co is the original concentration, K is the rate constant and t is 
time. 
Higuchi: Higuchi developed several theoretical models to study the release of water soluble 
and low soluble drugs incorporated into semi-solid and/or solid matrixes (Higuchi, 1961; 
Higuchi, 1963b). Mathematical expressions were obtained for drug particles dispersed in a 
uniform matrix behaving as the diffusion media. To study the dissolution from a planar system 
having a homogeneous matrix, Equation 3.7 is used 
Equation 3.7: 
𝐶 =  𝐶𝑜𝐾 √𝑡 
Where C is the concentration, Co is the original concentration, K is the rate constant and t is 
time 
Korsmeyer-Peppas Model: A simple, semi-empirical model that relates exponentially the drug 
release to the fractional release of the drug (Equation 3.8) (Korsmeyer et al., 1983; Peppas, 
1985). 
Equation 3.8: 
𝐶𝑡
𝐶
=  𝐾𝑡𝑛 
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where Ct/C is fraction of drug released at time t, k is the release rate constant and n is the 
release exponent. The n value is the diffusional exponent and is used to characterise release 
for cylindrical shaped matrices, the value of n can be used to describe the release mechanism 
as described in Table 3-2.  
 
Table 3-2: Description of how the diffusional exponent n may be used to characterise 
release for cylindrical shaped matrices 
< 0.5 0.5 – 1 1 >  1 
Fickian diffusion: Non–fickian 
diffusion 
Case II 
transport 
Super case II 
transport Case I transport 
t0.5 tn-1 Zero order tn-1 
 
Mathematical models to assess release kinetis were fit using Microsoft Excel®. Zero order and 
first order release profiles were applied to release from drug solution and drug loaded liposome 
solution following which regression analysis techniques were employed to determine the 
probable drug-release. The release kinetic model displaying with the highest r2 metric (≥0.95) 
was determined to be the mechanism, by which release occurs. Furthermore, the Higuchi 
release profile and Korsmeyer-Peppas Model was applied to release data obtained from gel 
formulations and liposomal gels to describe release from a polymeric system.  
3.3.11 Growth and passage of cells 
HDFa isolated from adult skin, cryopreserved at the end of the primary culture were revived in 
medium 106 supplemented with Low Serum Growth Supplement. HaCaT is a spontaneously 
transformed aneuploid immortal keratinocyte cell line from adult human skin. HDFa and HaCat 
cells were maintained in a humidified 37 °C incubator with 5 % CO2, grown, fed and split for 
further proliferation as detailed in section 2.3.6. 
3.3.12 Impact of liposomal formulation on In vitro cytotoxicity on HDFa and HaCat cells 
To determine the cytotoxicity profile of EGCG towards HDFa and HaCat cells, an XTT assay 
(Scudiero et al., 1988) was performed to measure cell death after exposure of cells to different 
concentrations of drug for 24 hours. Cells were trypsinised, centrifuged and re-suspended in 
fresh media. Cells were then counted and seeded in a 96-well plate as detailed in section 2.3.7. 
On day 3, media was removed. Cells were treated with 100 µL of either 100 µM, 50 µM, 10µM, 
5 µM, 1 µM and 0.1 µM of drug in prepared in <1% DMSO / media. Plates were incubated in 
a humidified incubator for 24 hours at 37°C with 5% CO2 following which a mixture of 12.5:1 
parts of XTT to menadione (25 µL) was added each well in a 96 well plate. Plates were 
incubated for 3 hours at 37°C and the absorbance read at 450 nm on a Thermo Scientific 
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Multiscan spectrum. Assessment of EGCG toxicity to these cells was conducted through 
analysis of changes in XTT absorbance with increasing drug concentration. 
3.3.13 Cellular liposomal uptake assay on HDFa and HaCat cells 
Liposomes, both deformable and non-deformable, were formulated with the addition the 
fluorescent dye, DilC, in DMSO as detailed in section 2.3.8. Coverslips were prepared and 
analysed with an upright confocal microscope (Leica SP5 TCS II MP) as detailed in section 
2.3.8. 
3.3.14 Liposome stability 
The stability of liposomes was determined, as prepared in water, through the assessment of 
particle size over a 28 day period as detailed in section 2.3.4. 
Furthermore, the encapsulation efficiency of drug loaded liposomes was assessed over 4 
weeks as detailed in section 3.3.6.  
3.3.15 Statistical analysis  
Unless otherwise stated, all results are presented as mean +/- SD.  Replicates of at least 3 
were used for all studies. For multiwell plate assays replicates of 6 were used for each 
experimental condition with the study replicated 3 times. 
A paired T test or a one way ANOVA was used to determine any statistically significant 
difference between means tested. A post-hoc Tukey’s multiple comparisons test was then 
applied to assess differences between groups. Results were deemed statistically significant if 
P < 0.05%. 
  
114 
 
3.4 Results and discussion  
EGCG is a flavonoid that is the most abundant catechin (anti-oxidant) in tea, thus may be 
potentially useful as a pharmacological anti-cancer agent (Casey et al., 2015). This flavonoid 
has been found to have cytotoxic effects in cancerous skin cells. Additionally, it may also 
increase the efficacy of chemotherapeutic treatment as well as have chemoprotective effects 
(Chen et al., 2003; Gupta et al., 2004; Hwang et al., 2007; McLoughlin et al., 2004; Shankar 
et al., 2008; Siddiqui et al., 2009; Yang et al., 2002). 
The use of naturally occurring compound as chemopreventative and chemoprotective 
strategies has been limited in success due to inefficient delivery systems and a limited 
bioavailability of promising agents. Liposomes could be valuable in enhancing the 
bioavailability of these compounds (Nishiyama, 2007; Siddiqui et al., 2009). Elastic liposomes 
have been found to be advantageous in dermal delivery of drugs (Cevc and Blume, 2001; El 
Maghraby et al., 1999; Oh et al., 2006; Romero et al., 2013). Whilst being able to act as 
solubilising agents for low solubility drugs, they may also protect the drug from degradation in 
the body and may be formulated for targeted, sustained drug release. They can also improve 
drug deposition within the skin at the site of action where the aim is to reduce systemic 
absorption thereby reducing side effects (Benson 20016, Cevc 1996).  
Elastic liposomes have been reported to penetrate the skin if applied non-occlusivley by the 
very high and self-optimizing deformability. The skin is an efficient and effective physical barrier 
to the external environment.  They have already been successfully employed in transdermal 
delivery of lipophilic and hydrophilic drugs including anti-inflammatory agents, plasmid DNA, 
anti-tumour agents and hormones (Cevc and Blume, 2001; El Maghraby et al., 1999; Oh et al., 
2006; Romero et al., 2013).  
In attempting to delivery nanoparticle formulations to the dermal layer, it is often necessary to 
employ carrier vehicles such as a gel or cream due to the liquid nature of the preparation. It 
has been confirmed that liposomes are compatible with viscosity increasing agents such as 
cellulose based gels including HEC and HPMC (Foldvari, 1996). These are known to be safe 
in topical, dermal and transdermal delivery (Forbes et al., 2011b; Hascicek et al., 2009; Patton 
et al., 2007).  
3.4.1 Liposome characterisation: particle size and polydispersity and zeta potential 
A target goal for the present studies was to increase drug loaded liposome permeation across 
the epidermal layer; the size of drug carrier is an important determinant of this. EGCG loaded 
MLV liposomes were formulated using the dry film method, MLV’s were formulated by 
vortexing for 5 min (section 3.3.2). Liposomes were formulated with cholesterol which provides 
membrane stabilising properties by filling voids in between the phospholipids (Gregoriadis and 
Davis 1979). The inclusion of cholesterol thereby reduces permeability of the liposome bilayer 
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and prevents drug leaching out of the liposome structure (Demel et al., 1972). Additionally, 
various loadings of Tween 20, a polysorbate surfactant, were added to the formulation so as 
to add elastic properties to the bilayer.  
As the surfactant loading in the bilayer of EGCG loaded liposomes increased, a decrease in 
size was noted (from 1292.2 ± 33.5 nm for liposomes formulated with no surfactant to 524.8 ± 
25.1 nm for liposomes formulated with 10% w/w Tween 20 surfactant (Figure 3.2)). The 
decrease in size was significant for liposomes loaded with no surfactant compared with 
liposomes loaded with 2, 6 and 10% w/w Tween 20. There was no significant difference 
between the size of liposomes loaded with 2, 6 and 10% w/w of surfactant. Surfactant has 
been found to decrease liposome size in comparison to conventional liposomes (Goindi et al., 
2013; Tsai et al., 2015). This may be as a result of the surfactant destabilising the bilayer (El 
Zaafarany et al., 2010) and allowing a greater interaction of the phospholipid bilayer with the 
aqueous phase resulting in the overall formation of liposomes with a smaller diameter giving a 
greater surface area in contact with the aqueous phase.  
EGCG loaded liposomes were found to have a larger diameter than blank liposomes; 1292.2 
± 33.5 nm compared with 1030.25 ± 182.5 nm for liposomes formulated with no surfactant and 
358.1 ± 57.1 nm compared with 524.8 ± 25.1 nm for liposomes formulated with 10% w/w 
loading of Tween 20 (Figure 3.2). EGCG is amphiphilic in character (Mignet et al., 2013) thus 
when encapsulated in liposomes it will be bound to the membrane surface rather than being 
present within the hydrophilic core. Therefore, to increase capsulation within bilayer, 
encapsulation into liposomes was performed as in the case of lipophilic compounds where the 
bioactive is added directly to the lipid and solvent mixture (Istenic et al., 2016). The inclusion 
of drug in the bilayer may have caused an increase in liposome size by increasing bilayer 
hydrophobicity as it had caused the bilayer to have less interaction with the aqueous phase.  
Similar to blank liposomes, as the surfactant loading increased in the EGCG loaded liposomes, 
the diameter decreased, however, increasing the Tween 20 content beyond 2% w/w 
demonstrated no statically significant differences in liposome size. This would indicate that 
either 2% w/w is the maximum loading of Tween 20 that can be added in either formulation or 
that, simply, between 2% and 10% w/w, the size of liposome does not decrease as there is not 
sufficient surfactant to decrease the interfacial tension to decrease liposome size.   
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Figure 3.2: Liposome size distribution. 
Liposome size distribution, determined by DLS, comparing blank and EGCG loaded 
formulations with increasing loadings of Tween 20 up to a maximum of 10% w/w. Liposomes 
were prepared via the dry film hydration method and compound was added during the lipid 
mixing stage. Data represents mean ± SD. n=3 independent batches. 
 
A liposome preparation homogenous in size is important as size will determine liposome 
distribution in vivo as well as influence drug release kinetics. A polydispersity of up to 0.3 is 
considered homogenous (Chen et al., 2012; Goindi et al., 2013; Kang et al., 2013). Liposomes 
formulated without surfactant were slightly out of this range (0.33 ± 0.09 and 0.32 ± 0.04 for 
blank and EGCG loaded liposomes respectively) however liposomes formulated with 
surfactant all had a polydispersity below 0.3 therefore can be considered homogenous (Figure 
3.3). The polydispersity for EGCG loaded liposomes formulated with Tween 20 was similar to 
blank liposomes formulated with Tween 20 (P ≥ 0.05). The polydispersity of EGCG loaded 
liposomes however had a greater standard deviation (0.06 compared with 0.02 for liposomes 
formulated with 2% w/w Tween 20, 0.07 compared with 0.03 for liposomes formulated with 6% 
w/w Tween 20) showing these liposomes were perhaps less homogenous than blank 
liposomes. This may be due to EGCG disrupting the bilayer of the membrane resulting in a 
wider range of liposome diameter. Additionally, as the loading of Tween 20 increased, the 
polydispersity decreased from 0.322 with no surfactant to 0.221 with 10% w/w of Tween 20. 
As discussed later on in section 3.4.3, as the loading of Tween 20 increased, the entrapment 
efficiency decreases. Therefore this indicated that the presence of EGCG with the bilayer led 
to a wider size range of formulated liposomes.  
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Figure 3.3: Polydispersity of blank and EGCG loaded liposomes. 
Polydispersity, determined with DLS, of blank and EGCG loaded liposomes formulated with 
increasing loadings of Tween 20 up to a maximum of 10% w/w. Liposomes were prepared via 
the dry film hydration method and compound was added during the lipid mixing stage.  Data 
represents mean ± SD. n=3 independent batches. 
  
The zeta potential may be defined as the potential difference between the dispersion medium 
and the stationary layer of fluid attached to the dispersed particle. The magnitude of the zeta 
potential indicates the degree of electrostatic repulsion between adjacent, similarly charged 
particles in a dispersion. Thus it is one of the fundamental parameters known to affect stability. 
The zeta potential of blank and EGCG liposomal formulations is displayed in Table 3-3. 
 
 
Table 3-3: Zeta potential of liposomal formulations formulated with and without drug with up 
to 10% w/w loading of Tween 20 
Surfactant 
loading (% w/w) 
Zeta potential (mV)  
Blank 
Liposomes 
EGCG loaded 
liposomes 
0 5.03 ± 1.03 2.412 ± 1.08 
2 4.67 ± 1.08 3. 667 ± 0.91 
6 3.71 ± 0.90 -0.985 ± 1.01 
10 -2.79 ± 0.20 -1.895 ± 0.88 
Results are presented as the mean ± standard deviation (n=3) 
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A neutral liposomal surface charge is ideal to avoid skin irritation (Prausnitz and Langer, 2008) 
however, this may lead to particle flocculation due to the lack of like-charge causing repulsion 
between liposomes (Weiner et al., 1992). Furthermore, positively charged liposomes have 
been found to be irritating to the skin therefore negatively charged liposomes may be ideal 
(Katahira et al., 1999). This study identified that the majority of formulations for both blank and 
EGCG loaded liposomes to have a near neutral charge however, as the loading of Tween 20 
increased from 0 to 10% w/w, there was a general decrease in the zeta potential from 2.4 mV 
to -1.9 mV (Table 3.3), this was not however statistically significant.  
3.4.2 HPLC calibration and validation of EGCG detection 
In order to develop a robust HPLC method for the detection of EGCG, validation of the final 
HPLC-UV method was performed according to the International Conference of Harmonization 
(ICH) guidelines in terms of linearity and range, limit of detection (LOD), limit of quantification 
(LOQ) and precision. 
Calibration data using the method outlined in section 3.3.5 was then obtained (Figure 3.4).  
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Figure 3.4: HPLC-UV calibration curve for EGCG 
Calibration data for EGCG over the concentration range of 0-0.5 mg/mL in water following 
HPLC-UV analysis. A proportional response was evident versus the analytical concentration 
over the working concentration range with an r2 of 0.997 and linear equation of y = 1 x 107 ∙ x. 
Data represents mean ± SD. n=9. 
 
For the linearity and range assessment (Figure 3.4), standard solutions ranging between 0 – 
0.5 mg/mL of EGCG in water were prepared. The method developed demonstrated a high 
correlation with a good linear fit, with the correlation coefficient (r2) being greater than 0.99. 
Assessment of repeatability/precision of the developed method was determined by assessing 
the intraday (same day) and interday (over the course of three days) variability (Figure 3.5). 
This was done to assess variation caused by temperature fluctuations and any variation in 
experimental method EGCG standards from 0.5-500 µg/mL carried out intraday and interday 
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are plotted in Figure 3.5a and b respectively. The results show that the values have no 
statistically significant difference for all the calibration curves carried out at different times on 
the same day and also on different days, meaning the method has good precision. 
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Figure 3.5: Calibration data of EGCG obtained over 3 days 
Calibration data of EGCG following HPLC-UV analysis obtained over 3 days expressed as the 
mean of 3 repeats + standard deviation. The a) intraday, b) interday data is displayed. The 
standards of EGCG ranged from 0.5-500 µg/mL. Data represents mean ± SD. n=3. 
 
A study of the sensitivity of the method was assessed by means of the calculation of the LOD 
and the LOQ (Figure 3.4). Values were determined from the standard deviation of the response 
(σ) and the slope (S) obtained from the calibration curves carried out during the linearity 
assessment. According to the ICH guidelines, a signal-to-noise ratio of three was assumed for 
the quantification of the LOD, whereas for the LOQ, a signal-to-noise ratio of ten was set. 
Therefore, following Equations 3.2 and 3.3, the sensitivity of the method for EGCG was 
calculated; the LOD and LOQ for EGCG was 0.04 µg/mL and 0.12 µg/mL respectively. 
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3.4.3 Determination of entrapment efficiency 
Drug loading is an important parameter to observe and optimise to ensure minimal drug 
wastage. The percentage of EGCG entrapped in the liposome in relation to how much 
compound was included in the lipid mix was observed. Tween 20 and EGCG are both 
amphiphilic therefore may compete for space within the bilayer (El Maghraby et al., 2000; 
Istenic et al., 2016). The change in EGCG entrapment following addition of surfactant was 
therefore studied.  
As Tween 20 loading increased, entrapment significantly decreased from 80.0 ± 3.0 % EGCG 
entrapped with no surfactant to 4.3 ± 3.0 % with a 10 % w/w loading of surfactant (Figure 3.6). 
A significant difference was noted between liposomes loaded with no Tween 20 and up 10 % 
w/w Tween 20, between 2 and 6 % w/w Tween 20, and 2 and 10 % w/w Tween 20 (P ≤ 0.0001), 
A significant difference in EGCG loading was also noted between 6 and 10% w/w loading of 
Tween 20 (P ≤ 0.05). 
 
 
Figure 3.6: Entrapment efficiency of EGCG in liposomes formulated with up to 10% w/w 
Tween 20 
Entrapment efficiency (%) of EGCG in liposomes formulated with varying amounts of Tween 
20 (0-10% w/w) Data represents mean ± SD. n=3 independent batches. 
 
Blank liposomes could entrap 80% ± 3 of EGCG attempted to be loaded into the bilayer.  The 
presence of surfactant in the bilayer of the liposome allowed less drug to be incorporated in 
the bilayer implying the surfactant has a higher affinity to the lipids than EGCG (Casas and 
Baszkin, 1992; El Maghraby et al., 2000; Levy et al., 1991). Tween 20 is much larger than 
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EGCG (1227.54 g/mol and 386.65 g/mol respectively), thus it may be assumed it is better 
poised to displace EGCG from the bilayer (Figure 3.7). The hydrophobic tail of Tween 20 would 
have a high affinity to the chains in PC therefore it would be more poised to displace EGCG 
from the bilayer. Furthermore, Tween 20 is able to increase compound solubility, therefore, as 
not all would be entrapped within the bilayer, this may allow EGCG to solubilise within the 
liposomal rehydration media (Almog et al., 1986b). Therefore, as the loading of Tween 20 
increased, this would increase the amount of free Tween 20 resulting in more EGCG being 
able to solubilise in the liposome rehydration media. An alternative explanation for the effect 
of surfactant decreasing entrapment efficiency could be due to the possible coexistence of 
vesicles and mixed micelles at high surfactant concentrations (Almog et al., 1986a), with the 
consequence of lower compound entrapment in mixed micelles. Furthermore, it has been 
observed that although drug lipophilicity doesn’t affect compound loading, molecular weight 
does with larger molecules resulting in a lower liposomal drug loading (Ali et al., 2010).  
 
 
Figure 3.7: Structure and MW of EGCG, cholesterol, Tween 20 and PC 
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3.4.4 Assessment of liposomal deformability  
The addition of surfactant to the lipid bilayer of liposomes has been found to give the liposome 
elastic properties (Almog et al., 1986a; Cevc, 1996; Trotta et al., 2002). This is useful in dermal 
drug delivery to allow the transport of molecules across the SC into the dermal layer. 
Liposomes loaded with up to 10% w/w of Tween 20 were formulated and the degree of 
deformability of each formulation was determined by extruding them through a polycarbonate 
filter with a pore size of 200, 100 and 50 nm (Figure 3.8).  
The DI is defined as the degree the liposomes deformed. The greater the degree of 
deformation the less elastic the liposomes are as they were unable to regain their previous 
larger size.  
Liposomes extruded through a membrane with a pore size of 200nm observed that as 
surfactant loading increased, the deformation following extrusion decreased from 73.6 ± 8.1 to 
34.1 ± 7.4 % for EGCG loaded liposomes (Figure 3.8). Significant differences were found when 
2, 6 and 10% w/w Tween 20 was added to the formulations (P ≤ 0.0001). Significant differences 
were also found between 2 and 6% and 2 and 10% (P ≤ 0.05). No significant differences were 
found between 6 and 10% w/w surfactant loadings. 
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Figure 3.8: Deformability index for blank and EGCG loaded liposomes 
Deformability index following extrusion through a) 200 nm, b) 100 nm, c) 50 nm membranes 
for blank and EGCG loaded liposomes with increasing surfactant loading up to a maximum of 
10% w/w. Liposomes were prepared adapting the dry film method adding the surfactant and 
adding EGCG during the lipid mixing stage. The preparation was vortexed and then extruded 
though the membranes. Data represents mean ± SD. n=3 independent batches. 
 
Additionally, studies extruding liposomes through a membrane with a pore size of 100 nm 
observed that as the surfactant loading in the liposomes being extruded through increased, 
the deformation following this decreased from 64.0 ±1.9 to 27.7 ± 18.6 % for drug loaded 
liposomes although no DI’s were significantly different from the other. No trend however was 
observed for formulations forced through a 50 nm pore size. This is in comparison with studies 
with blank liposomes found that only liposomes forced through membranes with a pore size of 
200 nm and 50 nm had a significant decrease in the DI as surfactant loading increased (section 
2.4.3). Though there was a decrease in DI with increasing surfactant loading for liposomes 
forced through 100 nm, this was not statistically significant (P ≥ 0.05). 
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These observations imply the liposomes were displaying elastic properties as they could 
deform to fit through a gap smaller than its diameter whilst somewhat retaining its size. A study 
by Goindi et al., (2013) also found the presence of surfactant to decrease the DI (52% for blank 
liposomes compared with 17% for liposomes formulated with surfactant). Drug loaded 
liposomes have a greater DI overall, however, their overall size prior to extrusion was greater 
than that of blank liposomes therefore they would have to deform to a greater degree to be 
able to pass through the filter.   
Liposomes formulated with surfactant can deform as the surfactant has a propensity for highly 
curved structures (e.g. micelles and liposomes), thus diminishing the energy required for 
particle deformation. The surfactant is able to diminish the energy required for particle 
deformation and accommodate particle shape changes of the liposomes under stress (Trotta 
et al., 2004). These surfactants may have interacted with the PC with strong affinity but in 
reversible mode. The fast reconstruction of liposome spheres after extrusion may be due to 
the strong affinity between the surfactant and PC. The reversible binding mode might have 
provided the deformability upon physical stress (Oh et al., 2006). 
 
Liposomes were expected to deform to a greater extent with decreasing pore size. However 
EGCG loaded liposomes without surfactant and blank liposomes with surfactant (to a lesser 
extent) were unexpectedly found to have a very low DI when forced through a 50 nm pore size.  
However the standard deviation for these values was extremely large demonstrating that the 
DI mean value is not the close representation of the actual data values obtained (Figure 3.8). 
Liposomes formulated with surfactant however were found to be able to retain some elasticity 
and reform following extrusion. Therefore, even up to 50 nm, surfactant loaded liposomes 
retained enough elastic energy to maintain the same size as when forced through the 200 nm 
membrane. 
As discussed in section 2.4.3, to be able to deform, the liposomes require energy (Fresta and 
Puglisi, 1996; Gompper and Kroll, 1995; Trotta et al., 2002). Energy was supplied to this 
system in terms of pressure. The more surfactant included in the bilayer, the more energy the 
liposome as a whole is be able to retain (Trotta et al., 2002). The energy is used to bend the 
lipid bilayer structure, and since all systems tend toward the lowest state of free energy, the 
energy stored in this structure will be expelled once the liposome has passed through the pore 
and there is no longer any pressure forcing the bilayer to remain in an ‘unnatural state’. This 
energy can then be expended into reforming the liposome. Some energy will be lost during 
passage as heat or non-plastic deformation. Therefore, even at 10% w/w Tween 20, complete 
initial liposomes size was not recovered and a 0% DI was not achieved. The energy used to 
bend the bilayer of a liposome containing no surfactant does not benefit from the extra ‘storage 
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space’ of a surfactant, thus energy may be expended to rupture the membrane causing 
liposome size to decrease (Trotta et al., 2002).  
In order to passage through a 50 nm pore compared to a 200 nm pore, more energy is required 
to deform the liposome, therefore, since the energy input was kept constant, the DI is expected 
to increase as pore size decreases. This was not observed within the parameters of this study. 
In fact, for both formulations without surfactant, the DI was lower, however, the standard 
deviation for these values is extremely large showing that the mean value is not the best 
representation of the actual data values obtained. The liposome size following extrusion for 
these formulations was extremely varied with some liposomes even having a larger size 
following extrusion compared with the original size. EGCG loaded liposomes formulated 
without surfactant had an original size of 1292.2 ± 33.5 nm compared with 1312.3 ± 325.2 nm 
following extrusion, liposomes loaded with 2% w/w surfactant had an original size of 539 ± 
24.2 nm compared with 572 ± 174.6 nm following extrusion (Figure 3.7). This implies these 
formulations didn’t retain enough elastic energy to be easily able to fit through the pores with 
some liposomes even rupturing and converging following extrusion (Goindi et al., 2013; Trotta 
et al., 2002). Surfactant loaded liposomes had slightly more reliable DI values, therefore, at 50 
nm, the amount of energy stored in the liposome membrane was enough to reform the 
liposome to a similar extent as for when forced through a 200 nm membrane.  
Despite the potential for excess energy in liposomes formulated with 10% w/w Tween 20, 
liposomes were not able to fully regain their pre-extrusion size. Some energy will always be 
lost in the friction of the particles moving through the pores as heat (Vajjha et al., 2010). An 
increase in surfactant loading may bring the liposomes closer to 100% reformation (Trotta et 
al., 2002). Further, liposomes unable to fit through the pores or lipid aggregates from ruptured 
liposomes may cause blockages. This may lead to an increase in pressure in the vessel 
causing more turbulence leading to the rupture and non-uniform reformation of liposomes.  
As previously stated, the DI liposomes forced through a 50 nm pore size had a larger SD 
(Figure 3.8). This suggests there may have been some liposome destruction and the 
formulation of lipid aggregates as well as smaller liposomes that didn’t reform. Liposome 
formulations in this study therefore were not suitable to pass through a 50 nm pore. This is not 
to say this is what would happen to liposomes when applied to the skin. Firstly there would not 
be an applied pressure, liposomes would be expected to move across the skin following the 
osmotic transepidermal gradient as has been found in many similar studies concerning the 
dermal and even transdermal delivery  of drug (Cevc, 1996; Goindi et al., 2013; Gompper and 
Kroll, 1995; Trotta et al., 2002). Additionally such lipid carriers are miscible with the epidermal 
lipids present within the barrier of the stratum corneum thus would be able to penetrate into 
deeper layers of the skin (El Maghraby et al., 2008; Kirjavainen et al., 1996; Schäfer-Korting 
et al., 2007). Furthermore, the skin is warmer than room temp (35 °C compared to 20 °C). 
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Temperature governs the energy term of enthalpy therefore the liposomes would have more 
energy to be even more flexible and cross the stratum corneum. Many studies using either in 
vivo methods or in vitro methods with excised skin have found surfactant loaded liposomes to 
have better skin penetration compared with conventional liposomes as well as other 
formulations. (Dubey et al., 2006; El Maghraby et al., 1999; Oh et al., 2006) 
 
3.4.5 Differential scanning calorimetry investigations of EGCG and EGCG lipid blends 
Differential scanning calorimetry (DSC) has been widely used in its application in 
understanding the thermal characteristics of materials where an insight into a range of thermal 
properties including melting temperatures, phase transitions and heat capacity changes can 
be obtained. Figure 3.9 illustrates the DSC thermogram for EGCG. 
 
 
Figure 3.9:  DSC scan of EGCG. 
All experimental runs commenced at an initial temperature of 0 °C with a scan rate of 10 °C/min 
to 300 °C. Peak a and b are related to the epimer of EGCG, GCG. Peak c represents the glass 
transition temperature (Tc) of EGCG was at 220 °C and the melting point (Tm) of EGCG was at 
245 °C. 
 
The glass transition temperature (Tc) of EGCG was identified at 220 °C (peak c) and the 
melting point (Tm) of EGCG was at 245 °C (peak d) (Figure 3.9) and concurred with those 
reported by Cho et al (2008) where the Tm of GCG (an epimer of EGCG) was at 223 °C, the 
Tc of EGCG was at 235 °C and the Tm of EGCG was at 246 °C. Cho et al also observed a peak 
c 
a 
b 
d 
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at 97 °C and determined it to be the conversion temperature of EGCG into GCG. Therefore, 
the first two troughs (peak a and b) observed in the scan may be representative of the epimer 
GCG (Cho et al., 2008).   
 
The DSC of the lipid (PC and cholesterol) and Tween 20 blend is illustrated in Figure 3.10a. 
The Tm of this mixture is 172 °C. Upon addition of EGCG to this mixture (Figure 3.10b), the 
melting point shifted to 191 °C (Figure 3.10b). This shows the surfactant loaded liposomes 
could decrease the Tm of EGCG. 
 
 
 
 
Figure 3.10: DSC analysis scans of PC, cholesterol and Tween 20 and EGCG blends. 
DSC analysis scans of a) PC, cholesterol and Tween 20 blend and b) PC, cholesterol, Tween 
20 and EGCG blend. The Tm of the lipid mixture is 172 °C, and upon addition of EGCG, the Tm 
was 191 °C. All experimental runs started at an initial temperature of 0 °C, purged under 
nitrogen gas, with a scan rate of 10 °C/min to 300 °C. 
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3.4.6 Development of a suitable dermal dissolution media  
PBS is a buffer solution commonly used as a release media. The osmolarity and ion 
concentrations of this solution match those of the human body (isotonic) (Sigma-Aldrich(d), 
2017). The HPLC methodology for each compound was established with water as the solvent, 
given the high water solubility of EGCG. However, method development for compounds in PBS 
proved problematic as, peaks either disappeared or split peaks were obtained. PBS therefore 
may have caused drug breakdown or ionised the drug such that it eluted out of the HPLC 
column straight away.  
The pH of PBS is 7.4. The pH of the dermal layer however ranges from 4-7.4 (Cordero et al., 
1997) and unlike, for example, gastric fluid, there are no standardised universally accepted 
formulas to simulate dermal fluid. The volume of dermal fluid is minimal and consists mainly of 
extracellular fluid (Groenendaal et al., 2010; Herting et al., 2014; van der Merwe et al., 2006; 
Wiig and Swartz, 2012). Studies therefore use a solution buffered to somewhere within the pH 
range of the dermal layer (Cordero et al., 1997; Giri et al., 2011; Hadgraft and Valenta, 2000; 
Herting et al., 2014; Trovatti et al., 2011).  
Release into a release media buffered to pH 5.2 using sodium acetate was attempted. Again, 
split peaks or disappearing peaks were observed. To aid in the analysis of the EGCG release 
from formulations, studies were conducted in purified water buffered to a pH of 7.2. This 
overcame issues with HPLC coupled with UV detection. Whilst this does not mimic dermal 
fluid, there are no standardised formulas for such a medium. Furthermore, countless studies 
observing simple dermal release use a solution buffered to a pH with the aforementioned range 
(Bhatia et al., 2004; Bragagni et al., 2012; Cevc and Blume, 2001; Fresta and Puglisi, 1996; 
Trovatti et al., 2011; Tsai et al., 2015).  
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3.4.7 In vitro EGCG release studies 
3.4.7.1 EGCG release studies from gel formulations 
Liposomes intended to be delivered dermally are required to be delivered in a carrier due to 
the liquid nature of the preparation. Suitable viscosity and application properties of liposomes 
can be achieved by incorporating in an appropriate vehicle. It has been confirmed that 
liposomes are compatible with viscosity increasing agents such as cellulose based gels 
(Foldvari, 1996). These are known to be safe in topical, dermal and transdermal delivery 
(Forbes et al., 2011b; Hascicek et al., 2009; Patton et al., 2007). Therefore HEC and HPMC 
were selected as polymer agents to compare as carriers of liposomal preparations for dermal 
drug delivery.  
 
A necessary step in the evaluation of drug delivery systems is the rate of drug release from 
the carrier. Dissolution/release tests are used to help predict the in vivo behaviour of medicinal 
formulations. The release of drug from a formulation is determined by many factors including 
diffusion, erosion of matrices followed by dissolution of drug.  
Two geometric systems have been considered for EGCG release from gel systems; three-
dimensional leaching from a cylinder of gel (one compartment release) and unidirectional 
leaching across a planar surface (two compartment release). A one compartment model can 
be used to study release and gel swelling behaviour whilst a two-compartment diffusion cell 
observes drug release across a membrane. A polycarbonate membrane with 50 nm was used 
to mimic the SC and the gaps in between the keratinocyte cells. The composition of both HPMC 
and HEC gels was varied between 1 and 5% w/v to study how gel viscosity influenced EGCG 
release from the gel.  
 
3.4.7.1.1 One compartment release studies  
Release from the aqueous gels HEC and HPMC gels loaded with 1% w/w EGCG using DDM 
as a release medium was studied over a 24-hour period (Figure 3.11 and 3.12). Both the HEC 
and HPMC gels displayed a similar pattern of release into the water. It is however, clear that 
at equal loading of polymer, HPMC was able to retard drug release. Furthermore, as the 
loading of polymer increased, drug release was slower. HEC gels formulated with 1% w/w of 
the polymer gave complete drug release by 1.5 hours, 3% w/w observed complete release by 
2 hours and 5% w/w observed complete release by 3 hours. 
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Figure 3.11: In vitro percentage EGCG release profiles from HEC gel. 
In vitro percentage EGCG release profiles from aqueous HEC gels (1, 3 and 5% w/v) over a) 
24 hours, b) 4 hours. Data represents mean ± SD. n=3 independent batches. 
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Figure 3.12: In vitro percentage EGCG release profiles from HPMC gels 
In vitro percentage EGCG release profiles from aqueous HPMC gels (1, 3 and 5% w/v) over 
a) 24 hours, b) 8 hours. Data represents mean ± SD. n=3 independent batches. 
 
Significant differences were found between 1 and 5 % w/w and 3 and 5% w/w polymer loadings 
(P< 0.05). No significant differences were found between 1 and 3% w/w polymer loadings. 
HPMC gels formulated with 1% w/w of the polymer gave complete drug release by 2 hours, 
3% w/w observed complete release by 3 hours and 5% w/w observed complete release by 4 
hours. Significant differences were found between 1 and 3 % w/w (P ≤ 0.05), 1 and 5% w/v, 
and 3 and 5% w/w polymer loadings (P< 0.01). At the point of complete release, the gel was 
observed to have completely dissipated into the release media. 
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Diffusion of solutes out of the polymer is known to depend on temperature, pressure, viscosity 
and solute size. Diffusion of solutes out of polymers is dependent upon the concentration and 
degree of swelling of polymers. Solvent diffusion is associated with the physical properties of 
the polymer network and the interactions between the polymer and solvent (Masaro and Zhu 
1999). Furthermore, a study using the molecular weight of the drugs as an approximation of 
molecular size could not find a relation to release rates. This indicates that molecular geometry 
plays a role in compound release from polymer networks (Ford, Rubinstein et al. 1987, Rao, 
Devi et al. 1990).  
 
The predominant molecular mechanism of drug release is a result of drug diffusion due to the 
concentration gradient and macromolecular relaxation of the polymer chains. This causes drug 
diffusion outward with a kinetic behaviour dependent on the relative ratio of diffusion and 
relaxation and due to the fact cellulose derivatives have limited solubility for lipophilic 
compounds thus the compound would diffuse out of the gel (Forbes et al., 2011b; Lee, 1985). 
As water penetrates the glassy hydrogel matrix containing the dispersed drug, the polymer will 
swell and its glass transition temperature is lowered. Concurrently, the dissolved drug diffuses 
through this swollen rubbery region out into the release medium (Bouwstra and Junginger, 
1993; Gupta et al., 2002; Lee, 1985; Rao et al., 1990). The rate-controlling factor mediating 
drug release is the resistance of polymer to a change in shape due to an increase in volume 
(Ranga Rao and Padmalatha Devi, 1988). 
 
It has been suggested that the addition of water-insoluble drug can increase the water uptake 
by the dosage form. Water influx weakens the network integrity of the polymer, as the polymer 
swells, the matrix experiences intra-matrix swelling force promoting disintegration and leaching 
of the drug leaving behind a highly porous matrix (Sai Cheong Wan et al., 1995). The drug 
particles in between the polymer chains therefore allow each chain to hydrate freely, which 
may result in weak hydrogen bonding areas around the drug molecule (Panomsuk et al., 1996). 
Further, the influence of drug on the swelling properties of the polymer matrix is largely 
dependent on the substituted groups of the polymer. The hydroxyl group in the molecules plays 
an important part in the matrix integrity of the swollen hydrophilic cellulose matrices. The 
amount and properties of the incorporated drug determine matrix integrity (Nafee et al., 2003). 
In this case, it appears the HEC matrix eroded/swelled quicker than HPMC giving a faster rate 
of release. This is in contrast with a study by Nafee et al (2003) comparing the release of 
miconazole from a 1.5% w/v HEC formulation with a 3% HPMC w/v formulation, where faster 
erosion was observed from the HPMC matrix. This highlights how the physiochemical 
properties of the drug, the polymer and the interaction between the two affect drug release 
from the formulation. 
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3.4.7.1.1.1 Kinetic assessment of drug release 
A necessary step in the evaluation of drug delivery systems is the rate of drug release from 
the carrier. Dissolution/release tests are used to help predict in vivo behaviour and to study the 
structure of the dissolving matrix. The release of drug from a formulation is determined by 
many factors including diffusion, and erosion of matrices as detailed in Figure 3.13.  
 
 
Figure 3.13: Methods of drug release from a pharmaceutical formulation 
 
Release from modern formulations can be very complex with multiple factors driving drug 
release and dissolution. The relationship between formulation variables and release profiles 
are not entirely understood. Mathematical models may be influential in understanding drug 
release.  
The mechanism of drug release from the carrier system if dependent upon the carrier system 
itself and drug interaction with it. A zero order release is observed when drug is released at a 
constant rate independent of the initial concentration. A first order release is observed when 
drug is released at a constant rate in proportion to the amount of drug available at that time. 
Additionally, Higuchi (Higuchi, 1961; Higuchi, 1963b) developed several theoretical models to 
study the release of water soluble and low soluble drugs incorporated into semi-solid and/or 
solid matrixes. 
The release profiles were evaluated by zero-order, first-order and Higuchi kinetics (Table 3-4). 
Release from the gels were observed to fit the first order release model. Thus, drug was 
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released at a constant rate in proportion to the amount of drug available at that time. A study 
by Hascicek et al., (2009) formulated HEC gels at 7.5% w/w with 1% w/w of drug. A kinetic 
analysis, observed release fitting the Higuchi model best. A study by Ford et al (1987) found 
drug release from HPMC tablets to fit the Higuchi release model. These differences may be 
explained by considering differences in formulation, and differences in experimental 
parameters for example their use of either Franz cells with only a thin film of gel spread over 
the membrane or dissolution chambers with large volumes of release media (Ford et al., 1987; 
Hascicek et al., 2009). Furthermore, release from gels formulated with a HPC cellulose 
polymer was found to follow first order kinetics indicating drug release depends on formulation 
parameters (Ranga Rao, Devi et al. 1988). A simple gel formulation was used in this study and 
the kinetic model of release data was not investigated further.  
 
Table 3-4: Kinetic assessment of release data of EGCG from HEC and HPMC aqueous gels. 
Kinetic model 
Formulation 
HEC (r2) HPMC (r2) 
1% w/v 3% w/v 5% w/v 1% w/v 3% w/v 5% w/v 
Zero order  -3.210   
± 0.467 
-2.350 
± 0.456 
-1.114 
± 0.321 
-2.468     
± 0.478 
-1.781 
± 0.432 
-0.447     
± 0.176 
First order  0.868      
± 0.0256 
0.971    
± 0.015 
0.928   
± 0.038 
0.975     
± 0.014 
0.930    
± 0.036 
0.938      
± 0.036 
Higuchi  -0.344    
± 0.184 
0.006    
± 0.150 
0.462   
± 0.077 
-0.004    
± 0.157 
0.256    
± 0.136 
0.647      
± 0.039 
 Results are presented as the mean ± standard deviation (n=3) 
 
Comparison of the rate constant of each formulation shows that as the loading of both HEC or 
HPMC polymers was increased the rate constant decreased (Table 3-5). This implies that as 
polymer and thus gel consistency is increased, the rate of release is retarded. A study by 
Gaikwad et al (2012) also found that the release of drug from an aqueous gel decreased as 
viscosity increased. As polymer loading increase, the gel viscosity increases. Drug is released 
from gel by the creation of pores dues to swelling, as viscosity increases polymer chains 
becoming more resistant to movement as they are physically restricted thus taking longer to 
dissipate into the media thus slowing release drug (Bouwstra and Junginger, 1993; Forbes et 
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al., 2011a; Gaikwad et al., 2012). Thus as polymer loading increases, the rate constant for 
drug release will decrease. 
Table 3-5: First order kinetics rate constant for EGCG release from formulations. 
First order kinetic rate constant (min-1) 
HEC HPMC 
1% w/v 3% w/v 5% w/v 1% w/v 3% w/v 5% w/v 
0.018 ± 
0.002 
0.014  ± 
0.002 
0.009 ± 
0.001 
0.014 ± 
0.002 
0.011 ± 
0.001 
0.006 ± 
0.001 
Results are presented as the mean ± standard deviation (n=3) 
 
Furthermore, the Korsmeyers-Peppa’s model was applied to the release data and the 
diffusional exponent (n) calculated (Table 3-6). The Korsmeyer-Peppas Model is a simple, 
semi-empirical model that relates exponentially the drug release to the fractional release of the 
drug (Korsmeyer et al., 1983; Peppas, 1985).The n value is used to characterise release for 
cylindrical shaped matrices, the value of n can be used to describe the release mechanism as 
described in Table 3-2. This can be used to suggest release mechanisms from polymers. 
Fickian release (case I) was observed for both polymers between 1 and 5% w/v loadings. A 
study by Ritger and Peppas found both Fickian and anomalous release from swellable devices 
(Ritger and Peppas, 1987). Additionally, a study using the polymer HPC observed both non 
fickian and super case II transport (Alfrey Jr et al., 1966; Ranga Rao et al., 1988).  
 
Table 3-6: Diffusional exponent n calculated from the Korsmeyer-Peppas model of drug 
release for EGCG release data from aqueous gels with the corresponding release 
mechanism. 
Formulation n Transport type 
HEC 
1% w/v 0.206 ± 0.015 Fickian 
3% w/v 0.240 ± 0.018 Fickian 
5% w/v 0.312 ± 0.023 Fickian 
HPMC 
1% w/v 0.238 ± 0.017 Fickian 
3% w/v 0.272 ± 0.023 Fickian 
5% w/v 0.373 ± 0.021 Fickian 
Results are presented as the mean ± standard deviation (n=3) 
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Fickian diffusion is often observed in polymer networks when the temperature is above the 
glass transition temperature of the polymer (Tg). When the polymer is in the rubbery state, the 
polymer chains have a higher mobility that allows an easier penetration of the solvent (Masaro 
and Zhu, 1999). This implies that, in the present studies, when Fickian transport was observed, 
the polymer chains could move sufficiently and that at those loadings of polymer, the gel was 
in a rubbery state.  
Fickian diffusion and Case II solute release behaviour in swelling-controlled release systems 
are distinctive as each can be described in terms of a single limitation. Fickian transport is 
described by a diffusion coefficient (flux due to molecular diffusion and the concentration 
gradient), while Case-II transport is described by a characteristic relaxation constant 
(associated with stresses and state-transition in hydrophilic glassy polymers which swell in 
water or biological fluids) (Peppas and Sahlin, 1989). Non-Fickian behaviour however requires 
two or more parameters to describe the coupling of diffusion and relaxation phenomena (Ritger 
and Peppas, 1987). As previously described, the predominant molecular mechanism of drug 
release is a coupling of drug diffusion and macromolecular relaxation of the polymer chains 
because of which the drug diffuses outward. Such diffusion and swelling generally does not 
usually follow a Fickian diffusion mechanism however, this may depend on experimental 
parameters (Lee, 1985; Peppas and Sahlin, 1989; Ritger and Peppas, 1987). The existence 
of some molecular relaxation process in addition to diffusion is believed to be responsible for 
the observed non-Fickian behaviour  (Lee, 1985). 
3.4.7.1.2 Two compartment release 
The release of EGCG from HEC and HPMC gel formulations at polymer loadings of 1 3 and 
5% w/v over a 24 hour period, across a 50 nm polycarbonate membrane in a two compartment 
model using a diffusion cell was also assessed. This was compared against release from 
solution in the donor compartment into the receiver compartment. Over 24 hours, 100% of 
EGCG release was observed from all formulations. HPMC and HEC gels at the compositions 
studied both slowed EGCG release in comparison to release from EGCG solution (Figure 3.14 
and 3.15). 
Release from HEC observed significant differences between release from 1 and 5 % w/v 
polymer (P ≤ 0.001), solution and 3 and 5 % w/v polymer as well as 1 and 3 %, additionally 3 
and 5 % w/v polymer (P ≤ 0.01), and solution and 1 % w/v loading of polymer (P ≤ 0.05). 
Release from HPMC observed significant differences between release from 1% and 5 % w/v 
loading of polymer (P ≤ 0.0001), solution and 5% w/v polymer as well as 1 and 3 % w/v polymer 
(P ≤ 0.001), solution and 1 and 3 % w/v polymer as well as 1 and 3% w/v polymer (P ≤ 0.01).  
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Figure 3.14: In vitro percentage EGCG release profiles from HEC gels and EGCG solution 
Release profiles from aqueous HEC gels (1, 3 and 5% w/v) with 1% w/v EGCG and EGCG 
solution over a) 24 hours, B) 8 hours. Data represents mean ± SD. n=3 independent batches. 
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Figure 3.15: In vitro percentage EGCG release profiles from HPMC gels and EGCG solution 
EGCG release profiles from aqueous HPMC gels (1, 3 and 5% w/v) with 1% w/v EGCG and 
EGCG solution over a) 24 hours, b) 8 hours. Data represents mean ± SD. n=3 independent 
batches. 
 
 
3.4.7.1.2.1 Kinetic assessment 
Release profiles were subsequently evaluated using the Zero-order, First-order and Higuchi 
kinetic models. Release from the solution was observed to fit the First order release model 
when compared to the Zero order model and the Higuchi model (r2 values were 0.19, 0.93 and 
0.80 for the zero order, first order ad Higuchi model respectively) (Table 3-7). 
Furthermore, based upon the r2 values, release from the gels was observed to fit the First order 
release model best upon comparison with those for the zero order model and the Higuchi 
model (Table 3-7). Thus drug was released at a constant rate in proportion to the amount of 
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drug available at that time. Following a kinetic analysis, a study formulating HEC gels at 7.5% 
w/w with 1% w/w of drug observed release to fit the Higuchi model (Hascicek et al., 2009). 
 This may be due to differences in formulation, and differences in experimental parameter 
including their use of Franz diffusion cells with only a thin film of gel spread over the membrane 
(Hascicek et al., 2009). Additionally, release from gels formulated with a HPC cellulose polymer 
was found to follow first order kinetics indicating drug release depends on formulation 
parameters (Ranga Rao, Devi et al. 1988). 
 
Table 3-7: Kinetic assessment of release data of EGCG from solution and aqueous gels. 
Kinetic 
model 
Formulation 
Solution 
(r2) 
HEC (r2) HPMC (r2) 
1% w/v 3% w/v 5% w/v 1% w/v 3% w/v 5% w/v 
Zero 
order 
0.188 ± 
0.0474 
0.140 ± 
0.133 
0.169 ± 
0.348 
0.692 ± 
0.168 
0.276 ± 
0.032 
0.689 ± 
0.036 
0.850 ± 
0.046 
First 
order 
0.929 ± 
0.020 
0.958 ± 
0.037 
0.948 ± 
0.034 
0.956 ± 
0.053 
0.960 ± 
0.028 
0.956 ± 
0.004 
0.987 ± 
0.005 
Higuchi 
model 
0.803 ± 
0.080 
0.859 ± 
0.065 
0.862 ± 
0.012 
0.903 ± 
0.067 
0.907 ± 
0.013 
0.908 ± 
0.031 
0.894 ± 
0.021 
Results are presented as the mean ± standard deviation (n=3) 
 
Comparison of the rate constant of each formulation demonstrates that as the loading of HEC 
or HPMC was increased the rate constant decreased (Table 3-8). This implies that as gel 
consistency is increased, the rate of release slows. As polymer loading increase, the gel 
viscosity increases. Drug is released from gel by the creation of pores dues to swelling, as 
viscosity increases polymer chains becoming more resistant to movement as they are 
physically restricted thus taking longer to dissipate into the media thus slowing release drug. 
Furthermore, comparison between the gels found that HEC at its respective loading of polymer 
in the HPMC gels always gave a faster release of drug. 
The water-insoluble drug incorporated in a gel matrix can increase the water uptake by the 
dosage form. Water influx weakens the network integrity of the polymer, as the polymer swells, 
the matrix experiences intra-matrix swelling force promoting disintegration and leaching of the 
drug leaving behind a highly porous matrix (Sai Cheong Wan, Wan Sia Heng et al. 1995). 
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Additionally, the influence of drug on the swelling properties of the polymer matrix is dependent 
on the substituted groups of the polymer (Nafee, Ismail et al. 2003). In this case, it appears the 
HEC matrix eroded/swelled quicker than HPMC giving a faster rate of release. This is in 
contrast with a similar study observing and comparing the release of miconazole from a 1.5% 
w/v HEC formulation with a 3% HPMC w/v formulation where faster erosion was observed from 
the HPMC matrix (even at double the polymer loading) (Nafee et al., 2003). This highlights 
how the physiochemical properties of the drug, the polymer and the interaction between the 
two affect drug release from the formulation. 
 
Table 3-8: First order kinetics rate constant for EGCG release from formulations 
Rate constant (× 10-3 min-1 ) 
Solution HEC HPMC 
1% w/v 3% w/v 5% w/v 1% w/v 3% w/v 5% w/v 
3.10 ± 
1.26 
3.98 ± 
5.79 
3.52 ± 
0.88 
1.91  ± 
0.37 
3.17 ± 
1.09 
2.28  ± 
0.14 
1.34 ± 
0.08 
Results are presented as the mean ± standard deviation (n=3) 
 
Furthermore, the Korsmeyers-Peppa’s model was applied to the release data and the 
diffusional exponent (n) calculated (Table 3-9). This can be used to suggest release 
mechanisms from polymers. Fickian release was observed for HEC gels at 1% w/w and 3% 
w/w of polymer, and HPMC gels at 1% w/w polymer. Non-fickian release was observed for the 
HEC gels at 5% w/w and HPMC gels at 3% and 5% w/w of polymer. It is not uncommon to 
observe multiple release mechanisms for gels formulated with various loading of polymers. A 
study by Ritger and Peppas found both Fickian and anomalous release from swellable devices 
(Ritger and Peppas, 1987). Additionally, a study using the polymer HPC observed both non 
Fickian and super case 2 transport (Alfrey Jr et al., 1966; Ranga Rao et al., 1988).  
Fickian diffusion is often observed in polymer networks when the temperature is above the 
glass transition temperature of the polymer (Tg). When the polymer is in the rubbery state, the 
polymer chains have a higher mobility that allows an easier penetration of the solvent. Non-
Fickian diffusion processes are mainly observed when the temperature of study is below Tg. 
At a specific temperature below Tg, the polymer chains are not sufficiently mobile to permit 
immediate penetration of the solvent in the polymer core (Masaro and Zhu, 1999). This implies 
that, in the present studies, when non-Fickian transport was observed, the polymer chains 
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were unable to move sufficiently and that at those loadings of polymer, the gel was in a glassy 
state.  
 
Table 3-9: Diffusional exponent n for EGCG release data with the corresponding release 
mechanism. 
Formulation  n 
Transport 
type 
HEC 
1% w/v 0.46 ± 0.03 Fickian 
3% w/v 0.48 ± 0.08 Fickian 
5% w/v 0.63 ± 0.11 Non-Fickian 
HPMC 
1% w/v 0.48 ± 0.01 Fickian 
3% w/v 0.61 ± 0.01 Non-Fickian 
5% w/v 0.70 ± 0.04 Non-Fickian 
Results are presented as the mean ± standard deviation (n=3) 
 
Diffusion of solution out of the polymer is known to depend on external parameters such as 
temperature and pressure as well as formulation parameters including solute size and gel 
viscosity. Diffusion in polymers is complex it depends strongly on the concentration and degree 
of swelling of polymers. Solvent diffusion is associated with the physical properties of the 
polymer network and the interactions between the polymer and solvent (Masaro and Zhu, 
1999). The membrane would have prevented the gel from completely swelling and releasing 
drug, whilst water could move across it, the polymer did not have much room to swell as the 
donor compartment was filled to near capacity. This can be likened to the skin in the sense 
that the skin is a barrier, as well as the polymer chains would slow the movement of drug into 
the skin. 
Gels formulated with 3% w/v of either HPMC or HEC were chosen for all further studies. This 
loading of polymer is within range of many other previous studies (Forbes et al., 2011b; Goci 
et al., 2014; Mahalingam et al., 2011). 
 
3.4.7.2 Comparison of EGCG release from HEC and HPMC gels at formulated at 3% 
w/v of polymer 
Release from EGCG loaded gels prepared from 3% w/v of either HPMC and HEC was 
compared. Polymer gels were observed to slow the release (Figure 3.14). HPMC 
demonstrated to be more pronounced than HEC in this phenomenon, for example at 6 hours, 
EGCG solution (in the absence of polymer gels) resulted in a 72.3 ± 4.9 % transfer of EGCG 
across the membrane, compared to 66.1 ± 3.4 % and 55.1 ± 1.9 % release of EGCG-
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formulated  from HEC and HPMC gels respectively (Figure 3.16). The solution gave 100% 
release by 8 hours whilst HEC and HPMC saw complete release by 24 hours. The difference 
in EGCG release between solution and HEC and HPMC was significant (P ≤ 0.01 and P ≤ 
0.001 respectively). There was no significant difference between the release of EGCG from 
HEC and HPMC (P ≥ 0.05). 
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Figure 3.16: In vitro percentage EGCG release profiles from HEC and HPMC gel 
EGCG release profiles from aqueous 3% w/v HEC and HPMC gel with 1% w/v EGCG over a) 
24 hours, b) 8 hours. Data represents mean ± SD. n=3 independent batches. 
 
3.4.7.3 EGCG release from liposomes 
Elastic liposomes have been reported to penetrate the skin if applied non-occlusivley by virtue 
of the very high and self-optimizing deformability. Liposome adhesion, fusion and penetration 
into the stratum corneum is possible with potentially deeper penetration into the dermal layer 
of deformable vesicles compared with traditional liposomes (El Maghraby et al., 1999). They 
have been effectively employed in transdermal delivery of lipophilic and hydrophilic drugs 
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including anti-inflammatory agents, plasmid DNA, anti-tumour agents and hormones (Cevc 
and Blume, 2001; El Maghraby et al., 1999; Oh et al., 2006; Romero et al., 2013). Release of 
EGCG from 0.1mg/mL solution, liposomes and liposomes formulated with either 2%, 6% or 
10% w/w of Tween 20 with was studied over a 24 hour period (Figure 3.17).  
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Figure 3.17: In vitro percentage EGCG release profiles from solution and liposomal 
formulations 
EGCG release profiles from solution and liposomes formulated with 0-10% w/w Tween 20 over 
24 hours.  Liposomes were prepared adapting the dry film method adding the surfactant and 
EGCG during the lipid mixing stage. A diffusion cell dialysis system was used to evaluate in 
vitro drug release. Data represents mean ± SD. n=3 independent batches. 
 
Liposomes appeared to slow release of EGCG in comparison to release across the membrane 
from the EGCG solution. Over the course of 24 hours 96.0 ± 3.9 % release of EGCG from 
solution was observed whilst liposomes formulated with 0%, 2%, 6% and 10% w/w of Tween 
20 gave a release of 13.7 ± 1.1 %, 17.0 ± 1.7 %, 36.4 ± 3.8 % and 94.4 ± 4.9 % respectively. 
The cumulative percentage released after 24 hours was significant between the solution and 
liposomes loaded with 0%, 2% as well as 6% w/w of Tween 20 (P ≤ 0.0001). This difference 
was also significant between liposomes loaded with 0% and 6% w/w as well as between 
liposomes loaded with 2% and 6% of Tween 20 (P ≤ 0.01). Finally, this difference was also 
significant between liposomes loaded with 10% and 0, 2 and 6% w/w of Tween 20 (P ≤ 0.0001). 
Release of EGCG observed significant differences between release from solution and all 
loadings of Tween 20 investigated (P ≤ 0.001). Release between Tween 20 loadings of 0 and 
10% w/w, 2 and 10% w/w and 6 and 10% w/w was also significantly different (P ≤ 0.01). 
Furthermore, release between 0 and 6% w/w was also significant (P ≤ 0.05). Release between 
0 and 2% w/w loading of Tween 20 was not significant. 
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3.4.7.3.1 Kinetic assessment of EGCG release from liposomal formulations 
A higher percentage of drug was released from the EGCG solution compared with liposome 
formulations. Release data from the solution and deformable liposomes complied with first 
order release kinetics implying rate of drug release was dependent on drug concentration at 
that time (Table 3-10). Release data from blank liposomes however seemed to fit the zero 
order model of release better than first order. This implies release from blank liposomes was 
independent of drug concentration. This is probably due to the lack of surfactant in the 
formulation which would increase solubility of the drug and encourage a faster release. It is 
usual to see a zero order release with controlled release formulations as this model describes 
release independent of drug concentration (Higuchi, 1963a). Release independent of drug 
concentration means higher loading of drug does not affect rate of release thus a controlled, 
sustained release of drug is maintained as long as drug is present in abundance i.e. above 
saturation point (Dash et al., 2010). Blank liposomes would give the slowest release as there 
is no surfactant to solubilise the drug thus aiding drug release from the formulation (Almog et 
al., 1986b). 
 
Table 3-10: Kinetic assessment of release data of EGCG from solution and aqueous gels. 
Kinetic model 
Formulation (r2) 
Solution 
Liposome 
 (% w/w loading of Tween 20) 
0 2 6 10 
Zero order 
0.188 ± 
0.0474 
0.988 ± 
0.004 
0.690 ± 
0.511 
0.929 ± 
0.069 
0.722 ± 
0.296 
First order 
0.929 ± 
0.020 
0.961 ± 
0.018 
0.986 ± 
0.006 
0.955 ± 
0.039 
0.937 ± 
0.063 
Results are presented as the mean ± standard deviation (n=3) 
 
This is further reiterated as presence of surfactant appears to increase drug release. Surfactant 
would increase drug solubility thus explaining why an increase in drug release is observed at 
higher loadings of surfactant. Single chain surfactants such as Tween 20 have a high radius 
of curvature (Cevc, 1996; El Maghraby et al., 1999; Ita et al., 2007; Oh et al., 2006). This 
component of the liposome destabilizes the vesicle bilayers by reducing the amount of work 
required to expand the interface allowing the liposome to become more flexible (Cevc, 1996; 
Ita et al., 2007; Oh et al., 2006). Additionally, it has been suggested that the mechanism of the 
in vitro release seems to be the formation of transient pores in the lipid bilayer, through which 
drugs are released from the inner aqueous core of the liposomes to the extra-liposomal 
medium (Wang, Wang et al. 2016). Therefore, the presence of more surfactant in the liposome 
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may also encourage the formation of transient pores. Goindi et al., (2013) found elastic 
liposomes were able to increase drug permeation into the skin in comparison to a conventional 
cream (2 fold). Further studies would have to be carried out to investigate if this can be 
achieved with Tween 20. 
Comparison of the rate constant of each formulation that fit the First order model demonstrated 
that EGCG solution had the highest rate of release, followed by liposomes formulated with 
10% w/w, then 6% w/w and then 2% w/w of Tween 20 (Table 3-11). Complete release, 94.4 ± 
4.9 %, was observed within 24 hours from liposomes loaded with 10% w/w of Tween 20. In 
addition, 36.4 ± 3.8 % release was observed with liposomes formulated with 6% w/w of Tween 
20, and 17.0 ± 1.7 % was seen both 2% w/w and 13.7 ± 1.1 %, was observed with blank 
liposomes. As surfactant loading increased, drug entrapment decreased, therefore, drug 
release would be expected to be slower as there is less of a concentration gradient. 
Furthermore, the drug is hydrophobic therefore less inclined to diffuse out of the liposomes.  
 
Table 3-11: First order kinetics rate constant for EGCG release from all formulations except 
liposomes formulated with 0% w/w Tween 20 where the zero order rate constant was 
observed. 
 
Results are presented as the mean ± standard deviation (n=3) 
 
In dynamic dialysis, the appearance of drug in the receiver compartment is the result of 
diffusion from liposomes followed by diffusion across the dialysis membrane, though it is 
generally treated as a simple first-order process (Modi and Anderson 2013). The rate constant 
obtained does not necessarily reflect rate of drug release from the liposomes, instead it is the 
net result of drug movement across two barriers in series (Figure 3.18). The driving force of 
drug movement, is not the total drug concentration entrapped within the liposome but the free 
aqueous drug concentration, a quantity of critical importance but never directly measured. 
Furthermore, reversible binding of the drug released from the liposome reduces the driving 
force for drug transport across the dialysis membrane leading to a slower overall apparent 
release rate (Modi and Anderson, 2013). Therefore, assessment of the reliability of rate 
Rate constant (× 10-3 min-1) 
Solution 
 
Liposome formulation (% w/w loading of Tween 20) 
0  2  6  10  
3.10 ± 1.26 1.07 ± 0.0005 1.27 ± 0.01 0.33 ± 0.06 1.5 ± 0.31 
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constants determined by dynamic dialysis require careful consideration of the pitfalls in 
interpreting apparent release data.  
In these studies, any effect of the membrane on diffusion of the compound is a constant as it 
has been used to study release across all formulations including EGCG solution. Therefore, 
the effect of the membrane on rate of release is the same throughout studies which are to be 
compared. The release data observed was because of drug release from the liposome and 
across the membrane or movement of the liposome across the barrier and then release from 
this. 
 
Figure 3.18: Diagram representing drug release kinetics from liposomes by dynamic dialysis. 
Diagram depicting the ionization and binding equilibria along with transport pathways 
representing drug release kinetics from liposomes by dynamic dialysis. Diw and Dim are the 
intra-vesicular aqueous and membrane bound drug concentration respectively, Dow and Dom 
are the extravesicular aqueous and membrane bound drug concentration respectively. Dm is 
the dialysis membrane bound drug concentration. km and kd are the rate constants for 
permeation across the bilayer membrane and dialysis membrane respectively. kon and koff are 
the apparent association and dissociation constants for the binding of the drug to dialysis 
membrane adapted from (Modi and Anderson 2013). 
 
3.4.7.4 Liposomal gel EGCG release studies  
Drug release from liposomes loaded into gels could not be measured/detected in the side-by-
side diffusion chamber.  Drug release in the side-by-side diffusion chamber may have been 
restricted by the small pore size of the membrane as well as the physical operation of the 
diffusion cell. Furthermore, the large receiver volume of the diffusion cell may have resulted in 
the drug concentration being lower than the LOD and LOQ of the HPLC-UV method. Therefore, 
an alternate method using 6-well plates and polyester permeable insert cups with a 400 nm 
pore size was employed. The purpose was to investigate if EGCG could be released from the 
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liposomes loaded into the gel (to ensure that only free drug samples were detected the 
samples were centrifuged and the supernatant analysed).  
Advantages of the diffusion cell include the larger receiver volume of 100 mL thus ability to 
maintain sink conditions. Whilst the 6 well plate only allowed a receiver volume of 4 mL, this 
also results in a more concentrated drug solution which allows for HPLC-UV detection and 
quantification. Additionally, the membrane used in the diffusion cell had a smaller pore size of 
50 nm compared with 400 nm in the inserts, which is more comparable to the gaps in the SC 
in the skin. A release study to observe drug release from the liposomes loaded into gels was 
conducted using a 6 well Thincert plate and 4 cm2 cylindrical cell culture ThincertTM insert with 
400 µm pore size. Drug release from solution was also observed to be able to compare any 
differences in release (Figure 3.19).  
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Figure 3.19: In vitro percentage EGCG release profiles from liposomal gels 
In vitro percentage EGCG release profiles using a a permeable insert of a 400 nm pore size 
from solution and gel loaded with either blank or elastic liposomes formulated with 2% w/w 
Tween 20 over a) 24 hours, b) just liposomal gels over 8 hours. F1: HEC and blank liposomes, 
F2: HEC and elastic liposomes, F3: HPMC and blank liposomes, F4: HMPC and elastic 
liposomes. Gels were prepared using 3% w/w loading of either HEC or HPMC with a 1% w/w 
of drug loading. Liposomes were prepared adapting the dry film method. Gels were prepared 
using 3% w/v loading of either HEC or HPMC. Data represents mean ± SD. n=3 independent 
batches. 
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Complete drug release from solution was observed by 4 hours (Figure 3.19). Over the course 
of 24 hours solution gave a release of 100.9 ± 6.8 % whilst F1, F2, F3 and F4 gave a release 
of 8.5 ± 0.95 %, 20.0 ± 2.5 %, 6.0 ± 0.3 % and 17.0 ± 0.8 %, respectively. The cumulative 
percentage released after 24 hours was significant between the solution and all liposomal gels 
(P ≤ 0.0001). The difference was also significant between F1 and F2, F2 and F3 as well as 
between F3 and F4 (P ≤ 0.01). Finally, the difference was also significant between F1 and F4 
(P ≤ 0.05). F1 and F3 contained no surfactant in the liposome and F2 and F4 contained 2% 
w/w of Tween 20. Therefore, release in the liposomal gels appeared to be affected by presence 
of surfactant in liposomal gels formulated with HEC but not HPMC. 
Overall the percentage of drug release from the liposome loaded gels quantified over 24 hours 
was slightly higher from the HEC gel (up to 19%). Furthermore, a higher percentage of drug 
was released from the liposomes formulated with 2% w/w Tween 20 (up to 19%). This shows 
elastic liposomes gave a faster rate of drug release.  
The difference in release profiles was significantly different between solution and all liposomal 
gels (P ≤ 0.001). A significant difference was also noted between the HEC gel loaded with 
blank liposomes and 2% w/w of Tween 20 as well as HEC Tween 20 2% w/w liposomal gels 
and HPMC gels loaded with liposomes with no Tween 20 (P ≤ 0.01). Additionally, a significant 
difference was also observed between HEC and HPMC gels loaded with 2% w/w Tween 20 
liposomes. No significant difference was observed between the HEC gel loaded with liposome 
with no Tween 20 and either HPMC liposomal gel or between the two HPMC gels.  
This study observed that, unlike the side by side diffusion chamber, EGCG could diffuse into 
the receiver compartment. It is unclear whether liposomes and gels have an additive effect at 
retarding the release of EGCG as over the same time of 24 hours because of the different 
physical parameters. A maximum of 19% release was observed in the permeable insert 
system, compared with 100% release from the gels and a maximum of 16% release from the 
liposomes formulated with 2% w/w Tween 20. A similar pattern of results was observed in a 
study comparing the release of lidocaine from liposome loaded gels to hydrogels. A faster 
release of lidocaine from the hydrogels compared with the liposome loaded was observed. 
This indicates the liposomal gels had an additive retardation effect on EGCG release (Glavas-
Dodov et al., 2002). It is possible liposomes diffuse through the gel and across the membrane 
prior to EGCG release or that EGCG diffused out of the liposomes into the gel and then across 
the membrane. This study was not able to determine the exact process of drug release. 
In order to comment on process of drug release from the gel, whether drug released from the 
liposome into the gel or if the liposome diffused out of the gel first, from which drug then 
diffused, an ELSD HPLC method was used. This detection method was used to attempt to 
149 
 
detect lipid in the receiver from the diffusion cell experiment however none was detected. This 
may have been due to the amount of lipid in the receiver compartment being lower than the 
detection limit. Liposomes did diffuse across the insert as the liposomal gel could be seen in 
the receiver compartment at 24 hours. Regardless of this, it is yet to be determined how 
liposomes may or may not diffuse across the SC in vivo and a skin study would be needed to 
determine an answer.  
The aim of this study was to develop a formulation that allowed liposomes to move through the 
gel carrier system and pass through the SC into the dermal skin layers where drug would 
slowly leach into the surrounding areas. The non-occlusive nature of the application should 
ensure the liposomes move into the skin across a hydration gradient. But that is only possible 
if liposomes move through the gel.  Similar studies have applied a 4% HEC liposomal gel 
indicating the formulation at 3% should be suitable for dermal delivery of drug loaded 
liposomes (Mourtas et al., 2007). Furthermore, in practice, a thinner layer of gel would be 
applied, liposome wouldn’t be moving though gel that is several millimetres thick. Additionally, 
the lipids in the skin would encourage liposomes to move through the skin. 
Similar studies have found, calcein (hydrophilic dye) release from liposomal gels to be slower 
compared to control gels, and can be further retarded by using rigid-membrane liposomes 
(Mourtas et al., 2007). This correlates with observations in the present studies as the rate of 
release was observed to be faster for liposomes formulated with more surfactant in release 
from both liposome solution and liposomal gels. On the other hand, griseofulvin (a lipophilic 
drug) release from liposomal gels is released with a constant rate from liposomal gels 
irrespective of liposome type. Therefore it is clear, compound properties (solubility, log P) 
determine the system behaviour (Mourtas et al., 2007). 
Further, release of EGCG from liposomal gels depends on the stability of the liposomes 
(membrane integrity and mechanical stability) during their dispersion in the gel formulation. 
This may be determined by the vesicle-membrane rigidity as well as the semisolid system 
physical properties (viscosity/rheological properties). Other parameters may also be 
concerned, as, the lipophilicity of the drug and its aqueous solubility will determine the driving 
force moving drug out of liposomes. 
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3.4.8 Impact of liposomal formulation on In vitro cytotoxicity on HDFA and HaCat 
cells 
Skin is composed of the dermis, epidermis and subcutaneous layer.  Each layer has a unique 
combination of cells, connective tissue, components and functions. Human keratinocyte and 
fibroblast cells were selected to test compound and formulation toxicity. 
To determine the concentration of drug which was toxic to HDFa and HaCat cells, an XTT 
assay was performed to measure cell death after exposure of cells to different concentrations 
of drug for 24 hours. Results of cell viability are shown in Figure 3.20. 
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Figure 3.20: Cellular toxicity of EGCG on a) HDFa and b) HaCat cells.  
Cells were grown on a 96-well plate at a density of 50 x 103 cells per well and exposed to 
various concentrations of EGCG (0.01 – 100 µM). After 24 hour incubation following which 25 
µL of a 12.5:1 parts mixture of XTT to menadione was added each well. Plates were incubated 
for 3 hours at 37°C and the absorbance read at 450 nm. The control cell (without drug) 
corresponded to a cell viability of 100%. Data is reported as mean ±SD with 6 replicates per 
compound in at 3 independent experiments. 
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As the concentration of EGCG was increased, there was a decrease in HDFa cell viability. This 
may be due to toxicity or death of damaged cells in which EGCG induced apoptosis (Bae et 
al., 2008; Tanigawa et al., 2014). In comparison to the control well, the viability in cells treated 
with 100 µM and 50 µM was significantly lower (P ≤ 0.0001), as well as cells treated with 10 
µM (P ≤ 0.001), 5 µM (P ≤ 0.01) and 1 µM (P ≤ 0.05) of EGCG. There was no significant 
difference in cell viability at the range of EGCG concentrations with the HaCat cells therefore 
within this concentration range, EGCG was safe for application on these cells (P ≥ 0.01).  
Whilst limited data exists on the cytotoxicity of EGCG towards dermal tissues, a study 
observing growth inhibition in a number of cell lines, observed that EGCG at 40 μM had little 
or no inhibitory effect on the growth of WI38 cells, normal human fibroblast cells (Chen et al., 
1998). 
3.4.9 Cellular liposomal uptake assay on HDFa and HaCat cells 
EGCG loaded liposomes were incubated with both HDFa and HaCat cells to assess the cellular 
uptake of these formulations.  Following a 2-hour incubation with the cells, the labelled 
liposomes were identified using confocal microscopy (Figure 3.21 and 3.22). Cytoplasmic 
accumulation of the formulations was apparent, confirming the successful uptake into both 
HDFa and HaCat cells.   
DilC labelled liposomes loaded with EGCG incubated for 2-hours with both HDFa and HaCat 
cells seeded onto collagen-coated coverslips and the cellular localisation of these liposomes 
was determined using confocal microscopy and z-stack image processing.  Single stage 
confocal imaging demonstrated generalised cellular location, with the presence of liposomes 
within the cellular membrane and cytoplasm (Figure 3.23).  However, to further discern the 
exact localisation within the cell, a z-stack multistage image capture was initiated to capture 
DilC labelled liposome fluorescence through the z-dimension of the cell (Figure 3.24). 
 
Figure 3.21: Localisation of DilC labelled liposomes loaded with EGCG and 2% w/w Tween 
20 in HaCat cells. 
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Cells were grown on the coverslips for 2 days. Cell nuclei were visualised using a) DAPI (Blue). 
Liposomes were formulated with DilC for visualisation b) (yellow). Liposome localisation within 
the cell is shown in the merged image c). 
 
Figure 3.22: Localisation of DilC labelled liposomes loaded with EGCG and 2% w/w Tween 
20 in HDFa cells. 
Cells were grown on the coverslips for 2 days. Cell nuclei were visualised using a) DAPI (Blue). 
Liposomes were formulated with DilC for visualisation b) (yellow). Liposome localisation within 
the cell is shown in the merged image c)
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Figure 3.23: z-dimension cellular localisation of DilC-EGCG loaded liposomes formulated with 2% w/w Tween 20 in HaCat cells. 
z-dimension cellular localisation of DilC labelled liposomes loaded with EGCG and 2% w/w Tween 20 (stage 2). DilC labelled liposomes previously incubated 
with HaCat cells for 2 hours were further subjected to a z-stack analysis with the lens positioned above the cell layer (12216 µm) and lowered through the 
cells to the bottom of the cell layer (12210 µm).  Images were captured of DilC (green) through the z-dimension. 
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Figure 3.24: z-dimension cellular localisation of DilC-EGCG loaded liposomes formulated with 2% w/w Tween 20 in HDFa cells 
z-dimension cellular localisation of DilC labelled liposomes loaded with EGCG and 2% w/w Tween 20 (stage 2). DilC labelled liposomes previously incubated 
with HDFa cells for 2 hours were further subjected to a z-stack analysis with the lens positioned above the cell layer (12216 µm) and lowered through the 
cells to the bottom of the cell layer (12210 µm).  Images were captured of DilC (green) through the z-dimension
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The confocal stage was set at the upper-most boundary of the HDFa/HaCat cells and the stage 
moved down towards the coverslip with images captured over a z-dimension of approximately 
5 µm. At the onset of the z-stack analysis, liposomes are localised on the exterior of the cell 
boundary and potentially on the surface of the cells (12216 µm).  As the stage progresses, the 
localisation of FITC-Fan-MSNP increases with clear demarked zones of cytoplasmic 
localisation near the ‘mid-to-bottom’ regions of the cells (Figure 3.23 and 3.24). 
 
There are four proposed methods of liposome interaction with cells as discussed in section 
2.4.5: stable adsorption, endocytosis, fusion of the lipid bilayer with the cell plasma membrane 
and lipid transfer (Martin and MacDonald, 1976; Pagano and Weinstein, 1978). It is unclear 
which of these occurred in this study, however, these methods of uptake are not mutually 
exclusive and any combination occur in a given experimental circumstance (Pagano and 
Weinstein, 1978). 
 
This formulation is aimed to be targeting the dermal layer. It is uncertain if the liposomes would 
completely pass through the keratinocytes into the dermal layer or whether they would 
accumulate in the SC. To be able to determine this, application onto excised skin would be 
necessary. Nonetheless it is clear liposomes were taken up by the cells, more importantly the 
fibroblasts thus the liposomes were successfully able to enter the cells.  
3.4.10 Stability of deformable liposomes 
The stability of deformable liposomes during storage at 20°C was studied in terms of size and, 
for drug loaded liposomes, encapsulation efficiency. It is important to assess stability of 
liposomes in terms of size to assess liposome aggregation and fusion as this may affect 
compound encapsulation and release. Confocal images were observed on day 1 of formulation 
to ensure the presence of liposomes (Figure 3.25). The size of blank and surfactant loaded 
liposomes was measured on days 1, 2, 7, 14, 21 and 28 (Figure 3.26).  
 
Figure 3.25: Confocal images of MLV liposomes formulated with 4% w/w of Tween 20 
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MLV liposomes were formulated with 4% either and were either a) blank, b) EGCG loaded. 
Fluorescently labelled liposomes where formulated by the addition of the fluorescent dye Dil C 
to the lipid mixing stage. The unentrapped marker was removed by centrifuging liposomes, 
removing the supernatant, re-suspending in water. Liposomes where imaged using an upright 
confocal microscope (Leica SP5 TCS II MP) and visualised with a 40× oil immersion objective. 
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Figure 3.26: Stability of EGCG loaded liposomes as determined by size. 
Size of EGCG loaded liposomes formulated with 0-10% w/w Tween 20, using DLS, formulated 
with up to 10% w/w Tween 20 measured on various days (1, 2, 7, 14, 21 and 28). Data 
represents mean ± SD. n=6 independent batches. 
 
EGCG loaded liposomes formulated with and without surfactant appear to decrease in size 
over time. This was unexpected as usually, aggregation is noted resulting in vesicle size growth 
(Seras et al., 1992). This is due to larger liposomes/aggregates settling as a creamy film that 
could be seen at the bottom of the cuvette.  Formulations with 0% w/w, 2% w/w, 6% w/w and 
10% w/w observed a size decrease from 1029 to 844 nm, 652 to 573 nm, 561 to 424 nm and 
551 to 448 nm respectively over the course of 28 days (Figure 3.25). As liposomes formulated 
with surfactant have a lower polydispersity, this results in a more homogenous mix with less 
larger liposomes/aggregates formulated thus there would be less of these to settle out over 
time.   
The size decrease of liposomes formulated without Tween 20 was significant between day 2 
and 14 (P ≤ 0.05), and between day 2 and 21 (P ≤ 0.001). There was no significant difference 
between days 7 onwards. This may be because all lipid aggregates settled out by this time 
confirmed by the presence of a creamy film at the bottom of the container holding the 
liposomes. The size decrease between liposomes formulated with 2% w/w Tween 20 between 
day 1 and 7 (P ≤ 0.01), and between day 1 and both 21 and 28 (P ≤ 0.05). There was no 
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significant difference between day 2 onwards. This may be because all lipid aggregates settled 
out by this time. The size decrease between liposomes formulated with 6% w/w Tween 20 
between day 1 and 14 (P ≤ 0.05), and between day 1 and 21 (P ≤ 0.01) and between day 1 
and 28 (P ≤ 0.0001). There was also a significant difference between day 2 and 21 (P ≤ 0.05) 
and between day 2 and 28 (P ≤ 0.001). There was also a significant difference between day 7 
and 28 and between day 14 and 28 (P ≤ 0.05). There was no significant difference between 
days 21 and 28. This may be because all lipid aggregates settled out by this time. The size 
decrease between liposomes formulated with 10% w/w Tween 20 between day 1 and 17 (P ≤ 
0.01), and between day 1 and both 14 and 21 (P ≤ 0.0001) and between day 1 and 28 (P ≤ 
0.01). There was also a significant difference between day 2 and 21 (P ≤ 0.05) and between 
day 2 and 28 (P ≤ 0.001). There was also a significant difference between day 2 and 14 (P ≤ 
0.01) and between day 2 and 21 (P ≤ 0.05). There was no significant difference between days 
7 onwards. This may be because all lipid aggregates settled out by this time. There was no 
significant difference between day 21 onwards. This may be because all lipid aggregates 
settled out by this time. 
Furthermore, encapsulation efficiency appears to decrease from 72% to 56%, 45% to 30%, 
22% to 11% and 10% to 1% respectively for 0 % w/w, 2 % w/w, 6 % w/w, 10 % w/w loading of 
surfactant (P > 0.05) (Figure 3.27). This suggests drug leaching is independent of surfactant 
loading. However, Tween 20 is able to increase compound solubility, therefore, as not all would 
be entrapped within the bilayer, this may allow EGCG to solubilise within the liposomal media 
(Almog, Kushnir et al. 1986). Therefore, as the loading of Tween 20 increased, this would 
increase the amount of free Tween 20 resulting in more EGCG being able to solubilise in the 
liposome media. 
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Figure 3.27: Liposome encapsulation efficiency for EGCG 
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Liposome encapsulation efficiency for EGCG in either 0% w/w, 2% w/w, 6% w/w or 10% w/w 
Tween 20 liposomes over 28 days. Liposomes were prepared adapting the dry film method 
adding the surfactant and drug during the lipid mixing stage. The preparation was then washed 
via centrifugation. The quantity of EGCG in supernatant over 28 days was then analysed by 
HPLC coupled with UV detection to assess liposome stability. Data represents mean ± SD. 
n=6 independent batches. 
 
Long-term stability of liposomes depends on the average elastic energy of the membrane 
being higher than the thermal energy. When this is no longer the case, liposomes will 
disintegrate (Lipowsky 1991). Therefore, temperature is an important determinate of stability 
and liposomes must be stored at a suitable temperature. Too high and the liposomes will break 
down, and, furthermore, liposomes formulated with surfactant cannot be stored in a fridge due 
to the freezing point of Tween 20 being 7°C (Natural-Sourcing, 2017). This suggests these 
liposomal formulations are not suitable for long term stability. Either additional excipients (such 
as a charged surfactant to reduce coalescence) are required or an additional step of freeze 
drying liposomes for reconstitution near the time of administration would need to be employed.   
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3.5 Conclusion  
The use of naturally occurring compounds such as EGCG have been found to be successful 
as chemopreventative and chemoprotective agents. However, formulation of such compounds 
has been limited in success due to a limited bioavailability of promising agents and inefficient 
delivery systems. Liposomes could be valuable in enhancing the bioavailability of these 
compounds (Nishiyama, 2007; Siddiqui et al., 2009). Furthermore, elastic liposomes have 
been found to be advantageous in dermal delivery of drugs as they have an increase ability to 
cross the SC (Cevc and Blume, 2001; El Maghraby et al., 1999; Oh et al., 2006; Romero et 
al., 2013). EGCG is a flavonoid found in tea, and has been observed to be useful as a 
pharmacological anti-cancer agent in skin cancer (Casey et al., 2015). This study aimed to 
formulate this compound into elastic liposomes formulated with Tween 20 within an aqueous 
gel carrier system intended to deliver a controlled release of EGCG within the dermal layer of 
the skin.  
As the amount of Tween 20 in the liposomal bilayer is increased, liposome size decreases. 
The presence of EGCG in elastic liposome increases the liposome diameter; however, the 
inclusion of surfactant decreases the diameter. Inclusion of surfactant in the bilayer decreases 
liposome DI implying liposomes retained enough elastic energy to pass through a pore size 
smaller than the liposome diameter which would be useful when applied to skin to pass through 
the SC. This was true when liposomes were forced through a 200 nm and 100 nm pore size 
however, liposome destruction was apparent when forced through a 50 nm pore size.   
As the loading of Tween 20 in the liposome was increased the EGCG encapsulation 
decreased. This may have been due to Tween 20 competing for space within the bilayer or 
due to Tween 20 increasing the solubilisation capacity of EGCG. Further, inclusion of EGCG 
within the liposome bilayer was able to reduce the phase transition temperature of EGCG. 
One compartment release models found HEC gels to release drug slightly faster than HPMC 
gels. Complete gel dissipation was observed between 3 and 4 hours. Two compartment 
release models found that the aqueous gels were found to hinder the release of drug compared 
to drug solution. Furthermore, as the polymer loading increased, the rate of release decreased. 
EGCG release from liposomes found liposomes were able to modify the release of drug with 
complete release observed within 24 hours. Liposomes added into gels may have had an 
additive effect in terms of retarding drug release. Release was faster from HEC gels and 
liposomes formulated with Tween 20. 
Toxicology assay’s found that between 0.1 and 100 µM EGCG was not harmful to either 
keratinocytes or fibroblasts. Cell uptake of the liposomes loaded with EGCG and 2% w/w 
160 
 
Tween 20 was apparent into both the keratinocyte cell line and the fibroblast cell line. It appears 
elastic liposomes are useful in enhancing drug penetration into dermal cells and furthermore 
may be useful in the development of a controlled release formulation.  
Liposome stability was studied in terms of size and encapsulation capacity over the course of 
a month. Liposomes were found to be stable regarding these two parameters over this time 
period.  
A strategy in the development of a controlled release formulation for naturally occurring anti-
cancer agents with a limited bioavailability may be the use of liposomal gels. Aqueous gels 
were found to hinder the release of drug compared to drug solution. Additionally EGCG release 
from liposomes found release was potentiated with the liposome carrier system with the 
presence of Tween 20 observing a faster rate of release.  
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4 Development of 
sustained release 
naringenin liposomal gel 
formulations for dermal 
drug delivery 
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4.1 Introduction 
Emerging approaches for cancer management is chemoprevention and chemoprotection with 
the use of naturally occurring nontoxic agents (Hwang et al., 2007; Siddiqui et al., 2009; Singh, 
Shankar, & Srivastava, 2011). Reactive oxygen species (ROS) play a major role in many 
pathological conditions including photo-carcinogenesis and immune suppression. The use of 
anti-oxidants to prevent oxidative skin damage appears to be a promising approach (Albini and 
Sporn, 2007; Casey et al., 2015; Huang et al., 2011). Naringenin is the predominant flavanone 
in grapefruit (Figure 4.1). It is an antioxidant, free radical scavenger, anti-inflammatory agent, 
and immune system modulator thus may be potentially useful as a pharmacological anti-
cancer agent (Casey et al., 2015; Chen et al., 2003; Huang et al., 2011). 
 
 
Figure 4.1: Molecular structure of naringenin 
 
Furthermore, naringenin has been found to regulate of fibrosis. Fibroblasts and myofibroblasts 
play a critical role in the formation of the extra-cellular matrix and inducing fibrosis within 
growing tumours (Casey et al., 2015). Tissue fibrosis is frequently observed in the tumour 
microenvironment associated with rapid proliferation of fibroblast cells (Kerkar et al., 2012). 
Additionally, naringenin can increase both tyrosinase activity and melanin content, indicating 
naringenin can be used to prevent oxidative skin damage (Huang et al 2011, Ohguchi et al 
2006, Chen et al., 2003).  
In recent years, nanotechnology has been implemented and assessed in different areas of 
cancer management and therapeutics (Nishiyama, 2007; Siddiqui et al., 2009). Naringenin is 
a poorly water soluble compound (41.76 ± 0.51 μg/mL (Tsai et al., 2015)). A nanoparticle 
mediated delivery system could be valuable in enhancing the solubility of such a compound. 
Thus liposomes may be useful as a drug carrier for the dermal delivery of this compound thus 
overcoming solubility issues as well as being able to provide a controlled release of the 
compound (Hsiu et al., 2002; Semalty et al., 2010b; Tsai et al., 2015).  
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One of the primary functions of the skin is to act as a barrier to the external environment. The 
use of liposomal formulations as drug-delivery vehicles provide a novel approach to the 
delivery and targeting of the dermal layer with benefits for both delivery of existing (poorly 
permeable) molecules and larger (often impermeable) biologics.  Elastic liposomes have been 
reported to penetrate the skin if applied non-occlusivley by the very high and self-optimizing 
deformability. They have successfully been employed in the transdermal delivery of lipophilic 
and hydrophilic drugs including anti-inflammatory agents, plasmid DNA, anti-tumour agents 
and hormones (Cevc and Blume, 2001; El Maghraby et al., 1999; Oh et al., 2006; Romero et 
al., 2013). Liposome adhesion, fusion and penetration into the stratum corneum is possible 
with potentially deeper penetration into the dermal layer of deformable vesicles compared with 
traditional liposomes (El Maghraby et al., 1999). 
Additionally, due to the liquid nature of liposomal preparations intended for application to the 
skin will need to be transported in a carrier. Liposomes are compatible with viscosity increasing 
agents such as cellulose based gels including HEC and HPMC (Foldvari, 1996) therefore these 
will be used as secondary carriers for EGCG.  
 
4.2 Aims and objectives 
In this body of work, a formulation aiming to deliver naringenin to the dermal layer in the 
management of skin cancer was developed. The effectiveness of the in vitro delivery of 
naringenin encapsulated in liposomes in an aqueous gel system to the dermal layer was 
assessed. The aim of this study was to formulate and characterise an aqueous gel system 
loaded with elastic liposomes formulated with Tween 20 for the dermal delivery of Naringenin. 
Liposomes were loaded with up to 10% w/w Tween 20 and 0.25 mg/mL of naringenin. They 
were characterised by size, zeta potential, DI and stability. naringenin release was observed 
from these liposomal formulations as well as from HEC and HPMC gels and from gels loaded 
with liposomes. Toxicity and uptake into HDFa and HaCat cells was then observed. 
 
To achieve the aims, the overall objectives were 
 Validate a HPLC method for naringenin detection  
 Formulate and characterise liposomes loaded with naringenin and observe the release 
profiles 
 Characterise naringenin loaded liposomes formulated with Tween 20 and quantify the 
release of naringenin delivered from these formulations. 
 Formulate HEC and HMPC aqueous gels and compare the release of naringenin 
delivered from these formulations. 
164 
 
 Formulate and compare naringenin release of drug from HEC and HPMC gels loaded 
with naringenin loaded liposomes  
 Apply formulations to fibroblast (HDFa) and keratinocyte (HaCat) cell lines to 
characterise toxicity of the formulations as well as cell localisation. 
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4.3 Materials and methods 
4.3.1 Materials 
The materials used to prepare liposomes, all reagents as well as materials used to grow HDFa 
and HaCat cells are detailed in chapter 2 (section 2.3.1) The materials used to prepare the 
gels are detailed in section 3.3.1. Naringenin was obtained from Sigma-Aldrich.  
4.3.2 Elastic liposome preparation  
Liposomes were prepared by using the film hydration method established by Bangham et al., 
(1965) detailed in section 2.3.2. Briefly, PC, cholesterol and surfactant were dispersed in 
chloroform and methanol in a 9:1 ratio. Ratios of lipids are detailed in Table 3.1 rational of 
which has been adapted from previous studies concerning the formulation of elastic liposomes 
(Hiruta et al., 2006; Ita et al., 2007; Oh et al., 2006; Tsai et al., 2015). Naringenin loaded 
liposomes were prepared by adding the required amount of naringenin to the lipid mixing stage.  
4.3.3 Liposome characterisation: particle size and polydispersity and zeta potential 
Mean particle size, polydispersity index and zeta potential of liposomes was measured as 
detailed in section 2.3.3 using a Zetaplus (Brookhaven Instruments). Each sample was 
measured 3 times.  
4.3.4 Assessment of liposomal deformability  
The deformability index (DI) of the elastic vesicles was determined using a mini filtration 
technique as detailed in section 3.3.4. 
4.3.5 HPLC methodology 
Detection of naringenin was assessed through reverse phase HPLC methodologies. A Waters 
Alliance separation module HPLC with UV detection was utilised at an operating wavelength 
of 287 nm (Wen et al., 2010a). A Waters X select column (5µm C18 4.6 x 150 mm column) 
was used. 10 μL of sample at room temperature was injected. The mobile phase comprised of 
a 50:50 ratio of 0.1% TFA in water to acetonitrile at a flow rate of 1mL/min. 
Stock solutions and standard solutions of naringenin were prepared with both water and 
ethanol ranging from 0.05-250 µg/mL. 
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4.3.5.1 HPLC validation 
The method was validated by assessing the linearity and range, repeatability and sensitivity in 
terms of the limit of detection (LOD) limit of quantification (LOQ) and precision as detailed in 
section 3.3.5.  
For the linearity and range assessment, standard solutions ranging between 0.05 - 250 µg/mL 
of naringenin in water were prepared. The mean peak area ± SD was calculated and plotted 
against the known concentration of the standard.  
4.3.6 Determination of entrapment efficiency 
The entrapment percentage of naringenin loaded in elastic liposomes was determined by 
centrifuging samples and quantifying drug in the supernatant as detailed in section 3.3.6.  
4.3.7 Differential scanning calorimetry investigations of naringenin and naringenin-
lipid blends 
Naringenin as well as naringenin combined with different ratio of lipid blends were analysed in 
the solid state using a TA Instruments Q200 Thermal Analysis DSC as described in section 
3.3.7.  
4.3.8 Naringenin loaded aqueous gel formulation  
Aqueous gels were prepared using HEC (3% w/v) and HPMC (3% w/v) which were mixed 
overnight using a mechanical mixer (Polytron PT 3100 D) as detailed in section 3.3.8. Gels 
with a drug loading of 1% w/w was manufactured.  
4.3.9 In vitro release studies 
Drug release from gels, liposomes and liposomal gels over 24 hours was observed using 
multiple methods.  
4.3.9.1 One compartment release model 
To study the in vitro release and swelling behaviour of gels over 24 hours naringenin loaded 
gel was syringed into plastic containers with 20ml of DDM as detailed in section 3.3.9.1 and 
aliquots removed at set time points and analysed using HPLC quantification with UV analysis 
(section 4.3.5). 
 
4.3.9.2 Two compartment release model 
A diffusion cell dialysis system was used to evaluate in vitro drug release over 24 hours from 
solution (0.1 mg/mL), gels (formulated with 1% w/w of drug) and liposomes into release media 
as detailed in section 3.3.9.2.  
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4.3.9.3 Liposomal gel release study 
Release from liposomal gels was observed with the use of a 6 well Thincert plate and 4 cm2 
cylindrical cell culture ThincertTM inserts (400 µm pore size) were filled with 1ml of formulation 
as detailed in section 3.3.9.3.  
4.3.10 Release kinetics  
Mathematical models to assess release kinetics were fit using Microsoft Excel® as detailed in 
section 3.3.10.  
4.3.11 Growth and passage of cells 
HDFa isolated from adult skin, cryopreserved at the end of the primary culture were revived in 
medium 106 supplemented with Low Serum Growth Supplement. HaCaT is a spontaneously 
transformed aneuploid immortal keratinocyte cell line from adult human skin. HDFa and HaCat 
cells were maintained in a humidified 37 °C incubator with 5 % CO2, grown, fed and split for 
further proliferation as detailed in section 2.3.6. 
4.3.12 Impact of liposomal formulation on in vitro cytotoxicity on HDFA and HaCat cells 
To determine the concentration of naringenin which was toxic to the HDFa and HaCat cells, 
an XTT assay (Scudiero et al., 1988) was performed to measure cell death after exposure of 
cells to different concentrations of drug for 24 hours. 
Cells were trypsinised, centrifuged and re-suspended in fresh media. Cells were then counted 
and seeded in a 96-well plate as detailed in section 2.3.7.  
On day 3, media was removed. Cells were treated with 100 µL of either 100 µM, 50 µM, 10 
µM, 5 µM, 1 µM or 0.1 µM of drug in DMSO (<1 %)/media. Plates were incubated for 24 hours 
(37 °C, 5% CO2) following which a mixture of 12.5:1 parts of XTT to menadione (25 µL) was 
added each well in a 96 well plate. Plates were incubated for 3 hours at 37 °C and the 
absorbance read at 450 nm. Assessment of Naringenin toxicity to these cells was conducted 
through analysis of changes in XTT absorbance with increasing drug concentration. 
4.3.13 Cellular liposomal uptake assay on HDFa and HaCat cells 
Liposomes, both deformable and non-deformable, were formulated with the addition the 
fluorescent dye, DilC, in DMSO as detailed in section 2.3.8. Coverslips were prepared and 
analysed with an upright confocal microscope (Leica SP5 TCS II MP) as detailed in section 
2.3.8. 
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4.3.14 Liposome stability 
The stability of liposomes was determined, as prepared in water, through the assessment of 
particle size over a 28 day period as detailed in section 2.3.4. 
Furthermore, the encapsulation efficiency of naringenin loaded liposomes was assessed over 
4 weeks as detailed in section 3.3.14.  
4.3.15 Statistical analysis  
Unless otherwise stated, all results are presented as mean +/- SD.  Replicates of at least 3 
where used for all studies.  For multiwall plate assays replicates of 6 were used for each 
experimental condition with the study replicated 3 times. 
A paired T test or a one way ANOVA was used to determine any statistically significant 
difference between means tested. A post-hoc Tukey’s multiple comparisons test was then 
applied to assess differences between groups. Results were deemed statistically significant if 
P < 0.05%. 
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4.4 Results and discussion  
Naringenin is the predominant flavanone in grapefruit. It is an antioxidant, free radical 
scavenger, anti-inflammatory agent, and immune system modulator thus may be potentially 
useful as pharmacological anti-cancer agent (Casey et al., 2015; Chen et al., 2003; Huang et 
al., 2011). 
The use of flavonoids in disease treatment is restricted in success due to inefficient delivery 
systems and the limited bioavailability of promising agents. Liposomes may enhancing the 
bioavailability of these compounds thus could prove useful as delivery agents (Nishiyama, 
2007; Siddiqui et al., 2009). Elastic liposomes have been found to be useful in dermal delivery 
of drugs as they can increase compound solubility, protect the drug from degradation and can 
be formulated for targeted, sustained drug release (Benson 20016, Cevc 1996). Elastic 
liposomes have been reported to penetrate the skin; an efficient and effective physical barrier 
to the external environment.  They have already been successfully employed in transdermal 
delivery of lipophilic and hydrophilic drugs including anti-inflammatory agents, plasmid DNA, 
anti-tumour agents and hormones (Cevc and Blume, 2001; El Maghraby et al., 1999; Oh et al., 
2006; Romero et al., 2013). They can also improve drug deposition within the skin at the site 
of action where the aim is to reduce systemic absorption thereby reducing side effects (Benson 
20016, Cevc 1996). 
Liposomes intended for dermal delivery require an additional carrier due to the liquid nature of 
the preparation. Liposomes are known to be compatible with viscosity increasing agents such 
as cellulose based gels including HEC and HPMC (Foldvari, 1996). These are known to be 
safe in topical, dermal and transdermal delivery (Forbes et al., 2011b; Hascicek et al., 2009; 
Patton et al., 2007).  
4.4.1 Liposome characterisation: particle size and polydispersity and zeta potential 
A principle aim for the present studies was to increase drug loaded liposome permeation 
across the epidermal layer; size of drug carrier is an important element of this. 
Naringenin loaded MLV liposomes were formulated using the dry film method (section 4.3.2). 
The bilayer included cholesterol to provide stabilising properties to the liposome bilayer by 
filling voids between the phospholipids as well as preventing drug from leaching out (Demel et 
al., 1972; Gregoriadis and Davis, 1979). Additionally, loadings of up to 10% w/w Tween 20, 
were added to the formulation thus adding elastic properties to the bilayer.  
Similar to liposomes formulated without naringenin, as the surfactant loading in the bilayer 
increased size decreased significantly from 1177.7 ± 153.8 nm to 693.4 ± 37.3 nm (Figure 4.2). 
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The decrease in size was significant between Tween 20 loadings of 0% w/w and both 6 and 
10% w/w (P ≤ 0.0001). This was again true between 0% and 2 % w/w of surfactant (P ≤ 0.001). 
The size decrease between Tween 20 loadings of 10% w/w and both 2 and 6% w/w was 
significant (P ≤ 0.01). There was no significant difference between the size of liposomes 
formulated with 2% w/w and 6% w/w of Tween 20. 
Surfactant is known to decrease liposome size in comparison to conventional liposomes 
(Goindi et al., 2013; Tsai et al., 2015). This is as a result of the surfactant destabilising the 
bilayer and its amphiphilic nature allowing a greater interaction of the phospholipid bilayer with 
the aqueous phase resulting in the overall formation of more liposomes of a smaller diameter 
thus giving a greater surface area in contact with the aqueous phase (El Zaafarany et al., 
2010). Unlike liposomes formulated with EGCG, only the size decrease between 6 and 10% 
w/w of surfactant is not significant. This implies that either the maximum loading of Tween 20 
is equal to or above 6% w/w, or that beyond this loading, there is no change in liposome size. 
Further studies to determine liposome composition would need to be conducted to confirm this.  
Naringenin loaded liposomes had a larger diameter than blank liposomes; 1177.8 ± 153.8 nm 
compared with 1032.3 ± 182.5 nm for liposomes formulated with no surfactant and 693.4 ± 
37.4 nm compared with 358.1 ± 57.1 nm for liposomes formulated with 10% w/w loading of 
surfactant. Naringenin is hydrophobic therefore was added in at the lipid mixing stage. The 
inclusion of drug in the bilayer may have caused an increase in liposome size by increasing 
bilayer hydrophobicity as it had caused the bilayer to have less interaction with the aqueous 
phase. Similar to blank liposomes, as the surfactant loading increased, the diameter 
decreased. 
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Figure 4.2: Liposome size distribution, comparing blank and naringenin loaded formulations. 
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Liposome size distribution, determined by DLS, comparing blank and naringenin loaded 
formulations with increasing loadings of Tween 20 up to a maximum of 10% w/w. Liposomes 
were prepared via the dry film hydration method and compound was added during the lipid 
mixing stage. Data represents mean ± SD. n=3 independent batches. 
 
A polydispersity of up to 0.3 is indicative of a homogenous formulation (Chen et al., 2012; 
Goindi et al., 2013; Kang et al., 2013).  Liposomes formulated without surfactant were slightly 
out of this range (0.32 ± 0.08 and 0.31 ± 0.06 for blank and drug loaded liposomes respectively) 
however liposomes formulated with surfactant all had a polydispersity below 0.3 therefore can 
be considered homogenous (Figure 4.3). Polydispersity for naringenin loaded liposomes was 
lowest at 0.21 when formulated with 6% w/w Tween 20 indicating this loading of surfactant 
produced the most homogenous mix of liposomes. The polydispersity for 10% w/w loading of 
surfactant increased to 0.3 indicating homogeneity deceased. This may have been due to the 
surfactant having surpassed its loading capacity within the liposome and the production of 
some micellar structures (Casas and Baszkin, 1992; Di Marzio et al., 2011).  A more 
homogenous mix could be obtained by using a probe sonicator in the production of liposomes. 
The polydispersity for drug loaded liposomes is similar to respective blank liposomes, any 
difference is not statistically significant (P = 0.57). As observed with EGCG loaded liposomes, 
naringenin loaded liposomes had a greater standard deviation than blank liposomes 
suggesting these liposomes were less homogenous than blank liposomes. This may be 
because of naringenin having been loaded into the bilayer membrane therefore disrupting the 
bilayer resulting in a wider size distribution. Additionally, as the loading of Tween 20 increased, 
the polydispersity decreased from 0.315 with no surfactant to 0.296 with 10% w/w of Tween 
20. As discussed later on in section 4.4.4, as the loading of Tween 20 increased, the 
entrapment efficiency decreases. Therefore, this indicated that the presence of EGCG with the 
bilayer led to a wider size range of formulated liposomes. 
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Figure 4.3: Polydispersity of blank and naringenin loaded liposomes 
Polydispersity, determined with DLS, of blank and naringenin loaded liposomes formulated 
with increasing loadings of Tween 20 up to a maximum of 10% w/w. Liposomes were prepared 
via the dry film hydration method and compound was added during the lipid mixing stage.  Data 
represents mean ± SD. n=3 independent batches. 
 
Comparison of the size between EGCG and naringenin observed that at 0% w/w loading of 
Tween 20, EGCG liposomes had a bigger diameter than naringenin (1292.2 compared with 
1177.8 nm). However, in the presence of surfactant, naringenin loaded liposomes maintained 
a greater diameter than EGCG loaded liposomes. EGCG is a larger molecule than naringenin 
and the loading of the molecule decreased as the loading of Tween 20 increased. Therefore, 
in the absence of Tween 20, this molecule resulted in the production of larger liposome than 
naringenin. However, as Tween 20 displaced EGCG, liposome size decreased.  
Comparison of the polydispersity between EGCG and naringenin observes at 0% w/w loading 
of surfactant EGCG liposomal formulations had a slight higher value than naringenin (0.322 
compared with 0.315). This indicates naringenin allowed the formulation of a slightly more 
homogenous mix of liposomes. However, in the presence of surfactant EGCG had a lower 
polydispersity than naringenin (0.263 comparted with 0.299 at 2% w/w loading of Tween 20). 
This maybe because EGCG has a slightly bigger structure than naringenin causing greater 
disruption in liposome shape at 0% w/w Tween 20. However, in the presence of surfactant, 
there was a higher loading naringenin in comparison to EGCG, therefore as surfactant loading 
increased, the assumed disruptive EGCG was less present to be able to cause disruption in 
the bilayer.  
The zeta potential of both blank and naringenin liposomal formulations is detailed in Table 4-
1. 
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Table 4-1: Zeta potential of liposomal formulations formulated with and without naringenin 
with up to 10% w/w loading of Tween 20 
Surfactant loading 
(% w/w) 
Zeta potential (mV) 
Blank Liposomes 
Naringenin 
loaded liposomes 
0 5.03 ±1.03 4.12 ± 1.14 
2 4.67 ± 1.08 3.30 ± 1.09 
6 3.71 ± 0.90 2.80 ± 0.60 
10 -2.79 ± 0.20 -0.22 ± 0.01 
Results are presented as the mean ± standard deviation (n=3) 
 
A neutral surface charge is ideal to avoid skin irritation (Prausnitz and Langer, 2008) however, 
neutral liposomes have a tendency to flocculate (Weiner et al., 1992). Additionally, positively 
charged liposomes are known to be irritating to the skin therefore negatively charged 
liposomes may be advantageous (Katahira et al., 1999). This study observed the majority of 
formulations for both blank and naringenin loaded liposomes to have a near neutral charge 
(Table 4.1).  Naringenin liposomal formulations formulated between 0 and 10% w/w Tween 20 
were found to have general decrease in zeta potential values from of 4.12 to -0.22 mV 
respectively. This was similar to the trend observed with EGCG (a decrease from 2.4 to -1.9 
mV). A study using Tween 80 in the liposomal formulation also found that in increase in 
surfactant loading did not affect liposomal charge. Although, contrasting with this study 
observing more positive zeta potential values, negative zeta potential values were observed 
(between -2.2 and -16) (Tsai et al., 2015). This may be due to differences in formulation 
parameters. 
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4.4.2 HPLC calibration and validation 
Chromatographic approaches must be tested to ensure trustworthy and reliable data. 
Consequently, validation of the HPLC-UV method was performed according to the 
International Conference of Harmonization (ICH) guidelines in terms of linearity and range, 
limit of detection (LOD), limit of quantification (LOQ) and precision. 
Stock solutions and standard solutions of naringenin were prepared in water ranging from 
0.125-10 µg/mL. Calibration data using the method outlined in section 4.3.5 was then obtained 
(Figure 4.4).  
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Figure 4.4: Calibration data for naringenin as determined by HPLC-UV analysis 
Calibration data for naringenin over the concentration range of 12.5-1000 µg/mL in water. A 
proportional response was evident versus the analytical concentration over the working 
concentration range with an r2 of 0.996 and polynomial equation of y = -6 x 107x2 + 1 x 107 ∙ x. 
Data represents mean ± SD. n=9. 
 
For the linearity and range assessment (Figure 4.4), standard solutions ranging between 12.5 
-1000 µg/mL of naringenin in water were prepared. The method developed demonstrated a 
high correlation with a good linear fit, with the correlation coefficient (r2) being greater than 
0.99. Assessment of repeatability/precision of the developed method was determined by 
assessing the intraday (same day) and interday (over the course of three days) variability 
(Figure 4.5). This was done to assess variation caused by temperature fluctuations and any 
variation in experimental method naringenin standards from 12.5-1000 µg/mL carried out 
intraday and interday are plotted in Figure 4.5a and b respectively. The results show that the 
values have no statistically significant difference for all the calibration curves carried out at 
different times on the same day and also on different days, meaning the method has good 
precision. The results show that the values did have some overlap at extremes of the 
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concentration range studied. Therefore, for all further studies, it is important to ensure the 
concentration of naringenin is between 12.5 µg and 500 µg. Calibration data for Naringenin 
was obtained on 3 separate days, each with 3 repeats. No statistically significant difference in 
either the peak areas for any one concentration across inter- and intra-day sampling across 
the 3 days was found (Figure 4.5b). 
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Figure 4.5: Calibration data of naringenin obtained over 3 days as determined by HPLC-UV 
analysis 
Calibration data of naringenin displaying a) intraday, b) interday data. The standards of 
naringenin ranged from 0.1-10 µg/mL. Data represents mean ± SD. n=3.  
 
Study of the sensitivity of this method was assessed by means of the calculation of the LOD 
and the LOQ. Values were determined from the standard deviation of the response (σ) and the 
slope (S) obtained from the calibration curves carried out during the linearity assessment 
(Figure 4.4). According to the ICH guidelines, a signal-to-noise ratio of three was assumed for 
the quantification of the LOD, whereas for the LOQ, a signal-to-noise ratio of ten was set. 
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Therefore, the sensitivity of the method for naringenin was calculated; the LOD and LOQ was 
1 µg/mL and 5 µg/mL respectively. 
4.4.3 Determination of entrapment efficiency 
The fraction of naringenin entrapped in the liposome compared with how much compound was 
added into the lipid mix was observed; the impact of surfactant addition on the amount of 
naringenin entrapped was therefore studied. As surfactant loading increased from 0% w/w to 
10% w/w, drug entrapment decreased from an efficiency of 90.8 ± 4.6 % to 64.3 ± 5.6 % (Figure 
4.6). A significant difference in naringenin entrapment was observed between surfactant 
loadings of 0% and 2% w/w (P ≤ 0.0001). There was also a significant difference in naringenin 
entrapment between surfactant loadings of 0% and 6% w/w as well as between 2% and 10% 
w/w (P ≤ 0.01). There was no significant difference in compound entrapment between other 
loadings of surfactant.  
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Figure 4.6: Entrapment efficiency of naringenin in liposomes formulated with up to 10% w/w 
Tween 20 
Entrapment efficiency (%) of naringenin in liposomes formulated with varying amounts of 
Tween 20 (0-10% w/w) Data represents mean ± SD. n=3 independent batches. 
 
Inclusion of surfactant in the bilayer of the liposome may have prevented drug inclusion within 
the bilayer implying the surfactant has a higher affinity to the lipids (Casas and Baszkin, 1992; 
Levy et al., 1991). Tween 20 is much larger than naringenin, thus it may be assumed it is better 
poised to displace naringenin from the bilayer (Figure 4.7). The hydrophobic tail of Tween 20 
would have a high affinity to the chains in PC therefore giving Tween 20 a better rooting in the 
bilayer than naringenin. Furthermore, Tween 20 is able to increase compound solubility, 
therefore, as not all would be entrapped within the bilayer, this may allow naringenin to 
solubilise within the liposomal rehydration media. Furthermore, studies using Tween 80 
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instead of Tween 20 were able to achieve a 99% entrapment efficiency (Tsai et al 2015). This 
may be due to the difference in the surfactant chains. Tween 80 has one more unsaturated 
bond causing a kink in the chain. This may then allow for the accommodation of more 
naringenin.  
 
Figure 4.7: Structure and MW of naringenin, cholesterol, Tween 20 and PC 
 
The entrapment efficiency of nariningen when compared to EGCG at increasing loadings of 
Tween 20 observed that naringenin always had a higher entrapment efficiency than EGCG 
(90.8 compared with 80.0% and 64.3 compared with 4.3% at 0 and 10% w/w loading of Tween 
20 respectively). EGCG is amphiphilic (Istenic et al., 2016) whereas naringenin is hydrophobic 
(Tsai et al., 2015) therefore naringenin would have a stronger affinity to the lipids in the bilayer. 
Therefore, as the loading of Tween 20 increased, EGCG was more liable to displacement out 
of the bilayer than naringenin.  
4.4.4 Assessment of liposomal deformability  
The addition of surfactant to the lipid bilayer of liposomes allows the liposome to display elastic 
properties (Almog et al., 1986a; Cevc, 1996; Trotta et al., 2002). This is advantageous when 
considering the design of a drug delivery system to deliver molecules across the SC into the 
dermal layer. Liposomes loaded with up to 10% w/w of Tween 20 were formulated and the 
extent of deformation of each formulation was determined by extruding them through a 
polycarbonate filter with a pore size of 200, 100 and 50 nm (Figure 4.8). The DI is the degree 
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the liposomes deformed. The greater the degree of deformation the less elastic the liposomes 
are as they were unable to regain their previous larger size.  
When liposomes were forced through the 200 nm pores the DI for naringenin loaded liposomes 
decreased significantly from 80.7 ± 2.0 to 59.2 ± 4.4 %. The decrease in deformation was 
significant between 0% w/w of surfactant and both 6 and 10% w/w of surfactant (P ≤ 0.0001). 
There was also a significant difference between the DI of liposomes formulated with 2% w/w 
of surfactant and both 0 and 10% w/w of surfactant (P ≤ 0.001). Additionally, there was a 
significant difference in the DI of liposomes formulated with 6% w/w of surfactant and 10% 
w/w. There was no significant difference between the DI of the other formulations.  
When liposomes were forced through the 100 nm pores, the deformability index for naringenin 
loaded liposomes decreased from 82.7 ± 0.7 to 66.4 ± 2.6 %. The decrease in deformation 
was not statistically significant between any of the loadings.  
No trend however was observed for formulations forced through a 50 nm pore size. Any 
differences in deformation between surfactant loadings was not significant between any of the 
formulations.  
The observed decrease in DI imply the liposomes were displaying elastic properties as they 
could deform to fit through a gap smaller than its diameter whilst somewhat regaining its size 
following extrusion. A study formulating liposomes with Phosphonlipon 90 G, stearylamine, 
Span 80 and cholesterol subjected liposomes to a similar mini-filtration technique used in this 
study observed the presence of surfactant added elastic properties to the liposome as the DI 
of these liposomes decreased (52% for blank liposomes compared with 17% for liposomes 
formulated with surfactant) (Goindi et al., 2013).  
Furthermore, the DI of the naringenin loaded liposomes forced through 200 and 100 nm was 
greater than blank loaded liposomes (P ≤ 0.05). Naringenin loaded liposomes have a greater 
deformability index overall, however, their overall size prior to extrusion was greater than that 
of blank liposomes therefore they would have to deform to a greater degree to be able to pass 
through the filter. This trend was not observed for liposomes forced through the 50 nm pores 
but this may be due to liposome destruction (discussed later in this section). 
Liposomes formulated with surfactant are able to deform as the surfactant has a tendency 
toward curved structures, thus diminishing the energy required for particle deformation. The 
surfactant can diminish the energy required for particle deformation and accommodate particle 
shape changes of the liposomes under stress (Trotta et al., 2004). 
Tween 20 may have interacted with the PC with strong affinity but in reversible mode. The fast 
reconstruction of liposome spheres after extrusion may be due to the strong affinity between 
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the surfactant and PC. The reversible binding mode might have provided the deformability 
upon physical stress (Oh, Y. K. et al., 2006). 
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Figure 4.8: Deformability index following extrusion for blank and naringenin loaded liposomes 
Deformability index following extrusion through a) 200 nm, b) 100 nm, c) 50 nm membranes 
for blank and naringenin loaded liposomes with increasing surfactant loading up to a maximum 
of 10% w/w. Liposomes were prepared adapting the dry film method adding the surfactant and 
adding naringenin during the lipid mixing stage. The preparation was vortexed and then 
extruded though the membranes. Data represents mean ± SD. n=3 independent batches. 
 
Deformability for both blank and drug loaded liposomes was not significantly affected by the 
different pore sizes investigated. Liposomes were expected to deform more so as pore size 
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decreased. This demonstrates that even up to 50 nm, liposomes retained enough elastic 
energy to maintain the same size as when forced through the 200 nm membrane.  
In order to deform liposomes require energy (Fresta and Puglisi, 1996; Gompper and Kroll, 
1995; Trotta et al., 2002). As detailed in section 3.4.4, in this system energy was supplied as 
pressure. The more surfactant included in the bilayer, the more energy the liposome will be 
able to retain (Trotta et al., 2002). This energy would be employed in bending the lipid bilayer 
structure, which will be expelled once the liposome has passed through the pore. This energy 
can then be used in reforming the liposome. Some energy is lost as heat or non-plastic 
deformation. Therefore, even at 10% w/w of Tween 20, 100% size was not recovered and a 
0% deformability index was not achieved. Liposome containing no surfactant does not benefit 
from the extra ‘storage space’ of a surfactant, thus energy may be spent in rupturing the 
membrane causing liposome size to decrease (Trotta et al., 2002).  
To fit through a 50 nm pore in comparison to a 200 nm pore, more energy is necessary to 
deform the liposome, therefore the deformability index is expected to increase as pore size 
decreases. This was not observed within the bounds of this study. The standard deviation of 
the DI for liposomes forced through a 50 nm pore size was extremely large (for liposomes 
formulated with 2% Tween 20 an SD of 30 was observed) therefore the mean value is not the 
best representation of the actual data values obtained. Liposome size following extrusion for 
these formulations was extremely varied with some liposomes coming through the pores larger 
than the original size. Naringenin loaded liposomes formulated without surfactant had an 
original size of 1012 nm compared with 1354 nm following extrusion, liposomes loaded with 
2% w/w surfactant had an original size of 694 nm compared with 737 nm following extrusion 
(Figure 4.8). This indicates these formulations didn’t retain enough elastic energy to be easily 
able to fit through the pores with some liposomes even converging following extrusion (Goindi 
et al., 2013; Trotta et al., 2002). However, even when forced through the 50 nm pores, the 
amount of energy stored in the liposome membrane was enough to reform at least a fraction 
of the liposomes to the same extent as for when forced through 200 nm pores.  
The larger standard deviations suggest there may have been smaller liposomes that didn’t 
reform alongside side some destroyed liposomes clumping together as lipid aggregates. 
Liposome formulations in this study therefore were not suitable to pass through a 50 nm pore. 
As detailed in section 2.4.3 this does not imply this is what would happen to liposomes when 
applied to the skin. The liposomes would instead be expected to move across the skin following 
the hydrogen based transepidermal gradient (Cevc, 1996; Goindi et al., 2013; Gompper and 
Kroll, 1995; Trotta et al., 2002). Additionally, the skin temperature is warmer than room 
temperature (35°C compared to 20°C) which will supply more energy to be even more flexible 
and cross the stratum corneum.  
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As discussed in section 2.4.3 even in an excess of energy, the liposomes did not fully regain 
their pre-extrusion size. Some energy is lost in the friction of the particles moving through the 
pores as heat. Increasing surfactant loading may result in an increase in liposome reformation 
(Trotta et al., 2002). Additionally, lipids may block membrane pores resulting in an increase in 
pressure in the vessel causing more turmoil leading to the rupture and non-uniform reformation 
of liposomes.  
Comparison of the DI between EGCG and naringenin loaded liposomes forced through 200, 
100 and 50 nm pore sized membranes observed that at 0, 2, 6 and 10% w/w loading of Tween 
20, naringenin loaded liposomes maintained a greater DI. This implies that these liposomes 
were less able to regain their pre-extrusion size thus were less elastic than EGCG loaded 
liposomes. This does not however imply that EGCG can add elastic properties to the liposome 
bilayer. Naringenin loaded liposomes also observed a greater liposomal size than their EGCG 
counterparts therefore would have to deform more to be able to fit through the pore size. This 
deformation will require more energy and if this requirement is not met, the liposome will 
rupture and form smaller vesicles thus not regain its original size (Fresta and Puglisi, 1996; 
Gompper and Kroll, 1995; Trotta et al., 2002). Furthermore, neither EGCG nor naringenin is 
known to be an elastic molecule. This was observed in this study; in comparison to their 
respective blank, Tween 20 loaded liposomes, as discussed earlier, when forced through 200 
nm, there was no difference in the DI EGCG loaded liposomes, however, naringenin loaded 
liposomes deformed more. However, as the loading of Tween 20 increased, the loading of 
EGCG decreased at a greater rate than the decrease observed with the loading of naringenin. 
Therefore, EGCG loaded liposomes may appear more elastic however, they contain less 
EGCG than their respective naringenin loaded liposomes thus allowing them to be more elastic 
at a loading of Tween 20.  
4.4.5 Differential scanning calorimetry investigations of naringenin and naringenin 
lipid blends  
Differential scanning calorimetry (DSC) is extensively used in its application in understanding 
the thermal characteristics of materials where an insight into a range of thermal properties 
including melting temperatures, phase transitions and heat capacity changes can be obtained. 
The investigations were carried out over the temperature range 0–300 °C with a heating rate 
of 10°C min-1. The thermogram of naringenin is displayed in Figure 4.9. Naringenin showed a 
sharp endothermic peak (Tm) at 253 °C. 
To substantiate the association of naringenin with the lipid/surfactant complex, DSC analysis 
was performed on, the lipid blend, and the naringenin-lipid/surfactant blend. In the 
lipid/surfactant mix a very small peak at 40 °C is noticeable, a larger peak at 172 °C and a 
medium peak at 212 °C. On the other hand naringenin–lipid/surfactant complex showed a 
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small peak at 40 °C and a large peak at 152 °C, differing from the peaks of the individual 
components of the complex (Figure 4.9). It is evident that the original peaks of naringenin and 
phospholipids disappear from the thermogram of complex and the phase transition 
temperature is lower than that of naringenin as there is no sharp peak around 253 °C. 
The Tm of Naringenin corresponds with similar studies (Khan et al., 2015; Semalty et al., 
2010b). Furthermore, Semalty et al., observed the association of naringenin with soy 
phosphatidylcholine. PC showed a smaller peak at 64.45 °C and major peaks at 83.21 °C and 
107.90 °C. They suggested the first peak was probably due to the hot movement of the 
phospholipids polar head group. The second peak was assumed to be due to phase transition 
from gel to liquid crystalline state. The non-polar hydrocarbon tail of phospholipids may be 
melted during this phase, yielding a sharp peak. This melting might have occurred in two 
phases which subsequently gave the next peak. The naringenin–PC complex showed two 
peaks at 51.23 °C and 62.21 °C, which is different from the peaks of the individual components 
of the complex. Therefore Semalty et al., also found that the original peaks of naringenin and 
PC disappear from the thermogram of the blend and the phase transition temperature is lower 
than that of naringenin alone.  
This interaction may be a result of hydrophobic interaction and/or hydrogen bonding (Semalty 
et al., 2010a). The –OH groups of the phenol rings of naringenin may be involved in hydrogen 
bonding and the aromatic rings may be involved in any hydrophobic interaction. Consequently, 
the major sharp peaks of phospholipids disappear and decrease the phase transition 
temperature.  
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Figure 4.9: DSC scan of naringenin and lipid blends. 
DSC scan of a) naringenin b) PC, cholesterol and Tween 20 blend and c) PC, cholesterol, 
Tween 20 and naringenin blend. All experimental runs commenced at an initial temperature of 
0°C with a scan rate of 10 °C/min to 300 °C. The peak in a) shows the melting point (Tm) of 
naringenin was at 253 °C. The Tm of the lipid mixture is 172 °C, and upon addition of naringenin, 
the Tm was 152 °C. 
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These DSC data are supported with the results of DSC thermograms of the phospholipid 
complexes of some phytoconstituents including silybin, puerarin and curcumin in which the 
thermogram of the complex also exhibited a single peak which was different from the peak of 
phytoconstituents and the phospholipids (Kumar et al., 2008; Li et al., 2008; Maiti et al., 2007; 
Yanyu et al., 2006). 
 
4.4.6 Naringenin release studies 
4.4.6.1 Naringenin release studies from gel formulations 
Liposomes employed in dermal drug delivery systems must be delivered in a carrier due to the 
liquid nature of the preparation. The viscosity and application properties can be adjusted by 
incorporating in an appropriate vehicle. Liposomes are known to be compatible with viscosity 
increasing agents such as cellulose based gels (Foldvari, 1996). These are established as 
safe in topical, dermal and transdermal delivery (Forbes et al., 2011b; Hascicek et al., 2009; 
Patton et al., 2007). Simple HEC and HPMC gel formulations were employed to compare as 
carriers of liposomal preparations.  
 
As with release studies for EGCG detailed in section 3.4.7.1, two geometric systems have 
been considered for naringenin release from gel systems; three-dimensional leaching from a 
cylinder of gel (one compartment release) and unidirectional leaching across a planar surface 
(two compartment release). A one compartment model was used to study release and gel 
swelling behaviour whilst a two compartment diffusion cell observed drug release across a 
membrane. A polycarbonate membrane with 50 nm was used to mimic the stratum corneum 
and the gaps in between the keratinocyte cells. The composition of both HPMC and HEC gels 
was kept at 3% w/v. The release of drug from a formulation is determined by many factors 
including diffusion, and erosion of matrices followed by dissolution of drug. Such 
dissolution/release tests are required to help predict in vivo behaviour and to study the 
structure of the dissolving matrix. 
 
4.4.6.1.1 One compartment release studies 
Naringenin release from the aqueous HEC and HPMC gels loaded with 1% w/w naringenin 
into DDM was studied over a 24-hour period (section 4.3.9.1) (Figure 4.10). 
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Figure 4.10: Naringenin release profiles from aqueous gels 
Naringenin release profiles from aqueous HEC and HPMC gels (3% w/v) over a) 24 hours, b) 
4 hours was observed. Data represents mean ± SD. n=3 independent batches.  
 
HEC and HPMC gels displayed a similar pattern of release into the DDM. It is clear however 
that at 3% w/v loading of polymer, HPMC could retard drug release to a greater degree up until 
3 hours at which time 100% of compound was released, HEC consistently had a higher 
cumulative percentage of drug released (at 1.5 hours HEC released 68% of Naringenin 
compared with 41% from HPMC). Similar trends were observed with EGCG. At the point of 
complete release, the gel was observed to have completely dissipated into the release media. 
 
As discussed in section 3.4.7.1.1, the diffusion of solution out of the polymer depends on 
temperature, pressure, viscosity and solute size. Diffusion in polymers is complex and the 
diffusion rates should lie between those in liquids and in solids. Solvent diffusion is associated 
with the physical properties of the polymer network and the interactions between the polymer 
and solvent (Masaro and Zhu 1999). Furthermore, molecular geometry has been observed to 
influence compound release from polymer networks (Ford, Rubinstein et al. 1987, Rao, Devi 
et al. 1990).  
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The principal mechanism of compound release is the net consequence of drug diffusion due 
to the concentration gradient, macromolecular relaxation of the polymer chains which causes 
drug diffusion outward with a kinetic behaviour dependent on the relative ratio of diffusion and 
relaxation and due to the fact cellulose derivatives have limited solubility for lipophilic 
compounds thus the compound would diffuse out of the gel (Forbes et al., 2011b; Lee, 1985). 
As water penetrates the glassy hydrogel matrix containing the dispersed drug, the polymer will 
swell thus its glass transition temperature is lowered. Simultaneously, dissolved drug diffuses 
through this swollen network into the release medium (Bouwstra and Junginger, 1993; Gupta 
et al., 2002; Lee, 1985; Rao et al., 1990). The rate-controlling factor mediating drug release is 
the resistance of the polymer to a change in shape owing to an increase in volume (Ranga 
Rao and Padmalatha Devi, 1988). 
 
Further, the addition of water-insoluble drug can increase the water uptake by the dosage form 
thus weakening the network integrity of the polymer, causing drug leaching (Sai Cheong Wan 
et al., 1995). The compound particles between polymer chains allow each chain to hydrate 
freely, which may result in weak hydrogen bonding areas around the drug molecule 
(Panomsuk et al., 1996). Additionally, the influence of drug on the swelling properties of the 
polymer matrix is largely dependent on the substituted groups of the polymer. The hydroxyl 
group in the molecules plays an important role in the matrix integrity of the swollen hydrophilic 
cellulose matrices. The amount and properties of the incorporated drug determine matrix 
integrity (Nafee et al., 2003). In this case, similar to release observed with EGCG, it appears 
the HEC matrix eroded/swelled quicker than HPMC giving a faster rate of release.  
4.4.6.1.1.1 Kinetic assessment  
Release profiles were evaluated by zero-order, first-order and Higuchi kinetics model (Table 
4-2). As with EGCG, release from the gels were observed to fit the first order release model 
best as the r2 values were highest upon comparison with those for the zero order model and 
the Higuchi model (for example for 3% w/v HEC the r2 values were -1.4, 0.92 and 0.33 for the 
zero order, first order and Higuchi model respectively). Thus, drug was released at a constant 
rate in proportion to the amount of drug available at that time. As discussed in section 3.4.7.1.1, 
other studies have found the other models better at describing release from polymer gel 
systems but this was dependent on formulation parameters. This was a simple gel formulation 
and no further investigation into kinetic release model was carried out. 
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Table 4-2: Kinetic assessment of release data of naringenin from HEC and HPMC aqueous 
gels. 
Kinetic model 
Formulation r2 
HEC (3% w/w) HPMC (3% w/w) 
Zero order -1.434 ± 0.170 -0.686 ± 0.071 
First order 0.923 ± 0.007 0.896 ± 0.013 
Higuchi model 0.330 ± 0.095 0.539 ± 0.021 
Results are presented as the mean ± standard deviation (n=3) 
 
Comparison of the rate constant between formulations found HEC to have a larger rate 
constant than HPMC (Table 4-3). This shows HEC gave a faster release of naringenin per unit 
time. Drug is released from gel by the creation of pores dues to swelling, as viscosity increases 
polymer chains becoming more resistant to movement as they are physically restricted thus 
taking longer to dissipate into the media thus slowing release drug. This implies HPMC had a 
greater viscosity than HEC. 
 
Table 4-3: First order kinetics rate constant for naringenin release from formulations 
Rate constant (min-1) 
HEC 3% w/v 
HPMC 3% 
w/v 
0.011 ± 0.001 0.009 ± 0.000 
Results are presented as the mean ± standard deviation (n=3) 
  
The Korsmeyers-Peppas model was applied to the release data and the diffusional exponent 
(I) calculated (Table 4-4). Fickian release (case I) was observed for both polymers at 3% w/v. 
A study by Ritger and Peppas found both Fickian and anomalous release from swellable 
devices (Ritger and Peppas, 1987). Additionally, a study using the polymer HPC observed 
both Non-Fickian and Super Case II transport (Alfrey Jr et al., 1966; Ranga Rao et al., 1988).  
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Table 4-4: Diffusional exponent n calculated from the Korsmeyer-Peppas model of drug 
release for naringenin release data from aqueous gels with the corresponding release 
mechanism. 
Formulation  n Transport type 
HEC 3% w/v 0.285 ± 0.015 Fickian 
HPMC 3% w/v 0.341 ± 0.007 Fickian 
Results are presented as the mean ± standard deviation (n=3) 
 
Fickian diffusion from polymer networks is regularly observed when the temperature is above 
the glass transition temperature of the polymer (Tg). In this state, the polymer chains have a 
higher mobility allowing  easier penetration of the solvent (Masaro and Zhu, 1999). Thus in this 
study it may be deduced that the polymer chains were able to move sufficiently, the gel was in 
a rubbery state.  
4.4.6.1.2 Two compartment release  
Release of naringenin from HEC and HPMC gel formulations at polymer loading of 3% w/v in 
a two-compartment model using a diffusion cell was also observed. Release across a 50 nm 
polycarbonate membrane was observed. This was compared against release from solution in 
the donor compartment into the receiver compartment. Naringenin loaded gels were prepared 
(section 4.3.8) and release over 24 hours observed.  
 
Gels appeared to slow the release of naringenin with HPMC proving to be more pronounced 
than HEC in this phenomenon (Figure 4.11). Over 24 hours, the solution gave 54.5 ± 4.2 % 
release whilst HEC and HPMC saw a 33.1 ± 2.0 and 31.1 ± 1.0 % release respectively. The 
release profile was significantly different between HPMC and both solution and HEC (P ≤ 
0.001). There was no significant difference in the release profile of naringenin from solution 
and the HEC gel implying HPMC is better at compound retardation in this case. Comparison 
between the gels found that HEC at its respective loading of polymer in the HPMC gels, 
consistently resulted in a faster release of drug (at the time point of 3 hours, 9.8 ± 0.5 % was 
released in comparison to 5.6 ± 0.2 %). Therefore, drug release was faster from the HEC gel 
compared to the HPMC gel.  
The addition of water-insoluble drug can increase the water uptake by the dosage form thus 
weakening network integrity thus drug loading will influence network integrity (Nafee et al., 
2003; Panomsuk et al., 1996). In this case, it appears the HEC matrix eroded/swelled quicker 
than HPMC giving a faster rate of release. This is in contrast with a study comparing the 
release of miconazole from a 1.5% w/v HEC formulation with a 3% HPMC w/v formulation 
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where a faster erosion was observed from the HPMC matrix (even at double the polymer 
loading) (Nafee et al., 2003). This highlights how the physiochemical properties of the drug, 
the polymer and the interaction between the two affect drug release from the formulation. 
 
 
Figure 4.11: In vitro percentage naringenin release profiles from aqueous gels 
Naringenin release profiles from HEC and HPMC (3% w/v) aqueous gels with 1% w/v 
naringenin and naringenin solution over a) 24 hours, B) 8 hours. Data represents mean ± SD. 
n=3 independent batches. 
 
Comparison of the release of naringenin to the release of EGCG from aqueous solution, HEC 
and HPMC observed a greater EGCG to have a greater rate of release from all formulations. 
After 24 hours, a release of 105 ± 4.9, 92 ± 4.9 and 109 ± 7.3 % EGCG from aqueous solution, 
HEC and HPMC was observed compared with 54.5 ± 4.2, 33.1 ± 2.0 and 31.1 ± 1.0 % release 
of naringenin. This may be due to the amphiphilic nature of EGCG, this compound has a 
solubility of ≥5 mg/mL (Sigma-Aldrich(e), 2017) compared with naringenin which is insoluble 
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in water at room temperature (Wen et al., 2010b). This would mean that EGCG would solubilise 
in water and diffusion would allow this compound to move across the polycarbonate 
membrane. Naringenin however may solubilise at a slower rate (due to the experimental 
conditions maintaining the environment at 35°C) therefore have a slower rate of release from 
any formulation.  
4.4.6.1.2.1 Kinetic assessment 
The release profiles were evaluated by the zero-order, first-order and Higuchi kinetic models. 
Release from the solution was observed to fit the first order release model best as the r2 values 
were highest upon comparison with those for the zero order model and the Higuchi model (the 
r2 values were 0.91 and 0.96 for the zero order and first order model respectively) (Table 4-5). 
This indicates rate of release was dependent on the amount of drug present at that time point. 
Release from the HEC gel fit the Higuchi model release model whereas release from the 
HPMC gel followed the first order release model (r2 values of 0.93 and 0.99 respectively).  
Following a kinetic analysis, a study formulating HEC gels at 7.5% w/w with 1% w/w of drug 
observed release to fit the Higuchi model. This may be due to differences in formulation, and 
differences in experimental parameter including their use of Franz diffusion cells with only a 
thin film of gel spread over the membrane (Hascicek et al., 2009). 
 
Table 4-5: Kinetic assessment of release data of naringenin from solution and aqueous gels. 
Kinetic model 
Formulation r2 
Solution HEC (3% w/w) HPMC (3% w/w) 
Zero order 0.917 ± 0.022 0.645 ± 0.116 0.970 ± 0.012 
First order 0.964 ± 0.021 0.789 ± 0.085 0.985 ± 0.004 
Higuchi model   0.933 ± 0.012 0.822 ± 0.023 
Results are presented as the mean ± standard deviation (n=3) 
 
Comparison of the rate constant of each formulation shows that HEC had a higher rate 
constant than HPMC (Table 4-6). This implies that HPMC had a higher gel consistency thus 
slowing naringenin release. Naringenin is released from gel by the creation of pores dues to 
swelling, as viscosity increases polymer chains becoming more resistant to movement as they 
are physically restricted consequently taking longer to dissipate into the media thus slowing 
drug release. This data is consistent with that of EGCG. 
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Table 4-6: First order kinetics rate constant for naringenin release from formulations 
Rate constant (min-1) 
Solution  HEC (3% w/w)  HPMC (3% w/w)  
5.9 × 10-4 ± 1.3 × 10-4 0.852  ± 0.018 2.7 × 10-4 ± 7.1 × 10-6 
Results are presented as the mean ± standard deviation (n=3) 
The Korsmeyers-Peppas model was applied to the release data and the diffusional exponent 
(n) calculated (Table 4-7). Non-Fickian release was observed for both HEC and HPMC gels at 
3% w/w polymer. A study by Ritger and Peppas found both Fickian and anomalous release 
from swellable devices (Ritger and Peppas, 1987). Additionally, a study using the polymer 
HPC observed both Non-Fickian and super case 11 transport (Alfrey Jr et al., 1966; Ranga 
Rao et al., 1988).  
At temperatures below the Tg, the polymer chains are not sufficiently able to move to permit 
immediate penetration of the solvent in the polymer core (Masaro and Zhu, 1999). This implies 
that, in our studies, when Non-Fickian transport was observed, the polymer chains were unable 
to move sufficiently and that at those particular loadings of polymer, the gel was in a glassy 
state.  
 
Table 4-7: Diffusional exponent n for naringenin release data with the corresponding release 
mechanism. 
Formulation n Transport type 
HEC (3% w/v) 0.590 ± 0.041 Non-Fickian 
HPMC (3% w/v) 0.851 ± 0.036 Non-Fickian 
Results are presented as the mean ± standard deviation (n=3) 
Diffusion of solution out of the polymer is known to depend on temperature, pressure, solute 
size and viscosity. Diffusion in polymers is complex and the diffusion rates should lie between 
those in liquids and in solids. It depends strongly on the concentration and degree of swelling 
of polymers. Solvent diffusion is associated with the physical properties of the polymer network 
and the interactions between the polymer and solvent (Masaro and Zhu 1999). Furthermore, 
a study using the molecular weight of the drugs as an approximation of molecular size could 
not find a relation to release rates. This indicates that molecular geometry plays a role in 
compound release from polymer networks (Ford, Rubinstein et al. 1987, Rao, Devi et al. 1990). 
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It has been suggested that drug release from aqueous gels is governed by a swelling- 
controlled mechanism in which the drug releases into the media due to the simultaneous 
absorption of water by the gel causing the gel to dissipate into the media thus releasing drug 
and due to  desorption of drug from the gel (Bouwstra and Junginger, 1993; Nafee et al., 2003; 
Ranga Rao and Padmalatha Devi, 1988; Sinha Roy and Rohera, 2002). The rate-controlling 
factor mediating drug release is the resistance of the polymer to a change in shape owing to 
an increase in volume (Ranga Rao and Padmalatha Devi, 1988). The membrane would have 
prevented the gel from completely swelling and releasing drug, whilst water could move across 
it, the polymer did not have much room to swell as the donor compartment was filled to near 
capacity. This can be likened to the skin in the sense that the skin is a barrier, as well as the 
polymer chains would slow the movement of drug into the skin. 
 
4.4.6.2 Naringenin release from liposomes  
Deformable liposomes have been successfully used in transdermal delivery of lipophilic and 
hydrophilic drugs (Cevc and Blume, 2001; El Maghraby et al., 1999; Oh et al., 2006; Romero 
et al., 2013). The use of elastic liposomes as drug carriers across the stratum corneum for 
dermal drug delivery is advantageous as they can penetrate the skin if applied non-occlusivley 
by virtue of the very high and self-optimizing deformability. Liposomes can penetrate the 
stratum corneum with potentially deeper penetration into the dermal layer of deformable 
vesicles compared with traditional liposomes (El Maghraby et al., 1999). Release of naringenin 
from 0.1mg /10mL solution, liposomes and liposomes formulated with either 2%, 6% or 10% 
w/w of Tween 20 with was studied over a 24 hour period (Figure 4.12).  
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Figure 4.12: In vitro percentage naringenin release profiles from solution and liposomes 
Liposomes were formulated with 0-10 % w/w Tween 20 and release was observed over a) 8 
hours, b) 24 hours. Liposomes were prepared adapting the dry film method adding the 
surfactant and naringenin during the lipid mixing stage. A diffusion cell dialysis system was 
used to evaluate in vitro drug release. Data represents mean ± SD. n=3 independent batches. 
 
A higher percentage of naringenin was released from liposomes compared with drug solution. 
Over the course of 24 hours solution gave a release of 54.5 ± 4.2 % whilst liposomes 
formulated with 0%, 2%, 6% and 10% w/w of Tween 20 gave a release of 109.7 ± 5.0 %, 79.5 
± 3.7 %, 61.3 ± 3.4 % and 48.5 ± 2.1 % respectively. The cumulative percentage released after 
24 hours was significant between the solution and liposomes loaded with 0 and 2% w/w of 
Tween 20 as well as between all liposomal formulations (P ≤ 0.0001 and P ≤ 0.01 between 
liposomes loaded with 6 and 10% Tween 20).  
As the loading of Tween 20 increased, the release from the liposomes slowed. This is in 
contrast with release of EGCG from the same formulations in which solution gave the fastest 
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release of drug and EGCG release increased with increased surfactant loading. This may be 
because at higher loadings of surfactant, less EGCG was loaded into the liposomes therefore 
the amount of surfactant available may have been able to solubilise EGCG thus aid the release 
of it from the liposomes. Release of naringenin observed significant differences over 24 hours 
between release from solution and 0% w/w Tween 20 (P ≤ 0.0001) as well as, 2 and 6% w/w 
Tween 20 (P ≤ 0.01). Release between 0 and 2, 6 and 10% w/w Tween 20 liposomes was 
significantly different (P ≤ 0.0001). The release profile was between 10% w/w Tween 20 and 2 
and 6% w/w was also significantly different (P ≤ 0.01 and P ≤ 0.0001 respectively).  
As surfactant loading increased, drug entrapment decreased, therefore, drug release would 
be expected to be slower as there is less of a concentration gradient. Furthermore, the drug is 
hydrophobic therefore less inclined to diffuse out of the hydrophobic liposome bilayer into the 
media. At higher concentrations of drug, if the bilayer becomes saturated with the drug, more 
would diffuse out of the liposome.  
4.4.6.2.1 Kinetic assessment of naringenin release from liposomal formulations 
Release data from the solution and all liposomal formulations complied with first order release 
kinetics implying rate of drug release was dependent on drug concentration at that time (Table 
4-8). 
A study comparing the deposition of naringenin in the skin from elastic liposomes and saturated 
solution found elastic liposomes (zero-order release) formulated with Tween 80 increased the 
deposition of naringenin in the skin significantly (by about 7.3~11.8-fold) compared with the 
saturated aqueous solution. Another study also found elastic liposomes were able to increase 
drug permeation into the skin in comparison to a conventional cream (2 fold) (Goindi et al., 
2013). Our studies do imply liposomal carriers would be able to increase permeation however, 
further studies with excised skin would have to be carried out to see if the same results can be 
achieved with Tween 20. It has been suggested that the mechanism of the in vitro release 
seems to be the formation of transient pores in the lipid bilayer, through which drugs are 
released from the inner aqueous core of the liposomes to the extra-liposomal medium (Wang 
et al., 2016). 
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Table 4-8: Kinetic assessment of release data of naringenin from solution and liposomal 
formulations. 
Kinetic model 
Formulation (r2) 
Solution 
Liposome                                                 
(% w/w loading of Tween 20) 
0 2 6 10 
Zero order 
0.917 ± 
0.022 
0.327 ± 
0.362 
0.600 ± 
0.150 
0.385 ± 
0.292 
0.558 ± 
0.079 
First order 
0.964 ± 
0.021 
0.855 ± 
0.095 
0.981 ± 
0.015 
0.815 ± 
0.125 
0.828 ± 
0.027 
Results are presented as the mean ± standard deviation (n=3) 
 
Comparison of the rate constant of each formulation shows liposomes formulated with 0% w/w 
Tween 20 had the highest rate of release, followed by liposomes formulated with 2% w/w 
Tween 20, then 6% w/w Tween 20, naringenin solution and then liposomes formulated with 
10% w/w of Tween 20 (Table 4-9).  
  
Table 4-9: First order kinetics rate constant for naringenin release from formulations 
Results are presented as the mean ± standard deviation (n=3) 
As discussed in section 3.4.7.2.1 in dynamic dialysis drug appearance in the receiver 
compartment is the result of diffusion from liposomes followed by diffusion across the 
membrane, though it is generally treated as a simple first-order process (Modi and Anderson 
2013). The driving force of drug movement is dependent on free aqueous drug concentration. 
Therefore, the reliability of rate constants determined by dynamic dialysis must be carefully 
considered (Modi and Anderson, 2013). The release data observed will be either as a 
consequence of drug release from the liposome and then the membrane or movement of the 
liposome across the barrier and then release from this. The diffusion cell system will see 
Rate constant (× 10-3 min-1) 
Solution 
 
Liposome formulation (% w/w loading of Tween 20) 
0% w/w 2% w/w  6% w/w 10% w/w  
5.85 ± 1.29 2.69 ± 1.4 1.59 ± 0.57 1.07 ± 0.22 0.74 ± 0.12 
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release from the liposome first owing to the physical set up of the cell and the smaller pore 
size of 50 nm.  
Furthermore, reversible binding of the drug released from the liposome reduces the driving 
force for drug transport across the dialysis membrane leading to a slower overall apparent 
release rate (Modi and Anderson, 2013). In this case, this reversible binding was greater as 
surfactant loading increased resulting in a slower rate of release for liposome formulated with 
10% w/w Tween 20 in comparison to liposomes formulated with no Tween 20. 
4.4.6.3 Liposomal gel naringenin release studies 
Drug release from liposomal gels could not be measured/detected in the side by side diffusion 
chamber therefore a different method using 6- well Thincert plate and 4 cm2 cylindrical cell 
culture ThincertTM insert with 400 µm pore size was employed. Neither the diffusion cell nor 
the insert mimic what would happen following formulation application on the skin. The diffusion 
cell observed how drug diffused across a membrane with a pore size similar to that of the gaps 
in the SC whilst maintaining sink conditions. The plate with inserts was used simply to observe 
ability of drug release from a liposomal gel. To ensure we were only detecting free drug 
samples were centrifuged and supernatant analysed. Naringenin release from liposomal gels 
is displayed in Figure 4.13. 
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Figure 4.13: In vitro percentage naringenin release profiles from liposomal gels 
Naringenin release profiles using a transwell system with permeable inserts of a 400nm pore 
size from solution and gel loaded with either blank or elastic liposomes formulated with 2% 
w/w Tween 20 over a) 24 hours, b) just liposomal gel formulations. F1: HEC and blank 
liposomes, F2: HEC and elastic liposomes, F3: HPMC and blank liposomes, F4: HMPC and 
elastic liposomes. Gels were prepared using 3% w/v loading of either HEC or HPMC with a 
1% w/w of drug loading. Liposomes were prepared adapting the dry film method. Data 
represents mean ± SD. n=3 independent batches. 
 
Drug release from solution seemed to reach a maximum between the 4th and 5th hour (~55%). 
Solution saturation may have been reached beyond this point thus appearing as though 100% 
release was not achieved. Over all the percentage of drug release from the liposome loaded 
gels quantified over 24 hours was slightly higher from the HEC gel (up to 23%). Furthermore, 
a higher percentage of drug was released from the elastic liposome (up to 23%). This followed 
the same trend as seen with EGCG liposomal gels.  
Over the course of 24 hours solution gave a release of 59.2 ± 5.6 % whilst F1, F2, F3 and F4 
gave a release of 13.9 ± 2.0 %, 23.2 ± 4.1 %, 11.8 ± 0.4 % and 19.8 ± 1.5 %, respectively. The 
cumulative percentage released after 24 hours was significant between the solution and all 
liposomal gels (P ≤ 0.0001). The difference was also significant between F1 and F2 as well as 
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between F2 and F3. F1 and F3 contained no surfactant in the liposome and F2 and F4 
contained 2% w/w of Tween 20. Therefore, release in the liposomal gels appeared to be 
affected by presence of surfactant in liposomal gels formulated with HEC but not HPMC. 
This indicated that either elastic liposomes where more able to move through the HEC gel 
compared with blank liposomes (movement based on weight of liposomes, being denser hence 
sedimenting within the gel) or that the presence of surfactant increased the solubility of drug 
thus encouraging release from the liposome bilayer. (Some gel could possibly have seeped 
through the inserts which could result in false higher drug detection toward the end of this 
study). A study observing lidocaine HCL release from liposome loaded gels had similar results 
with hydrogel formulations having a faster release rate of lidocaine HCl compared to liposomal 
gel formulations (Glavas-Dodov et al., 2002). 
As discussed in section 3.4.8.3, drug properties (solubility, log P) as well as liposome stability 
when formulated as part of a gel system determines the entire system behaviour and thus drug 
release (Mourtas et al., 2007). 
4.4.7 Impact of liposomal formulation on In vitro cytotoxicity on HDFa and HaCat 
cells 
To assess the toxicity of naringenin on HDFa and HaCat cells, an XTT assay was performed 
to measure cell death after exposure of cells to different concentrations of drug for 24 hours. 
Results of cell viability are shown in Figure 4.14. 
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Figure 4.14: Cellular toxicity of naringenin towards HDFa and HaCat cells.  
Cellular toxicity of naringenin a), HDFa b), HaCat cells. Cells were grown on a 96-well plate at 
a density of 50 x 103 cells per well and exposed to various concentrations of naringenin (0.1 – 
100 µM). After 24 hour incubation following which 25 µL of a 12.5:1 parts mixture of XTT to 
menadione was added each well. Plates were incubated for 3 hours at 37°C and the 
absorbance read at 450 nm. The control cell (without drug) corresponded to a cell viability of 
100%. Data is reported as mean ±SD with 6 replicates per compound in at 3 independent 
experiments. 
 
As the concentration of naringenin was increased, no decrease in HDFa cell viability when 
compared with the control well was observed. As the concentration of naringenin was 
increased on the keratinocytes, no change in cell viability was observed. Any differences in 
these percentages was not significant (P = 0.4246) therefore, at these concentrations 
naringenin was not toxic to this line of keratinocytes. 
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4.4.8 Cellular uptake assay on HDFa and HaCat cells 
Fluorescently labelled liposomes loaded with naringenin were incubated with both HDFa and 
HaCat cells to assess the cellular uptake of these formulations.  Following a 2-hour incubation 
with the cells, the labelled liposomes were identified using confocal microscopy (Figure 4.15, 
4.16, 4.17 and 4.18). Cytoplasmic accumulation of the formulations was apparent, confirming 
the successful uptake into both HDFa and HaCat cells.   
 
Figure 4.15: Localisation of DilC-naringenin loaded liposomes in HaCat cells 
Localisation of DilC labelled liposomes loaded with naringenin and 2% w/w Tween 20 in HaCat 
cells. Cells were grown on the coverslips for 2 days. Cell nuclei were visualised using a) DAPI 
(Blue). Liposomes were formulated with DilC for visualisation b) (yellow). Liposome localisation 
within the cell is shown in the merged image c). 
 
Figure 4.16: Localisation of DilC-naringenin loaded liposomes in HDFa cells 
Localisation of DilC labelled liposomes loaded with naringenin and 2% w/w Tween 20 in HDFa 
cells. Cells were grown on the coverslips for 2 days. Cell nuclei were visualised using a) DAPI 
(Blue). Liposomes were formulated with b) DilC for visualisation (red). Liposome localisation 
within the cell is shown in the merged image c).
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Figure 4.17: z-dimension cellular localisation of DilC-naringenin loaded liposomes formulated with 2% w/w Tween 20 in HaCat cells 
z-dimension cellular localisation of DilC labelled liposomes loaded with naringenin and 2% w/w Tween 20 (stage 2). DilC labelled liposomes previously 
incubated with HaCaT cells for 2 hours were further subjected to a z-stack analysis with the lens positioned above the cell layer (12216 µm) and lowered 
through the cells to the bottom of the cell layer (12210 µm).  Images were captured of DilC (green) through the z-dimension. 
 
202 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18: z-dimension cellular localisation of DilC-naringenin loaded liposomes formulated with 2% w/w Tween 20 in HDFa cells 
z-dimension cellular localisation of DilC labelled liposomes loaded with naringenin and 2% w/w Tween 20 (stage 2). DilC labelled liposomes previously 
incubated with HDFa cells for 2 hours were further subjected to a z-stack analysis with the lens positioned above the cell layer (12216 µm) and lowered 
through the cells to the bottom of the cell layer (12210 µm).  Images were captured of DilC (green) through the z-dimension.
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The confocal stage was set at the upper-most boundary of the HDFa/HaCat cells and the stage 
moved down towards the coverslip with images captured over a z-dimension of approximately 
5 µm. At the onset of the z-stack analysis, liposomes are localised on the exterior of the cell 
boundary and potentially on the surface of the cells (12334 µm).  As the stage progresses, the 
localisation of FITC-Fan-MSNP increases with clear demarked zones of cytoplasmic 
localisation near the ‘mid-to-bottom’ regions of the cells (Figure 4.17 and 4.18). 
 
There are four proposed methods of liposome interaction with cells as discussed in section 
2.4.5: stable adsorption, endocytosis, fusion of the lipid bilayer with the cell plasma membrane 
and lipid transfer (Martin and MacDonald, 1976; Pagano and Weinstein, 1978). It is unclear 
which of these occurred in this study, however, these methods of uptake are not mutually 
exclusive and any combination occur in a given experimental circumstance (Pagano and 
Weinstein, 1978). 
 
This formulation is aimed to be targeting the dermal layer. It is uncertain if the liposomes would 
completely pass through the keratinocytes into the dermal layer or whether they would 
accumulate in the SC. To be able to determine this, application onto excised skin would be 
necessary. Nonetheless it is clear liposomes were taken up by the cells, more importantly the 
fibroblasts thus the liposomes were successfully able to enter the cells.  
4.4.9 Stability of deformable liposomes 
The stability of deformable liposomes during storage at 20°C was studied in terms of size and, 
for drug loaded liposomes, encapsulation efficiency. Confocal images were observed on day 
1 of formulation to ensure the presence of liposomes (Figure 4.19). The size of blank and 
surfactant loaded liposomes was measured on day 1, 2, 7, 14, 21 and 28 (Figure 4.20).  
 
Figure 4.19: Confocal images of MLV liposomes formulated with 4% w/w Tween 20 
Confocal images of MLV liposomes formulated with 4% w/w Tween 20 either a) blank, b) drug 
loaded. Fluorescently labelled liposomes where formulated by the addition of the fluorescent 
dye Dil C to the lipid mixing stage. The unentrapped marker was removed by centrifuging 
liposomes, removing the supernatant, re-suspending in water. Liposomes where imaged using 
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an upright confocal microscope (Leica SP5 TCS II MP) and visualised with a 40× oil immersion 
objective. 
 
Drug loaded liposomes formulated with no surfactant appear to decrease in size from 1217 nm 
to 556 nm over time. This was unexpected as usually, aggregation is noted resulting in vesicle 
size growth (Seras et al., 1992). This may be a result of larger, denser liposomes/aggregates 
settling as a creamy film which could be observed at the bottom of the cuvette.   
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Figure 4.20: Stability of naringenin loaded liposomes as determined by size 
Size of naringenin loaded liposomes formulated with 0-10% w/w Tween 20, using DLS, 
formulated with up to 10% w/w Tween 20 measured on various days (1, 2, 7, 14, 21 and 28). 
Liposomes were prepared adapting the dry film method. Liposome size was assessed via DLS. 
Data represents mean ± SD. n=6 independent batches. 
 
The inclusion of surfactant seemed to decrease this phenomenon to a degree. Formulations 
with 2% w/w, 6% w/w and 10% w/w observed a size decrease from 825 to 572 nm, 705 to 565 
nm and 731 to 511 nm respectively over the course of 28 days. Liposomes formulated without 
surfactant have a lower polydispersity, thus inclusion of surfactant provides a more 
homogenous mix with less larger liposomes/aggregates formulated thus there would be less 
of these to settle out over time.   
The size decrease of liposomes formulated without Tween 20 was significant between day 1 
2 (P ≤ 0.01) and between 1 and all other days (P ≤ 0.0001), as well as between day 2 and 7, 
14 and 28 (P ≤ 0.05), and between day 2 and 21 (P ≤ 0.01). There was no significant difference 
between days 7 onwards. This may be because all lipid aggregates settled out by this time. 
The size decrease between liposomes formulated with 2% w/w Tween 20 between day 1 and 
7 (P ≤ 0.05), as well as between day 1 and 28 (P ≤ 0.001), as well as between day 2 and 28 
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(P ≤ 0.05). There was no significant difference between day 7 onwards. This may be because 
all lipid aggregates settled out by this time. The size decrease between liposomes formulated 
with 6% w/w Tween 20 between day 1 and 14 (P ≤ 0.05), as well as between day 1 and both 
21 and 28 (P ≤ 0.01). There was no significant difference between day 2 onwards. This may 
be because all lipid aggregates settled out by this time. The size decrease between liposomes 
formulated with 10% w/w Tween 20 between day 1 and both 7 and 21 (P ≤ 0.05), as well as 
between day 1 and and 28 (P ≤ 0.001). There was no significant difference between day 2 
onwards. This may be because all lipid aggregates settled out by this time. 
Additionally, encapsulation efficiency appears to decrease from 93% to 87%, 85% to 81%, 
75% to 67% and 64% to 59% respectively for 0 % w/w, 2 % w/w, 6 % w/w, 10 % w/w loading 
of surfactant (Figure 4.21). All of these decreases where however non-significant. Liposome 
aggregation may have led to drug leaching or vice versa. This suggests a lower loading of 
surfactant is best to ensure stability. 
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Figure 4.21: Liposome encapsulation efficiency for naringenin over 28 days. 
Liposome encapsulation efficiency for naringenin in either 0% w/w, 2% w/w, 6% w/w or 10% 
w/w Tween 20 liposomes over 28 days. Liposomes were prepared adapting the dry film method 
adding the surfactant and drug during the lipid mixing stage. The preparation was then washed 
via centrifugation. The quantity of naringenin in supernatant over 28 days was then analysed 
by HPLC coupled with UV detection to assess liposome stability. Data represents mean ± SD. 
n=6 independent batches. 
 
Long-term stability of liposomes depends on the average elastic energy of the membrane 
being higher than the thermal energy. When this is no longer the case, liposomes will 
disintegrate (Lipowsky 1991). Therefore, temperature is an important determinate of stability 
and liposomes must be stored at a suitable temperature. Too high and the liposomes will break 
down, and, furthermore, liposomes formulated with surfactant cannot be stored in a fridge due 
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to the freezing point being at 7°C (Natural-Sourcing, 2017). This suggests these liposomal 
formulations are not suitable for long term stability. Either additional excipients (such as a 
charged surfactant to reduce coalescence) are required or an additional step of freeze drying 
liposomes for reconstitution near the time of administration.  Formulations including Tween 20 
appeared the most stable over the 4-week period. A study by Tsai et al., (2015) found 
deformable liposomes formulated with Tween 80 loaded with Naringenin were stable over a 3-
month period with no significant size difference noted. Similar to observations in this study 
however, creaming was noted.   
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4.5 Conclusion  
Developing strategies in cancer management is chemoprevention and chemoprotection with 
the use of naturally occurring agents (Hwang et al., 2007; Siddiqui et al., 2009; Singh, Shankar, 
& Srivastava, 2011). The use of anti-oxidants to prevent oxidative skin damage appears to be 
a favourable strategy (Albini & Sporn, 2007; Casey et al., 2015; Huang et al., 2011). Naringenin 
is a major flavanone in found in grapefruit. It is an antioxidant, free radical scavenger, anti-
inflammatory agent, and immune system modulator thus may be potentially useful as 
pharmacological anti-cancer agent (Casey et al., 2015; Chen et al., 2003; Huang et al., 2011). 
The use of such flavonoids in disease management is limited due to poor bioavailability of 
promising agents. Liposomes are able to improve the bioavailability profile of these compounds 
thus could prove useful as compound carriers (Nishiyama, 2007; Siddiqui et al., 2009). In 
particular, elastic liposomes have been observed to be useful in dermal drug delivery as they 
can increase compound solubility and can be formulated for targeted, sustained drug release 
(Benson 20016, Cevc 1996). Furthermore, elastic liposomes have been reported to penetrate 
the SC barrier layer of the skin. This study aimed to formulate this naringenin into elastic 
liposomes formulated with Tween 20 within an aqueous gel carrier system intended to deliver 
a controlled release of this compound within the dermal layer of the skin.  
As the amount of Tween 20 in the bilayer of the liposome is increased, liposome size 
decreases. The presence of naringenin in elastic liposome increases the liposome diameter; 
however, the inclusion of surfactant decreases the diameter. Inclusion of surfactant in the 
bilayer decreases liposome DI implying liposomes retained enough elastic energy to pass 
through a pore size smaller than the liposome diameter thus may be useful in being able to 
pass through the gaps in the SC. This was true when liposomes where forced through a 200 
nm and 100 nm pore size however, liposome destruction was apparent when forced through 
a 50 nm pore size.  
As the loading of Tween 20 in the liposome was increased naringenin encapsulation 
decreased. This may have been due to Tween 20 competing for space within the bilayer or 
due to Tween 20 increasing the solubilisation capacity of naringenin. Further, inclusion of 
naringenin within the liposome bilayer was able to reduce the phase transition temperature of 
naringenin. 
One compartment release models found HEC gels to release drug slightly faster than HPMC 
gels. Complete gel dissipation was observed between 3 and 4 hours. Two compartment 
release models found that the aqueous gels were found to slow the release of drug compared 
to drug solution. Naringenin release from liposomes found liposomes were able to modify the 
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release of drug with complete release observed within 24 hours. Over the course of 24 hours 
solution gave a release of 54.5 ± 4.2 % whilst liposomes formulated with 0%, and 10% w/w of 
Tween 20 gave a release of 109.7 ± 5.0 %, and 48.5 ± 2.1 % respectively. Therefore, the 
loading of Tween 20 influenced compound release. Liposomes added into gels seemed to 
have an additive effect in terms of retarding drug release. Release was faster from HEC gels 
and liposomes formulated with Tween 20. 
Toxicology assay’s found that between 0.1 and 100 µM naringenin was not harmful to either 
keratinocytes or fibroblasts. Cell uptake of the liposomes loaded with naringenin and 2% w/w 
Tween 20 was apparent into both the keratinocyte cell line and the fibroblast cell line. It appears 
elastic liposomes are useful in enhancing drug penetration into dermal cells and furthermore 
may be useful in the development of a controlled release formulation.  
Liposome stability was studied in terms of size and encapsulation capacity over the course of 
a month. Liposomes were found to be stable regarding these two parameters over this time 
period. 
 
Liposomal gels appear to be useful in the development of a controlled release formulation of 
anti-cancer agents with a limited bioavailability. Aqueous gels were found to hinder the release 
of naringenin compared to naringenin solution. Additionally release of naringenin from the 
liposomes was influenced by Tween 20 loading in the bilayer.  
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5 Development of sustained 
release MTL-004 
liposomal gel 
formulations for dermal 
drug delivery 
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5.1 Introduction 
Skin cancer is emerging as an increasing public health problem especially in developed 
countries. Poor treatment results in 2,500 deaths annually in the UK. The most common 
treatment is surgical excision of the tumour. However this may not be suitable for all patients 
thus development of alternative treatments is necessary. 
MTL-004 (Figure 5.1) is a potent cytotoxic agent proposed for use in the local treatment of 
non-melanoma skin cancer and pre-cancerous lesions. MTL-004 is the active form of the 
prodrug, Tretazicar. Tretazicar is reduced to the cytotoxic bifunctional alkylating agent MTL-
004 when in the presence of an endogenous enzyme (NQO1 or NQO2). When originally 
discovered and tested in rats, tretazicar seemed to be the ideal compound for cancer 
chemotherapy a simple, selective, low molecular weight compound able to treat tumours with 
minimal side-effects. However, it was not found to be active against human cancers as human 
NQO1 is not as efficient at metabolising Tretazicar. 
MTL-004 forms DNA interstrand crosslinks and these are poorly repaired resulting in cell death. 
A significant advantage is the lack of systemic toxicity due to the high reactivity of MTL-004 
with serum proteins. Furthermore MTL-004 has been found to have no effect on normal cells 
as it only works in rapidly dividing cells (Knox et al., 1991). 
 
Figure 5.1: Molecular structure and relative molecular weight of MTL-004 
The chief function of the skin is to form a barrier against the external environment. Liposomal 
formulations may prove useful as dermal drug-delivery vehicles with benefits for delivery of 
poorly permeable molecules and larger biologics. Liposome adhesion, fusion and penetration 
into the SC is possible with potentially deeper penetration into the dermal layer of deformable 
vesicles compared with traditional liposomes (El Maghraby et al., 1999). 
Furthermore, chemotherapy agents are notoriously difficult to formulate with one of the 
principle concerns being solubility. Formulations must overcome this limitation with the use of 
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appropriate excipients all the while limiting adverse effects. Liposomes would offer this benefit 
and have already been employed in the transdermal delivery of lipophilic and hydrophilic drugs 
including anti-inflammatory agents , anti-tumour agents and hormones (Cevc and Blume, 
2001; El Maghraby et al., 1999; Oh et al., 2006; Romero et al., 2013).  
Due to the liquid nature of liposomal formulations, an additional excipient to increase the 
viscosity is required to allow for topical application. Liposomes are compatible with viscosity 
increasing agents such as cellulose based gels including HEC and HPMC (Foldvari, 1996) 
therefore these will be employed in this study. 
 
5.2 Aims and objectives 
In this body of work, a formulation aiming to deliver MTL-004 to the dermal layer in the 
management of skin cancer was developed. The effectiveness of the in vitro delivery of MTL-
004 encapsulated in liposomes in an aqueous gel system to the dermal layer was assessed. 
The aim of this study was to formulate and characterise an aqueous gel system loaded with 
elastic liposomes formulated with Tween 20 for the dermal delivery of MTL-004. Liposomes 
were loaded with up to 10% w/w Tween 20 and 0.25 mg/mL of MTL-004. They were 
characterised by size, zeta potential, DI and stability. MTL-004 release was observed from 
these liposomal formulations as well as from HEC and HPMC gels and from gels loaded with 
liposomes. Toxicity and uptake into HDFa and HaCat cells was then observed. 
To achieve the aims, the overall objectives were 
 Formulate and characterise liposomes loaded with MTL-004 and observe the release 
profiles 
 Develop, optimise and validate a HPLC coupled with either UV or fluorescent detection  
 Characterise MTL-004 loaded liposomes formulated with Tween 20 and quantify the 
release of MTL-004 from these 
 Formulate HEC and HMPC aqueous gels loaded with and MTL-004 compare release 
of drug from these 
 Formulate and compare MTL-004 release of drug from HEC and HPMC gels loaded 
MTL-004 loaded liposomes  
 Apply formulations to fibroblast (HDFa) and keratinocyte (HaCat) cell lines to 
characterise toxicity  
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5.3 Materials and methods 
5.3.1 Materials 
The materials used to prepare liposomes, all reagents as well as materials used to grow HDFa 
and HaCat cells are detailed in chapter 2 (section 2.3.1) The materials used to prepare the 
gels are detailed in chapter 3 (section 3.3.1). MTL-004 was acquired from Morvus (Morvus 
Technology Ltd © 2013, Llanvetherine Court, Llanvetherine, Monmouthshire, NP7 8NL).  
5.3.2 Elastic liposome preparation  
Liposomes were prepared by using the film hydration method established by Bangham et al., 
(1965) detailed in section 2.3.2. Briefly, PC, cholesterol and surfactant were dispersed in 
chloroform and methanol in a 9:1 ratio. Ratios of lipids are detailed in Table 3.1 rational of 
which has been adapted from previous studies concerning the formulation of elastic liposomes 
(Hiruta et al., 2006; Ita et al., 2007; Oh et al., 2006; Tsai et al., 2015). MTL-004 loaded 
liposomes were prepared by adding the required amount of MTL-004 to the lipid mixing stage.  
5.3.3 Liposome characterisation: particle size and polydispersity and zeta potential 
Mean particle size, polydispersity index and zeta potential of liposomes was measured as 
detailed in section 2.3.3 using a Zetaplus (Brookhaven Instruments). Each sample was 
measured 3 times.  
5.3.4 Assessment of liposomal deformability  
The deformability index (DI) of the elastic vesicles was determined using a mini filtration 
technique as detailed in section 2.3.5. 
5.3.5 HPLC methodology 
Detection of MTL-004 was assessed through reverse phase HPLC methodologies. A Waters 
Alliance separation module HPLC with UV detection was utilised at an operating wavelength 
of 263 nm. A Waters X select column (5 µm C18 4.6 x 150 mm column) was used. 10 μL of 
sample at room temperature was injected. The mobile phase comprised of a 50:50 ratio of 
0.1% TFA in water to acetonitrile at a flow rate of 1mL/min. 
Stock solutions and standard solutions of MTL-004 in water were prepared with ranging from 
2.5-100 µg/mL. 
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5.3.5.1 HPLC method establishment  
5.3.5.2 UV spectrometry  
A UV scan was run on MTL-004 in water in a quartz crystal cuvette to determine the λ max 
using Thermo Scientific Genesys 10S UV-vis Spectroscopy between the wavelengths 100 – 
600 nm.  
5.3.5.3 Chromatographic separation  
Mobile phase ratios using 0.1% TFA in water with either methanol or acetonitrile were varied 
for optimal peak shape of a 5µg/mL of MTL-004 in water. 
5.3.5.4 Fluorescence detection  
In an attempt to improve the detection limits of MTL-004, a method using HPLC coupled with 
fluorescence detection was attempted to be optimised. Detection of MTL-004 was again 
assessed through reverse phase HPLC methodologies. A Waters Alliance separation module 
HPLC with a fluorescence detector running Empower software was utilised at an operating 
wavelength of 263 nm. A Waters X select column (5µm C18 4.6 x 150 mm column) was used. 
10μl of sample at room temperature was injected. The mobile phase comprised of a 50:50 ratio 
of 0.1% TFA in water to acetonitrile at a flow rate of 1ml/min. 
The emission and excitation wavelengths were varied to find the optimum combination. The 
excitation wavelength was set at 20 nm higher than the λ max (263 nm) and an emission scan 
was then run. After obtaining a 3D image of the scan, the optimum emission was selected 
against which the excitation wavelength was varied.  
5.3.5.5 HPLC validation 
The method was validated by assessing the linearity and range, repeatability and sensitivity in 
terms of the limit of detection (LOD) limit of quantification (LOQ) and precision as detailed in 
section 3.3.5.1.  
For the linearity and range assessment, standard solutions ranging between 2.5 - 100 µg/mL 
of MTL-004 in water were prepared. The mean peak area ± SD was calculated and plotted 
against the known concentration of the standard.  
5.3.6 Physicochemical properties  
5.3.6.1 Solubility determination 
The solubility of MTL-004 in water was determined by removing the supernatant of a saturated 
solution and quantifying by HPLC separation with UV analysis (section 5.3.6).  
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5.3.6.2 Log P determination 
The log P of MTL-004 across octanol and water (pH 7) was determined by adding drug to a 
vial containing both solvents and shaking. The sample was then left to sit to allow the drug to 
partition over 24 hours (Cordero et al., 1996). Samples were then withdrawn from both phases 
and quantified by HPLC analysis with UV detection (section 5.3.6). Data was then put into 
Equation 5.1 
Equation 5.1: 
𝐿𝑜𝑔 𝑃 = log(
𝐶𝑜
𝐶𝑤
) 
Where Co is the concentration in octanol and Cw is the concentration in water 
5.3.7 Determination of entrapment efficiency 
The entrapment percentage of MTL-004 loaded in elastic liposomes was determined by 
centrifuging samples and quantifying drug in the supernatant as detailed in section 3.3.6.  
 
5.3.8 Differential scanning calorimetry investigations of MTL-004 and MTL-004 lipid 
blends 
MTL-004 as well as MTL-004 combined with different ratio of lipid blends were analysed in the 
solid state using a TA Instruments Q200 Thermal Analysis DSC as described in section 3.3.7.  
5.3.9 MTL-004 loaded aqueous gel formulation  
Aqueous gels were prepared using HEC (3% w/v) and HPMC (3% w/v) which were mixed 
overnight using a mechanical mixer (Polytron PT 3100 D) as detailed in section 3.3.8. Gels 
with a drug loading of 1% w/w was manufactured.  
5.3.10 In vitro release studies 
Drug release from gels, liposomes and liposomal gels over 24 hours was observed using 
multiple methods.  
5.3.10.1 One compartment release model 
To study the in vitro release and swelling behaviour of gels over 24 hours naringenin loaded 
gel was syringed into plastic containers with 20ml of DDM as detailed in section 3.3.9.1 and 
aliquots removed at set time points and analysed using HPLC quantification with UV analysis 
(section 5.3.6). 
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5.3.10.2 Two compartment release model 
A diffusion cell dialysis system was used to evaluate in vitro drug release over 24 hours from 
solution (0.1mg/mL), gels (formulated with 1% w/w of drug) and liposomes into release media 
as detailed in section 3.3.9.2.  
5.3.11 Liposomal gel release study 
Release from liposomal gels was observed with the use of a 6 well Thincert plate and 4 cm2 
cylindrical cell culture ThincertTM inserts (400 µm pore size) were filled with 1ml of formulation 
as detailed in section 3.3.9.3.  
5.3.12 Release kinetics 
Mathematical models to assess release kinetics were fit using Microsoft Excel® as detailed in 
section 3.3.10.  
5.3.13 Growth and passage of cells 
HDFa isolated from adult skin, cryopreserved at the end of the primary culture were revived in 
medium 106 supplemented with Low Serum Growth Supplement. HaCaT is a spontaneously 
transformed aneuploid immortal keratinocyte cell line from adult human skin. HDFa and HaCat 
cells were maintained in a humidified 37 °C incubator with 5 % CO2, grown, fed and split for 
further proliferation as detailed in section 2.3.6. 
5.3.14 Impact of liposomal formulation on In vitro cytotoxicity on HDFa and HaCat 
cells 
To determine the concentration of MTL-004 which was toxic to the HDFa and HaCat cells, an 
XTT assay (Scudiero et al., 1988) was performed to measure cell death after exposure of cells 
to different concentrations of drug for 24 hours. Cells were trypsinised, centrifuged and re-
suspended in fresh media. Cells were then counted and seeded in a 96-well plate as detailed 
in section 2.3.9.  On day 3, media was removed. Cells were treated with 100 µL of either 100 
µM, 50 µM, 10 µM, 5 µM, 1 µM or 0.1 µM of drug in DMSO (<1%)/media. Plates were incubated 
for 24 hours (37°C, 5% CO2) following which a mixture of 12.5:1 parts of XTT to menadione 
(25µL) was added each well in a 96 well plate. Plates were incubated for 3 hours at 37°C and 
the absorbance read at 450 nm. Assessment of MTL-004 toxicity to these cells was conducted 
through analysis of changes in XTT absorbance with increasing drug concentration. 
5.3.15 Cellular liposomal uptake assay on HDFa and HaCat cells 
Liposomes, both deformable and non-deformable, were formulated with the addition the 
fluorescent dye, DilC, in DMSO as detailed in section 2.3.10. Coverslips were prepared and 
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analysed with an upright confocal microscope (Leica SP5 TCS II MP) as detailed in section 
2.3.8. 
5.3.16 Liposome stability 
The stability of liposomes was determined, as prepared in water, through the assessment of 
particle size over a 28 day period as detailed in section 2.3.4. 
Furthermore, the encapsulation efficiency of MTL-004 loaded liposomes was assessed over 4 
weeks as detailed in section 3.3.6.  
5.3.17 Statistical analysis  
Unless otherwise stated, all results are presented as mean ± SD.  Replicates of at least 3 
where used for all studies.  For multiwall plate assays replicates of 6 were used for each 
experimental condition with the study replicated 3 times 
A paired T test or a one way ANOVA was used to determine any statistically significant 
difference between means tested. A post-hoc Tukey’s multiple comparisons test was then 
applied to assess differences between groups. Results were deemed statistically significant if 
P < 0.05 %. 
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5.4 Results and discussion  
MTL-004 is a potent cytotoxic agent proposed for use in the local treatment of non-melanoma 
skin cancer. MTL-004 forms DNA interstrand crosslinks and these are poorly repaired resulting 
in cell death. A significant advantage is the lack of systemic toxicity due to the high reactivity 
of MTL-004 with serum proteins. Furthermore MTL-004 has been found to have no effect on 
normal cells as it only works in rapidly dividing cells. 
Chemotherapeutic agents are notoriously difficult to formulate particularly due to compounds 
having a low solubility. Liposomes may enhance the bioavailability of these agents thus could 
prove useful as delivery agents. Elastic liposomes have been found to be useful in dermal 
delivery of drugs as they can increase compound solubility, protect the drug from degradation 
and can be formulated for targeted, sustained drug release (Benson 20016, Cevc 1996). 
Elastic liposomes have been reported to penetrate the skin; an efficient and effective physical 
barrier to the external environment.  They have already been used in the topical, dermal and 
transdermal delivery of chemotherapeutic agents (Fang et al., 2008; Lau et al., 2005; Trotta et 
al., 2004).  
Liposomes proposed for dermal delivery require an additional carrier due to the liquid nature 
of the preparation. Liposomes are known to be compatible with viscosity increasing agents 
such as cellulose based gels including HEC and HPMC (Foldvari, 1996). Furthermore, these 
are established as safe in skin application (Forbes et al., 2011b; Hascicek et al., 2009; Patton 
et al., 2007).  
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5.4.1 MTL-004 concerns and supply issues  
Due to a very limited supply from the manufacturers alongside batch to batch inconsistencies 
(Figure 5.2), it was not possible to repeat studies showing anomalous results. This has been 
noted throughout the discussion and points of future work highlighted.    
 
Figure 5.2: Images of MTL-004 batches 
Images of three MTL-004 batches received from Morvus over the course of this study 
 
5.4.2 Liposome characterisation: particle size and polydispersity and zeta potential 
Liposome size is a key determinant in liposome permeation across the SC thus the effect of 
surfactant loading on size was investigated. Loadings of up to 10 % w/w Tween 20, were added 
to the formulation thus adding elastic properties to the bilayer. MTL-004 loaded MLV liposomes 
were formulated using the dry film method. The bilayer included cholesterol to provide 
stabilising properties to the liposome bilayer as well as limiting drug leaching (Demel et al., 
1972; Gregoriadis and Davis, 1979). 
Similar to liposomes formulated without drug, as the surfactant loading in the bilayer increased 
size decreased significantly from 1362.1 ± 75.9  nm to 800.1 ± 69.5 nm (Figure 5.3). The 
decrease in size was significant between Tween 20 loadings of 0% w/w and all other loadings 
of surfactant (P ≤ 0.0001). There was no significant difference between the sizes of liposomes 
formulated with any loading of Tween 20 investigated. This implies either surfactant loading 
reached a maximum at 2% w/w, or, that between 4 and 10% w/w there is not enough surfactant 
to decrease the size any further. 
As discussed in section 3.4.1 surfactant decreases liposome size in comparison to 
conventional liposomes (Goindi et al., 2013; Tsai et al., 2015). This is due to the amphiphilic 
nature of Tween 20 allowing a greater interaction of the phospholipid bilayer with the aqueous 
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phase resulting in the overall formation of more liposomes of a smaller diameter thus giving a 
greater surface area in contact with the aqueous phase (El Zaafarany et al., 2010).  
Drug loaded liposomes had a larger than blank liposomes; 1032.3 ± 182.5 nm compared with 
1362.1 ± 75.9 nm for liposomes formulated with no surfactant and 358.1 ± 57.1 nm compared 
with 800.1 ± 69.5 nm for liposomes formulated with 10% w/w loading of surfactant. The 
inclusion of drug in the bilayer may have caused an increase in liposome size by increasing 
bilayer hydrophobicity as it had caused the bilayer to have less interaction with the aqueous 
phase. Similar to blank liposomes, as the surfactant loading increased in drug loaded 
liposomes, the diameter decreased. 
 
 
Figure 5.3: Liposome size distribution comparing blank and MTL-004 loaded formulations 
Figure 5.3: Liposome size distribution, determined by DLS, comparing blank and MTL-004 
loaded formulations with increasing loadings of Tween 20 up to a maximum of 10% w/w. 
Liposomes were prepared via the dry film hydration method and compound was added during 
the lipid mixing stage. Data represents mean ± SD. n=3 independent batches. 
 
A homogenous liposome preparation in terms of size is essential to ensure uniform liposome 
distribution in vivo as well as influence drug release kinetics. A polydispersity of up to 0.3 
indicates a homogenous formulation (Chen et al., 2012; Goindi et al., 2013; Kang et al., 2013).  
Blank liposomes formulated without surfactant were slightly out of this range at 0.32 however 
blank liposomes formulated with surfactant and all drug loaded liposomes had a polydispersity 
below 0.3 therefore can be considered homogenous (Figure 5.4). Polydispersity for MTL-004 
loaded liposomes was lowest at 0.24 when formulated with 10% w/w Tween 20 indicating this 
loading of surfactant produced the most homogenous mix of liposomes.  
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Figure 5.4: Polydispersity of blank and MTL-004 loaded liposomes 
Polydispersity of blank and MTL-004 loaded liposomes formulated with increasing loadings of 
Tween 20 up to a maximum of 10% w/w was determined with DLS. Liposomes were prepared 
via the dry film hydration method and compound was added during the lipid mixing stage.  Data 
represents mean ± SD. n=3 independent batches. 
 
The zeta potential is the potential difference between the dispersion medium and the stationary 
layer of fluid directly surrounding the dispersed particle. The scale of the zeta potential 
illustrates the degree of electrostatic repulsion between adjacent, similarly charged particles in 
a dispersion. Thus, it is one of the fundamental factors influencing stability. The zeta potential 
of blank and MTL-004 liposomal formulations is displayed in Table 5-1. 
 
Table 5-1: Zeta potential of liposomal formulations formulated with and without drug with up 
to 10% w/w loading of Tween 20 
Surfactant 
loading (% w/w) 
Zeta potential (mV)  
Blank Liposomes 
MTL-004 loaded 
liposomes 
0 5.03 ± 1.03 -23.11 ± 6.08 
2 4.67 ± 1.08 -18.94 ± 2.73 
6 3.71 ± 0.90 -5.4 ± 0.9 
10 -2.79 ± 0.20 -9.6 ± 2.16 
Results are presented as the mean ± standard deviation (n=3) 
 
Liposomes are miscible with the lipids in the skin thus are advantageous when employed as 
dermal drug delivery carriers as they can penetrate into deeper layers. Thus a neutral surface 
charge is ideal (Prausnitz and Langer, 2008). Positively charged liposomes are known to be 
irritating to the skin, whilst neutral liposomes have a tendency to flocculate (Weiner et al., 
1992). Negatively charged liposomes have been observed to provide better skin retention for 
S u r fa c ta n t  L o a d in g  (% w /w )
P
o
ly
d
is
p
e
r
s
it
y
0 2 4 6 8 1 0
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
B la n k
M T L -0 04
221 
 
drugs intended for topical use (Katahira et al., 1999). This study observed the majority of 
formulations for MTL-004 loaded liposomes to have a slight negative charge (Table 5-1).  MTL-
004 liposomal formulations formulated with 0 %, 2 %,  6 % and 10 % w/w Tween 20 were 
found to have zeta potential values of -23.1 ± 6.1, -18.9 ± 2.7, -5.4 ± 0.9, -9.6 ± 2.2 mV 
respectively. Such charges appear optimal for dermal drug delivery as these particles will not 
flocculate whilst they will not irritate the skin. 
Additionally charged bilayers repel each other, thereby increasing the trapped volume of 
encapsulated aqueous medium within MLV (Schroeder et al., 2009; Zuidam and Barenholz, 
1997). Furthermore, introducing molecules of the same charge into the membrane causes 
more repulsion within the bilayer, thereby increasing the permeability of the liposome 
(Crommelin, 1984; Lichtenberg and Barenholz, 1988).  
5.4.3 HPLC methodology establishment  
Prior to any formulation and release studies, a HPLC method for the detection of MTL-004 was 
developed and optimised. Reversed phase HPLC is an effective and sensitive technique able 
to separate and detect a range of molecules including charged and non-polar compounds. A 
range of variables such as organic solvent type, concentration, pH, temperature all influence 
compound elution. Chromatographic approaches must be tested to ensure trustworthy and 
reliable data. Consequently, validation of the HPLC-UV method was performed according to 
the International Conference of Harmonization (ICH) guidelines in terms of linearity and range, 
limit of detection (LOD), limit of quantification (LOQ) and precision. 
5.4.3.1 UV spectroscopy  
To establish the UV wavelength at which to detect the drug on the HPLC apparatus, a UV scan 
was run on MTL-004 in water. UV absorption spectroscopy is the measurement of the 
attenuation of a beam of light after it passes through a sample and is dependent on electrons 
able to absorb this energy. Absorption measurements may be at a single wavelength or over 
a range. The optimal wavelength at which to detect the drug was determined to be 263 ± 2.03 
nm. 
5.4.3.2 HPLC method optimisation 
Mobile phase ratios using 0.1 % TFA in water with either methanol or acetonitrile were varied 
for optimal peak shape of a 5 µg/mL of MTL-004 in water (Table 5-2 and 5-3). 
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Table 5-2: Effect of variations in the mobile phase ratio of the elution of MTL-004 in water 
where A is 0.1% TFA in water and B in acetonitrile 
 
Acetonitrile  
Mobile Phase 
Ratio (A:B) 
Retention 
time (min) 
Standard 
deviation 
Peak area 
(µV • s) 
Standard 
deviation 
00:100 1.99 0.01 53021.11 60.55 
10:90 1.98 0.06 53034.11 45.23 
20:80 2.06 0.07 53052.07 72.43 
30:70 2.09 0.11 53023.13 93.78 
40:60 2.07 0.03 52821.89 131.22 
50:50 2.09 0.04 52927.78 47.14 
60:40 1.8 0.01 52530.32 36.21 
70:30 1.67 0.04 52567.28 75.29 
 
 
Table 5-3: Effect of variations in the mobile phase ratio of the elution of MTL-004 in water 
where A is 0.1% TFA in water and B in methanol 
 
Methanol 
Mobile Phase 
Ratio (A:B) 
Retention 
time (min) 
Standard 
deviation 
Peak area 
(µV • s) 
Standard 
deviation 
00:100 2.03 0.03 53345.24 124.76 
10:90 2.04 0.1 53265.42 91.63 
20:80 2.11 0.11 53332.36 204.85 
30:70 2.14 0.13 53148.68 56.84 
40:60 2.16 0.15 53459.55 306.86 
50:50 2.18 0.05 53859.38 118.59 
60:40 2.09 0.14 53343.25 205.86 
70:30 2.07 0.08 53750.63 121.23 
80:20 2.23 0.05 53676.47 63.27 
90:10 2.17 0.03 53232.65 137.75 
100:00 2.17 0.05 53223.84 144.53 
 
 
The compound eluted around 2 minutes regardless of mobile phase composition. It was noted 
that the drug eluted a fraction later when methanol was used as the mobile phase. Acetonitrile 
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is more polar than methanol. Methanol would therefore be faster at eluting hydrophobic 
compounds. Variations in the mobile phase ratio only very slightly affected peak shape. 0.1% 
TFA in water/methanol at 50:50 appeared to give the sharpest peak at 2.17 + 0.05 minutes. 
The calibration curve for MTL-004 with this mobile phase is shown in Figure 5.5. 
5.4.3.3 HPLC calibration  
Stock solutions and standard solutions of MTL-004 were prepared in water ranging from 2.5 
µg/mL – 100 µg/mL. Calibration data using the method outlined in section 5.3.5 was then 
obtained (Figure 5.5).  
 
Figure 5.5: Calibration data for MTL-004 as determined by HPLC-UV analysis. 
Calibration data for MTL-004 over the concentration range of 0.125-10 µg/mL in water. A 
proportional response was evident versus the analytical concentration over the working 
concentration range with an r2 of 0.99 and linear equation of y = 1 x 107 ∙ x. Data represents 
mean ± SD. n=9. 
 
5.4.3.4 HPLC Validation  
To assess the linearity and range MTL-004 concentrations ranging from 2.5 - 100 µg/mL in 
water were prepared. The method developed demonstrated a high correlation with a good 
linear fit, with the correlation coefficient (r2) being greater than 0.99 (Figure 5.5).  
Assessment of repeatability/precision of the developed method was determined by assessing 
the intraday (same day) and interday (over the course of three days) variability (Figure 5.6a 
and 5.6b). This was done to assess variation caused by temperature fluctuations and any 
variation in experimental method. MTL-004 standards from 2.5 - 100 µg/mL carried out within 
the intraday and interday are plotted in Figure 5.6a and b respectively. The results show that 
the values have no statistically significant difference for all the calibration curves carried out at 
different times on the same day and also on different days, meaning the method has good 
precision. Calibration data for MTL-004 was obtained on 3 separate days, each with 3 repeats. 
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No statistically significant difference in either the peak areas for any one particular 
concentration across inter- and intra-day sampling across the 3 days was found.  
 
 
Figure 5.6: Calibration data of MTL-004 as determined by HPLC-UV analysis obtained over 
3 days. 
The a) intraday, b) interday data is displayed. The standards of MTL-004 ranged from 2.5-100 
µg/mL. Data represents mean ± SD. n=3. 
 
Study of the sensitivity of this method was assessed by means of the calculation of the LOD 
and the LOQ. Values were determined from the standard deviation of the response (σ) and the 
slope (S) obtained from the calibration curves carried out during the linearity assessment. 
According to the ICH guidelines, a signal-to-noise ratio of three was assumed for the 
quantification of the LOD, whereas for the LOQ, a signal-to-noise ratio of ten was set. 
Therefore, following Equations 3.2 and 3.3, the sensitivity of the method for MTL-004 was 
calculated; the LOD and LOQ was 2.5 × 10-5 µg/mL and 8.1 × 10-4 µg/mL respectively. 
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5.4.3.5 Fluorescence detection 
Fluorescence spectroscopy is the most sensitive optical detection technique used with HPLC 
therefore, to develop a more sensitive MTL-004 detection method, optimisation of such 
detection was attempted. The λ max of MTL-004 in water (263 nm) was selected as the 
excitation wavelength and the emission scan run from 273-600 nm. A 3D image was obtained 
from which the peak emission wavelength was selected from which to run an excitation scan 
to optimise fluorescent detection. As the images shown in Figure 5.7 shows, peak emission 
and excitation wavelengths could not be clearly ascertained, and due to MTL-004 supply 
issues, this method was not optimised and HPLC detection with UV detection was used.  
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Figure 5.7: Fluorescence scans of MTL-004 
a) 3D emission scan, b) 3D excitation scan. The λ max of MTL-004 in water (263 nm) was 
selected as the excitation wavelength and the emission scan run from 273-600 nm. A 3D image 
was obtained from which the peak emission wavelength was selected from which to run an 
excitation scan to optimise fluorescent detection. 
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5.4.4 Physiochemical properties  
5.4.4.1 Solubility  
The solubility of MTL-004 in water was determined to be 1.41 ± 0.2 mg/mL. Stability studies of 
MTL-004 in a range of solvents needs to be determined; detection of MTL-004 degradation 
products may then be optimised.  Due to supply limitations as well as batch to batch 
inconsistencies, this was unable to be completed in this body of work. 
 
5.4.4.2 Log P determination 
The partition characteristics of compounds into the lipids of the SC can be approximated using 
octanol as the solvent (Hadgraft and Valenta, 2000). The Log P between octanol and water 
was determined to be -0.82 ± 0.077. This implies the drug is more hydrophilic and would be 
contained in the aqueous core contradicting the information provided by Morvus. Due to supply 
limitations as well as batch to batch inconsistencies this value cannot be considered reliable. 
Further studies would need to be carried out to confirm the log P value. Regardless, it is known 
drugs with a log P < 5 are better at permeating the skin therefore this is a beneficial 
characteristic. 
 
5.4.5 Determination of entrapment efficiency 
The fraction of MTL-004 entrapped in the liposome in comparison to how much compound was 
added into the lipid mix was assessed. Surfactant and MTL-004 may compete for space within 
the bilayer. The impact of surfactant addition on the amount of compound entrapped was 
therefore studied.  As surfactant loading increased from 0 % w/w to 10 % w/w, drug entrapment 
decreased from an efficiency of 44.0 ± 4.8 % to 20.7 ± 2.6 % (Figure 5.8). A significant 
difference in MTL-004 entrapment was observed between surfactant loadings of 0 % w/w and 
both 6 and 10 % w/w as well as between 2 % w/w and 10 % w/w (P ≤ 0.0001). There was a 
significant difference in entrapment between surfactant loadings of 0 % and 2 % w/w (P ≤ 
0.001). There was a significant difference in entrapment between surfactant loadings of 6 % 
w/w and 10 % w/w (P ≤ 0.01). There was a significant difference in entrapment between 
surfactant loadings of 2 % w/w and 6 % w/w (P ≤ 0.05). 
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Figure 5.8: Entrapment efficiency of MTL-004 in liposomes formulated with up to 10% w/w 
Tween 20 
Liposomes were formulated with varying amounts of Tween 20 (0-10 % w/w) Data represents 
mean ± SD. n=3 independent batches. 
 
As with both previously reported flavonoids, addition of surfactant in the liposomal bilayer may 
have limited drug inclusion within the bilayer implying the surfactant has a higher affinity to the 
lipids (Casas and Baszkin, 1992; Levy et al., 1991). Tween 20 is much larger than MTL-004, 
thus it may be assumed it is better poised to displace MTL-004 from the bilayer (Figure 5.9). 
The hydrophobic tail of Tween 20 would have a high affinity to the chains in PC therefore giving 
Tween 20 a better rooting in the bilayer than MTL-004. Furthermore, Tween 20 is able to 
increase compound solubility, therefore, as not all would be entrapped within the bilayer, this 
may allow MTL-004 to solubilise within the liposomal rehydration media.  
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Figure 5.9: Structure and MW of MTL-004, cholesterol, Tween 20 and PC 
 
5.4.6 Assessment of liposomal deformability  
Inclusion of surfactant within the liposomal bilayer allows the liposome to display elastic 
properties (Almog et al., 1986a; Cevc, 1996; Trotta et al., 2002). This attribute may be useful 
when employing such carriers in topical formulations intended for dermal delivery. Liposomes 
loaded with up to 10 % w/w of Tween 20 were formulated and deformation following extrusion 
was determined by extruding through a polycarbonate filter with a pore size of 200, 100 and 
50 nm (Figure 5.10).  The DI is defined as the degree the liposomes deformed following 
extrusion. The greater the degree of deformation the less elastic the liposomes are as they 
were unable to regain their previous larger size.  
When liposomes were forced through 200 nm the DI for MTL-004 loaded liposomes decreased 
significantly from 84.3 ± 1.1 to 35.7 ± 5.1 %. The decrease in deformation was significant 
between 0% w/w of surfactant and 10% w/w of surfactant (P ≤ 0.001). There was also a 
significant difference between the DI of liposomes formulated with 0 % w/w and 6 % w/w of 
surfactant as well as 2 % w/w and 10 % w/w of surfactant (P ≤ 0.05). There was no significant 
difference between the DI of the other formulations.  
230 
 
 
Figure 5.10: Deformability index of liposomes following extrusion 
Liposomes were extruded through a) 200 nm, b) 100 nm, c) 50 nm membranes for blank and 
MTL-004 loaded liposomes with increasing surfactant loading up to a maximum of 10 % w/w. 
Liposomes were prepared adapting the dry film method adding the surfactant and adding MTL-
004 during the lipid mixing stage. The preparation was vortexed and then extruded though the 
membranes. Data represents mean ± SD. n=3 independent batches. 
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When liposomes were forced through 100 nm pores, the deformability index for MTL-004 
loaded liposomes decreased from 88.4 ± 5.6 to 44.9 ± 8.1 %. The decrease in deformation 
was significant between 0 % w/w of surfactant and 2, 6 and 10 % w/w of surfactant (P ≤ 
0.0001). The decrease in deformation was significant between 2 % w/w of surfactant and 10 
% w/w of surfactant (P ≤ 0.001). The decrease in deformation was also significant between 2 
% w/w of surfactant and 6 % w/w of surfactant (P ≤ 0.01). There was no significant difference 
between the DI of the other formulations.  
As with the flavonoids, no trend was observed for formulations forced through a 50nm pore 
size. Any differences in deformation between surfactant loadings was not significant between 
any of the formulations. The decrease in DI observed suggest liposomes were displaying 
elastic properties as they deformed to fit through a gap smaller than its diameter whilst to some 
extent regaining its size following extrusion. As noted in previous works, the presence the 
presence of surfactant added elastic properties to the liposome as the DI of these liposomes 
decreased (section 3.4.4) 
Furthermore, the deformability index of the MTL-004 loaded liposomes forced through 200 and 
100 nm was greater than blank loaded liposomes (P ≤ 0.05). MTL-004 loaded liposomes have 
a greater deformability index overall, however, their overall size prior to extrusion was greater 
than that of blank liposomes therefore they would have to deform to a greater degree to be 
able to pass through the filter. This trend was not observed for liposomes forced through 50 
nm pores but this may be due to liposome destruction (see section 3.4.4). 
As discussed in section 3.4.4, surfactant has a tendency toward curved structures, thus 
liposomes formulated with surfactant can deform thus lessening the energy required for 
particle deformation and permit liposomes shape change whilst under stress (Trotta et al., 
2004). Further, the fast reconstruction of liposome spheres after extrusion may be due to the 
strong affinity between the surfactant and PC. This phenomenon might have provided the 
deformability upon physical stress (Oh, Y. K. et al., 2006).  
 
Deformability for both blank and drug loaded liposomes was not significantly between 
extrusions though 200 nm and 100 nm. Liposomes were expected to deform more so as pore 
size decreased. This shows that even up to extrusion through a 50 nm pore size, liposomes 
retained enough elastic energy to maintain the same size as when forced through the 200 nm 
membrane.  
Deformation and the subsequent reformation liposomes require energy (Fresta and Puglisi, 
1996; Gompper and Kroll, 1995; Trotta et al., 2002). As detailed in section 3.4.4, in this system 
energy was supplied as pressure. The more surfactant included in the bilayer, the more energy 
the liposome was able to retain (Trotta et al., 2002). This energy was used in bending the 
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liposomal bilayer, and was expelled once the liposome passed through the pore. This energy 
was then being used in reforming the liposome. Some energy was lost as heat or non-plastic 
deformation. Consequently, even at 10 % w/w of Tween 20, 100 % size was not recovered. 
Liposome formulated with no surfactant does not have the extra ‘storage space’ of a surfactant, 
thus energy may be spent in rupturing the membrane causing liposome size to decrease 
(Trotta et al., 2002).  
As with liposomes loaded with flavonoid, the deformability index did not increase as membrane 
pore size decreased. The standard deviation of the DI for liposomes extruded through a 50 nm 
pore size was extremely large (for liposomes formulated with 2 % Tween 20 a standard 
deviation of 14 was observed) therefore the mean value perhaps is not the best representation 
of the actual data values. The liposome size following extrusion for these formulations was 
extremely varied with some liposomes coming out larger than the original size. Drug loaded 
liposomes formulated without surfactant had an original size of 1451.2 ± 256.1 nm compared 
with 1636.6 ± 512.5 nm following extrusion, liposomes loaded with 2 % w/w surfactant had an 
original size of 1015.7 ± 247.1 nm compared with 1178.5 ± 298.4 nm following extrusion. This 
implies these formulations were not able to maintain enough elastic energy to be easily able 
to fit through the pores with some liposomes even converging following extrusion (Goindi et 
al., 2013; Trotta et al., 2002).  
Whilst even when forced through 50 nm, the amount of energy retained in the liposome was 
enough to reform at least a portion of the liposomes, it can be concluded that in this study 
liposome formulations were not suitable to pass through a 50 nm pore. As detailed in section 
2.4.3 this is not necessarily what would happen to liposomes when applied to the skin. 
Liposomes would instead move across the skin following the hydrogen based transepidermal 
gradient (Cevc, 1996; Goindi et al., 2013; Gompper and Kroll, 1995; Trotta et al., 2002). 
Moreover, the warmer skin temperature will supply more energy to be even more flexible and 
cross the stratum corneum. 
As with liposomes loaded with flavonoids, even in an excess of energy, liposomes were not 
able fully return to their pre-extrusion size. This is because energy was lost through other 
means (friction of the particles moving through the pores as heat). Increasing surfactant 
loading may result in an increase in liposome reformation (Trotta et al., 2002). However, this 
must be balanced with drug loading capacity.  
5.4.7 Differential scanning calorimetry investigations of MTL-004 and MTL-004 lipid 
blends 
Differential scanning calorimetry (DSC) is used to understanding the thermal characteristics of 
materials where an insight into a range of thermal properties including melting temperatures, 
phase transitions and heat capacity changes can be obtained. The investigations were carried 
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out over the temperature range 0 – 300 °C with a heating rate of 10 °C min-1. The DSC plot of 
MTL-004 is displayed in Figure 5.11. MTL-004 showed a sharp endothermic peak signifying 
crystallisation (Tc) at 201 °C (Figure 5.11). The Tm was not able to be determined due to short 
sample supply but it may be assumed it would be after 300 °C as no exothermic peak was 
observed within this temperature range. 
 
 
 
 
Figure 5.11: DSC scan of MTL-004 and lipid blends 
DSC scan of a) MTL-004 b) PC, cholesterol and Tween 20 blend and c) PC, cholesterol, Tween 
20 and MTL-004 blend. All experimental runs commenced at an initial temperature of 0 °C with 
a scan rate of 10 °C/min to 300 °C. The peak in a) shows the Tc of MTL-004 was at 201 °C. 
The Tm of the lipid mixture is 172 °C, and upon addition of MTL-004, the Tm was 169 °C. 
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To demonstrate the association of MTL-004 with the lipid/surfactant complex, DSC analysis 
was performed on, the lipid blend, and the MTL-004, lipid/surfactant blend. In the 
lipid/surfactant mix we see a very small peak at 40 °C and then a large peak at 172 °C a 
medium peak at 212 °C. 
On the other hand, MTL-004, lipid/surfactant complex showed a small peak at 40 °C and a 
large peak at 169 °C which is different from the peaks of the individual components of the 
complex. (Figure 5.11). It is evident that the original peaks of MTL-004 and phospholipids 
disappear from the thermogram of complex and the phase transition temperature can be 
assumed to be lower than that of MTL-004. This disappearance of peaks may be a result of 
hydrophobic interaction and/or hydrogen bonding determined by the functional groups on MTL-
004 (Semalty et al., 2010b). 
5.4.8 MTL-004 release studies 
5.4.8.1 MTL-004 release studies from gel formulations 
Due to the liquid nature of liposomal preparations a carrier is required if they are to be 
employed in dermal drug delivery systems. Liposomes are known to be compatible with 
viscosity increasing agents such as cellulose based gels (Foldvari, 1996). Furthermore, such 
gels are established as safe in topical, dermal and transdermal delivery (Forbes et al., 2011b; 
Hascicek et al., 2009; Patton et al., 2007). HEC and HPMC were employed to compare as 
carriers of liposomal preparations.  
 
The drug release from a gel is determined by many factors including diffusion, and erosion of 
matrices followed by dissolution of drug. As with release studies for both flavonoids, two 
geometric systems have been considered for MTL-004 release from gel systems. A one 
compartment model was employed to study release and gel swelling behaviour whilst a two-
compartment diffusion cell observed drug release across a membrane. A polycarbonate 
membrane with 50 nm was used to mimic the stratum corneum and the gaps in between the 
keratinocyte cells. The composition of both HPMC and HEC gels was kept at 3% w/v. Such 
dissolution/release tests are required to help predict in vivo behaviour and to study the 
structure of the dissolving matrix. 
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5.4.8.2 One compartment release studies 
MTL-004 release from the aqueous gels HEC and HPMC gels loaded with 1 % w/w MTL-004 
using water as a release medium was studied over a 24-hour period (Figure 5.12). 
 
 
Figure 5.12: In vitro percentage MTL-004 release profiles from HEC and HPMC gels 
MTL-004 release profiles from aqueous HEC and HPMC gels (3 % w/v) over a) 24 hours, b) 8 
hours. Data represents mean ± SD. n=3 independent batches. 
 
MTL-004 release from both HEC and HPMC gels displayed a similar pattern of release into 
the DDM (Figure 5.12). As with flavonoids, at 3 % w/v loading of polymer, HPMC could retard 
drug release to a greater degree. Up until 3 hours at which time 100 % of compound was 
released, HEC consistently had a higher cumulative percentage of drug released. At the point 
of complete release, the gel was observed to have completely dissipated into the release 
media. 
 
As discussed previously (section 3.4.7.1.1), diffusion of solution out of the polymer depends 
on a range of factors including temperature, pressure, viscosity, solute size and interactions 
between the polymer and solvent (Masaro and Zhu 1999). Furthermore, molecular geometry 
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can influence drug release from the gel matrix (Ford, Rubinstein et al. 1987, Rao, Devi et al. 
1990).  
 
5.4.8.2.1 Kinetic assessment  
Release profiles were evaluated by zero-order, first-order and Higuchi kinetics model (Table 
5-4). As with the flavonoids, release from the gels were observed to fit the first order release 
model. This indicates drug was released at a constant rate in proportion to the amount of drug 
available at that time. As discussed in section 3.4.7.1.1.1, other studies have found the other 
models better at describing release from polymer gel systems but is dependent on particular 
formulations parameters. 
 
Table 5-4: Kinetic assessment of release data of MTL-004 from HEC and HPMC aqueous 
gels. 
Kinetic model 
Formulation r2 
HEC (3 % w/w) HPMC (3 % w/w) 
Zero order -2.332 ± 0.077 -1.571 ± 0.083 
First order 0.954 ± 0.009 0.945 ± 0.050 
Higuchi model 0.112 ± 0.022 0.351 ± 0.011 
Results are presented as the mean ± standard deviation (n=3) 
 
Comparison of the rate constant between formulations found HEC to have a larger rate 
constant (Table 5-5). This shows HEC gave a faster release of MTL-004 per unit time. Drug is 
released from gel by the creation of pores due to the uptake of water, as viscosity increases 
polymer chains becoming more resistant to movement as they are physically restricted thus 
taking longer to dissipate into the media thus slowing release drug. This implies HPMC had a 
greater viscosity than HEC. 
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Table 5-5: First order kinetics rate constant for MTL-004 release from formulations 
Rate constant (min-1) 
HEC 3% w/v HPMC 3% w/v 
0.013 ± 4.075 × 10-4 0.010 ± 0.002 
Results are presented as the mean ± standard deviation (n=3) 
 
The Korsmeyers-Peppa’s model was then applied to the release data and the diffusional 
exponent (n) calculated (Table 5-6). Fickian release (case I) was observed for both polymers 
at 3% w/v. As discussed with both flavonoids, both Fickian and anomalous release is possible 
from swellable matrixes (Ritger and Peppas, 1987).  
 
Table 5-6: Diffusional exponent n calculated from the Korsmeyer-Peppas model of drug 
release for MTL-004 release data from aqueous gels with the corresponding release 
mechanism. 
Formulation n Transport type 
HEC 3% w/v 0.250 ± 0.002 Fickian 
HPMC 3% w/v 0.284 ± 0.001 Fickian 
Results are presented as the mean ± standard deviation (n=3) 
 
Fickian diffusion from polymer networks is observed when the temperature is above the 
polymers glass transition temperature (Tg). In this study, it may be deduced that the polymer 
chains were able to move sufficiently, thus the gel was in a rubbery state.  
5.4.8.3 Two compartment release  
Release of MTL-004 from HEC and HPMC gel formulations at polymer loading of 3 % w/v in a 
two-compartment model using a diffusion cell with a 50 nm pore polycarbonate membrane was 
also observed. This was compared against release from solution in the donor compartment 
into the receiver compartment. MTL-004 loaded gels were prepared and release over 24 hours 
was observed.  
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The gel formulations did appear to slow the release of MTL-004. As with both flavonoids, 
HPMC proved to be more pronounced than HEC in this phenomenon (Figure 5.13). 
 
Figure 5.13: In vitro percentage MTL-004 release profiles from HEC and HPMC 
MTL-004 release profiles from HEC and HPMC (3 % w/v) aqueous gels with 1 % w/v MTL-004 
and MTL-004 solution over a) 8 hours, B) 24 hours. Data represents mean ± SD. n=3 
independent batches. 
 
Complete release of solution across the membrane was observed between the 6th and 7th hour 
whilst HEC and HPMC saw 84.4 ± 6.0 % and 89.2 ± 8.7 % release respectively at the 24th 
hour. The release profile was significantly different between the solution and both gels but not 
between the gels (P ≤ 0.0001). However, comparison between the gels found that HEC at its 
respective loading of polymer in the HPMC gels, always gave a faster release of drug (at the 
time point of 5 hours, 46.5 ± 3.6 % was released in comparison to 32.7 ± 7.9 %). Additionally, 
within the first couple of hours of this study, no drug release was observed, this may have been 
due to the amount of drug being lower than that of the limit of detection. 
 
As discussed in section 3.4.7.1.1, the addition of water-insoluble drug can increase the water 
uptake by the gel thus weakening network integrity thus drug loading will influence network 
integrity (Nafee et al., 2003; Panomsuk et al., 1996). In this case, it appears the HEC matrix 
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eroded/swelled quicker than HPMC giving a faster rate of release. The physiochemical 
properties of the drug, the polymer and the interaction between the two affect drug release 
from the formulation. 
 
5.4.8.3.1 Kinetic assessment 
The release profiles were evaluated by the zero-order, first-order and Higuchi kinetic models. 
Release from the solution, HEC and HMPC gels was observed to fit the first order release 
model with r2 values of 0.885, 0.861 and 0.884 respectively, (Table 5-7). This indicates rate of 
release was dependent on the amount of drug present at that time point.  
Table 5-7: Kinetic assessment of release data of MTL-004 from solution and aqueous gels. 
Kinetic model 
Formulation r2 
Solution HEC (3% w/w) HPMC (3% w/w) 
Zero order -1.442 ± 0.763 0.684 ± 0.081 0.809 ± 0.070 
First order 0.885 ± 0.025 0.884 ± 0.047 0.861 ± 0.050 
Higuchi model  0.727 ± 0.052 0.741 ± 0.041 
Results are presented as the mean ± standard deviation (n=3) 
Comparison of the rate constant of each formulation shows that HEC had a higher rate 
constant than HPMC (Table 5-8). This implies that HPMC had a higher gel consistency thus 
slowing MTL-004 release. MTL-004 is released from gel following swelling which allows for the 
creation of pores, as viscosity increases polymer chains become more resistant to movement 
taking longer to dissipate into the media thus slowing release drug. This data is consistent with 
that of both flavonoids. 
 
Table 5-8: First order kinetics rate constant for MTL-004 release from formulations. 
Rate constant (min-1) 
Solution HEC (3% w/w) HPMC (3% w/w) 
0.007 ± 0.001 2.0 ± 1.355 × 10-3 1.01 ± 1.638 × 10-3 
Results are presented as the mean ± standard deviation (n=3) 
The Korsmeyers-Peppas model was applied to the releases data and the diffusional exponent 
(n) calculated (Table 5-9). Non-Fickian release was observed for both HEC and HPMC gels at 
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3 % w/w polymer. At temperatures below the Tg, the polymer chains are not sufficiently able to 
move to permit immediate penetration of the solvent in the polymer core (Masaro and Zhu, 
1999). This implies that, in our studies, when Non-Fickian transport was observed, the polymer 
chains were unable to move sufficiently and that at those particular loadings of polymer, the 
gel was in a glassy state.  
 
Table 5-9: Diffusional exponent n for MTL-004 release data with the corresponding release 
mechanism. 
Formulation (3 % w/w) n Transport type 
HEC 0.698 ± 0.037 Non-Fickian 
HPMC 0.781 ± 0.036 Non-Fickian 
Results are presented as the mean ± standard deviation (n=3) 
As discussed in section 3.4.7, diffusion of solution out of the polymer depends upon 
temperature, pressure, solute size, molecular geometry and on the concentration and degree 
of swelling of polymers. Solvent diffusion is associated with the physical properties of the 
polymer network and the interactions between the polymer and solvent (Ford et al., 1987; 
Masaro and Zhu, 1999; Rao et al., 1990). Drug release from aqueous gels is governed by a 
swelling- controlled mechanism in which the drug releases into the media due to the 
simultaneous absorption of water by the gel causing the gel to dissipate into the media thus 
releasing drug and due to  desorption of drug from the gel (Bouwstra and Honeywell-Nguyen, 
2002; Nafee et al., 2003; Ranga Rao and Padmalatha Devi, 1988; Sinha Roy and Rohera, 
2002). The membrane would have prevented the gel from completely swelling and releasing 
drug.  
5.4.9 MTL-004 release from liposomes  
Elastic liposomes employed to carry drugs across the SC for dermal drug delivery are 
advantageous as they can penetrate the skin if applied non-occlusivley by virtue of the very 
high and self-optimizing deformability. Liposomes can penetrate the SC with potentially deeper 
penetration into the dermal layer of deformable vesicles compared with traditional liposomes 
(El Maghraby et al., 1999). Deformable liposomes have been effectively employed in 
transdermal delivery of lipophilic and hydrophilic drugs including anti-inflammatory agents, 
plasmid DNA, anti-tumour agents and hormones (Cevc and Blume, 2001; El Maghraby et al., 
1999; Oh et al., 2006; Romero et al., 2013). Release of MTL-004 from a 0.01 mg/ mL solution, 
liposomes and liposomes formulated with either 2 %, 6 % or 10 % w/w of Tween 20 with was 
studied over a 24-hour period (Figure 5.14). 
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Figure 5.14: In vitro percentage MTL-004 release profiles from solution and liposomes 
MTL-004 release profiles from solution and liposomes formulated with 0-10 % w/w Tween 20 
over a) 24 hours, b) 8 hours.  Liposomes were prepared adapting the dry film method adding 
the surfactant and MTL-004 during the lipid mixing stage. A diffusion cell dialysis system was 
used to evaluate in vitro drug release. Data represents mean ± SD. n=6 independent batches. 
 
Liposomes appeared to slow release of MTL-004 in comparison to release across the 
membrane from the MTL-004 solution. As the loading of surfactant increased, drug release 
also increased. This was similar to the release pattern seen with EGCG. Within I hour or the 
release study, drug release was not detected from any of the formulations. This does not 
necessarily suggest there was no release from the formulation, instead, this is perhaps more 
likely concerning detection issues. The drug release into the donor compartment must have 
been lower than the LOD thus was not detected by the HPLC-UV apparatus.  
Over the course of 24 hours’ solution gave a release of 100.0 ± 6.8 % whilst liposomes 
formulated with 0 %, 2 %, 6 % and 10 % w/w of Tween 20 gave a release of 59.8 ± 1.2 %, 51.8 
± 3.6 %, 56.0 ± 2.7 % and 74.0 ± 1.8 % respectively. The cumulative percentage released after 
24 hours was significant between the solution and all liposomal formulations as well as 
between 2 % and 10 % w/w of Tween 20 (P ≤ 0.0001). This difference was also significant 
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between liposomes loaded with 0 % and 10 % w/w Tween 20 (P ≤ 0.01). Finally, this difference 
was also significant between liposomes loaded with 6 % and 10 % w/w of Tween 20 (P ≤ 
0.001). 
Release of MTL-004 observed significant differences between release from solution and all 
loadings of surfactant was significant (P ≤ 0.0001). Release between 10 % w/w and 0 and 2 
and 6 % of surfactant was significantly different (P ≤ 0.001). The release profile between 2 % 
w/w and 6 % w/w Tween 20 was significantly different (P ≤ 0.01). The release profile between 
0 % w/w and 6 % w/w Tween 20 was significantly different (P ≤ 0.05). The release profile 
between 0 % w/w and 2 % w/w of surfactant was not significantly different. Complete release 
of the solution was observed between the 6th and 7th hour. Liposomes formulated with 0, 2, 6 
and 10 % w/w Tween 20 gave 60 %, 52 %, 56 %, and 74 % release respectively.  
5.4.9.1 Kinetic assessment of MTL-004 release from liposomal formulations 
MTL-004 release data from the solution and all liposomal formulations complied with first order 
release kinetics implying rate of drug release was dependent on drug concentration at that 
time (Table 5-10 and 5-11).  
Presence of surfactant appears to decrease drug release between 0 % and 2 % w/w loading 
of Tween 20, after which drug release increased and at 10 % cumulative percentage release 
surpassed that of liposome containing no surfactant. At lower loadings of surfactant, compared 
with liposomes containing no surfactant there is less entrapped drug thus less of a 
concentration gradient for the drug to diffuse across. However, surfactant would increase drug 
solubility thus explaining why an increase in drug release is observed at higher loadings of 
surfactant. Furthermore, the mechanism of the in vitro release from liposomes may be due to 
be the formation of transient pores in the lipid bilayer, through which drugs are released from 
the inner aqueous core of the liposomes to the extra-liposomal medium (Wang, Wang et al. 
2016). Therefore, the presence of more surfactant in the liposome may also encourage the 
formation of transient pores.  
Table 5-10: Kinetic assessment of release data of MTL-004 from solution and liposomal 
formulations. 
Kinetic 
model 
Formulation (r2) 
Solution 
Liposome                                                 
(% w/w loading of Tween 20) 
0 2 6 10 
Zero 
order 
-1.442 ± 
0.763 
0.706 ± 
0.019 
0.474 ± 
0.145 
0.642 ± 
0.062 
0.004 ± 
0.017 
First 
order 
0.885 ± 
0.025 
0.907 ± 
0.011 
0.776 ± 
0.079 
0. 076 
± 0.064 
0.740 ± 
0.017 
Results are presented as the mean ± standard deviation (n=3) 
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Comparison of the rate constant of each formulation shows MTL-004 solution had the highest 
rate of release liposomes followed by liposomes formulated with 10% w/w Tween 20, followed 
by liposomes formulated with 0% w/w Tween 20, then 6% w/w Tween 20 and then liposomes 
formulated with 2% w/w of Tween 20 (Table 5-11).  
 
Table 5-11: First order kinetics rate constant for MTL-004 release from formulations. 
Formulation (× 10-3 min-1) 
Solution Liposome formulation (% w/w loading of tween 20) 
0 2 6 10 
7.10 ± 1.02 0.45 ± 0.04 0.08 ± 0.04 0.91 ± 0.004 1.963 ± 0.2 
Results are presented as the mean ± standard deviation (n=3) 
As discussed in section 3.4.7.3 the release data observed will be either because of drug 
release from the liposome and then the membrane or movement of the liposome across the 
barrier and then release from this. The diffusion cell system will see release from the liposome 
first owing to the physical set up of the cell and the smaller pore size of 50 nm. Additionally, 
reversible binding of the drug released from the liposome reduces the driving force for drug 
transport across the dialysis membrane leading to a slower overall apparent release rate (Modi 
and Anderson, 2013). In this case, this reversible binding was greater with lower loadings of 
surfactant loading resulting in a slower rate of release for liposome formulated with 2 % and 6 
% Tween 20 in comparison to liposomes formulated with no Tween 20 or 10 % w/w Tween 20. 
5.4.10 Liposomal gel MTL-004 release studies 
Similar to both flavonoids, drug release from liposomal gels could not be measured/detected 
in the side by side diffusion chamber therefore a cell culture ThincertTM insert (400 µm pore 
size) was filled with 1 mL of formulation and release into 4 mL of DDM in a 6-well ThincertTM 
plate was quantified. Neither the diffusion cell nor the ThincertTM system mimic what would 
happen following formulation application on the skin. The diffusion cell was used to see how 
drug diffused across a membrane with a pore size similar to that of the gaps in the strateum 
coreum whilst maintaining sink conditions. The ThincertTM plate with inserts was used simply 
to overcome detection/experimental limitations of the diffusion cell and see if drug was able to 
come out from the liposomes loaded into the gel and then the release media. To ensure we 
were only detecting free drug samples were centrifuged and supernatant analysed. 
Both HEC and HPMC gels were loaded with either drug loaded liposomes or drug loaded 
elastic liposomes formulated with 2 % Tween 20. Only liposomes loaded with 2 % of Tween 
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20 were investigated since an increase in surfactant results in a decrease of drug loading of 
which would make drug detection even harder. Within the first 2 hours of the study, drug 
release was not detected from any of the formulations, suggesting there was no release (Figure 
5.15). This is perhaps more likely concerning detection issues. The drug release into the donor 
compartment must have been lower than the LOD thus was not detected by the HPLC-UV 
apparatus. 
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Figure 5.15: In vitro percentage MTL-004 release profiles from liposomal gels 
In vitro percentage MTL-004 release profiles using a transwell system with permeable inserts 
of a 400 nm pore size from solution and gel loaded with either blank or elastic liposomes 
formulated with 2 % w/w Tween 20 over a) 24 hours, b) 8 hours. F1: HEC and blank liposomes, 
F2: HEC and elastic liposomes, F3: HPMC and blank liposomes, F4: HMPC and elastic 
liposomes. Liposomes were prepared adapting the dry film method. Gels were prepared using 
3 % w/w loading of either HEC or HPMC. Data represents mean ± SD. n=3 independent 
batches. 
 
Complete drug release from solution seemed to reach a maximum occur between the 3rd and 
4th hour (Figure 5.15). As with both flavonoids, over all, the percentage of drug release from 
the liposome loaded gels quantified over 24 hours was slightly higher from the HEC gel (up to 
66 %). Furthermore, a higher percentage of drug was released from the elastic liposome (up 
to 66 %).  
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Over the course of 24-hours solution gave a release of 99.9 ± 0.9 % whilst F1, F2, F3 and F4 
gave a release of 28.3 ± 5.4 %, 65.7 ± 1.5 %, 20.3 ± 1.9 % and 61.6 ± 6.1 %, respectively. The 
cumulative percentage released after 24 hours was significant between the solution and all 
liposomal gels as well as between all liposomal gels except between formulation 1 and 3 as 
well as 2 and 4 (P ≤ 0.0001). F1 and F3 contained no surfactant in the liposome and F2 and 
F4 contained 2 % w/w of Tween 20. Therefore, release in the liposomal gels appeared to be 
affected by presence on surfactant rather than the type of aqueous gel used. 
This implies that either elastic liposomes where more able to move through the gel compared 
with blank liposomes or that the presence of surfactant increased the solubility of drug thus 
encouraging release from the liposome bilayer. As discussed in section 3.4.7.4, drug 
properties (solubility, log P), liposome stability during their dispersion in the gel formulation 
determine the system behaviour and thus drug release (Mourtas et al., 2007). 
5.4.11 Impact of liposomal formulation on In vitro cytotoxicity on HDFA and HaCat cells 
To assess the toxicity of MTL-004 on HDFa and HaCat cells, an XTT assay was performed to 
measure cell death after exposure of cells to different concentrations of drug for 24 hours. 
Results of cell viability are shown in Figure 5.16. 
As the concentration of MTL-004 was increased, there was a decrease in HDFa cell viability. 
In comparison to the control well, the viability in cells treated with 100, 50, 10, 5 and 0.1 µM 
was significantly lower (P ≤ 0.0001), as well as cells treated with 1 µM (P ≤ 0.05) of MTL-004. 
At 100 µM MTL-004 concentration cell viability decreased to 46.1 ± 3.9 %. An IC50 value of 
191.1 µM was observed. This may be due to toxicity or death of damaged cells in which MTL-
004 induced apoptosis (Bae et al., 2008; Tanigawa et al., 2014).  
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Figure 5.16: Cellular toxicity of MTL-004 on HDFa and HaCat cells. 
Cellular toxicity of MTL-004 (A), HDFa (B), HaCat cells. Cells were grown on a 96-well plate 
at a density of 50 x 103 cells per well and exposed to various concentrations of MTL-004 (0.1 
– 100 µM). After 24 hour incubation following which 25 µL of a 12.5:1 parts mixture of XTT to 
menadione was added each well. Plates were incubated for 3 hours at 37°C and the 
absorbance read at 450 nm. The control cell (without drug) corresponded to a cell viability of 
100 %. Data is reported as mean ± SD with 6 replicates per compound in 3 independent 
experiments. 
 
There was no significant difference in cell viability at the range of MTL-004 concentrations 
studied with the HaCat cells therefore within this concentration range, MTL-004 was safe for 
application on these cells (P ≥ 0.01). This was also observed with both flavonoid and is not 
unexpected as keratinocytes are by nature more resilient cells owing to their barrier function 
property. Any differences in these percentages was not significant therefore, at these 
concentrations MTL-004 was not toxic to this line of keratinocytes. 
5.4.12 Cellular liposomal uptake assay on HDFa and HaCat cells 
Fluorescently labelled liposomes loaded with MTL-004 were incubated with both HDFa and 
HaCat cells to assess the cellular uptake of these formulations.  Following a 2-hour incubation 
with the cells, the labelled liposomes were identified using confocal microscopy (Figure 5.17 
and 5.18). Cytoplasmic accumulation of the formulations was apparent, confirming the 
successful uptake into both HDFa and HaCat cells.   
247 
 
 
Figure 5.17: Localisation DilC-liposomes loaded with MTL-004 and 2% w/w Tween 20 in 
HaCat cells 
Localisation of DilC labelled liposomes loaded with MTL-004 and 2% w/w Tween 20 in HaCat 
cells. Cells were grown on the coverslips for 2 days. Cell nuclei were visualised using a) DAPI 
(Blue). Liposomes were formulated with DilC for visualisation b) (yellow). Liposome localisation 
within the cell is shown in the merged image c). 
 
 
Figure 5.18: Localisation of DilC-liposomes loaded with MTL-004 and 2% w/w Tween 20 in 
HDFa cells. 
Localisation of DilC labelled liposomes loaded with MTL-004 and 2% w/w Tween 20 in HDFa 
cells. Cells were grown on the coverslips for 2 days. Cell nuclei were visualised using a) DAPI 
(Blue). Liposomes were formulated with b) DilC for visualisation (red). Liposome localisation 
within the cell is shown in the merged image c). 
248 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19: z-dimension cellular localisation of DilC-MTL-004 loaded liposomes formulated with 2% w/w Tween 20 in HaCat cells 
z-dimension cellular localisation of DilC labelled liposomes loaded with MTL-004 and 2 % w/w Tween 20 (stage 2). DilC labelled liposomes previously 
incubated with HaCat cells for 2 hours were further subjected to a z-stack analysis with the lens positioned above the cell layer (12216 µm) and lowered 
through the cells to the bottom of the cell layer (12210 µm).  Images were captured of DilC (green) through the z-dimension. 
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Figure 5.20: z-dimension cellular localisation of DilC-MTL-004 loaded liposomes formulated with 2% w/w Tween 20 in HDFa cells 
z-dimension cellular localisation of DilC labelled liposomes loaded with MTL-004 and 2 % w/w Tween 20 (stage 2). DilC labelled liposomes previously 
incubated with HDFa cells for 2 hours were further subjected to a z-stack analysis with the lens positioned above the cell layer (12216 µm) and lowered 
through the cells to the bottom of the cell layer (12210 µm).  Images were captured of DilC (green) through the z-dimension.
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The confocal stage was set at the upper-most boundary of the HDFa/HaCat cells and the stage 
moved down towards the coverslip with images captured over a z-dimension of approximately 
5 µm (Figure 5.19 and 5.20). At the onset of the z-stack analysis, liposomes are localised on 
the exterior of the cell boundary and potentially on the surface of the cells (10614 µm).  As the 
stage progresses, the localisation of FITC-Fan-MSNP increases with clear demarked zones of 
cytoplasmic localisation near the ‘mid-to-bottom’ regions of the cells. 
 
There are four methods of liposome interaction with cells as discussed in section 2.4.5: stable 
adsorption, endocytosis, fusion of the lipid bilayer with the cell plasma membrane and lipid 
transfer (Martin and MacDonald, 1976; Pagano and Weinstein, 1978). It is unclear which of 
these occurred in this study, however, these methods of uptake are not mutually exclusive and 
any given amalgamation could have occurred in these circumstances (Pagano and Weinstein, 
1978). 
 
This formulation is aimed to be targeting the dermal layer. Liposomes may completely pass 
through the keratinocytes into the dermal layer or they may accumulate in the stratum 
corneum. To be able to determine this, application onto excised skin would be necessary. 
Nonetheless it is clear liposomes were taken up by the cells, more importantly the fibroblasts 
thus the liposomes were successfully able to enter the cells.  
5.4.13 Stability of deformable liposomes 
The stability of deformable liposomes during storage at 20°C was studied in terms of size and, 
for drug loaded liposomes, encapsulation efficiency. Confocal images were observed on day 
1 of formulation to ensure the presence of liposomes (Figure 5.21). The size of blank and 
surfactant loaded liposomes was measured on day 1, 2, 7, 14, 21 and 28 (Figure 5.22).  
 
Figure 5.21: Confocal images of MLV liposomes formulated with MTL-004 
MLV liposomes formulated with MTL-004 were loaded with either a) 0 % w/w Tween 20, b) 2 
% w/w Tween 20. Fluorescently labelled liposomes where formulated by the addition of the 
fluorescent dye DilC to the lipid mixing stage. The unentrapped marker was removed by 
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centrifuging liposomes, removing the supernatant, re-suspending in water. Liposomes where 
imaged using an upright confocal microscope (Leica SP5 TCS II MP) and visualised with a 
40× oil immersion objective. 
 
 
Figure 5.22: Stability of MTL-004 loaded liposomes as determined by size 
Size of MTL-004 loaded liposomes formulated with 0-10% w/w Tween 20 was determined 
using DLS, formulated with up to 10 % w/w Tween 20 measured on various days (1, 2, 7, 14, 
21 and 28). Liposomes were prepared adapting the dry film method. Liposome size was 
assessed via DLS. Data represents mean ± SD. n=6 independent batches.  
 
Drug loaded liposomes formulated with no surfactant appear to decrease in size from 1362 nm 
to 850 nm over time. This was unexpected as usually, aggregation is noted resulting in vesicle 
size growth (Seras et al., 1992). This may be a result of to larger, more dense 
liposomes/aggregates settling as a creamy film could be seen at the bottom of the cuvette.  
This trend was however also spotted with both flavonoid loaded liposomes.   
The inclusion of surfactant seemed to decrease this phenomenon to a degree. Formulations 
with 2 % w/w, 6 % w/w and 10 % w/w observed a size decrease from 937 to 663 nm, 878 to 
562 nm and 801 to 543 nm respectively over the course of 28 days. Liposomes formulated 
without surfactant have a lower polydispersity, thus inclusion of surfactant provides a more 
homogenous mix with less larger liposomes/aggregates formulated thus there would be less 
of these to settle out over time.   
The size decrease of liposomes formulated without Tween 20 was significant between day 1 
and all other days (P ≤ 0.0001), as well as between day 2 and 7 (P ≤ 0.01), and between day 
2 and 14, 21, and 28 (P ≤ 0.05). There was no significant difference between days 7 onwards. 
This may be because all lipid aggregates settled out by this time. The size decrease between 
liposomes formulated with 2 % w/w Tween 20 between day 1 and all other days (P ≤ 0.0001), 
as well as between day 2 and 14 (P ≤ 0.01), and between day 2 and 28 (P ≤ 0.05). There was 
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no significant difference between days 7 onwards. This may be because all lipid aggregates 
settled out by this time. The size decrease of liposomes formulated with 6 % w/w Tween 20 
was significant between day 1 and all other days (P ≤ 0.0001), as well as between day 2 and 
both 7 and 14 (P ≤ 0.01), and between day 2 and 28 (P ≤ 0.05). There was no significant 
difference between days 7 onwards. This may be because all lipid aggregates settled out by 
this time. The size decrease of liposomes formulated with 10 % w/w Tween 20 was significant 
between day 1 and 2 (P ≤ 0.01), 1 and 7 (P ≤ 0.001) and between day 1 and 14, 21 and 28 (P 
≤ 0.0001), There was no significant difference between day 2 onwards. This may be because 
all lipid aggregates settled out by this time. There may have been less large lipid aggregates 
to settle out of this formulation because the presence of more surfactant would solubilise the 
lipids leading to less aggregation. 
Additionally, encapsulation efficiency appears to decrease from 44 % to 39 %, 35 % to 25 %, 
29 % to 20 % and 21 % to 13 % respectively for 0 % w/w, 2 % w/w, 6 % w/w, 10 % w/w loading 
of surfactant (Figure 5.23). This drug leaching phenomenon was non-significant in liposomes 
loaded with no surfactant. The decrease in encapsulation efficiency was significant for 
liposomes loaded with 2 % w/w Tween 20 between days 1 and 28 (P ≤ 0.0001), 2 and 28, 7 
and 21 (P ≤ 0.001), 1 and 21, 14 and 28 (P ≤ 0.01) and finally, 7 and 21 (P ≤ 0.05). For 
liposomes loaded with 6 % w/w Tween 20, the decrease in encapsulation efficiency was 
significant between days 1 and 28 (P ≤ 0.001), 1 and 21, 2 and 28 (P ≤ 0.01) and finally 
between days 1 and 14 as well as 7 and 28 (P ≤ 0.05). For liposomes loaded with 10 % w/w 
Tween 20, the decrease in encapsulation efficiency was significant between days 1 and 28 (P 
≤ 0.0001), between days 1 and 21, 2 and 28 (P ≤ 0.001), between days 1 and 14 as well as 2 
and 21 (P ≤ 0.01), and finally between days 2 and 14 as well as 7 and 28 (P ≤ 0.05). Liposome 
aggregation may have led to drug leaching or visa versa. This suggests a lower loading of 
surfactant is best to ensure stability. 
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Figure 5.23: Liposome encapsulation efficiency for MTL-004 over 28 days 
Liposome encapsulation efficiency for MTL-004 in either 0 % w/w, 2 % w/w, 6 % w/w or 10 % 
w/w Tween 20 liposomes over 28 days. Liposomes were prepared adapting the dry film method 
adding the surfactant and drug during the lipid mixing stage. The preparation was then washed 
via centrifugation. The quantity of MTL-004 in supernatant over 28 days was then analysed by 
HPLC coupled with UV detection to assess liposome stability. Data represents mean ± SD. 
n=6 independent batches. 
 
As discussed in section 3.4.10 the long-term stability of liposomes depends on the average 
elastic energy of the membrane being higher than the thermal energy (Lipowsky 1991). 
Therefore, temperature is an important determinate of stability and liposomes must be stored 
at a suitable temperature. This suggests these liposomal formulations may not be suitable for 
long term stability. Either additional excipients are required or an additional step of freeze 
drying liposomes for reconstitution near the time of administration.  
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5.5 Conclusion  
MTL-004 is a novel potent cytotoxic agent suggested for use in the local treatment of NMSC. 
This drug elicits an effect by forming DNA interstrand crosslinks which are poorly repaired 
resulting in cell death. An additional advantage is the lack of systemic toxicity due to the high 
reactivity of MTL-004 with serum proteins. Moreover MTL-004 has been found to have no 
effect on normal cells as it only works in rapidly dividing cells. 
Chemotherapeutic agents are infamously problematic when considering formulation options 
due to compounds having a low solubility. Liposomes can improve the bioavailability of these 
agents and are therefore useful as delivery agents. Furthermore, elastic liposomes have been 
found to be useful in dermal drug delivery as they increase compound solubility, protect the 
drug from degradation, can be formulated for targeted, controlled drug release (Benson 20016, 
Cevc 1996) and are able to penetrate the SC (Fang et al., 2008; Lau et al., 2005; Trotta et al., 
2004).  
As the loading of Tween 20 in the liposomal bilayer increased, liposome size decreased. The 
presence of MTL-004 in elastic liposome increases the liposome diameter; however, the 
inclusion of surfactant decreases the diameter. Inclusion of surfactant in the bilayer decreases 
liposome deformability index implying such elastic carriers may be useful in dermal drug 
delivery as they would be able to pass through the gaps in the SC.  
As the loading of Tween 20 in the liposome increased MTL-004 encapsulation decreased. This 
may have been due to Tween 20 competing for space within the bilayer or due to Tween 20 
increasing the solubilisation capacity of MTL-004. 
Aqueous gels were found to slow the release of drug compared to drug solution. MTL-004 
release from liposomes found liposomes were able to modify the release of drug and complete 
release was not observed within 24 hours. Furthermore, as surfactant loading in the bilayer 
increased, the rate of release per unit time also increased. Liposomes added into gels seemed 
to have an additive effect in terms of retarding drug release. Release was faster from HEC 
gels and liposomes formulated with Tween 20. 
Toxicology assay’s found that between 0.1 and 100 µM MTL-004 did decrease fibroblast cell 
viability but not keratinocytes viability. Cell uptake of the liposomes loaded with EGCG and 2 
% w/w Tween 20 was apparent into both the keratinocyte cell line and the fibroblast cell line. 
It appears elastic liposomes are useful in enhancing drug penetration into dermal cells and 
furthermore may be useful in the development of a controlled release formulation.  
Deformable liposomes appear to be a useful carrier in the development of a controlled release 
formulation for novel chemotherapeutic agents. Aqueous gels were found to hinder the release 
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of MTL-004 compared to MTL-004 solution. Furthermore, MTL-004 release from liposomes 
observed rate of release was influenced by the liposome carrier system with the presence of 
Tween 20 observing a faster rate of release. 
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6     General conclusions 
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6.1 General conclusions  
 
The overall aim of this work was to formulate and develop formulations for the dermal delivery 
of potential anti-cancer agents following topical application to NMSC tumours.  Skin cancer is 
emerging as an increasing public health problem especially in developed countries. The most 
common treatment is surgical excision of the tumour. However this may not be suitable for all 
patients thus development of alternative treatments is necessary. 
The use of anti-oxidants to prevent oxidative skin damage appears to be a promising approach. 
EGCG and naringenin have been found to affect specific biological processes that could be 
exploited as targets for the prevention and treatment of cancer. MTL-004 is a new compound 
developed by Morvus to target NMSC tumours unique in its ability to detect and target cancer 
cells only. 
Liposomes were investigated as the primary drug carriers as they can protect compounds from 
degradation as well as provide sustained release of drug. Current topical treatments for NMSC 
suffer with a multi dosing regimen that is met with poor patient compliance. A sustained release 
drug delivery system would overcome this. Elastic liposomes were developed with the aim to 
be able to pass through the gaps in the SC into the dermal layer where they would provide a 
slow release of compound. Liposome elasticity was modified with the use of the surfactants 
Tween 80, Tween 20 or sodium cholate. Furthermore, the aqueous gels HEC and HPMC were 
investigated as carriers for the liposomes to be applied topically. 
Chapter 2 concerned the formulation and characterisation of liposomes formulated with either 
Tween 80, Tween 20 or sodium cholate. As the loading of Tween 80, Tween 20 or sodium 
cholate in the bilayer was increased, liposome size decreased. Furthermore, the inclusion of 
surfactant within the bilayer seemed to produce a more homogenous formulation as defined 
by the polydispersity index.  
Stability studies concerning liposome size for liposomes formulated with either Tween 80, 
Tween 20 or sodium cholate found that over the first 2 days, liposome size decreased although 
this may have been due to lipid aggregates settling out (as confirmed by creaming at the 
bottom of the liposome container). Beyond this, over 28 days, the liposome size was 
maintained for liposomes formulated with Tween 20 and sodium cholate, a slight decrease in 
size was observed for liposomes formulated with Tween 80. 
Inclusion of either Tween 80, Tween 20 or sodium cholate in the bilayer decreased the 
liposome DI and increased the amount of lipid able to pass through a membrane. Increasing 
the loading of the surfactant decreased the DI across all three surfactants. Sodium cholate 
appeared to increase deformability the greatest, however, at the loadings investigated, Tween 
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80 and Tween 20 appeared the most stable. Therefore, only Tween 20 was selected for all 
further studies.  
Increasing loadings of Tween 20 within the liposomal bilayer appeared to increase the amount 
of energy stored within the bilayer which allowed the liposome to reform following extrusion 
rather than deforming permanently into smaller liposomal structures/aggregates. This 
suggests that liposomes loaded with Tween 20 may be better poised than conventional 
liposomes to pass through gaps in the SC and reach the dermal layer of the skin. 
As the loading of Tween 20 increased, the difference in pre- and post- extrusion lipid 
concentration decreased as detected by the HPLC-ELSD equipment. This was due to the 
Tween 20 increasing fluidity of the liposome, thus decreasing liposome destruction, therefore 
less constituents become stuck within the pores. This implies that increasing loadings of 
Tween 20 allow the liposome, closer to its original composition, to pass through the pore.  
Following application of liposomes onto dermal cell lines, 50% of the liposome solution 
containing 16:8 mM of PC:cholesterol and up to 10% w/w of Tween 20 decreased fibroblast 
cell viability. This was only true for liposomes formulated with 10% w/w Tween 20 on the 
keratinocytes; these cells were not affected by blank liposomes or those formulated with 2% 
w/w of Tween 20. This highlights fibroblast cells are more sensitive therefore further 
formulation development must consider this phenomenon. 
Chapters 3, 4 and 5 concerned the formulation of liposomes loaded with EGCG, naringenin 
and MTL-004 respectively as well as 16:8 mM of PC:cholesterol and varying ratios of Tween 
20. As with blank liposomes, as the amount of surfactant in the bilayer is increased, liposome 
size decreases. The presence of EGCG, naringenin and MTL-004 in elastic liposome 
increased the liposome diameter; however, the inclusion of surfactant decreased the diameter. 
Inclusion of surfactant in the bilayer decreases liposome DI implying liposomes retained 
enough elastic energy to pass through a pore size smaller than the liposome diameter. This 
suggests that compound loaded liposomes formulated with Tween 20 may be better able to 
pass through gaps in the SC and reach the dermal layer of the skin than conventional 
liposomes. This was true when liposomes where forced through a 200 nm and 100 nm pore 
size however, liposome destruction was apparent when forced through a 50 nm pore size.   
As the loading of Tween 20 in the liposome was increased the EGCG, naringenin and MTL-
004 encapsulation decreased. This may have been due to Tween 20 competing for space 
within the bilayer or due to Tween 20 increasing the solubilisation capacity of the compound. 
Further, inclusion of all three compounds within the liposome bilayer could reduce the phase 
transition temperature of the individual compound. 
Across all three compounds, the one compartment release models found HEC gels to release 
drug slightly faster than HPMC gels. Complete gel dissipation was observed between 3 and 4 
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hours. Two compartment release models found that the aqueous gels were found to hinder the 
release of all three compounds compared to compound solutions. Furthermore, as the polymer 
loading increased, the rate of release decreased.  
EGCG release from liposomes found they could modify the release of drug with complete 
release observed within 24 hours. Comparison of the rate constant of each EGCG liposomal 
formulation that fit the first order model shows that the EGCG solution had the highest rate of 
release, followed by liposomes formulated with 10% w/w, then 6% w/w and then 2% w/w of 
Tween 20. Complete release, 94.4 ± 4.9 %, was observed within 24 hours from liposomes 
loaded with 10% w/w of Tween 20. In addition, 36.4 ± 3.8 % release was observed with 
liposomes formulated with 6% w/w of Tween 20, and 17.0 ± 1.7 % was seen both 2% w/w and 
13.7 ± 1.1 %, was observed with blank liposomes. As surfactant loading increased, drug 
entrapment decreased, therefore, drug release would be expected to be slower as there is less 
of a concentration gradient. Furthermore, the drug is hydrophobic therefore less inclined to 
diffuse out of the liposomes.  
Comparison of the rate constant of each naringenin liposomal formulation showed liposomes 
formulated with 0% w/w Tween 20 had the highest rate of release, followed by liposomes 
formulated with 2% w/w Tween 20, then 6% w/w Tween 20, naringenin solution and then 
liposomes formulated with 10% w/w of Tween 20. Surfactant appeared to have the opposite 
effect on naringenin release when compared with EGCG where surfactant increased the rate 
of drug release. This indicates that compounds individual physiochemical properties influences 
the release of compound from liposomes. EGCG is amphiphilic in nature and naringenin is not, 
EGCG may therefore have been more inclined to diffuse out of the liposomal bilayer. A higher 
percentage of naringenin was released from liposomes compared with drug solution. Over the 
course of 24 hours the EGCG solution gave a release of 54.5 ± 4.2 % whilst liposomes 
formulated with 0%, 2%, 6% and 10% w/w of Tween 20 gave a release of 109.7 ± 5.0 %, 79.5 
± 3.7 %, 61.3 ± 3.4 % and 48.5 ± 2.1 % respectively.  
As with EGCG, comparison of the rate constant of each MTL-004 formulation showed MTL-
004 solution had the highest rate of release followed by liposomes formulated with 10% w/w 
Tween 20, followed by liposomes formulated with 0% w/w Tween 20, then 6% w/w Tween 20 
and then liposomes formulated with 2% w/w of Tween 20.  Over the course of 24 hours the 
MTL-004 solution gave a release of 100.0 ± 6.8 % whilst liposomes formulated with 0 %, 2 %, 
6 % and 10 % w/w of Tween 20 gave a release of 59.8 ± 1.2 %, 51.8 ± 3.6 %, 56.0 ± 2.7 % 
and 74.0 ± 1.8 % respectively.  
EGCG, naringenin and MTL-004 loaded liposomes added into the aqueous HEC or HPMC 
gels may have had an additive effect in terms of retarding drug release. Release was faster 
from HEC gels and liposomes formulated with Tween 20. 
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Toxicology assay’s used to assay compound toxicology on both HDFa and HaCat cells found 
that 0.1-100 µM EGCG was not harmful to either HDFa or HaCat cells. Additionally, between 
0.1 and 100 µM naringenin was not harmful to either HDFa or HaCat cells.  
Cell uptake of the liposomes loaded with either EGCG, naringenin and MTL-004 and 2% w/w 
Tween 20 was apparent into both the keratinocyte cell line and the fibroblast cell line. It appears 
elastic liposomes are useful in enhancing drug penetration into dermal cells and furthermore 
may be useful in the development of a controlled release formulation.  
A clear challenge in targeting the dermal layer via the topical route is the ability of drug carriers 
to penetrate the SC. Elastic liposomes may not only be able to overcome this challenge but 
provide a controlled release of drug. The main aim of the study was to develop a dermal drug 
delivery system for the controlled release of anti-cancer agents and it appears, elastic 
liposomal gels may be useful in achieving this objective.  
6.2 Future studies 
Application of formulations to excised skin is necessary to determine how the formulations will 
interact with the different skin components and how compound will move out of the carrier 
across the stratum corneum and into the dermal layer. Confocal microscopy on the different 
layers of skin separated by the skin stripping method will be useful to view this interaction and 
determine how the liposome moves through the gel and into the skin. Further studies 
surrounding in vivo work will need to consider how the increased solubilisation of the active 
compound will affect the pharmacokinetic and pharmacodynamic profile of the drug thus 
careful monitoring is required to assess clinically adverse effects caused by this phenomenon 
or by the excipients themselves. 
Further work surrounding MTL-004 and its characteristics and stability will need to be carried 
out. MTL-004 is acid labile and the dermal layer is acidic. When release studies into a release 
media buffered at pH 5.2 where carried out split peaks or disappearing peaks were observed. 
In fact MTL-004 is known to be acid labile therefore, release into media buffered at this pH was 
problematic. In fact one of the aims of the liposomes is to protect the MTL-004 whilst it is being 
delivered to cells. 
Additionally, gel characterisation work that contribute to patient acceptability and clinical 
efficacy including optimal mechanical properties, good bioadhesion and appropriate viscosity 
need to be investigated for the various gel formulations loaded with liposomes in order to 
optimise the formulation.  Rheology studies could be carried out to assess how the gels 
respond to applied forces to deduce information on the viscosity and spreadability of the gel. 
Ease of product removal from a tube may be determined using a Texture Analyser fitted with 
the texture profile analysis probe in compression mode. 
261 
 
 
7 References  
 
Al-Khalili, M., Meidan, V.M., Michniak, B.B., 2003. Iontophoretic transdermal delivery of buspirone 
hydrochloride in hairless mouse skin. AAPS PharmSci 5, E14. 
Albini, A., Sporn, M.B., 2007. The tumour microenvironment as a target for chemoprevention. Nature 
Reviews Cancer 7, 139-147. 
Alexander, A., Dwivedi, S., Giri, T.K., Saraf, S., Saraf, S., Tripathi, D.K., 2012. Approaches for breaking 
the barriers of drug permeation through transdermal drug delivery. J Control Release 164, 26-40. 
Alfrey Jr, T., Gurnee, E., Lloyd, W., 1966. Sci. Part C 12, 249. 
Ali, M.H., Kirby, D.J., Mohammed, A.R., Perrie, Y., 2010. Solubilisation of drugs within liposomal 
bilayers: alternatives to cholesterol as a membrane stabilising agent. J Pharm Pharmacol 62, 1646-
1655. 
Ali, M.H., Moghaddam, B., Kirby, D.J., Mohammed, A.R., Perrie, Y., 2013. The role of lipid geometry in 
designing liposomes for the solubilisation of poorly water soluble drugs. Int J Pharmaceut 453, 225-
232. 
Almog, S., Kushnir, T., Nir, S., Lichtenberg, D., 1986a. Kinetic and structural aspects of reconstitution of 
phosphatidylcholine vesicles by dilution of phosphatidylcholine-sodium cholate mixed micelles. 
Biochemistry 25, 2597-2605. 
Almog, S., Kushnir, T., Nir, S., Lichtenberg, D., 1986b. Kinetic and structural aspects of reconstitution 
of phosphatidylcholine vesicles by dilution of phosphatidylcholine-sodium cholate mixed micelles. 
Biochemistry 25, 2597-2605. 
Anlezark, G.M., Melton, R.G., Sherwood, R.F., Coles, B., Friedlos, F., Knox, R.J., 1992. The bioactivation 
of 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954)—I: purification and properties of a nitroreductase 
enzyme from Escherichia coli—a potential enzyme for antibody-directed enzyme prodrug therapy 
(ADEPT). Biochemical pharmacology 44, 2289-2295. 
Armstrong, B.K., Kricker, A., 1993. Cutaneous melanoma. Cancer surveys 19, 219-240. 
Aungst, B.J., 1989. Structure/Effect Studies of Fatty Acid Isomers as Skin Penetration Enhancers and 
Skin Irritants. Pharm Res-Dord 6, 244-247. 
Bae, J.Y., Choi, J.S., Choi, Y.J., Shin, S.Y., Kang, S.W., Han, S.J., Kang, Y.H., 2008. (-)Epigallocatechin 
gallate hampers collagen destruction and collagenase activation in ultraviolet-B-irradiated human 
dermal fibroblasts: involvement of mitogen-activated protein kinase. Food and chemical toxicology : 
an international journal published for the British Industrial Biological Research Association 46, 1298-
1307. 
Baier, G., Cavallaro, A., Friedemann, K., Müller, B., Glasser, G., Vasilev, K., Landfester, K., 2014. 
Enzymatic degradation of poly(l-lactide) nanoparticles followed by the release of octenidine and their 
bactericidal effects. Nanomedicine: Nanotechnology, Biology and Medicine 10, 131-139. 
Bangham, A.D., Standish, M.M., Watkins, J.C., 1965. Diffusion of univalent ions across the lamellae of 
swollen phospholipids. Journal of molecular biology 13, 238-252. 
Barry, B.W., 2001. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur 
J Pharm Sci 14, 101-114. 
Berger, N., Sachse, A., Bender, J., Schubert, R., Brandl, M., 2001. Filter extrusion of liposomes using 
different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. 
Int J Pharmaceut 223, 55-68. 
Berman, B., 2002. Imiquimod: a new immune response modifier for the treatment of external genital 
warts and other diseases in dermatology. Int J Dermatol 41 Suppl 1, 7-11. 
Bernoulli, D., 1738. Danielis Bernoulli Joh. fil. med. prof. Basil. ... Hydrodynamica, sive De viribus et 
motibus fluidorum commentarii. Opus academicum ab auctore, dum Petropoli ageret, congestum. 
Sumptibus J.R. Dulseckeri, Argentorati. 
Bhaskar, K., Anbu, J., Ravichandiran, V., Venkateswarlu, V., Rao, Y.M., 2009. Lipid nanoparticles for 
transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis 
8, 6. 
262 
 
Bhatia, A., Kumar, R., Katare, O.P., 2004. Tamoxifen in topical liposomes: development, 
characterization and in-vitro evaluation. J Pharm Pharm Sci 7, 252-259. 
Boland, M.P., Knox, R.J., Roberts, J.J., 1991. The differences in kinetics of rat and human DT diaphorase 
result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-
dinitrobenzamide). Biochemical pharmacology 41, 867-875. 
Bommannan, D., Potts, R.O., Guy, R.H., 1991. Examination of the effect of ethanol on human stratum 
corneum in vivo using infrared spectroscopy. J Control Release 16, 299-304. 
Bos, J.D., Meinardi, M.M., 2000. The 500 Dalton rule for the skin penetration of chemical compounds 
and drugs. Experimental dermatology 9, 165-169. 
Bouwstra, J., Junginger, H., 1993. Hydrogels. Encyclopaedia of Pharmaceutical Technology, 441-465. 
Bouwstra, J.A., Honeywell-Nguyen, P.L., 2002. Skin structure and mode of action of vesicles. Adv Drug 
Deliv Rev 54 Suppl 1, S41-55. 
Bradfield, A., Penney, M., 1948. 456. The catechins of green tea. Part II. Journal of the Chemical Society 
(Resumed), 2249-2254. 
Bragagni, M., Mennini, N., Maestrelli, F., Cirri, M., Mura, P., 2012. Comparative study of liposomes, 
transfersomes and ethosomes as carriers for improving topical delivery of celecoxib. Drug Deliv 19, 
354-361. 
Brandner, J.M., Zorn-Kruppa, M., Yoshida, T., Moll, I., Beck, L.A., De Benedetto, A., 2015. Epidermal 
tight junctions in health and disease. Tissue barriers 3, e974451. 
Brooks, G., Idson, B., 1991. Skin lipids. International journal of cosmetic science 13, 103-113. 
CancerResearchUK, 2014. CancerResearchUK, Skin cancer incidence. CancerResearchUK. 
Casas, M., Baszkin, A., 1992. Interactions of a non-ionic surfactant with mixed phospholipid—oleic acid 
monolayers. Surface potential and surface pressure studies at constant area. Colloid Surface 63, 301-
309. 
Casey, S.C., Amedei, A., Aquilano, K., Azmi, A.S., Benencia, F., Bhakta, D., Bilsland, A.E., Boosani, C.S., 
Chen, S., Ciriolo, M.R., Crawford, S., Fujii, H., Georgakilas, A.G., Guha, G., Halicka, D., Helferich, W.G., 
Heneberg, P., Honoki, K., Keith, W.N., Kerkar, S.P., Mohammed, S.I., Niccolai, E., Nowsheen, S., 
Vasantha Rupasinghe, H.P., Samadi, A., Singh, N., Talib, W.H., Venkateswaran, V., Whelan, R.L., Yang, 
X., Felsher, D.W., 2015. Cancer prevention and therapy through the modulation of the tumor 
microenvironment. Seminars in cancer biology. 
Cevc, G., 1996. Transfersomes, liposomes and other lipid suspensions on the skin: permeation 
enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 13, 
257-388. 
Cevc, G., Blume, G., 2001. New, highly efficient formulation of diclofenac for the topical, transdermal 
administration in ultradeformable drug carriers, Transfersomes. Biochimica et Biophysica Acta (BBA) - 
Biomembranes 1514, 191-205. 
Cevc, G., Gebauer, D., Stieber, J., Schätzlein, A., Blume, G., 1998. Ultraflexible vesicles, Transfersomes, 
have an extremely low pore penetration resistance and transport therapeutic amounts of insulin 
across the intact mammalian skin. Biochimica et Biophysica Acta (BBA) - Biomembranes 1368, 201-
215. 
Cevc, G., Schätzlein, A., Blume, G., 1995. Transdermal drug carriers: Basic properties, optimization and 
transfer efficiency in the case of epicutaneously applied peptides. J Control Release 36, 3-16. 
Cevc, G., Vierl, U., 2010. Nanotechnology and the transdermal route: A state of the art review and 
critical appraisal. J Control Release 141, 277-299. 
Chakrabarty, A., Geisse, J.K., 2004. Medical therapies for non-melanoma skin cancer. Clin Dermatol 22, 
183-188. 
Chapman, D., 1975. Phase transitions and fluidity characteristics of lipids and cell membranes. 
Quarterly reviews of biophysics 8, 185-235. 
Chaudhary, H., Rohilla, A., Rathee, P., Kumar, V., 2013. Optimization and formulation design of 
carbopol loaded Piroxicam gel using novel penetration enhancers. International journal of biological 
macromolecules 55, 246-253. 
Chen, C., Shen, G., Hebbar, V., Hu, R., Owuor, E.D., Kong, A.N., 2003. Epigallocatechin-3-gallate-induced 
stress signals in HT-29 human colon adenocarcinoma cells. Carcinogenesis 24, 1369-1378. 
263 
 
Chen, Y., Wu, Q., Zhang, Z., Yuan, L., Liu, X., Zhou, L., 2012. Preparation of curcumin-loaded liposomes 
and evaluation of their skin permeation and pharmacodynamics. Molecules 17, 5972-5987. 
Chen, Z.P., Schell, J.B., Ho, C.-T., Chen, K.Y., 1998. Green tea epigallocatechin gallate shows a 
pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer 
letters 129, 173-179. 
Chitwood, K., Etzkorn, J., Cohen, G., 2013. Topical and intralesional treatment of nonmelanoma skin 
cancer: efficacy and cost comparisons. Dermatol Surg 39, 1306-1316. 
Cho, H.H., Han, D.-W., Matsumura, K., Tsutsumi, S., Hyon, S.-H., 2008. The behavior of vascular smooth 
muscle cells and platelets onto epigallocatechin gallate-releasing poly(l-lactide-co-ε-caprolactone) as 
stent-coating materials. Biomaterials 29, 884-893. 
Chtourou, Y., Fetoui, H., Jemai, R., Slima, A.B., Makni, M., Gdoura, R., 2015. Naringenin reduces 
cholesterol-induced hepatic inflammation in rats by modulating matrix metalloproteinases-2, 9 via 
inhibition of nuclear factor κB pathway. Eur J Pharmacol 746, 96-105. 
Chung, H., Caffrey, M., 1994. The curvature elastic-energy function of the lipid-water cubic mesophase. 
Nature 368, 224-226. 
Coates, A., Abraham, S., Kaye, S.B., Sowerbutts, T., Frewin, C., Fox, R.M., Tattersall, M.H., 1983. On the 
receiving end--patient perception of the side-effects of cancer chemotherapy. European journal of 
cancer & clinical oncology 19, 203-208. 
Cockcroft, M., Latham, D., 1968. Ductility and the workability of metals. J Inst Metals 96, 33-39. 
Conklin, K.A., 2000. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic 
effectiveness and development of side effects. Nutrition and cancer 37, 1-18. 
Cordero, J.A., Alarcon, L., Escribano, E., Obach, R., Domenech, J., 1997. A comparative study of the 
transdermal penetration of a series of nonsteroidal antiinflammatory drugs. J Pharm Sci 86, 503-508. 
Cornwell, P.A., Barry, B.W., Bouwstra, J.A., Gooris, G.S., 1996. Modes of action of terpene penetration 
enhancers in human skin; Differential scanning calorimetry, small-angle X-ray diffraction and enhancer 
uptake studies. Int J Pharmaceut 127, 9-26. 
Crommelin, D.J., 1984. Influence of lipid composition and ionic strength on the physical stability of 
liposomes. J Pharm Sci 73, 1559-1563. 
Cui, J., Li, C., Deng, Y., Wang, Y., Wang, W., 2006. Freeze-drying of liposomes using tertiary butyl 
alcohol/water cosolvent systems. Int J Pharm 312, 131-136. 
Cullis, P.R., Hope, M.J., Tilcock, C.P., 1986. Lipid polymorphism and the roles of lipids in membranes. 
Chem Phys Lipids 40, 127-144. 
Dash, S., Murthy, P.N., Nath, L., Chowdhury, P., 2010. Kinetic modeling on drug release from controlled 
drug delivery systems. Acta poloniae pharmaceutica 67, 217-223. 
Dayan, N., Touitou, E., 2000. Carriers for skin delivery of trihexyphenidyl HCl: ethosomes vs. liposomes. 
Biomaterials 21, 1879-1885. 
de Visser, K.E., Eichten, A., Coussens, L.M., 2006. Paradoxical roles of the immune system during cancer 
development. Nature reviews. Cancer 6, 24-37. 
Demel, R.A., Geurts van Kessel, W.S.M., van Deenen, L.L.M., 1972. The properties of polyunsaturated 
lecithins in monolayers and liposomes and the interactions of these lecithins with cholesterol. 
Biochimica et Biophysica Acta (BBA) - Biomembranes 266, 26-40. 
Di Marzio, L., Marianecci, C., Petrone, M., Rinaldi, F., Carafa, M., 2011. Novel pH-sensitive non-ionic 
surfactant vesicles: comparison between Tween 21 and Tween 20. Colloids and Surfaces B: 
Biointerfaces 82, 18-24. 
Diepgen, T.L., Mahler, V., 2002. The epidemiology of skin cancer. The British journal of dermatology 
146 Suppl 61, 1-6. 
Dillaha, C.J., Jansen, G.T., Honeycutt, W.M., Bradford, A.C., 1963. Selective Cytotoxic Effect of Topical 
5-Fluorouracil. Archives of dermatology 88, 247-256. 
Donaldson, M.R., Coldiron, B.M., 2011. No end in sight: the skin cancer epidemic continues, Seminars 
in cutaneous medicine and surgery. Frontline Medical Communications, pp. 3-5. 
Doolittle, G.M., Chang, T.Y., 1982. Solubilization, partial purification, and reconstitution in 
phosphatidylcholine-cholesterol liposomes of acyl-CoA: cholesterol acyltransferase. Biochemistry 21, 
674-679. 
264 
 
Dragicevic-Curic, N., Fahr, A., 2012. Liposomes in topical photodynamic therapy. Expert Opin Drug Del 
9, 1015-1032. 
Dreher, F., Fouchard, F., Patouillet, C., Andrian, M., Simonnet, J.T., Benech-Kieffer, F., 2002. 
Comparison of cutaneous bioavailability of cosmetic preparations containing caffeine or alpha-
tocopherol applied on human skin models or human skin ex vivo at finite doses. Skin Pharmacol Appl 
15, 40-58. 
Drobits, B., Holcmann, M., Amberg, N., Swiecki, M., Grundtner, R., Hammer, M., Colonna, M., Sibilia, 
M., 2012. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into 
tumor-killing effector cells. The Journal of clinical investigation 122, 575. 
Du, G., Jin, L., Han, X., Song, Z., Zhang, H., Liang, W., 2009. Naringenin: a potential immunomodulator 
for inhibiting lung fibrosis and metastasis. Cancer research 69, 3205-3212. 
du Plessis, J., Weiner, N., Müller, D., 1994a. The influence of in vivo treatment of skin with liposomes 
on the topical absorption of a hydrophilic and a hydrophobic drug in vitro. Int J Pharmaceut 103, R1-
R5. 
du Plessis, J., Weiner, N., Müller, D.G., 1994b. The influence of in vivo treatment of skin with liposomes 
on the topical absorption of a hydrophilic and a hydrophobic drug in vitro. Int J Pharmaceut 103, R1-
R5. 
Dubey, V., Mishra, D., Asthana, A., Jain, N.K., 2006. Transdermal delivery of a pineal hormone: 
melatonin via elastic liposomes. Biomaterials 27, 3491-3496. 
Dummer, R., Becker, J.C., Boser, B., Hartmann, A.A., Burg, G., 1992. Successful therapy of metastatic 
eccrine poroma using perilesional interferon alfa and interleukin 2. Archives of dermatology 128, 1127-
1128. 
Egbaria, K., Weiner, N., 1990. Liposomes as a topical drug delivery system. Adv Drug Deliver Rev 5, 287-
300. 
Ehrenstrom Reiz, G.M., Reiz, S.L., 1982. EMLA--a eutectic mixture of local anaesthetics for topical 
anaesthesia. Acta Anaesthesiol Scand 26, 596-598. 
El-Kattan, A., Asbill, C.S., Haidar, S., 2000. Transdermal testing: practical aspects and methods. 
Pharmaceutical science & technology today 3, 426-430. 
El Maghraby, G., Williams, A.C., Barry, B., 2004. Interactions of surfactants (edge activators) and skin 
penetration enhancers with liposomes. Int J Pharmaceut 276, 143-161. 
El Maghraby, G.M., Barry, B.W., Williams, A.C., 2008. Liposomes and skin: From drug delivery to model 
membranes. Eur J Pharm Sci 34, 203-222. 
El Maghraby, G.M., Williams, A.C., Barry, B.W., 1999. Skin delivery of oestradiol from deformable and 
traditional liposomes: mechanistic studies. J Pharm Pharmacol 51, 1123-1134. 
El Maghraby, G.M.M., Williams, A.C., Barry, B.W., 2000. Oestradiol skin delivery from ultradeformable 
liposomes: refinement of surfactant concentration. Int J Pharmaceut 196, 63-74. 
El Zaafarany, G.M., Awad, G.A., Holayel, S.M., Mortada, N.D., 2010. Role of edge activators and surface 
charge in developing ultradeformable vesicles with enhanced skin delivery. Int J Pharm 397, 164-172. 
Essa, E.A., Bonner, M.C., Barry, B.W., 2002. Iontophoretic estradiol skin delivery and tritium exchange 
in ultradeformable liposomes. Int J Pharm 240, 55-66. 
Fahy, E., Cotter, D., Sud, M., Subramaniam, S., 2011. Lipid classification, structures and tools. 
Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 1811, 637-647. 
Fang, J.Y., Liu, P.F., Huang, C.M., 2008. Decreasing systemic toxicity via transdermal delivery of 
anticancer drugs. Current drug metabolism 9, 592-597. 
Felicio, L., Ferreira, J., Kurachi, C., Bentley, M., Tedesco, A., Bagnato, V., 2009. Long-term follow-up of 
topical 5-aminolaevulinic acid photodynamic therapy diode laser single session for non-melanoma skin 
cancer. Photodiagnosis and photodynamic therapy 6, 207-213. 
Feng, L., Yang, X., Shi, X., Tan, X., Peng, R., Wang, J., Liu, Z., 2013. Polyethylene Glycol and 
Polyethylenimine Dual-Functionalized Nano-Graphene Oxide for Photothermally Enhanced Gene 
Delivery. Small 9, 1989-1997. 
Ferderber, K., Hook, S., Rades, T., 2009. Phosphatidyl choline-based colloidal systems for dermal and 
transdermal drug delivery. J Liposome Res 19, 267-277. 
Ferry, J.D., 1980. Viscoelastic properties of polymers. John Wiley & Sons. 
265 
 
Foldvari, M., 1996. Effect of vehicle on topical liposomal drug delivery: petrolatum bases. J 
Microencapsul 13, 589-600. 
Forbes, C.J., Lowry, D., Geer, L., Veazey, R.S., Shattock, R.J., Klasse, P.J., Mitchnick, M., Goldman, L., 
Doyle, L.A., Muldoon, B.C., 2011a. Non-aqueous silicone elastomer gels as a vaginal microbicide 
delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release 156, 161-169. 
Forbes, C.J., Lowry, D., Geer, L., Veazey, R.S., Shattock, R.J., Klasse, P.J., Mitchnick, M., Goldman, L., 
Doyle, L.A., Muldoon, B.C., Woolfson, A.D., Moore, J.P., Malcolm, R.K., 2011b. Non-aqueous silicone 
elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J 
Control Release 156, 161-169. 
Ford, J.L., Rubinstein, M.H., McCaul, F., Hogan, J.E., Edgar, P.J., 1987. Importance of drug type, tablet 
shape and added diluents on drug release kinetics from hydroxypropylmethylcellulose matrix tablets. 
Int J Pharmaceut 40, 223-234. 
Fresta, M., Puglisi, G., 1996. Application of liposomes as potential cutaneous drug delivery systems. In 
vitro and in vivo investigation with radioactively labelled vesicles. J Drug Target 4, 95-101. 
Friedlos, F., Quinn, J., Knox, R.J., Roberts, J.J., 1992. The properties of total adducts and interstrand 
crosslinks in the DNA of cells treated with CB 1954: Exceptional frequency and stability of the crosslink. 
Biochemical pharmacology 43, 1249-1254. 
Gaikwad, V.L., Yadav, V.D., Dhavale, R.P., Choudhari, P.B., Jadhav, S.D., 2012. Effect of carbopol 934 
and 940 on fluconazole release from topical gel formulation: a factorial approach. Current Pharma 
Research 2, 487-493. 
Ganesan, M.G., Weiner, N.D., Flynn, G.L., Ho, N., 1984. Influence of liposomal drug entrapment on 
percutaneous absorption. Int J Pharmaceut 20, 139-154. 
Garrison, M.D., Doh, L.M., Potts, R.O., Abraham, W., 1994. Effect of oleic acid on human epidermis: 
Fluorescence spectroscopic investigation. J Control Release 31, 263-269. 
Gaspari, A.A., Sauder, D.N., 2003. Immunotherapy of basal cell carcinoma: evolving approaches. 
Dermatol Surg 29, 1027-1034. 
Gay, C., Murphy, T., Hadgraft, J., Kellaway, I., Evans, J., Rowlands, C., 1989. An electron spin resonance 
study of skin penetration enhancers. Int J Pharmaceut 49, 39-45. 
Ghosal, K., Nanda, A., 2013. Development of diclofenac potassium gel from hydrophobically modified 
HPMC. Iranian Polymer Journal 22, 457-464. 
Giles, G.G., Marks, R., Foley, P., 1988. Incidence of non-melanocytic skin cancer treated in Australia. Br 
Med J (Clin Res Ed) 296, 13-17. 
Giri, A., Bhowmick, M., Pal, S., Bandyopadhyay, A., 2011. Polymer hydrogel from carboxymethyl guar 
gum and carbon nanotube for sustained trans-dermal release of diclofenac sodium. International 
journal of biological macromolecules 49, 885-893. 
Glass, A.G., Hoover, R.N., 1989. The emerging epidemic of melanoma and squamous cell skin cancer. 
Jama 262, 2097-2100. 
Glavas-Dodov, M., Goracinova, K., Mladenovska, K., Fredro-Kumbaradzi, E., 2002. Release profile of 
lidocaine HCl from topical liposomal gel formulation. Int J Pharm 242, 381-384. 
Gloster, H.M., Jr., Brodland, D.G., 1996. The epidemiology of skin cancer. Dermatol Surg 22, 217-226. 
Goci, E., Haloci, E., Xhulaj, S., Malaj, L., 2014. Formulation and in vitro evaluation of diclofenac sodium 
gel. Int J Pharm Pharm Sci 6, 259-261. 
Godin, B., Touitou, E., 2007. Transdermal skin delivery: predictions for humans from in vivo, ex vivo 
and animal models. Adv Drug Deliver Rev 59, 1152-1161. 
Goindi, S., Kumar, G., Kumar, N., Kaur, A., 2013. Development of novel elastic vesicle-based topical 
formulation of cetirizine dihydrochloride for treatment of atopic dermatitis. Aaps Pharmscitech 14, 
1284-1293. 
Golden, G.M., Guzek, D.B., Harris, R.R., McKie, J.E., Potts, R.O., 1986. Lipid thermotropic transitions in 
human stratum corneum. J Invest Dermatol 86, 255-259. 
Gompper, G., Kroll, D.M., 1995. Driven transport of fluid vesicles through narrow pores. Physical 
review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics 52, 4198-4208. 
Good, L.M., Miller, M.D., High, W.A., 2011. Intralesional agents in the management of cutaneous 
malignancy: a review. Journal of the American Academy of Dermatology 64, 413-422. 
266 
 
Green, A., 1992. Changing patterns in incidence of non-melanoma skin cancer. Epithelial cell biology 1, 
47-51. 
Gregoriadis, G., 1973. Drug entrapment in liposomes. Febs Lett 36, 292-296. 
Gregoriadis, G., Davis, C., 1979. Stability of liposomes in vivo and in vitro is promoted by their 
cholesterol content and the presence of blood cells. Biochemical and biophysical research 
communications 89, 1287-1293. 
Groenendaal, W., von Basum, G., Schmidt, K.A., Hilbers, P.A., van Riel, N.A., 2010. Quantifying the 
composition of human skin for glucose sensor development. Journal of diabetes science and 
technology 4, 1032-1040. 
Grossman, D., Mcniff, J.M., Li, F., Altieri, D.C., 1999. Expression of the apoptosis inhibitor, survivin, in 
nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Laboratory investigation; a 
journal of technical methods and pathology 79, 1121-1126. 
Guideline, I.H.T., 2005. Validation of analytical procedures: text and methodology. Q2 (R1) 1. 
Gupta, P., Vermani, K., Garg, S., 2002. Hydrogels: from controlled release to pH-responsive drug 
delivery. Drug discovery today 7, 569-579. 
Gupta, S., Hastak, K., Afaq, F., Ahmad, N., Mukhtar, H., 2004. Essential role of caspases in 
epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. 
Oncogene 23, 2507-2522. 
Gusterson, B., Cui, W., Iwobi, M., Crompton, M., Harold, G., Hobbs, S., Kamalati, T., Knox, R., Neil, C., 
Yull, F., 1997. Selective cell ablation in the mammary gland of transgenic mice. Endocrine-Related 
Cancer 4, 67-74. 
Guy, R.H., Hadgraft, J., 1985. Transdermal drug delivery: a simplified pharmacokinetic approach. Int J 
Pharmaceut 24, 267-274. 
Hadgraft, J., 1999. Passive enhancement strategies in topical and transdermal drug delivery. Int J 
Pharmaceut 184, 1-6. 
Hadgraft, J., Valenta, C., 2000. pH, pKa and dermal delivery. Int J Pharmaceut 200, 243-247. 
Hascicek, C., Bediz-Ölçer, A., Gönül, N., 2009. Preparation and evaluation of different gel formulations 
for transdermal delivery of meloxicam. Turk J. Pharm. Sci 6, 177-186. 
Herting, G., Jiang, T., Sjostedt, C., Odnevall Wallinder, I., 2014. Release of Si from silicon, a ferrosilicon 
(FeSi) alloy and a synthetic silicate mineral in simulated biological media. PloS one 9, e107668. 
Heurtault, B., Saulnier, P., Pech, B., Proust, J.-E., Benoit, J.-P., 2003. Physico-chemical stability of 
colloidal lipid particles. Biomaterials 24, 4283-4300. 
Higuchi, T., 1961. Rate of release of medicaments from ointment bases containing drugs in suspension. 
J Pharm Sci 50, 874-875. 
Higuchi, T., 1963a. Mechanism of sustained-action medication. Theoretical analysis of rate of release 
of solid drugs dispersed in solid matrices. J Pharm Sci 52, 1145-1149. 
Higuchi, T., 1963b. Mechanism of sustained‐action medication. Theoretical analysis of rate of release 
of solid drugs dispersed in solid matrices. J Pharm Sci 52, 1145-1149. 
Hiruta, Y., Hattori, Y., Kawano, K., Obata, Y., Maitani, Y., 2006. Novel ultra-deformable vesicles 
entrapped with bleomycin and enhanced to penetrate rat skin. J Control Release 113, 146-154. 
Holme, S.A., Malinovszky, K., Roberts, D.L., 2000. Changing trends in non-melanoma skin cancer in 
South Wales, 1988-98. The British journal of dermatology 143, 1224-1229. 
Honeywell-Nguyen, P.L., Bouwstra, J.A., 2003. The in vitro transport of pergolide from surfactant-
based elastic vesicles through human skin: a suggested mechanism of action. J Control Release 86, 145-
156. 
Honeywell-Nguyen, P.L., de Graaff, A.M., Groenink, H.W., Bouwstra, J.A., 2002. The in vivo and in vitro 
interactions of elastic and rigid vesicles with human skin. Biochimica et Biophysica Acta (BBA)-General 
Subjects 1573, 130-140. 
Hsiu, S.L., Huang, T.Y., Hou, Y.C., Chin, D.H., Chao, P.D., 2002. Comparison of metabolic 
pharmacokinetics of naringin and naringenin in rabbits. Life Sci 70, 1481-1489. 
Huang, Y.C., Yang, C.H., Chiou, Y.L., 2011. Citrus flavanone naringenin enhances melanogenesis 
through the activation of Wnt/beta-catenin signalling in mouse melanoma cells. Phytomedicine : 
international journal of phytotherapy and phytopharmacology 18, 1244-1249. 
267 
 
Hwang, J.-T., Ha, J., Park, I.-J., Lee, S.-K., Baik, H.W., Kim, Y.M., Park, O.J., 2007. Apoptotic effect of 
EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer letters 247, 115-121. 
Istenic, K., Cerc Korosec, R., Poklar Ulrih, N., 2016. Encapsulation of (-)-epigallocatechin gallate into 
liposomes and into alginate or chitosan microparticles reinforced with liposomes. Journal of the 
science of food and agriculture 96, 4623-4632. 
Ita, K.B., Du Preez, J., Lane, M.E., Hadgraft, J., du Plessis, J., 2007. Dermal delivery of selected 
hydrophilic drugs from elastic liposomes: effect of phospholipid formulation and surfactants. J Pharm 
Pharmacol 59, 1215-1222. 
Jaeger, A., Walti, M., Neftel, K., 1988. Side effects of flavonoids in medical practice. Progress in clinical 
and biological research 280, 379-394. 
Jain, S.K., Jain, R.K., Chourasia, M.K., Jain, A.K., Chalasani, K.B., Soni, V., Jain, A., 2005. Design and 
development of multivesicular liposomal depot delivery system for controlled systemic delivery of 
acyclovir sodium. Aaps Pharmscitech 6, E35-E41. 
Jiang, A.J., Jiang, G., Li, L.T., Zheng, J.N., 2015. Curcumin induces apoptosis through mitochondrial 
pathway and caspases activation in human melanoma cells. Molecular biology reports 42, 267-275. 
Jousma, H., Talsma, H., Spies, F., Joosten, J.G.H., Junginger, H.E., Crommelin, D.J.A., 1987. 
Characterization of liposomes. The influence of extrusion of multilamellar vesicles through 
polycarbonate membranes on particle size, particle size distribution and number of bilayers. Int J 
Pharmaceut 35, 263-274. 
Kajihara, M., Sugie, T., Hojo, T., Maeda, H., Sano, A., Fujioka, K., Sugawara, S., Urabe, Y., 2001. 
Development of a new drug delivery system for protein drugs using silicone (II). J Control Release 73, 
279-291. 
Kakkar, S., Pal Kaur, I., 2013. A novel nanovesicular carrier system to deliver drug topically. Pharm Dev 
Technol 18, 673-685. 
Kalluri, R., Zeisberg, M., 2006. Fibroblasts in cancer. Nature Reviews Cancer 6, 392-401. 
Kang, S.N., Hong, S.-S., Kim, S.-Y., Oh, H., Lee, M.-K., Lim, S.-J., 2013. Enhancement of liposomal stability 
and cellular drug uptake by incorporating tributyrin into celecoxib-loaded liposomes. Asian Journal of 
Pharmaceutical Sciences 8, 128-133. 
Kaplan, B., Moy, R.L., 2000. Effect of perilesional injections of PEG-interleukin-2 on basal cell 
carcinoma. Dermatol Surg 26, 1037-1040. 
Katahira, N., Murakami, T., Kugai, S., Yata, N., Takano, M., 1999. Enhancement of topical delivery of a 
lipophilic drug from charged multilamellar liposomes. J Drug Target 6, 405-414. 
Katalinic, A., Kunze, U., Schäfer, T., 2003. Epidemiology of cutaneous melanoma and non‐melanoma 
skin cancer in Schleswig‐Holstein, Germany: incidence, clinical subtypes, tumour stages and 
localization (epidemiology of skin cancer). Brit J Dermatol 149, 1200-1206. 
Katiyar, S.K., 2011. Green tea prevents non-melanoma skin cancer by enhancing DNA repair. Arch 
Biochem Biophys 508, 152-158. 
Keith, A.D., 1983. Polymer matrix considerations for transdermal devices. Drug Dev Ind Pharm 9, 605-
625. 
Kerkar, S.P., Restifo, N.P., 2012. Cellular constituents of immune escape within the tumor 
microenvironment. Cancer research 72, 3125-3130. 
Khan, A.W., Kotta, S., Ansari, S.H., Sharma, R.K., Ali, J., 2015. Enhanced dissolution and bioavailability 
of grapefruit flavonoid Naringenin by solid dispersion utilizing fourth generation carrier. Drug Dev Ind 
Pharm 41, 772-779. 
Kirjavainen, M., Urtti, A., Jääskeläinen, I., Marjukka Suhonen, T., Paronen, P., Valjakka-Koskela, R., 
Kiesvaara, J., Mönkkönen, J., 1996. Interaction of liposomes with human skin in vitro — The influence 
of lipid composition and structure. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 
1304, 179-189. 
Knox, R., 2012. MTL-004 - A contact anti-tumour agent for skin cancers. 
Knox, R.J., Friedlos, F., Biggs, P.J., Flitter, W.D., Gaskell, M., Goddard, P., Davies, L., Jarman, M., 1993. 
Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA 
crosslinking agent derived from CB1954. Biochemical pharmacology 46, 797-803. 
Knox, R.J., Friedlos, F., Jarman, M., Roberts, J.J., 1988. A new cytotoxic, DNA interstrand crosslinking 
agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-
268 
 
dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochemical 
pharmacology 37, 4661-4669. 
Knox, R.J., Friedlos, F., Lydall, D.A., Roberts, J.J., 1986. Mechanism of cytotoxicity of anticancer 
platinum drugs: evidence that cis-diamminedichloroplatinum (II) and cis-diammine-(1, 1-
cyclobutanedicarboxylato) platinum (II) differ only in the kinetics of their interaction with DNA. Cancer 
research 46, 1972-1979. 
Knox, R.J., Friedlos, F., Marchbank, T., Roberts, J.J., 1991. Bioactivation of CB 1954: reaction of the 
active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand 
crosslinking species. Biochemical pharmacology 42, 1691-1697. 
Ko, C.B., Walton, S., Keczkes, K., Bury, H.P., Nicholson, C., 1994. The emerging epidemic of skin cancer. 
The British journal of dermatology 130, 269-272. 
Kootstra, A., 1994. Protection from UV-B-induced DNA damage by flavonoids. Plant Molecular Biology 
26, 771-774. 
Korsmeyer, R.W., Gurny, R., Doelker, E., Buri, P., Peppas, N.A., 1983. Mechanisms of solute release 
from porous hydrophilic polymers. Int J Pharmaceut 15, 25-35. 
Küchler, S., Radowski, M.R., Blaschke, T., Dathe, M., Plendl, J., Haag, R., Schäfer-Korting, M., Kramer, 
K.D., 2009. Nanoparticles for skin penetration enhancement–a comparison of a dendritic core-
multishell-nanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm 71, 243-250. 
Kuflik, E.G., 1994. Cryosurgery updated. Journal of the American Academy of Dermatology 31, 925-
944. 
Kumar, M., Ahuja, M., Sharma, S.K., 2008. Hepatoprotective study of curcumin-soya lecithin complex. 
Scientia pharmaceutica 76, 761. 
Kunnumakkara, A.B., Anand, P., Aggarwal, B.B., 2008. Curcumin inhibits proliferation, invasion, 
angiogenesis and metastasis of different cancers through interaction with multiple cell signaling 
proteins. Cancer letters 269, 199-225. 
Kuntsche, J., Bunjes, H., Fahr, A., Pappinen, S., Ronkko, S., Suhonen, M., Urtti, A., 2008. Interaction of 
lipid nanoparticles with human epidermis and an organotypic cell culture model. Int J Pharm 354, 180-
195. 
Laouini, A., Jaafar-Maalej, C., Limayem-Blouza, I., Sfar, S., Charcosset, C., Fessi, H., 2012. Preparation, 
characterization and applications of liposomes: state of the art. Journal of colloid Science and 
Biotechnology 1, 147-168. 
Lapinski, M.M., Castro-Forero, A., Greiner, A.J., Ofoli, R.Y., Blanchard, G.J., 2007. Comparison of 
liposomes formed by sonication and extrusion: rotational and translational diffusion of an embedded 
chromophore. Langmuir 23, 11677-11683. 
Lasic, D.D., Barenholz, Y., 1996. Handbook of nonmedical applications of liposomes: Theory and basic 
sciences. CRC Press. 
Lau, K.G., Hattori, Y., Chopra, S., O’Toole, E.A., Storey, A., Nagai, T., Maitani, Y., 2005. Ultra-deformable 
liposomes containing bleomycin: In vitro stability and toxicity on human cutaneous keratinocyte cell 
lines. Int J Pharmaceut 300, 4-12. 
Lee, A., 1975. Fluoroscence studies of chloropyll α incorporated into lipid mixtures, and the 
interpretation of “phase” diagrams. Biochimica et Biophysica Acta (BBA)-Biomembranes 413, 11-23. 
Lee, E.H., Kim, A., Oh, Y.-K., Kim, C.-K., 2005. Effect of edge activators on the formation and transfection 
efficiency of ultradeformable liposomes. Biomaterials 26, 205-210. 
Lee, M.-H., Yoon, S., Moon, J.-O., 2004. The flavonoid naringenin inhibits dimethylnitrosamine-induced 
liver damage in rats. Biological and Pharmaceutical Bulletin 27, 72-76. 
Lee, P.I., 1985. Kinetics of drug release from hydrogel matrices. J Control Release 2, 277-288. 
Lee, R.W., Shenoy, D.B., Sheel, R., 2010. Micellar nanoparticles: applications for topical and passive 
transdermal drug delivery. Handbook of Non-Invasive Drug Delivery Systems. Burlington, MA: Elsevier 
Inc, 37-58. 
Lentz, B.R., Carpenter, T.J., Alford, D.R., 1987. Spontaneous fusion of phosphatidylcholine small 
unilamellar vesicles in the fluid phase. Biochemistry 26, 5389-5397. 
Levy, M.Y., Benita, S., Baszkin, A., 1991. Interactions of a non-ionic surfactant with mixed 
phospholipid—oleic acid monolayers. Studies under dynamic conditions. Colloid Surface 59, 225-241. 
269 
 
Li, Y., Yang, D.-J., Chen, S.-L., Chen, S.-B., Chan, A.S.-C., 2008. Comparative physicochemical 
characterization of phospholipids complex of puerarin formulated by conventional and supercritical 
methods. Pharm Res-Dord 25, 563-577. 
Lichtenberg, D., Barenholz, Y., 1988. Liposomes: preparation, characterization, and preservation. 
Methods of biochemical analysis 33, 337-462. 
Lindley, C., McCune, J.S., Thomason, T.E., Lauder, D., Sauls, A., Adkins, S., Sawyer, W.T., 1999. 
Perception of Chemotherapy Side Effects Cancer versus Noncancer Patients. Cancer Practice 7, 59-65. 
Liu, B., Krieger, M., 2002. Highly purified scavenger receptor class B, type I reconstituted into 
phosphatidylcholine/cholesterol liposomes mediates high affinity high density lipoprotein binding and 
selective lipid uptake. Journal of Biological Chemistry 277, 34125-34135. 
Liu, Y., Steiniger, S.C., Kim, Y., Kaufmann, G.F., Felding-Habermann, B., Janda, K.D., 2007. Mechanistic 
studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery. Molecular pharmaceutics 4, 
435-447. 
Lomas, A., Leonardi-Bee, J., Bath-Hextall, F., 2012. A systematic review of worldwide incidence of 
nonmelanoma skin cancer. The British journal of dermatology 166, 1069-1080. 
Lorenz, W., Schmal, A., Schult, H., Lang, S., Ohmann, C., Weber, D., Kapp, B., Luben, L., Doenicke, A., 
1982. Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: 
analysis of various components in cremophor El and development of a compound with reduced 
toxicity. Agents and actions 12, 64-80. 
MacLennan, R., Green, A.C., McLeod, G.R., Martin, N.G., 1992. Increasing incidence of cutaneous 
melanoma in Queensland, Australia. Journal of the National Cancer Institute 84, 1427-1432. 
Madan, V., Lear, J.T., Szeimies, R.-M., Non-melanoma skin cancer. The Lancet 375, 673-685. 
Mahalingam, A., Simmons, A.P., Ugaonkar, S.R., Watson, K.M., Dezzutti, C.S., Rohan, L.C., Buckheit, 
R.W., Kiser, P.F., 2011. Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with 
a dual mechanism of action against HIV-1. Antimicrob Agents Ch 55, 1650-1660. 
Maiti, K., Mukherjee, K., Gantait, A., Saha, B.P., Mukherjee, P.K., 2007. Curcumin–phospholipid 
complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharmaceut 330, 
155-163. 
Marcil, I., Stern, R.S., 2000. Risk of developing a subsequent nonmelanoma skin cancer in patients with 
a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Archives of 
dermatology 136, 1524-1530. 
Marks, R., 1996. Squamous cell carcinoma. The Lancet 347, 735-738. 
Marks, R., Gebauer, K., Shumack, S., Amies, M., Bryden, J., Fox, T.L., Owens, M.L., Group, T.A.M.T., 
2001. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 
6-week dose-response trial. Journal of the American Academy of Dermatology 44, 807-813. 
Martin, F.J., MacDonald, R.C., 1976. Lipid vesicle-cell interactions. I. Hemagglutination and hemolysis. 
The Journal of cell biology 70, 494-505. 
Masaro, L., Zhu, X.X., 1999. Physical models of diffusion for polymer solutions, gels and solids. Progress 
in Polymer Science 24, 731-775. 
Mashaghi, A., Partovi-Azar, P., Jadidi, T., Nafari, N., Maass, P., Tabar, M.R., Bonn, M., Bakker, H.J., 2012. 
Hydration strongly affects the molecular and electronic structure of membrane phospholipids. The 
Journal of chemical physics 136, 114709. 
Mashak, A., Rahimi, A., 2009. Silicone polymers in controlled drug delivery systems: a review. Iranian 
Polymer Journal 18, 279-295. 
McGraw-HillCompanies, 2003. Skin Structure and Function. 
McLoughlin, P., Roengvoraphoj, M., Gissel, C., Hescheler, J., Certa, U., Sachinidis, A., 2004. 
Transcriptional responses to epigallocatechin-3 gallate in HT 29 colon carcinoma spheroids. Genes to 
cells : devoted to molecular & cellular mechanisms 9, 661-669. 
Melchior, D.L., Steim, J.M., 1976. Thermotropic transitions in biomembranes. Annual review of 
biophysics and bioengineering 5, 205-238. 
Meyer, T., Nindl, I., Schmook, T., Ulrich, C., Sterry, W., Stockfleth, E., 2003. Induction of apoptosis by 
Toll‐like receptor‐7 agonist in tissue cultures. Brit J Dermatol 149, 9-13. 
Middleton Jr, E., 1998. Effect of plant flavonoids on immune and inflammatory cell function, Flavonoids 
in the Living System. Springer, pp. 175-182. 
270 
 
Mignet, N., Seguin, J., Chabot, G.G., 2013. Bioavailability of polyphenol liposomes: a challenge ahead. 
Pharmaceutics 5, 457-471. 
Mihara, M., Nakayama, H., Nakamura, K., Morimura, T., Hagari, Y., Shimao, S., 1990. Histologic changes 
in superficial basal cell epithelioma and Bowen's disease by intralesional injection of recombinant 
interleukin 2: recombinant interleukin 2 may induce redifferentiation of malignant tumor cells in vivo. 
Archives of dermatology 126, 1107. 
Modi, S., Anderson, B.D., 2013. Determination of drug release kinetics from nanoparticles: overcoming 
pitfalls of the dynamic dialysis method. Molecular pharmaceutics 10, 3076-3089. 
Mogensen, M., Joergensen, T.M., NÜRnberg, B.M., Morsy, H.A., Thomsen, J.B., Thrane, L., Jemec, 
G.B.E., 2009. Assessment of Optical Coherence Tomography Imaging in the Diagnosis of Non-
Melanoma Skin Cancer and Benign Lesions Versus Normal Skin: Observer-Blinded Evaluation by 
Dermatologists and Pathologists. Dermatol Surg 35, 965-972. 
Mohammed, A.R., Weston, N., Coombes, A.G., Fitzgerald, M., Perrie, Y., 2004. Liposome formulation 
of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability. Int J Pharm 
285, 23-34. 
Mourtas, S., Fotopoulou, S., Duraj, S., Sfika, V., Tsakiroglou, C., Antimisiaris, S.G., 2007. Liposomal drugs 
dispersed in hydrogels. Effect of liposome, drug and gel properties on drug release kinetics. Colloids 
and surfaces. B, Biointerfaces 55, 212-221. 
Mukhtar, H., Ahmad, N., 2000. Tea polyphenols: prevention of cancer and optimizing health. The 
American journal of clinical nutrition 71, 1698s-1702s. 
Nafee, N.A., Ismail, F.A., Boraie, N.A., Mortada, L.M., 2003. Mucoadhesive buccal patches of 
miconazole nitrate: in vitro/in vivo performance and effect of ageing. Int J Pharmaceut 264, 1-14. 
Nagarajan, R., 2002. Molecular packing parameter and surfactant self-assembly: the neglected role of 
the surfactant tail. Langmuir 18, 31-38. 
Naik, A., Kalia, Y.N., Guy, R.H., 2000. Transdermal drug delivery: overcoming the skin’s barrier function. 
Pharmaceutical science & technology today 3, 318-326. 
Natural-Sourcing, 2017. Material safety data sheet, Polysorbate 20. Natural Sourcing 341 Christian 
Street, Oxford, CT 06478, USA. 
Neville, J.A., Welch, E., Leffell, D.J., 2007. Management of nonmelanoma skin cancer in 2007. Nat Clin 
Prac Oncol 4, 462-469. 
Nguyen, T.H., Ho, D.Q., 2002. Nonmelanoma skin cancer. Current treatment options in oncology 3, 
193-203. 
Nishiyama, N., 2007. Nanomedicine: Nanocarriers shape up for long life. Nat Nano 2, 203-204. 
Oguz Acartürk, T., Edington, H., 2005. Nonmelanoma Skin Cancer. Clinics in plastic surgery 32, 237-248. 
Oh, Y.K., Kim, M.Y., Shin, J.Y., Kim, T.W., Yun, M.O., Yang, S.J., Choi, S.S., Jung, W.W., Kim, J.A., Choi, 
H.G., 2006. Skin permeation of retinol in Tween 20-based deformable liposomes: in-vitro evaluation in 
human skin and keratinocyte models. J Pharm Pharmacol 58, 161-166. 
Pagano, R.E., Weinstein, J.N., 1978. Interactions of liposomes with mammalian cells. Annual review of 
biophysics and bioengineering 7, 435-468. 
Panomsuk, S.P., Hatanaka, T., Aiba, T., Katayama, K., Koizumi, T., 1996. A Study of the Hydrophilic 
Cellulose Matrix : Effect of Drugs on Swelling Properties. Chemical & pharmaceutical bulletin 44, 1039-
1042. 
Paolino, D., Cosco, D., Muzzalupo, R., Trapasso, E., Picci, N., Fresta, M., 2008. Innovative bola-
surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J 
Pharm 353, 233-242. 
Papahadjopoulos, D., Kimelberg, H.K., 1974. Phospholipid vesicles (liposomes) as models for biological 
membranes: their properties and interactions with cholesterol and proteins. Progress in surface 
science 4, 141IN9145-144232. 
Papahajdopoulos, D., 1976. The role of cholesterol as a membrane component: effects on lipid-protein 
interactions. Lipids.(R. Paoletti, G. Porcelatti, and G. Lacini, editors. Raven Press, New York. 1: 187-196. 
Pappinen, S., Hermansson, M., Kuntsche, J., Somerharju, P., Wertz, P., Urtti, A., Suhonen, M., 2008. 
Comparison of rat epidermal keratinocyte organotypic culture (ROC) with intact human skin: lipid 
composition and thermal phase behavior of the stratum corneum. Biochim Biophys Acta 1778, 824-
834. 
271 
 
Park, S.-I., Lee, E.-O., Yang, H.-M., Park, C.W., Kim, J.-D., 2013. Polymer-hybridized liposomes of poly 
(amino acid) derivatives as transepidermal carriers. Colloids and Surfaces B: Biointerfaces 110, 333-
338. 
Patton, D., Sweeney, Y.C., Balkus, J., Rohan, L., Moncla, B., Parniak, M., Hillier, S., 2007. Preclinical 
safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. 
Antimicrob Agents Ch 51, 1608-1615. 
Peng, P.-L., Hsieh, Y.-S., Wang, C.-J., Hsu, J.-L., Chou, F.-P., 2006. Inhibitory effect of berberine on the 
invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and 
matrix metalloproteinase-2. Toxicology and applied pharmacology 214, 8-15. 
Peppas, N.A., 1985. Analysis of Fickian and non-Fickian drug release from polymers. Pharmaceutica 
acta Helvetiae 60, 110-111. 
Peppas, N.A., Sahlin, J.J., 1989. A simple equation for the description of solute release. III. Coupling of 
diffusion and relaxation. Int J Pharmaceut 57, 169-172. 
Phan, C.T., Tso, P., 2001. Intestinal lipid absorption and transport. Frontiers in bioscience : a journal 
and virtual library 6, D299-319. 
Prausnitz, M.R., Langer, R., 2008. Transdermal drug delivery. Nat Biotech 26, 1261-1268. 
Proceedings of the National Academy of Sciences of the United States of America, 2014. Role of lipid 
polymorphism in G protein-membrane interactions: Nonlamellar-prone phospholipids and peripheral 
protein binding to membranes. 
Prow, T.W., Grice, J.E., Lin, L.L., Faye, R., Butler, M., Becker, W., Wurm, E.M., Yoong, C., Robertson, 
T.A., Soyer, H.P., 2011. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliver Rev 
63, 470-491. 
Puri, R., Jain, S., 2012. Ethogel topical formulation for increasing the local bioavailability of 5-
fluorouracil: a mechanistic study. Anti-Cancer Drug 23, 923-934. 
Ranga Rao, K.V., Devi, K.P., Buri, P., 1988. Cellulose Matrices for Zero-Order Release of Soluble Drugs. 
Drug Dev Ind Pharm 14, 2299-2320. 
Ranga Rao, K.V., Padmalatha Devi, K., 1988. Swelling controlled-release systems: recent developments 
and applications. Int J Pharmaceut 48, 1-13. 
Rao, K.V.R., Devi, K.P., Buri, P., 1990. Influence of molecular size and water solubility of the solute on 
its release from swelling and erosion controlled polymeric matrices. J Control Release 12, 133-141. 
Rashidinejad, A., Birch, E.J., Sun-Waterhouse, D., Everett, D.W., 2014. Delivery of green tea catechin 
and epigallocatechin gallate in liposomes incorporated into low-fat hard cheese. Food chemistry 156, 
176-183. 
Ritger, P.L., Peppas, N.A., 1987. A simple equation for description of solute release II. Fickian and 
anomalous release from swellable devices. J Control Release 5, 37-42. 
Rogalski, C., Dummer, R., Burg, G., 1999. Immunomodulators in the treatment of cutaneous 
lymphoma. Journal of the European Academy of Dermatology and Venereology 13, 83-90. 
Romero, E.L., Morilla, M.J., 2013a. Highly deformable and highly fluid vesicles as potential drug delivery 
systems: theoretical and practical considerations. Int J Nanomedicine 8, 3171-3186. 
Romero, E.L., Morilla, M.J., 2013b. Highly deformable and highly fluid vesicles as potential drug delivery 
systems: theoretical and practical considerations. Int J Nanomedicine 8, 86. 
Romero, H.L., Dellaert, N.P., van der Geer, S., Frunt, M., Jansen-Vullers, M.H., Krekels, G.A., 2013. 
Admission and capacity planning for the implementation of one-stop-shop in skin cancer treatment 
using simulation-based optimization. Health care management science 16, 75-86. 
Rubin, A.I., Chen, E.H., Ratner, D., 2005. Basal-cell carcinoma. The New England journal of medicine 
353, 2262-2269. 
S˘ kalko, N.a., C˘ ajkovac, M., Jals˘ enjak, I., 1998. Liposomes with metronidazole for topical use: the 
choice of preparation method and vehicle. J Liposome Res 8, 283-293. 
Sabın, J., Prieto, G., Ruso, J., Hidalgo-Alvarez, R., Sarmiento, F., 2006. Size and stability of liposomes: a 
possible role of hydration and osmotic forces. The European Physical Journal E: Soft Matter and 
Biological Physics 20, 401-408. 
Sackmann, E., 1994. The seventh Datta Lecture. Membrane bending energy concept of vesicle- and 
cell-shapes and shape-transitions. Febs Lett 346, 3-16. 
272 
 
Sai Cheong Wan, L., Wan Sia Heng, P., Fun Wong, L., 1995. Matrix swelling: A simple model describing 
extent of swelling of HPMC matrices. Int J Pharmaceut 116, 159-168. 
Sato, K., Oda, T., Sugibayashi, K., Morimoto, Y., 1988. Estimation of blood concentration of drugs after 
topical application from in vitro skin permeation data. I. Prediction by convolution and confirmation 
by deconvolution. Chemical & pharmaceutical bulletin 36, 2232-2238. 
Sauder, D., 2003. Imiquimod: modes of action. Brit J Dermatol 149, 5-8. 
Schäfer-Korting, M., Mehnert, W., Korting, H.-C., 2007. Lipid nanoparticles for improved topical 
application of drugs for skin diseases. Adv Drug Deliver Rev 59, 427-443. 
Schmuth, M., Blunder, S., Dubrac, S., Gruber, R., Moosbrugger-Martinz, V., 2015. Epidermal barrier in 
hereditary ichthyoses, atopic dermatitis, and psoriasis. Journal der Deutschen Dermatologischen 
Gesellschaft = Journal of the German Society of Dermatology : JDDG 13, 1119-1123. 
Schreier, H., Bouwstra, J., 1994. Liposomes and niosomes as topical drug carriers: dermal and 
transdermal drug delivery. J Control Release 30, 1-15. 
Schroeder, A., Kost, J., Barenholz, Y., 2009. Ultrasound, liposomes, and drug delivery: principles for 
using ultrasound to control the release of drugs from liposomes. Chem Phys Lipids 162, 1-16. 
Schubert, M., Müller-Goymann, C., 2003. Solvent injection as a new approach for manufacturing lipid 
nanoparticles–evaluation of the method and process parameters. Eur J Pharm Biopharm 55, 125-131. 
Scudiero, D.A., Shoemaker, R.H., Paull, K.D., Monks, A., Tierney, S., Nofziger, T.H., Currens, M.J., Seniff, 
D., Boyd, M.R., 1988. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug 
sensitivity in culture using human and other tumor cell lines. Cancer research 48, 4827-4833. 
Semalty, A., Semalty, M., Singh, D., Rawat, M.S.M., 2010a. Preparation and characterization of 
phospholipid complexes of naringenin for effective drug delivery. J Incl Phenom Macro 67, 253-260. 
Semalty, A., Semalty, M., Singh, D., Rawat, M.S.M., 2010b. Preparation and characterization of 
phospholipid complexes of naringenin for effective drug delivery. J Incl Phenom Macro 67, 253-260. 
Seras, M., Handjani-Vila, R.-M., Ollivon, M., Lesieur, S., 1992. Kinetic aspects of the solubilization of 
non-ionic monoalkyl amphiphile-cholesterol vesicles by octylglucoside. Chem Phys Lipids 63, 1-14. 
Shakeel, F., Ramadan, W., Faisal, M.S., Rizwan, M., Faiyazuddin, M., Mustafa, G., Shafiq, S., 2010. 
Transdermal and topical delivery of anti-inflammatory agents using nanoemulsion/microemulsion: an 
updated review. Current nanoscience 6, 184-198. 
Shankar, S., Ganapathy, S., Hingorani, S.R., Srivastava, R.K., 2008. EGCG inhibits growth, invasion, 
angiogenesis and metastasis of pancreatic cancer. Frontiers in bioscience : a journal and virtual library 
13, 440-452. 
Siddiqui, I.A., Adhami, V.M., Bharali, D.J., Hafeez, B.B., Asim, M., Khwaja, S.I., Ahmad, N., Cui, H., 
Mousa, S.A., Mukhtar, H., 2009. Introducing Nanochemoprevention as a Novel Approach for Cancer 
Control: Proof of Principle with Green Tea Polyphenol Epigallocatechin-3-Gallate. Cancer research 69, 
1712-1716. 
Siepmann, J., Peppas, N., 2012. Modeling of drug release from delivery systems based on 
hydroxypropyl methylcellulose (HPMC). Adv Drug Deliver Rev 64, 163-174. 
Sigler, K., Ruch, R.J., 1993. Enhancement of gap junctional intercellular communication in tumor 
promoter-treated cells by components of green tea. Cancer letters 69, 15-19. 
Sigma-Aldrich(a), 2017. Tween 80. 
Sigma-Aldrich(b), 2017. Tween 20. 
Sigma-Aldrich(c), 2017. Sodium cholate. 
Sigma-Aldrich(d), 2017. Phosphate buffered saline. 
Sigma-Aldrich(e), 2017. Epigallocatechin gallate. Sigma Aldrich. 
Singh, B.N., Shankar, S., Srivastava, R.K., 2011a. Green tea catechin, epigallocatechin-3-gallate (EGCG): 
Mechanisms, perspectives and clinical applications. Biochemical pharmacology 82, 1807-1821. 
Singh, T., Vaid, M., Katiyar, N., Sharma, S., Katiyar, S.K., 2011b. Berberine, an isoquinoline alkaloid, 
inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, 
prostaglandin E(2) and prostaglandin E(2) receptors. Carcinogenesis 32, 86-92. 
Sinha Roy, D., Rohera, B.D., 2002. Comparative evaluation of rate of hydration and matrix erosion of 
HEC and HPC and study of drug release from their matrices. Eur J Pharm Sci 16, 193-199. 
Sitzia, J., Huggins, L., 1998. Side effects of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) 
chemotherapy for breast cancer. Cancer Practice 6, 13-21. 
273 
 
Soltani-Arabshahi, R., Tristani-Firouzi, P., 2013. Chemoprevention of nonmelanoma skin cancer. Facial 
Plastic Surgery 29, 373-383. 
Sou, K., 2011. Electrostatics of carboxylated anionic vesicles for improving entrapment capacity. Chem 
Phys Lipids 164, 211-215. 
Specht, C., Stoye, I., Muller-Goymann, C.C., 1998. Comparative investigations to evaluate the use of 
organotypic cultures of transformed and native dermal and epidermal cells for permeation studies. 
Eur J Pharm Biopharm 46, 273-278. 
Sternberg, B., Sorgi, F.L., Huang, L., 1994. New structures in complex formation between DNA and 
cationic liposomes visualized by freeze—fracture electron microscopy. Febs Lett 356, 361-366. 
Stott, P.W., Williams, A.C., Barry, B.W., 1998. Transdermal delivery from eutectic systems: enhanced 
permeation of a model drug, ibuprofen. J Control Release 50, 297-308. 
Sullivan, T.P., Dearaujo, T., Vincek, V., Berman, B., 2003. Evaluation of superficial basal cell carcinomas 
after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. 
Dermatol Surg 29, 1181-1186. 
Sun Spot Melanoma Awareness, 2013. Skin Care Awareness. 
Szoka, F., Papahadjopoulos, D., 1978. Procedure for preparation of liposomes with large internal 
aqueous space and high capture by reverse-phase evaporation. Proceedings of the National Academy 
of Sciences of the United States of America 75, 4194-4198. 
Szoka Jr, F., Papahadjopoulos, D., 1980. Comparative properties and methods of preparation of lipid 
vesicles (liposomes). Annual review of biophysics and bioengineering 9, 467-508. 
Tan, Z., Zhang, J., Wu, J., Fang, L., He, Z., 2009. The Enhancing Effect of Ion-pairing on the Skin 
Permeation of Glipizide. Aaps Pharmscitech 10, 967. 
Tanigawa, T., Kanazawa, S., Ichibori, R., Fujiwara, T., Magome, T., Shingaki, K., Miyata, S., Hata, Y., 
Tomita, K., Matsuda, K., Kubo, T., Tohyama, M., Yano, K., Hosokawa, K., 2014. (+)-Catechin protects 
dermal fibroblasts against oxidative stress-induced apoptosis. BMC complementary and alternative 
medicine 14, 133. 
ten Tije, A.J., Verweij, J., Loos, W.J., Sparreboom, A., 2003. Pharmacological effects of formulation 
vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42, 665-685. 
Teow, H.M., Zhou, Z., Najlah, M., Yusof, S.R., Abbott, N.J., D'Emanuele, A., 2013. Delivery of paclitaxel 
across cellular barriers using a dendrimer-based nanocarrier. Int J Pharm 441, 701-711. 
Thawonsuwan, J., Kiron, V., Satoh, S., Panigrahi, A., Verlhac, V., 2010. Epigallocatechin-3-gallate (EGCG) 
affects the antioxidant and immune defense of the rainbow trout, Oncorhynchus mykiss. Fish 
physiology and biochemistry 36, 687-697. 
Thewalt, J.L., Bloom, M., 1992. Phosphatidylcholine. Biophys J 63, 1176-1181. 
Thomas, B.J., Finnin, B.C., 2004. The transdermal revolution. Drug discovery today 9, 697-703. 
Touitou, E., Dayan, N., Bergelson, L., Godin, B., Eliaz, M., 2000. Ethosomes—novel vesicular carriers for 
enhanced delivery: characterization and skin penetration properties. J Control Release 65, 403-418. 
Touitou, E., Fabin, B., Dany, S., Almog, S., 1988. Transdermal delivery of tetrahydrocannabinol. Int J 
Pharmaceut 43, 9-15. 
Trotta, M., Peira, E., Carlotti, M.E., Gallarate, M., 2004. Deformable liposomes for dermal 
administration of methotrexate. Int J Pharm 270, 119-125. 
Trotta, M., Peira, E., Debernardi, F., Gallarate, M., 2002. Elastic liposomes for skin delivery of 
dipotassium glycyrrhizinate. Int J Pharmaceut 241, 319-327. 
Trotta, M., Ugazio, E., Peira, E., Pulitano, C., 2003. Influence of ion pairing on topical delivery of retinoic 
acid from microemulsions. J Control Release 86, 315-321. 
Trovatti, E., Silva, N.H., Duarte, I.F., Rosado, C.F., Almeida, I.F., Costa, P., Freire, C.S., Silvestre, A.J., 
Neto, C.P., 2011. Biocellulose membranes as supports for dermal release of lidocaine. 
Biomacromolecules 12, 4162-4168. 
Tsai, M.J., Huang, Y.B., Fang, J.W., Fu, Y.S., Wu, P.C., 2015. Preparation and Characterization of 
Naringenin-Loaded Elastic Liposomes for Topical Application. PloS one 10, e0131026. 
Urosevic, M., Dummer, R., 2002. Immunotherapy for nonmelanoma skin cancer: does it have a future? 
Cancer 94, 477-485. 
Utreja, P., Jain, S., Tiwary, A.K., 2011. Localized delivery of paclitaxel using elastic liposomes: 
Formulation development and evaluation. Drug Deliv 18, 367-376. 
274 
 
Vajjha, R.S., Das, D.K., Kulkarni, D.P., 2010. Development of new correlations for convective heat 
transfer and friction factor in turbulent regime for nanofluids. International Journal of Heat and Mass 
Transfer 53, 4607-4618. 
Valenta, C., Auner, B.G., 2004. The use of polymers for dermal and transdermal delivery. Eur J Pharm 
Biopharm 58, 279-289. 
van den Bergh, B.A., Vroom, J., Gerritsen, H., Junginger, H.E., Bouwstra, J.A., 1999. Interactions of 
elastic and rigid vesicles with human skin in vitro: electron microscopy and two-photon excitation 
microscopy. Biochimica et Biophysica Acta (BBA)-Biomembranes 1461, 155-173. 
van der Merwe, D., Brooks, J.D., Gehring, R., Baynes, R.E., Monteiro-Riviere, N.A., Riviere, J.E., 2006. A 
physiologically based pharmacokinetic model of organophosphate dermal absorption. Toxicological 
sciences : an official journal of the Society of Toxicology 89, 188-204. 
van Kuijk-Meuwissen, M.E., Junginger, H.E., Bouwstra, J.A., 1998. Interactions between liposomes and 
human skin in vitro, a confocal laser scanning microscopy study. Biochimica et Biophysica Acta (BBA)-
Biomembranes 1371, 31-39. 
van Winden, E.C.A., Zhang, W., Crommelin, D.J.A., 1997. Effect of Freezing Rate on the Stability of 
Liposomes During Freeze-Drying and Rehydration. Pharm Res-Dord 14, 1151-1160. 
Vázquez-González, M.L., Bernad, R., Calpena, A.C., Domènech, O., Montero, M., Hernández-Borrell, J., 
2014. Improving ex vivo skin permeation of non-steroidal anti-inflammatory drugs: enhancing 
extemporaneous transformation of liposomes into planar lipid bilayers. Int J Pharmaceut 461, 427-436. 
Verma, D.D., Verma, S., Blume, G., Fahr, A., 2003. Particle size of liposomes influences dermal delivery 
of substances into skin. Int J Pharmaceut 258, 141-151. 
Vilar, G., Tulla-Puche, J., Albericio, F., 2012. Polymers and drug delivery systems. Current drug delivery 
9, 367-394. 
Vivero-Escoto, J.L., Slowing, I.I., Wu, C.-W., Lin, V.S.-Y., 2009. Photoinduced intracellular controlled 
release drug delivery in human cells by gold-capped mesoporous silica nanosphere. Journal of the 
American Chemical Society 131, 3462-3463. 
Vogt, A., Blume-Peytavi, U., 2014. Selective hair therapy: bringing science to the fiction. Experimental 
dermatology 23, 83-86. 
Voss, N., Kim-Sing, C., 1998. Radiotherapy in the treatment of dermatologic malignancies. 
Dermatologic clinics 16, 313-320. 
Wadajkar, A.S., Bhavsar, Z., Ko, C.-Y., Koppolu, B., Cui, W., Tang, L., Nguyen, K.T., 2012. Multifunctional 
particles for melanoma-targeted drug delivery. Acta biomaterialia 8, 2996-3004. 
Wang, Y., Wang, S., Firempong, C.K., Zhang, H., Wang, M., Zhang, Y., Zhu, Y., Yu, J., Xu, X., 2016. 
Enhanced Solubility and Bioavailability of Naringenin via Liposomal Nanoformulation: Preparation and 
In Vitro and In Vivo Evaluations. Aaps Pharmscitech. 
Warner, R., Lilly, N., 1994. Correlation of water content with ultrastructure in the stratum corneum. 
Bioengineering of the skin. Water and the stratum corneum 1, 3-12. 
Weiner, N., Egbaria, K., Ramachandran, C., 1992. Topical Delivery of Liposomally Encapsulated 
Interferon Evaluated by In Vitro Diffusion Studies and in a Cutaneous Herpes Guinea Pig Model, in: 
Braun-Falco, O., Korting, H.C., Maibach, H.I. (Eds.), Liposome Dermatics: Griesbach Conference. 
Springer Berlin Heidelberg, Berlin, Heidelberg, pp. 242-250. 
Wen, J., Liu, B., Yuan, E., Ma, Y., Zhu, Y., 2010a. Preparation and physicochemical properties of the 
complex of naringenin with hydroxypropyl-beta-cyclodextrin. Molecules 15, 4401-4407. 
Wen, J., Liu, B., Yuan, E., Ma, Y., Zhu, Y., 2010b. Preparation and physicochemical properties of the 
complex of naringenin with hydroxypropyl-β-cyclodextrin. Molecules 15, 4401-4407. 
Wiig, H., Swartz, M.A., 2012. Interstitial fluid and lymph formation and transport: physiological 
regulation and roles in inflammation and cancer. Physiological reviews 92, 1005-1060. 
Yamashita, F., Bando, H., Koyama, Y., Kitagawa, S., Takakura, Y., Hashida, M., 1994. In vivo and in vitro 
analysis of skin penetration enhancement based on a two-layer diffusion model with polar and 
nonpolar routes in the stratum corneum. Pharm Res 11, 185-191. 
Yang, C.S., Maliakal, P., Meng, X., 2002. Inhibition of carcinogenesis by tea. Annual review of 
pharmacology and toxicology 42, 25-54. 
Yanyu, X., Yunmei, S., Zhipeng, C., Qineng, P., 2006. The preparation of silybin–phospholipid complex 
and the study on its pharmacokinetics in rats. Int J Pharmaceut 307, 77-82. 
275 
 
Yong, C.S., Jung, S.H., Rhee, J.D., Choi, H.G., Lee, B.J., Kim, D.C., Choi, Y.W., Kim, C.K., 2003. Improved 
solubility and in vitro dissolution of Ibuprofen from poloxamer gel using eutectic mixture with menthol. 
Drug Deliv 10, 179-183. 
Zuidam, N.J., Barenholz, Y., 1997. Electrostatic parameters of cationic liposomes commonly used for 
gene delivery as determined by 4-heptadecyl-7-hydroxycoumarin1. Biochimica et Biophysica Acta 
(BBA) - Biomembranes 1329, 211-222. 
 
